Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{ | { | ||
"articlesQuery" : { | "articlesQuery" : { | ||
"articles" : [ | "articles" : [ | ||
{ | { | ||
"title" : "Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study", | |||
"pmid" : "28533265", | |||
"statusUsableDate" : "2019-09-12", | |||
"abbreviation" : "3C", | |||
"published" : "2017-05-22", | |||
"timestamp" : "2019-09-12T17:46:55Z", | "timestamp" : "2019-09-12T17:46:55Z", | ||
"briefDesignDescription" : "Antibiotic strategies in lower respiratory tract infections", | "briefDesignDescription" : "Antibiotic strategies in lower respiratory tract infections", | ||
"fulltexturl" : "https://www.bmj.com/content/357/bmj.j2148.long", | "fulltexturl" : "https://www.bmj.com/content/357/bmj.j2148.long", | ||
"subspecialties" : "Infectious Disease;Pulmonology", | |||
"pdfurl" : "https://www.bmj.com/content/bmj/357/bmj.j2148.full.pdf", | |||
"expansion" : "Cough Complication Cohort", | |||
"pageid" : 2956, | "pageid" : 2956, | ||
"citation" : "Little P, <i>et al</i>. \"Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study\". <i>The British Medical Journal</i>. 2017. 357:j2148.", | "citation" : "Little P, <i>et al</i>. \"Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study\". <i>The British Medical Journal</i>. 2017. 357:j2148.", | ||
"pageName" : "3C", | "pageName" : "3C", | ||
"diseases" : "Pneumonia", | "diseases" : "Pneumonia", | ||
" | "briefResultsDescription" : "Similar outcomes in upfront, delayed, and no antibiotic strategies", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500964", | ||
"briefDesignDescription" : "Central line complications by insertion site", | "briefDesignDescription" : "Central line complications by insertion site", | ||
"subspecialties" : "Critical Care;Infectious Disease", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1500964", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1500964", | ||
" | "abbreviation" : "3SITES", | ||
" | "timestamp" : "2017-12-03T22:32:58Z", | ||
"published" : "2015-09-24", | |||
"title" : "Intravascular Complications of Central Venous Catheterization by Insertion Site", | |||
"pmid" : "26398070", | |||
"statusUsableDate" : "2015-11-01", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "pageName" : "3SITES", | ||
"briefResultsDescription" : "Subclavian lines yield fewer CRBSIs and DVTs compared to IJ/femoral lines", | "briefResultsDescription" : "Subclavian lines yield fewer CRBSIs and DVTs compared to IJ/femoral lines", | ||
"diseases" : "Critical Illness;Catheter-Related Bloodstream Infection", | "diseases" : "Critical Illness;Catheter-Related Bloodstream Infection", | ||
" | "citation" : "Parienti JJ, <i>et al</i>. \"Intravascular Complications of Central Venous Catheterization by Insertion Site\". <i>The New England Journal of Medicine</i>. 2015. 373(13):1220-1229.", | ||
"pageid" : 2479, | |||
" | "expansion" : "" | ||
}, | }, | ||
{ | { | ||
"title" : "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)", | |||
"statusUsableDate" : "2013-08-01", | |||
"pmid" : "7968073", | |||
"abbreviation" : "4S", | |||
"published" : "1994-11-19", | |||
"timestamp" : "2017-12-14T19:22:25Z", | "timestamp" : "2017-12-14T19:22:25Z", | ||
"briefDesignDescription" : "Simvastatin in stable CAD", | "briefDesignDescription" : "Simvastatin in stable CAD", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "", | |||
"expansion" : "Scandinavian Simvastatin Survival Study", | |||
"pageid" : 1587, | "pageid" : 1587, | ||
"citation" : "Pedersen TR, <i>et al</i>. \"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\". <i>The Lancet</i>. 1994. 344(8934):1383-1389.", | "citation" : "Pedersen TR, <i>et al</i>. \"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)\". <i>The Lancet</i>. 1994. 344(8934):1383-1389.", | ||
"pageName" : "4S", | "pageName" : "4S", | ||
"diseases" : "Hyperlipidemia;Coronary Artery Disease", | "diseases" : "Hyperlipidemia;Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Simvastatin reduces all mortality in stable CAD", | ||
"trainingLevel" : "Student" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Hypotension", | ||
" | "briefResultsDescription" : "No difference in mortality between groups", | ||
" | "pageName" : "65 Trial", | ||
"trainingLevel" : "resident", | |||
"expansion" : "", | |||
"pageid" : 4436, | "pageid" : 4436, | ||
"citation" : "Lamontagne F, <i>et al</i>. \"Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension; A Randomized Clinical Trial\". <i>JAMA</i>. 2020. 323(10):938-949.", | "citation" : "Lamontagne F, <i>et al</i>. \"Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension; A Randomized Clinical Trial\". <i>JAMA</i>. 2020. 323(10):938-949.", | ||
"fulltexturl" : "https://doi.org/10.1001/jama.2020.0930", | |||
"subspecialties" : "Critical Care;Neurology;Geriatrics", | "subspecialties" : "Critical Care;Neurology;Geriatrics", | ||
" | "briefDesignDescription" : "MAP 60-65 vs. usual care in vasodilatory hypotension in ICU", | ||
"pdfurl" : "", | |||
"statusUsableDate" : "2021-08-19", | "statusUsableDate" : "2021-08-19", | ||
" | "pmid" : "32049269", | ||
"title" : "Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension; A Randomized Clinical Trial", | |||
"published" : "2020-02-12", | "published" : "2020-02-12", | ||
" | "timestamp" : "2021-08-21T01:56:39Z", | ||
"abbreviation" : "65 Trial" | |||
"abbreviation" : "65 Trial | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Improved survival among black patients with HF", | ||
" | "pageName" : "A-HeFT", | ||
"trainingLevel" : "Student", | |||
"expansion" : "African-American Heart Failure Trial", | |||
"pageid" : 41, | "pageid" : 41, | ||
"citation" : "Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.", | "citation" : "Taylor AL, <i>et al</i>. \"Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure\". <i>The New England Journal of Medicine</i>. 2004. 351(20):2049-2057.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa042934", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "ISDN/hydralazine for black patients with HFrEF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa042934", | |||
"pmid" : "15533851", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure", | ||
"published" : "2004-11-11", | "published" : "2004-11-11", | ||
" | "timestamp" : "2019-02-22T06:12:34Z", | ||
"abbreviation" : "A-HeFT" | |||
"abbreviation" : "A-HeFT | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Nephrology", | ||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/195530", | |||
"briefDesignDescription" : "BP management for CKD in African Americans", | "briefDesignDescription" : "BP management for CKD in African Americans", | ||
"pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/195530/joc20772.pdf", | "pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/195530/joc20772.pdf", | ||
"statusUsableDate" : "2019-08-29", | "statusUsableDate" : "2019-08-29", | ||
"pmid" : "12435255", | |||
"title" : "Intensive blood-pressure control in hypertensive chronic kidney disease", | |||
"timestamp" : "2019-10-29T18:24:45Z", | |||
"published" : "2002-11-20", | |||
"abbreviation" : "AASK", | |||
"briefResultsDescription" : "Intensive BP control didn't prevent progression of kidney disease but ACE-inhibitors did", | "briefResultsDescription" : "Intensive BP control didn't prevent progression of kidney disease but ACE-inhibitors did", | ||
" | "diseases" : "Chronic Kidney Disease;Hypertension", | ||
"pageName" : "AASK", | "pageName" : "AASK", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "African American Study of Kidney Disease and Hypertension", | ||
" | "citation" : "Wright JT Jr., <i>et al</i>. \"Intensive blood-pressure control in hypertensive chronic kidney disease\". <i>JAMA</i>. 2002. 288(19):2421-2431.", | ||
" | "pageid" : 2666 | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device", | ||
" | "pageid" : 2829, | ||
" | "citation" : "Di Biase <i>et al</i>. \"Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device\". <i>Circulation</i>. 2016. 133(17):1637-1634.", | ||
" | "diseases" : "Atrial Fibrillation;Heart Failure", | ||
" | "briefResultsDescription" : "AF ablation superior to amiodarone in HFrEF with LVEF ≤40%", | ||
"pageName" : "AATAC", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "27029350", | ||
"statusUsableDate" : "2016-09-01", | "statusUsableDate" : "2016-09-01", | ||
" | "title" : "Ablation vs. amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device", | ||
"published" : "2016-04-26", | "published" : "2016-04-26", | ||
" | "timestamp" : "2017-12-03T22:33:01Z", | ||
"abbreviation" : "AATAC", | "abbreviation" : "AATAC", | ||
" | "fulltexturl" : "http://circ.ahajournals.org/content/early/2016/03/30/CIRCULATIONAHA.115.019406", | ||
" | "subspecialties" : "Cardiology", | ||
"briefDesignDescription" : "AF ablation vs. amiodarone in HFrEF with LVEF ≤40%", | |||
"pdfurl" : null | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2025-05-29", | |||
"pmid" : "7723155", | |||
"title" : "Endarterectomy for Asymptomatic Carotid Artery Stenosis", | |||
"published" : "1995-05-10", | |||
"timestamp" : "2025-05-29T18:18:33Z", | "timestamp" : "2025-05-29T18:18:33Z", | ||
"abbreviation" : "ACAS", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/article-abstract/388335", | |||
"subspecialties" : "Surgery;Neurology;Cardiology", | |||
"briefDesignDescription" : "CEA vs. medical therapy in asymptomatic carotid stenosis", | "briefDesignDescription" : "CEA vs. medical therapy in asymptomatic carotid stenosis", | ||
" | "pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/388335/jama_273_18_035.pdf", | ||
"expansion" : "Asymptomatic Carotid Artery Stenosis Trial", | |||
"pageid" : 4279, | "pageid" : 4279, | ||
"citation" : "Micheal Walker, <i>et al</i>. \"Endarterectomy for Asymptomatic Carotid Artery Stenosis\". <i>Journal of the American Medical Association</i>. 1995. 273(18):1421-1428.", | "citation" : "Micheal Walker, <i>et al</i>. \"Endarterectomy for Asymptomatic Carotid Artery Stenosis\". <i>Journal of the American Medical Association</i>. 1995. 273(18):1421-1428.", | ||
" | "diseases" : "Carotid Stenosis;Stroke;Transient Ischemic Attack", | ||
"briefResultsDescription" : "CEA reduced stroke/death rate compared to medical management", | "briefResultsDescription" : "CEA reduced stroke/death rate compared to medical management", | ||
"pageName" : "ACAS", | "pageName" : "ACAS", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
"title" : "Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients", | |||
"statusUsableDate" : "2013-06-01", | |||
"pmid" : "19052124", | |||
"abbreviation" : "ACCOMPLISH", | |||
"timestamp" : "2018-01-11T18:23:02Z", | "timestamp" : "2018-01-11T18:23:02Z", | ||
"published" : "2008-12-04", | |||
"briefDesignDescription" : "Benazepril/amlodipine vs. benazepril/HCTZ in HTN", | "briefDesignDescription" : "Benazepril/amlodipine vs. benazepril/HCTZ in HTN", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0806182", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0806182", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0806182", | ||
" | "expansion" : "Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension", | ||
"citation" : "Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.", | "citation" : "Jamerson K, <i>et al</i>. \"Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2008. 359(23):2417-2428.", | ||
" | "pageid" : 1448, | ||
"pageName" : "ACCOMPLISH", | |||
" | |||
"briefResultsDescription" : "Benazepril/amlodipine is associated with fewer CV events", | "briefResultsDescription" : "Benazepril/amlodipine is associated with fewer CV events", | ||
"diseases" : "Hypertension", | "diseases" : "Hypertension", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743", | ||
"subspecialties" : "Endocrinology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802743", | |||
"briefDesignDescription" : "Intensive glycemic therapy in T2DM", | "briefDesignDescription" : "Intensive glycemic therapy in T2DM", | ||
" | "timestamp" : "2019-12-18T14:23:33Z", | ||
" | "published" : "2008-06-12", | ||
" | "abbreviation" : "ACCORD", | ||
"pmid" : "18539917", | |||
"statusUsableDate" : "2012-03-01", | |||
"title" : "Effects of Intensive Glucose Lowering in Type 2 Diabetes", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"briefResultsDescription" : "Increased mortality and no cardiovascular benefit with intensive glycemic control", | "briefResultsDescription" : "Increased mortality and no cardiovascular benefit with intensive glycemic control", | ||
" | "diseases" : "Diabetes Mellitus", | ||
"pageName" : "ACCORD", | "pageName" : "ACCORD", | ||
" | "citation" : "Gerstein HC, <i>et al</i>. \"Effects of Intensive Glucose Lowering in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2545-59.", | ||
"pageid" : 105, | |||
"expansion" : "Action to Control Cardiovascular Risk in Diabetes" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "ACCORD Study Group. \"Effects of intensive blood-pressure control in type 2 diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2010. 362(17):1575-1585.", | ||
"pageid" : 1760, | "pageid" : 1760, | ||
" | "expansion" : "ACCORD Study Group", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"briefResultsDescription" : "Intensive BP control doesn't reduce CV events in T2DM", | "briefResultsDescription" : "Intensive BP control doesn't reduce CV events in T2DM", | ||
"diseases" : "Diabetes Mellitus;Hypertension", | |||
"pageName" : "ACCORD BP", | |||
"timestamp" : "2024-12-12T20:32:12Z", | |||
"published" : "2010-03-14", | "published" : "2010-03-14", | ||
"abbreviation" : "ACCORD BP", | "abbreviation" : "ACCORD BP", | ||
"pmid" : "20228401", | |||
"statusUsableDate" : "2014-08-01", | |||
"title" : "Effects of intensive blood-pressure control in type 2 diabetes mellitus", | "title" : "Effects of intensive blood-pressure control in type 2 diabetes mellitus", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001286", | ||
"subspecialties" : "Endocrinology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1001286", | |||
"briefDesignDescription" : "Intensive BP control in T2DM" | |||
}, | }, | ||
{ | { | ||
"pmid" : "20228404", | |||
"statusUsableDate" : "2018-01-17", | |||
"title" : "Effects of combination lipid therapy in type 2 diabetes mellitus", | |||
"timestamp" : "2018-01-31T01:55:15Z", | "timestamp" : "2018-01-31T01:55:15Z", | ||
"published" : "2010-04-29", | |||
"abbreviation" : "ACCORD Lipid", | |||
"subspecialties" : "Cardiology;Endocrinology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1001282", | |||
"briefDesignDescription" : "Fibrate add-on to statins in T2DM", | "briefDesignDescription" : "Fibrate add-on to statins in T2DM", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001282", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001282", | ||
" | "expansion" : "Action to Control Cardiovascular Risk in Diabetes-Lipid", | ||
"citation" : "ACCORD Study Group. \"Effects of combination lipid therapy in type 2 diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2010. 362(17):1563-1574.", | "citation" : "ACCORD Study Group. \"Effects of combination lipid therapy in type 2 diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2010. 362(17):1563-1574.", | ||
" | "pageid" : 3520, | ||
"briefResultsDescription" : "Fenofibrates don't reduce CVD among adults with T2DM on statins", | "briefResultsDescription" : "Fenofibrates don't reduce CVD among adults with T2DM on statins", | ||
" | "diseases" : "Diabetes Mellitus;Coronary Artery Disease;Stroke", | ||
"pageName" : "ACCORD Lipid", | "pageName" : "ACCORD Lipid", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : null, | ||
"briefDesignDescription" : "Empiric cefepime vs. pip-tazo for infection", | "briefDesignDescription" : "Empiric cefepime vs. pip-tazo for infection", | ||
"subspecialties" : "Infectious Disease;Critical Care;Emergency Medicine", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2810592", | "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2810592", | ||
" | "abbreviation" : "ACORN", | ||
" | "timestamp" : "2024-03-28T17:22:37Z", | ||
"published" : "2023-10-14", | |||
"title" : "Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection", | |||
"pmid" : "37837651", | |||
"statusUsableDate" : "2024-02-22", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "ACORN", | ||
"briefResultsDescription" : "Similar rates of AKI; cefepime causes more CNS toxicity", | "briefResultsDescription" : "Similar rates of AKI; cefepime causes more CNS toxicity", | ||
"diseases" : "Infection", | "diseases" : "Infection", | ||
" | "citation" : "Qian E, <i>et al</i>. \"Cefepime vs. piperacillin-tazobactam in adults hospitalized with acute infection\". <i>JAMA</i>. 2023. 330(16):1557-1567.", | ||
"pageid" : 5478, | |||
" | "expansion" : "Antibiotic Choice on Renal Outcomes" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/645514/joc15004_569_575.pdf", | ||
"briefDesignDescription" : "ALND in SLND-positive breast cancer", | "briefDesignDescription" : "ALND in SLND-positive breast cancer", | ||
"subspecialties" : "Oncology;Surgery", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/645514", | "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/645514", | ||
" | "abbreviation" : "ACOSOG Z0011", | ||
" | "timestamp" : "2018-09-06T17:17:42Z", | ||
"published" : "2011-02-09", | |||
"title" : "Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial", | |||
"pmid" : "21304082", | |||
"statusUsableDate" : "2018-09-06", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pageName" : "ACOSOG Z0011", | ||
"briefResultsDescription" : "ALND no better than monitoring in SLNB-positive disease", | "briefResultsDescription" : "ALND no better than monitoring in SLNB-positive disease", | ||
"diseases" : "Breast Cancer", | "diseases" : "Breast Cancer", | ||
" | "citation" : "Giuliano AE, <i>et al</i>. \"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial\". <i>The Journal of the American Medical Association</i>. 2011. 305(6):569-575.", | ||
"pageid" : 3545, | |||
" | "expansion" : "The American College of Surgeons Oncology Group (ACOSOG) Z0011" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://circ.ahajournals.org/cgi/pmidlookup?view", | ||
"subspecialties" : "Nephrology;Cardiology", | |||
"briefDesignDescription" : "Acetylcysteine with IV contrast", | "briefDesignDescription" : "Acetylcysteine with IV contrast", | ||
"pdfurl" : "http://circ.ahajournals.org/content/124/11/1250.full.pdf", | "pdfurl" : "http://circ.ahajournals.org/content/124/11/1250.full.pdf", | ||
"statusUsableDate" : "2015-08-01", | "statusUsableDate" : "2015-08-01", | ||
"pmid" : "21859972", | |||
"title" : "Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography", | |||
"published" : "2011-06-28", | |||
"timestamp" : "2017-12-03T22:33:07Z", | |||
"abbreviation" : "ACT", | |||
"diseases" : "Acute Kidney Injury;Acute Coronary Syndrome", | |||
"briefResultsDescription" : "Acetylcysteine doesn't prevent contrast-induced acute kidney injury", | "briefResultsDescription" : "Acetylcysteine doesn't prevent contrast-induced acute kidney injury", | ||
"pageName" : "ACT", | "pageName" : "ACT", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "Acetylcysteine for Contrast-Induced Nephropathy Trial", | ||
" | "pageid" : 2425, | ||
"citation" : "ACT Investigators. \"Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Angiography\". <i>Circulation</i>. 2011. 124:1250-1259." | |||
}, | }, | ||
{ | { | ||
"pageid" : 2721, | |||
"pageid" : 2721 | |||
"citation" : "Rosenfield K, <i>et al</i>. \"Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis\". <i>The New England Journal of Medicine</i>. 2016. 374(11):1011-20.", | "citation" : "Rosenfield K, <i>et al</i>. \"Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis\". <i>The New England Journal of Medicine</i>. 2016. 374(11):1011-20.", | ||
"expansion" : "Stent versus endarterectomy for asymptomatic carotid stenosis", | "expansion" : "Stent versus endarterectomy for asymptomatic carotid stenosis", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "ACT I", | "pageName" : "ACT I", | ||
"diseases" : "Carotid Stenosis", | "diseases" : "Carotid Stenosis", | ||
"briefResultsDescription" : "Carotid stenting noninferior to endarterectomy in asymptomatic carotid stenosis", | |||
"abbreviation" : "ACT I", | "abbreviation" : "ACT I", | ||
"published" : "2016-02-17", | |||
"timestamp" : "2023-02-03T04:55:43Z", | |||
"title" : "Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis", | "title" : "Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis", | ||
"pmid" : "26886419" | "statusUsableDate" : "2023-02-01", | ||
"pmid" : "26886419", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1515706", | |||
"briefDesignDescription" : "Carotid stenting vs. endarterectomy", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1515706", | |||
"subspecialties" : "Cardiology" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2012-04-01", | |||
"pmid" : "19336502", | |||
"title" : "Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation", | |||
"timestamp" : "2017-12-03T22:33:09Z", | "timestamp" : "2017-12-03T22:33:09Z", | ||
"published" : "2009-05-14", | |||
"abbreviation" : "ACTIVE A", | |||
"subspecialties" : "Cardiology;Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0901301", | |||
"briefDesignDescription" : "ASA/clopidogrel vs. ASA in AF", | "briefDesignDescription" : "ASA/clopidogrel vs. ASA in AF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0901301", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0901301", | ||
" | "expansion" : "Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events", | ||
"citation" : "Connolly SJ, <i>et al</i>. \"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 360(20):2066-78.", | "citation" : "Connolly SJ, <i>et al</i>. \"Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 360(20):2066-78.", | ||
" | "pageid" : 360, | ||
"briefResultsDescription" : "ASA/clopidogrel ↓ composite of stroke, non-CNS embolism, MI, or CV death and ↑ bleeding", | "briefResultsDescription" : "ASA/clopidogrel ↓ composite of stroke, non-CNS embolism, MI, or CV death and ↑ bleeding", | ||
" | "diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | ||
"pageName" : "ACTIVE A", | "pageName" : "ACTIVE A", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"pageid" : 1438, | "pageid" : 1438, | ||
"citation" : "Connolly SJ, <i>et al</i>. \"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.\". <i>The Lancet</i>. 2006. 367(9526):1903-12.", | "citation" : "Connolly SJ, <i>et al</i>. \"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.\". <i>The Lancet</i>. 2006. 367(9526):1903-12.", | ||
"expansion" : "Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events", | "expansion" : "Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "ACTIVE W", | "pageName" : "ACTIVE W", | ||
"diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | "diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | ||
"briefResultsDescription" : "Warfarin is superior to ASA/clopidogrel for stroke prevention in AF", | |||
"abbreviation" : "ACTIVE W", | "abbreviation" : "ACTIVE W", | ||
"published" : "2006-06-10", | |||
"timestamp" : "2017-12-03T22:33:10Z", | |||
"title" : "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.", | "title" : "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.", | ||
"pmid" : "16765759" | "statusUsableDate" : "2013-05-01", | ||
"pmid" : "16765759", | |||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606688454.pdf", | |||
"briefDesignDescription" : "ASA/clopidogrel vs. warfarin in AF", | |||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68845-4", | |||
"subspecialties" : "Cardiology;Neurology" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"pageName" : "ACTT-1", | |||
"briefResultsDescription" : "Remdesivir modestly shortens time to recovery mostly in severe disease", | |||
"diseases" : "Covid-19", | |||
"citation" : "Beigel JH, <i>et al</i>. \"Remdesivir for the Treatment of Covid-19 - Preliminary Report\". <i>The New England Journal of Medicine</i>. 2020. 1-12.", | "citation" : "Beigel JH, <i>et al</i>. \"Remdesivir for the Treatment of Covid-19 - Preliminary Report\". <i>The New England Journal of Medicine</i>. 2020. 1-12.", | ||
"pageid" : 4238, | |||
"expansion" : "Adaptive Covid-19 Treatment Trial", | |||
"pdfurl" : "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/pdf/NEJMoa2007764.pdf", | |||
"briefDesignDescription" : "Remdesivir vs. placebo in Covid-19", | |||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2007764", | ||
" | "abbreviation" : "ACTT-1", | ||
" | "timestamp" : "2020-07-02T17:55:05Z", | ||
"published" : "2020-05-22", | "published" : "2020-05-22", | ||
"title" : "Remdesivir for the Treatment of Covid-19 - Preliminary Report", | "title" : "Remdesivir for the Treatment of Covid-19 - Preliminary Report", | ||
"pmid" : "32445440" | "pmid" : "32445440", | ||
"statusUsableDate" : "2020-06-30" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "resident", | ||
" | "briefResultsDescription" : "Cisatracurium improves 90-day survival and increases ventilator-free days", | ||
" | "diseases" : "Acute Respiratory Distress Syndrome", | ||
"pageName" : "ACURASYS", | |||
"citation" : "Papazian L, <i>et al</i>. \"Neuromuscular blockers in early acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2010. 363(12):1107-1116.", | |||
"pageid" : 1119, | "pageid" : 1119, | ||
"expansion" : "ARDS et Curarisation Systematique", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005372", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005372", | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1005372", | ||
" | "briefDesignDescription" : "Cisatracurium in ARDS", | ||
" | "timestamp" : "2019-06-05T22:43:36Z", | ||
"published" : "2010-09-16", | "published" : "2010-09-16", | ||
"abbreviation" : "ACURASYS", | "abbreviation" : "ACURASYS", | ||
"title" : "Neuromuscular blockers in early acute respiratory distress syndrome | "pmid" : "20843245", | ||
"statusUsableDate" : "2013-06-01", | |||
"title" : "Neuromuscular blockers in early acute respiratory distress syndrome" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Age-adjusted D-dimer for PE", | "briefDesignDescription" : "Age-adjusted D-dimer for PE", | ||
"subspecialties" : "Hematology;Emergency Medicine", | |||
"fulltexturl" : "http://bit.ly/1QgJ5k1", | "fulltexturl" : "http://bit.ly/1QgJ5k1", | ||
"pdfurl" : "http://bit.ly/1HTY4kQ", | "pdfurl" : "http://bit.ly/1HTY4kQ", | ||
" | "title" : "Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study", | ||
"pmid" : "24643601", | |||
" | |||
"statusUsableDate" : "2015-05-01", | "statusUsableDate" : "2015-05-01", | ||
" | "abbreviation" : "ADJUST-PE", | ||
"timestamp" : "2021-12-19T22:24:03Z", | |||
"published" : "2014-03-19", | "published" : "2014-03-19", | ||
"pageName" : "ADJUST-PE", | "pageName" : "ADJUST-PE", | ||
"briefResultsDescription" : "Age-adjusted D-dimer (age × 10 in patients >50) rules out PE", | |||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism", | "diseases" : "Pulmonary Embolism;Venous Thromboembolism", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Age aDJUSTed D-Dimer to rule out PE", | ||
" | "citation" : "Righini M, <i>et al</i>. \"Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study\". <i>JAMA</i>. 2014. 311(11):1117-1124.", | ||
"pageid" : 2367 | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2018-02-08", | |||
"pmid" : "29347874", | |||
"title" : "Adjunctive glucocorticoid therapy in patients with septic shock", | |||
"timestamp" : "2018-02-08T17:58:17Z", | "timestamp" : "2018-02-08T17:58:17Z", | ||
"published" : "2018-01-19", | |||
"abbreviation" : "ADRENAL", | |||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1705835", | |||
"briefDesignDescription" : "Hydrocortisone in septic shock", | "briefDesignDescription" : "Hydrocortisone in septic shock", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1705835", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1705835", | ||
" | "expansion" : "Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock", | ||
"citation" : "Venkatesh B, <i>et al</i>. \"Adjunctive glucocorticoid therapy in patients with septic shock\". <i>New England Journal of Medicine</i>. 2018. Epub 2018-01-19:1-12.", | "citation" : "Venkatesh B, <i>et al</i>. \"Adjunctive glucocorticoid therapy in patients with septic shock\". <i>New England Journal of Medicine</i>. 2018. Epub 2018-01-19:1-12.", | ||
" | "pageid" : 3528, | ||
"briefResultsDescription" : "Hydrocortisone provides no benefit in 90-day mortality", | "briefResultsDescription" : "Hydrocortisone provides no benefit in 90-day mortality", | ||
" | "diseases" : "Sepsis;Shock", | ||
"pageName" : "ADRENAL", | "pageName" : "ADRENAL", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "ADVANCE", | |||
"published" : "2008-06-06", | |||
"timestamp" : "2014-09-19T13:02:39Z", | "timestamp" : "2014-09-19T13:02:39Z", | ||
"title" : "Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes", | |||
"pmid" : "18539916", | |||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802987", | |||
"briefDesignDescription" : "Intensive glycemic therapy in T2DM", | "briefDesignDescription" : "Intensive glycemic therapy in T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802987", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802987", | ||
"subspecialties" : "Endocrinology", | |||
"pageid" : 248, | "pageid" : 248, | ||
"citation" : "Patel A, <i>et al</i>. \"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2560-2572.", | "citation" : "Patel A, <i>et al</i>. \"Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2008. 358(24):2560-2572.", | ||
"expansion" : "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation", | "expansion" : "Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "ADVANCE", | "pageName" : "ADVANCE", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Intensive therapy reduces microvascular complications" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "ADVOR", | ||
"briefResultsDescription" : "Acetazolamide improves diuresis in acute HF", | |||
"diseases" : "Heart Failure", | |||
"trainingLevel" : "Student", | |||
"expansion" : "Acetazolamide in Decompensated Heart Failure With Volume OveRload", | |||
"citation" : "Mullens W, <i>et al</i>. \"Acetazolamide in Acute Decompensated Heart Failure with Volume Overload\". <i>NEJM</i>. 2022. Epub 2022-08-27:1-11.", | |||
"pageid" : 4655, | |||
"briefDesignDescription" : "Acetazolamide vs. placebo in acute HF", | "briefDesignDescription" : "Acetazolamide vs. placebo in acute HF", | ||
"subspecialties" : "Cardiology;Emergency Medicine;Critical Care", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2203094", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2203094", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2203094", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2203094", | ||
" | "title" : "Acetazolamide in Acute Decompensated Heart Failure with Volume Overload", | ||
"pmid" : "36027559", | |||
" | |||
"statusUsableDate" : "2022-09-15", | "statusUsableDate" : "2022-09-15", | ||
"abbreviation" : "ADVOR", | "abbreviation" : "ADVOR", | ||
" | "timestamp" : "2022-12-20T15:19:03Z", | ||
" | "published" : "2022-08-27" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Atrial Fibrillation and Congestive Heart Failure", | ||
" | "citation" : "Roy D, <i>et al</i>. \"Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure\". <i>The New England Journal of Medicine</i>. 2008. 358(25):2667-2677.", | ||
"pageid" : 2800, | "pageid" : 2800, | ||
" | "briefResultsDescription" : "Rhythm control does not reduce CV mortality in AF with HF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "AF-CHF", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "18565859", | ||
"statusUsableDate" : "2018-12-07", | "statusUsableDate" : "2018-12-07", | ||
" | "title" : "Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure", | ||
"timestamp" : "2018-12-21T13:20:11Z", | |||
"published" : "2008-06-19", | "published" : "2008-06-19", | ||
" | "abbreviation" : "AF-CHF", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0708789", | ||
" | "briefDesignDescription" : "Rhythm control for AF in HFrEF", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0708789" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa021328", | ||
"briefDesignDescription" : "Rate vs. rhythm control in AF", | "briefDesignDescription" : "Rate vs. rhythm control in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021328", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021328", | ||
" | "abbreviation" : "AFFIRM", | ||
" | "timestamp" : "2025-05-15T20:16:04Z", | ||
"published" : "2002-11-05", | |||
"title" : "A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "12466506", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "pageName" : "AFFIRM", | ||
"briefResultsDescription" : "No mortality difference, trend towards harm with rhythm control", | "briefResultsDescription" : "No mortality difference, trend towards harm with rhythm control", | ||
"diseases" : "Atrial Fibrillation", | "diseases" : "Atrial Fibrillation", | ||
" | "citation" : "Wyse DG, <i>et al</i>. \"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2002. 347(23):1825-1833.", | ||
"pageid" : 87, | |||
" | "expansion" : "Atrial Fibrillation Follow-up Investigation of Rhythm Management" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Student", | ||
" | "pageName" : "Age Trial", | ||
" | "briefResultsDescription" : "Mammograms don't reduce breast cancer mortality in age 40-49 year old women", | ||
"diseases" : "Breast Cancer", | |||
"citation" : "Moss SM, <i>et al</i>. \"Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial\". <i>The Lancet</i>. 2006. 368(9552):2053-2060.", | |||
"pageid" : 2307, | "pageid" : 2307, | ||
"expansion" : "", | |||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "briefDesignDescription" : "Mammograms for 40-49 year old women", | ||
"subspecialties" : "Oncology;Preventive Medicine", | "subspecialties" : "Oncology;Preventive Medicine", | ||
" | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69834-6", | ||
" | "abbreviation" : "Age Trial", | ||
" | "timestamp" : "2017-12-03T22:33:43Z", | ||
"published" : "2006-12-09", | "published" : "2006-12-09", | ||
"title" : "Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial", | "title" : "Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: A randomised controlled trial", | ||
"statusUsableDate" : "2015-01-01", | |||
"pmid" : "17161727" | "pmid" : "17161727" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2211868", | ||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "Haloperidol for ICU delirium", | "briefDesignDescription" : "Haloperidol for ICU delirium", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2211868", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2211868", | ||
" | "pmid" : "36286254", | ||
"statusUsableDate" : "2022-11-02", | "statusUsableDate" : "2022-11-02", | ||
" | "title" : "Haloperidol for the Treatment of Delirium in ICU Patients", | ||
"published" : "2022-10-26", | "published" : "2022-10-26", | ||
"timestamp" : "2023-01-15T01:17:39Z", | |||
"abbreviation" : "AID-ICU", | |||
"diseases" : "Delirium", | |||
"briefResultsDescription" : "Haloperidol does not improve days alive out of hospital", | |||
"pageName" : "AID-ICU", | "pageName" : "AID-ICU", | ||
" | "trainingLevel" : "resident", | ||
" | "expansion" : "Agents Intervening against Delirium in the Intensive Care Unit", | ||
" | "pageid" : 5131, | ||
"citation" : "Andersen-Ranberg NC, <i>et al</i>. \"Haloperidol for the Treatment of Delirium in ICU Patients\". <i>The New England Journal of Medicine</i>. 2022. Online ahead of print(2022-10-26):1-11." | |||
}, | }, | ||
{ | { | ||
"pmid" : "28402237", | |||
"statusUsableDate" : "2017-06-01", | |||
"title" : "Bioresorbable scaffolds versus metallic stents in routine PCI", | |||
"published" : "2017-06-14", | |||
"timestamp" : "2017-12-03T22:33:14Z", | "timestamp" : "2017-12-03T22:33:14Z", | ||
"abbreviation" : "AIDA", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1614954", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Scaffold vs. stent in PCI", | "briefDesignDescription" : "Scaffold vs. stent in PCI", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1614954", | ||
"expansion" : "Amsterdam Investigator-Initiated Absorb Strategy All-Comers Trial", | |||
"pageid" : 2940, | "pageid" : 2940, | ||
"citation" : "Wykrzykowska JJ <i>et al</i>. \"Bioresorbable scaffolds versus metallic stents in routine PCI\". <i>The New England Journal of Medicine</i>. 2017. 376(24):2319-2328.", | "citation" : "Wykrzykowska JJ <i>et al</i>. \"Bioresorbable scaffolds versus metallic stents in routine PCI\". <i>The New England Journal of Medicine</i>. 2017. 376(24):2319-2328.", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"briefResultsDescription" : "Scaffold inferior to stent in PCI", | "briefResultsDescription" : "Scaffold inferior to stent in PCI", | ||
"pageName" : "AIDA", | "pageName" : "AIDA", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"pmid" : "29710295", | |||
"statusUsableDate" : "2024-10-24", | |||
"title" : "Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial", | |||
"published" : "2018-03-01", | |||
"timestamp" : "2024-10-17T19:52:36Z", | "timestamp" : "2024-10-17T19:52:36Z", | ||
"abbreviation" : "AIDA-WP2", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/article-abstract/2679131", | |||
"subspecialties" : "Infectious Disease;Emergency Medicine", | |||
"briefDesignDescription" : "Nitrofurantoin vs. fosfomycin in UTI", | "briefDesignDescription" : "Nitrofurantoin vs. fosfomycin in UTI", | ||
" | "pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/2679131/jama_huttner_2018_oi_180034.pdf", | ||
"expansion" : "", | |||
"pageid" : 3640, | "pageid" : 3640, | ||
"citation" : "Huttner A, <i>et al</i>. \"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial\". <i>JAMA</i>. 2018. 319(17):1781-1789.", | "citation" : "Huttner A, <i>et al</i>. \"Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial\". <i>JAMA</i>. 2018. 319(17):1781-1789.", | ||
" | "diseases" : "Urinary Tract Infection", | ||
"briefResultsDescription" : "Nitrofurantoin improved outcomes uncomplicated UTI", | "briefResultsDescription" : "Nitrofurantoin improved outcomes uncomplicated UTI", | ||
"pageName" : "AIDA-WP2", | "pageName" : "AIDA-WP2", | ||
" | "trainingLevel" : "Medical Student" | ||
}, | }, | ||
{ | { | ||
"pmid" : "27825009", | |||
"statusUsableDate" : "2016-12-01", | |||
"title" : "Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence", | |||
"published" : "2016-11-08", | |||
"timestamp" : "2018-10-16T05:18:00Z", | "timestamp" : "2018-10-16T05:18:00Z", | ||
"abbreviation" : "AIRTRIP", | |||
"fulltexturl" : "http://jamanetwork.com/journals/jama/article-abstract/2579869", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Anakinra in colchicine-resistant pericarditis", | "briefDesignDescription" : "Anakinra in colchicine-resistant pericarditis", | ||
" | "pdfurl" : null, | ||
"expansion" : "AnakInRa for Treatment of Recurrent Idiopathic Pericarditis", | |||
"pageid" : 2865, | "pageid" : 2865, | ||
"citation" : "Brucato A, <i>et al</i>. \"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence\". <i>Journal of the American Medical Association</i>. 2016. 316(18):1906-1912.", | "citation" : "Brucato A, <i>et al</i>. \"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence\". <i>Journal of the American Medical Association</i>. 2016. 316(18):1906-1912.", | ||
" | "diseases" : "Pericarditis", | ||
"briefResultsDescription" : "Anakinra superior to placebo in colchicine resistant, steroid-dependent pericarditis", | "briefResultsDescription" : "Anakinra superior to placebo in colchicine resistant, steroid-dependent pericarditis", | ||
"pageName" : "AIRTRIP", | "pageName" : "AIRTRIP", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Artificial Kidney Initiation in Kidney Injury", | ||
"pageid" : 2937, | "pageid" : 2937, | ||
"citation" : "Gaudry S, <i>et al</i>. \"Initiation strategies for renal-replacement therapy in the intensive care unit\". <i>The New England Journal of Medicine</i>. 2016. 375(2):122-133.", | "citation" : "Gaudry S, <i>et al</i>. \"Initiation strategies for renal-replacement therapy in the intensive care unit\". <i>The New England Journal of Medicine</i>. 2016. 375(2):122-133.", | ||
"pageName" : "AKIKI", | "pageName" : "AKIKI", | ||
"diseases" : "Acute Kidney Injury", | "diseases" : "Acute Kidney Injury", | ||
"briefResultsDescription" : "No mortality difference between early or delayed RRT in ICU patients with AKI", | |||
"trainingLevel" : "Resident", | |||
"title" : "Initiation strategies for renal-replacement therapy in the intensive care unit", | |||
"statusUsableDate" : "2017-08-01", | |||
"pmid" : "27181456", | |||
"abbreviation" : "AKIKI", | "abbreviation" : "AKIKI", | ||
" | "published" : "2016-07-14", | ||
" | "timestamp" : "2019-03-27T18:29:53Z", | ||
"briefDesignDescription" : "Early vs. late RRT in severe AKI in ICU", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1603017", | |||
"subspecialties" : "Critical Care;Nephrology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603017" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305727", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1305727", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1305727", | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
" | "briefDesignDescription" : "Daily albumin in severe sepsis", | ||
"published" : "2014-03-18", | |||
"timestamp" : "2018-07-03T03:04:07Z", | |||
"abbreviation" : "ALBIOS", | |||
"statusUsableDate" : "2014-03-01", | "statusUsableDate" : "2014-03-01", | ||
"pmid" : "24635772", | |||
"title" : "Albumin replacement in patients with severe sepsis or septic shock", | |||
"trainingLevel" : "resident", | |||
"diseases" : "Sepsis", | |||
"briefResultsDescription" : "Daily albumin with no mortality benefit at 28 days", | "briefResultsDescription" : "Daily albumin with no mortality benefit at 28 days", | ||
"pageName" : "ALBIOS", | "pageName" : "ALBIOS", | ||
" | "pageid" : 1781, | ||
" | "citation" : "Caironi P, <i>et al</i>. \"Albumin replacement in patients with severe sepsis or septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1412-1421.", | ||
"expansion" : "Albumin Italian Outcome Sepsis" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199908053410603", | ||
"briefDesignDescription" : "Albumin for SBP in cirrhosis", | "briefDesignDescription" : "Albumin for SBP in cirrhosis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199908053410603", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199908053410603", | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | "subspecialties" : "Gastroenterology;Infectious Disease", | ||
" | "abbreviation" : "", | ||
"published" : "1999-08-05", | "published" : "1999-08-05", | ||
"timestamp" : "2017-12-03T22:33:45Z", | |||
"title" : "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis", | |||
"pmid" : "10432325", | |||
"statusUsableDate" : "2017-09-01", | |||
"trainingLevel" : "Intern", | |||
"pageName" : "Albumin for SBP", | "pageName" : "Albumin for SBP", | ||
"diseases" : "Spontaneous Bacterial Peritonitis;Cirrhosis", | "diseases" : "Spontaneous Bacterial Peritonitis;Cirrhosis", | ||
" | "briefResultsDescription" : "Albumin reduces AKI and mortality in SBP in cirrhosis", | ||
" | "pageid" : 2501, | ||
" | "citation" : "Sort P, <i>et al</i>. \"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis\". <i>The New England Journal of Medicine</i>. 1999. 341(6):403-409.", | ||
"expansion" : "" | |||
}, | }, | ||
{ | { | ||
"pageid" : 171, | "pageid" : 171, | ||
"citation" : "Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.", | "citation" : "Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.", | ||
"expansion" : "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial", | "expansion" : "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "ALLHAT", | "pageName" : "ALLHAT", | ||
"diseases" : "Hypertension", | "diseases" : "Hypertension", | ||
"briefResultsDescription" : "Chlorthalidone performs similarly to lisinopril and amlodipine", | |||
"abbreviation" : "ALLHAT", | "abbreviation" : "ALLHAT", | ||
"published" : "2002-12-18", | |||
"timestamp" : "2018-09-14T00:37:12Z", | |||
"title" : "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic", | "title" : "Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic", | ||
"pmid" : "12479763" | "pmid" : "12479763", | ||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : null, | |||
"briefDesignDescription" : "Chlorthalidone in HTN", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/vol/288/pg/2981", | |||
"subspecialties" : "Nephrology;Cardiology" | |||
}, | }, | ||
{ | { | ||
"pmid" : "28531241", | |||
"statusUsableDate" : "2020-11-20", | |||
"title" : "Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial", | |||
"published" : "2017-07-01", | |||
"timestamp" : "2020-11-11T16:18:38Z", | "timestamp" : "2020-11-11T16:18:38Z", | ||
"abbreviation" : "ALLHAT-LLT", | |||
"fulltexturl" : "http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2628971", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Pravastatin vs usual care for ASCVD primary prevention", | "briefDesignDescription" : "Pravastatin vs usual care for ASCVD primary prevention", | ||
" | "pdfurl" : "http://www.natap.org/2017/HIV/jamainternal_Han_2017_oi_170031.pdf", | ||
"expansion" : "", | |||
"pageid" : 2949, | "pageid" : 2949, | ||
"citation" : "Han BH, <i>et al</i>. \"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial\". <i>JAMA Internal Medicine</i>. 2017. 177(7):955-965.", | "citation" : "Han BH, <i>et al</i>. \"Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial\". <i>JAMA Internal Medicine</i>. 2017. 177(7):955-965.", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"briefResultsDescription" : "Pravastatin does not decrease mortality", | "briefResultsDescription" : "Pravastatin does not decrease mortality", | ||
"pageName" : "ALLHAT-LLT Elderly", | "pageName" : "ALLHAT-LLT Elderly", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Nephrology;Rheumatology", | ||
"fulltexturl" : "http://jasn.asnjournals.org/content/20/5/1103.long", | |||
"briefDesignDescription" : "MMF vs. CTX in lupus nephritis", | "briefDesignDescription" : "MMF vs. CTX in lupus nephritis", | ||
"pdfurl" : "http://jasn.asnjournals.org/content/20/5/1103.full.pdf", | "pdfurl" : "http://jasn.asnjournals.org/content/20/5/1103.full.pdf", | ||
"statusUsableDate" : "2017-11-01", | "statusUsableDate" : "2017-11-01", | ||
"pmid" : "19369404", | |||
"title" : "Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.", | |||
"timestamp" : "2018-02-04T17:46:37Z", | |||
"published" : "2009-05-01", | |||
"abbreviation" : "ALMS", | |||
"briefResultsDescription" : "MMF similar to cyclophosphamide in lupus nephritis", | "briefResultsDescription" : "MMF similar to cyclophosphamide in lupus nephritis", | ||
" | "diseases" : "Lupus Nephritis;Lupus", | ||
"pageName" : "ALMS", | "pageName" : "ALMS", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Aspreva Lupus Management Study", | ||
" | "citation" : "Appel GB, <i>et al</i>. \"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.\". <i>Journal of American Society of Nephrology</i>. 2009. 20(5):1103–1112.", | ||
" | "pageid" : 2655 | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "AMAZES", | ||
"diseases" : "Asthma", | |||
"briefResultsDescription" : "Athithromycin reduced rate of exacerbations and improved QOL", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Azithromycin on Asthma Exacerbations and Quality of Life in Adults With Persistent Uncontrolled Asthma", | |||
"pageid" : 3615, | |||
"citation" : "Gibson PG, <i>et al</i>. \"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial\". <i>Lancet</i>. 2017. 390(10095):659-668.", | |||
"briefDesignDescription" : "Azithromycin in chronic asthma", | "briefDesignDescription" : "Azithromycin in chronic asthma", | ||
"fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)31281-3", | "fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)31281-3", | ||
" | "subspecialties" : "Pulmonology", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "title" : "Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomised, double-blind, placebo-controlled trial", | ||
"pmid" : "28687413", | |||
" | |||
"statusUsableDate" : "2020-06-29", | "statusUsableDate" : "2020-06-29", | ||
" | "abbreviation" : "AMAZES", | ||
"published" : "2017-08-12", | "published" : "2017-08-12", | ||
" | "timestamp" : "2020-07-02T15:32:34Z" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "AMBITION", | |||
"published" : "2015-08-27", | |||
"timestamp" : "2025-06-19T18:32:30Z", | "timestamp" : "2025-06-19T18:32:30Z", | ||
"title" : "Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension", | |||
"statusUsableDate" : "2025-02-26", | |||
"pmid" : "26308684", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1413687", | |||
"briefDesignDescription" : "Combination of ambrisentan & tadalafil vs monotherapy in PAH", | "briefDesignDescription" : "Combination of ambrisentan & tadalafil vs monotherapy in PAH", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1413687", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1413687", | ||
"subspecialties" : "Pulmonology", | |||
"pageid" : 4410, | "pageid" : 4410, | ||
"citation" : "Galiè N, <i>et al</i>. \"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension\". <i>The New England Journal of Medicine</i>. 2015. 373(9):834-44.", | "citation" : "Galiè N, <i>et al</i>. \"Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension\". <i>The New England Journal of Medicine</i>. 2015. 373(9):834-44.", | ||
"expansion" : "Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension", | "expansion" : "Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "AMBITION", | "pageName" : "AMBITION", | ||
"diseases" : "Pulmonary Hypertension", | "diseases" : "Pulmonary Hypertension", | ||
" | "briefResultsDescription" : "Ambrisentan & tadalafil combination therapy resulted in fewer clinical failures than monotherapy" | ||
}, | }, | ||
{ | { | ||
"pmid" : "23808982", | |||
"statusUsableDate" : "2013-08-01", | |||
"title" : "Oral apixaban for the treatment of acute venous thromboembolism", | |||
"timestamp" : "2023-06-22T19:17:55Z", | "timestamp" : "2023-06-22T19:17:55Z", | ||
"published" : "2013-07-01", | |||
"abbreviation" : "AMPLIFY", | |||
"subspecialties" : "Hematology;Pulmonology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1302507", | |||
"briefDesignDescription" : "Apixaban vs. warfarin in VTE", | "briefDesignDescription" : "Apixaban vs. warfarin in VTE", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302507", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302507", | ||
" | "expansion" : "Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy", | ||
"citation" : "Agnelli G, <i>et al</i>. \"Oral apixaban for the treatment of acute venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 369(9):799-808.", | "citation" : "Agnelli G, <i>et al</i>. \"Oral apixaban for the treatment of acute venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 369(9):799-808.", | ||
" | "pageid" : 1609, | ||
"briefResultsDescription" : "Apixaban noninferior to warfarin for VTE recurrence; less bleeding", | "briefResultsDescription" : "Apixaban noninferior to warfarin for VTE recurrence; less bleeding", | ||
" | "diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | ||
"pageName" : "AMPLIFY", | "pageName" : "AMPLIFY", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "AMPLIFY-EXT", | ||
" | "diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | ||
" | "briefResultsDescription" : "Apixaban reduces recurrent VTE", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment", | |||
"pageid" : 1245, | "pageid" : 1245, | ||
"citation" : "Agnelli G, <i>et al</i>. \"Apixaban for extended treatment of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 368(8):699-708.", | "citation" : "Agnelli G, <i>et al</i>. \"Apixaban for extended treatment of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2013. 368(8):699-708.", | ||
"briefDesignDescription" : "Apixaban after VTE treatment", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1207541", | |||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1207541", | ||
"title" : "Apixaban for extended treatment of venous thromboembolism", | |||
"pmid" : "23216615", | |||
"statusUsableDate" : "2013-05-01", | "statusUsableDate" : "2013-05-01", | ||
" | "abbreviation" : "AMPLIFY-EXT", | ||
"published" : "2013-02-21", | "published" : "2013-02-21", | ||
" | "timestamp" : "2023-04-19T12:49:42Z" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "diseases" : "Sepsis;Shock", | ||
" | "briefResultsDescription" : "Corticosteroids reduce mortality in septic shock with adrenal insufficiency", | ||
"pageName" : "Annane Trial", | |||
"pageid" : 939, | "pageid" : 939, | ||
"citation" : "Annane D, <i>et al</i>. \"Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock\". <i>Journal of the American Medical Association</i>. 2002. 288(7):862-871.", | |||
"expansion" : "", | |||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4844/JCE10061.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4844/JCE10061.pdf", | ||
" | "fulltexturl" : "http://jama.jamanetwork.com/article.aspx?articleid", | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
" | "briefDesignDescription" : "Corticosteroids in septic shock", | ||
"published" : "2002-08-21", | "published" : "2002-08-21", | ||
" | "timestamp" : "2020-03-17T17:50:15Z", | ||
"abbreviation" : "Ger-Inf-05", | "abbreviation" : "Ger-Inf-05", | ||
"title" : "Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock | "pmid" : "12186604", | ||
"statusUsableDate" : "2013-02-01", | |||
"title" : "Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "ANNEXA", | ||
"briefResultsDescription" : "Andexanet reverses Xa inhibitors", | |||
"diseases" : "Hemorrhage", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors", | |||
"citation" : "Siegal DM, <i>et al</i>. \"Andexanet alfa for the reversal of factor Xa inhibitor activity\". <i>The New England Journal of Medicine</i>. 2015. 373(25):2413-2424.", | |||
"pageid" : 2502, | |||
"briefDesignDescription" : "Andexanet for reversing Xa inhibitors", | "briefDesignDescription" : "Andexanet for reversing Xa inhibitors", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1510991", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1510991", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510991", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510991", | ||
" | "title" : "Andexanet alfa for the reversal of factor Xa inhibitor activity", | ||
"pmid" : "26559317", | |||
" | |||
"statusUsableDate" : "2017-03-01", | "statusUsableDate" : "2017-03-01", | ||
"abbreviation" : "ANNEXA", | "abbreviation" : "ANNEXA", | ||
" | "timestamp" : "2018-07-11T03:22:16Z", | ||
" | "published" : "2015-12-17" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "Andexanet alfa achieved hemostasis in 80%", | ||
" | "diseases" : "Hemorrhage", | ||
"pageName" : "ANNEXA-4", | |||
"citation" : "Connolly SJ, <i>et al</i>. \"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors\". <i>The New England Journal of Medicine</i>. 2016. 375(12):1131-1141.", | |||
"pageid" : 3641, | "pageid" : 3641, | ||
"expansion" : "Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607887", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1607887", | ||
"subspecialties" : "Hematology;Emergency Medicine;Cardiology", | "subspecialties" : "Hematology;Emergency Medicine;Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1607887", | ||
" | "briefDesignDescription" : "Andexanet alfa for factor Xa inhibitor reversal", | ||
" | "timestamp" : "2019-03-07T17:07:14Z", | ||
"published" : "2016-09-22", | "published" : "2016-09-22", | ||
"abbreviation" : "ANNEXA-4", | "abbreviation" : "ANNEXA-4", | ||
"title" : "Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors | "pmid" : "27573206", | ||
"statusUsableDate" : "2019-02-07", | |||
"title" : "Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2649, | "pageid" : 2649, | ||
"citation" : "Molina JM, <i>et al</i>. \"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2237-2246.", | "citation" : "Molina JM, <i>et al</i>. \"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2237-2246.", | ||
"pageName" : "ANRS IPERGAY", | "pageName" : "ANRS IPERGAY", | ||
"diseases" : "HIV", | "diseases" : "HIV", | ||
"briefResultsDescription" : "Pre-exposure prophylaxis reduces HIV transmission in high-risk men", | |||
"trainingLevel" : "Student", | |||
"title" : "On-demand preexposure prophylaxis in men at high risk for HIV-1 infection", | |||
"pmid" : "26624850", | |||
"statusUsableDate" : "2015-12-01", | |||
"abbreviation" : "ANRS IPERGAY", | "abbreviation" : "ANRS IPERGAY", | ||
" | "published" : "2015-12-03", | ||
" | "timestamp" : "2017-12-03T22:33:27Z", | ||
"briefDesignDescription" : "Pre-exposure prophylaxis in high-risk men", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1506273", | |||
"subspecialties" : "Infectious Disease", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506273" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "", | |||
"published" : "2006-10-01", | |||
"timestamp" : "2016-04-01T23:26:41Z", | "timestamp" : "2016-04-01T23:26:41Z", | ||
"title" : "Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage", | |||
"pmid" : "17030175", | |||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : "http://www.gastrojournal.org/article/S0016-5085(06)01535-6/pdf", | |||
"briefDesignDescription" : "Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed", | "briefDesignDescription" : "Ceftriaxone vs. norfloxacin in cirrhotics with GI bleed", | ||
"fulltexturl" : "http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext", | "fulltexturl" : "http://www.gastrojournal.org/article/S0016-5085(06)01535-6/fulltext", | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | |||
"pageid" : 82, | "pageid" : 82, | ||
"citation" : "Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.", | "citation" : "Fernández J, <i>et al</i>. \"Norfloxacin vs. ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage\". <i>Gastroenterology</i>. 2006. 131(4):1049-56.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "Antibiotics in Cirrhosis with Hemorrhage", | "pageName" : "Antibiotics in Cirrhosis with Hemorrhage", | ||
"diseases" : "Cirrhosis;Gastrointestinal Hemorrhage", | "diseases" : "Cirrhosis;Gastrointestinal Hemorrhage", | ||
" | "briefResultsDescription" : "Ceftriaxone reduces the incidence of bacterial infection" | ||
}, | }, | ||
{ | { | ||
"pageid" : 4441, | "pageid" : 4441, | ||
"citation" : "Lewis G, <i>et al</i>. \"Maintenance or discontinuation of antidepressants in primary care\". <i>The New England Journal of Medicine</i>. 2021. 385(14):1257-1267.", | "citation" : "Lewis G, <i>et al</i>. \"Maintenance or discontinuation of antidepressants in primary care\". <i>The New England Journal of Medicine</i>. 2021. 385(14):1257-1267.", | ||
"expansion" : "Antidepressants to Prevent Relapse in Depression", | "expansion" : "Antidepressants to Prevent Relapse in Depression", | ||
" | "trainingLevel" : "student", | ||
"pageName" : "ANTLER", | "pageName" : "ANTLER", | ||
"diseases" : "Depression", | "diseases" : "Depression", | ||
"briefResultsDescription" : "Maintenance of antidepressants associated with less depression relapse", | |||
"abbreviation" : "ANTLER", | "abbreviation" : "ANTLER", | ||
"published" : "2021-09-30", | |||
"timestamp" : "2021-10-08T13:12:27Z", | |||
"title" : "Maintenance or discontinuation of antidepressants in primary care", | "title" : "Maintenance or discontinuation of antidepressants in primary care", | ||
"pmid" : "34587384" | "statusUsableDate" : "2021-09-30", | ||
"pmid" : "34587384", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2106356", | |||
"briefDesignDescription" : "Maintenance vs. discontinuation of antidepressants", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2106356", | |||
"subspecialties" : "Psychiatry" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Cohen AT, <i>et al</i>. \"Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients\". <i>The New England Journal of Medicine</i>. 2016. 375(6):534-44.", | ||
"pageid" : 3713, | "pageid" : 3713, | ||
" | "expansion" : "Acutely Medically Ill VTE Prevention with Extended Duration Betrixaban", | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
"briefResultsDescription" : "Betrixaban did not meet its primary endpoint", | "briefResultsDescription" : "Betrixaban did not meet its primary endpoint", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | |||
"pageName" : "APEX", | |||
"timestamp" : "2018-11-15T17:21:28Z", | |||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
"abbreviation" : "APEX", | "abbreviation" : "APEX", | ||
"statusUsableDate" : "2018-11-15", | |||
"pmid" : "27232649", | |||
"title" : "Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients", | "title" : "Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1601747", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1601747", | |||
"briefDesignDescription" : "Betrixaban for extended VTE prophylaxis" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Surgery;Infectious Disease", | ||
"fulltexturl" : "https://jamanetwork.com/journals/jama/article-abstract/2703354", | |||
"briefDesignDescription" : "Antibiotics vs. surgery for acute appendicitis", | "briefDesignDescription" : "Antibiotics vs. surgery for acute appendicitis", | ||
"pdfurl" : null, | "pdfurl" : null, | ||
"statusUsableDate" : "2018-07-26", | "statusUsableDate" : "2018-07-26", | ||
"pmid" : "26080338", | |||
"title" : "Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial", | |||
"timestamp" : "2019-01-03T23:02:05Z", | |||
"published" : "2015-06-16", | |||
"abbreviation" : "AAPAC", | |||
"briefResultsDescription" : "Antibiotics not non-inferior to surgeyr", | "briefResultsDescription" : "Antibiotics not non-inferior to surgeyr", | ||
" | "diseases" : "Appendicitis", | ||
"pageName" : "APPAC", | "pageName" : "APPAC", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Appendicitis Acuta", | ||
" | "citation" : "Salminen P, <i>et al</i>. \"Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial\". <i>JAMA</i>. 2018. 320(12):1259-1265.", | ||
" | "pageid" : 3539 | ||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"pageName" : "APROCCHSS", | |||
"briefResultsDescription" : "Hydrocortisone plus fludrocortisone improved survival in septic shock", | |||
"diseases" : "Sepsis", | |||
"citation" : "Annane D, <i>et al</i>. \"Hydrocortisone plus Fludrocortisone for Adults with Septic Shock\". <i>The New England Journal of Medicine</i>. 2018. 378(9):809-818.", | "citation" : "Annane D, <i>et al</i>. \"Hydrocortisone plus Fludrocortisone for Adults with Septic Shock\". <i>The New England Journal of Medicine</i>. 2018. 378(9):809-818.", | ||
" | "pageid" : 3551, | ||
"expansion" : "Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock", | "expansion" : "Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1705716", | ||
" | "briefDesignDescription" : "Steroids in septic shock", | ||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1705716", | |||
"abbreviation" : "APROCCHSS", | |||
"timestamp" : "2021-04-08T18:21:59Z", | |||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
"title" : "Hydrocortisone plus Fludrocortisone for Adults with Septic Shock", | "title" : "Hydrocortisone plus Fludrocortisone for Adults with Septic Shock", | ||
"pmid" : "29490185" | "pmid" : "29490185", | ||
"statusUsableDate" : "2021-03-30" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Acute Respiratory Distress Syndrome Network", | ||
" | "citation" : "Brower RG, <i>et al</i>. \"Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2000. 342(18):1301-1308.", | ||
"pageid" : 114, | "pageid" : 114, | ||
" | "briefResultsDescription" : "Mortality benefit and more ventilator-free days with lung-protective strategy", | ||
"diseases" : "Acute Respiratory Distress Syndrome", | |||
"pageName" : "ARDSNet", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pmid" : "10793162", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "Ventilation With Lower Tidal Volumes As Compared With Traditional Tidal Volumes For Acute Lung Injury And The Acute Respiratory Distress Syndrome", | ||
"timestamp" : "2021-02-23T14:31:34Z", | |||
"published" : "2000-05-04", | "published" : "2000-05-04", | ||
"abbreviation" : "ARDSNet", | "abbreviation" : "ARDSNet", | ||
" | "subspecialties" : "Critical Care", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200005043421801", | ||
"briefDesignDescription" : "Low vs. traditional volumes in ARDS", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200005043421801" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2025-06-05", | |||
"pmid" : "19064828", | |||
"title" : "Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy", | |||
"published" : "2008-12-08", | |||
"timestamp" : "2025-06-05T17:23:41Z", | "timestamp" : "2025-06-05T17:23:41Z", | ||
"abbreviation" : "ARIC", | |||
"fulltexturl" : "http://archinte.jamanetwork.com/article.aspx?articleid", | |||
"subspecialties" : "Endocrinology", | |||
"briefDesignDescription" : "HbA1c and CKD risk in DM", | "briefDesignDescription" : "HbA1c and CKD risk in DM", | ||
" | "pdfurl" : "http://archinte.jamanetwork.com/article.aspx?articleid", | ||
"expansion" : "Atherosclerosis Risk in Communities", | |||
"pageid" : 2701, | "pageid" : 2701, | ||
"citation" : "Bash LD, <i>et al</i>. \"Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy\". <i>Archives of Internal Medicine</i>. 2008. 168(22):2440-2447.", | "citation" : "Bash LD, <i>et al</i>. \"Poor Glycemic Control in Diabetes and the Risk of Incident Chronic Kidney Disease Even in the Absence of Albuminuria and Retinopathy\". <i>Archives of Internal Medicine</i>. 2008. 168(22):2440-2447.", | ||
" | "diseases" : "Diabetes Mellitus;Diabetic Nephropathy", | ||
"briefResultsDescription" : "Elevated HbA1c increases risk of CKD", | "briefResultsDescription" : "Elevated HbA1c increases risk of CKD", | ||
"pageName" : "ARIC A1c and CKD", | "pageName" : "ARIC A1c and CKD", | ||
" | "trainingLevel" : "Fellow" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1404380", | ||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "EGDT vs. usual care in sepsis", | "briefDesignDescription" : "EGDT vs. usual care in sepsis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404380", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1404380", | ||
" | "pmid" : "25272316", | ||
"statusUsableDate" : "2014-11-01", | "statusUsableDate" : "2014-11-01", | ||
" | "title" : "Goal-directed resuscitation for patients with early septic shock", | ||
"published" : "2014-10-16", | "published" : "2014-10-16", | ||
"timestamp" : "2017-12-03T22:33:28Z", | |||
"abbreviation" : "ARISE", | |||
"diseases" : "Sepsis", | |||
"briefResultsDescription" : "EGDT doesn't reduce mortality in sepsis", | |||
"pageName" : "ARISE", | "pageName" : "ARISE", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "Australasian Resuscitation in Sepsis Evaluation", | ||
" | "pageid" : 2216, | ||
"citation" : "ARISE and ANZICS writers. \"Goal-directed resuscitation for patients with early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 371(16):1496-1506." | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation", | ||
"pageid" : 1497, | "pageid" : 1497, | ||
" | "citation" : "Granger CB, <i>et al</i>. \"Apixaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(11):981-982.", | ||
"diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | |||
"briefResultsDescription" : "Apixaban better for CVA prevention in AF", | |||
"pageName" : "ARISTOTLE", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pmid" : "21870978", | ||
"statusUsableDate" : "2013-06-01", | "statusUsableDate" : "2013-06-01", | ||
" | "title" : "Apixaban versus warfarin in patients with atrial fibrillation", | ||
"published" : "2011-09-15", | "published" : "2011-09-15", | ||
" | "timestamp" : "2018-03-29T18:55:04Z", | ||
"abbreviation" : "ARISTOTLE", | "abbreviation" : "ARISTOTLE", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1107039", | ||
" | "subspecialties" : "Cardiology;Neurology", | ||
"briefDesignDescription" : "Apixaban vs. warfarin in AF", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107039" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Adjunctive rifampicin for Staphylococcus Aureus Bacteraemia", | ||
" | "citation" : "Thwaites GE, <i>et al</i>. \"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial\". <i>The Lancet</i>. 2017. 391(10121):668-678.", | ||
"pageid" : 3569, | "pageid" : 3569, | ||
" | "pageName" : "ARREST", | ||
"briefResultsDescription" : "Adjunctive rifampin does not reduce mortality in S. aureus bacteremia", | |||
"diseases" : "Bacteremia", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial", | ||
" | "pmid" : "29249276", | ||
"statusUsableDate" : "2019-07-31", | "statusUsableDate" : "2019-07-31", | ||
" | "abbreviation" : "ARREST", | ||
"timestamp" : "2019-08-02T19:20:32Z", | |||
"published" : "2017-12-14", | "published" : "2017-12-14", | ||
" | "briefDesignDescription" : "Rifampin in S. aureus bacteremia", | ||
" | "subspecialties" : "Infectious Disease", | ||
" | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32456-X/fulltext", | ||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32456-X.pdf" | |||
" | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2019-10-17T17:40:06Z", | "timestamp" : "2019-10-17T17:40:06Z", | ||
" | "published" : "2019-01-31", | ||
"abbreviation" : "ART", | |||
"statusUsableDate" : "2019-02-02", | |||
"pmid" : "30699314", | |||
"title" : "Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1610021", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1610021", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1610021", | ||
"briefDesignDescription" : "Bilateral vs. single IMA graft in multivessel CAD", | |||
"citation" : "Taggart DP, <i>et al</i>. \"Bilateral versus Single Internal-Thoracic-Artery Grafts at 10 Years\". <i>The New England Journal of Medicine</i>. 2019. 380(5):437-446.", | |||
"pageid" : 3756, | "pageid" : 3756, | ||
" | "expansion" : "Arterial Revascularization Trial", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Single IMA grafting non-inferior to bilateral IMA grafting in multivessel CAD", | "briefResultsDescription" : "Single IMA grafting non-inferior to bilateral IMA grafting in multivessel CAD", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "pageName" : "ART" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Apixaban for the Reduction of Thromboembolism in Patients with Device-Detected Subclinical Atrial Fibrillation", | ||
"pageid" : 5604, | "pageid" : 5604, | ||
" | "citation" : "Healey JS, <i>et al</i>. \"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2023. 390(2):107-117.", | ||
"diseases" : "Atrial Fibrillation", | |||
"briefResultsDescription" : "Apixaban reduced stroke, but increased major bleeding", | |||
"pageName" : "ARTESIA", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "37952132", | ||
"statusUsableDate" : "2025-01-30", | "statusUsableDate" : "2025-01-30", | ||
" | "title" : "Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation", | ||
"published" : "2023-11-12", | "published" : "2023-11-12", | ||
" | "timestamp" : "2025-01-30T19:13:30Z", | ||
"abbreviation" : "ARTESIA", | "abbreviation" : "ARTESIA", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2310234", | ||
" | "subspecialties" : "Cardiology", | ||
"briefDesignDescription" : "Apixaban vs. aspirin in subclinical AF", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2310234" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "ASCEND", | |||
"published" : "2018-08-26", | |||
"timestamp" : "2019-09-03T18:02:52Z", | "timestamp" : "2019-09-03T18:02:52Z", | ||
"title" : "Effects of aspirin for primary prevention in persons with diabetes mellitus", | |||
"statusUsableDate" : "2018-09-06", | |||
"pmid" : "30146931", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1804988", | |||
"briefDesignDescription" : "Aspirin for vascular disease prevention in DM", | "briefDesignDescription" : "Aspirin for vascular disease prevention in DM", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1804988", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1804988", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 3698, | "pageid" : 3698, | ||
"citation" : "Bowman L, <i>et al</i>. \"Effects of aspirin for primary prevention in persons with diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2018. epub 2018-08-26:1-11.", | "citation" : "Bowman L, <i>et al</i>. \"Effects of aspirin for primary prevention in persons with diabetes mellitus\". <i>The New England Journal of Medicine</i>. 2018. epub 2018-08-26:1-11.", | ||
"expansion" : "A Study of Cardiovascular Events in Diabetes", | "expansion" : "A Study of Cardiovascular Events in Diabetes", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "ASCEND (Aspirin)", | "pageName" : "ASCEND (Aspirin)", | ||
"diseases" : "Diabetes", | "diseases" : "Diabetes", | ||
" | "briefResultsDescription" : "Aspirin reduces cardiovascular events but increases bleeding vs. placebo" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "ASCEND", | |||
"published" : "2014-05-29", | |||
"timestamp" : "2018-09-13T17:56:54Z", | "timestamp" : "2018-09-13T17:56:54Z", | ||
"title" : "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", | |||
"statusUsableDate" : "2014-07-01", | |||
"pmid" : "24836312", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402582", | |||
"briefDesignDescription" : "Pirfenidone in IPF", | "briefDesignDescription" : "Pirfenidone in IPF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402582", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402582", | ||
"subspecialties" : "Pulmonology", | |||
"pageid" : 1825, | "pageid" : 1825, | ||
"citation" : "King TE, <i>et al</i>. \"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2083-2092.", | "citation" : "King TE, <i>et al</i>. \"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2083-2092.", | ||
"expansion" : "Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis", | "expansion" : "Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis", | ||
" | "trainingLevel" : "Fellow", | ||
"pageName" : "ASCEND (IPF)", | "pageName" : "ASCEND (IPF)", | ||
"diseases" : "Pulmonary Fibrosis", | "diseases" : "Pulmonary Fibrosis", | ||
" | "briefResultsDescription" : "Pirfenidone reduces progression of IPF" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "ASPEN", | ||
"briefResultsDescription" : "Similar efficacy, zanubrutinib perhaps less toxic", | |||
"diseases" : "Waldenström Macroglobulinemia;Lymphoma", | |||
"trainingLevel" : "Fellow", | |||
"expansion" : "", | |||
"citation" : "Tam C, <i>et al</i>. \"ASPEN\". <i>Blood</i>. 2020. 136(18):2038-2050.", | |||
"pageid" : 4448, | |||
"briefDesignDescription" : "Zanubrutinib vs. ibrutinib in WM", | "briefDesignDescription" : "Zanubrutinib vs. ibrutinib in WM", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs", | "fulltexturl" : "https://ashpublications.org/blood/article/136/18/2038/461625/A-randomized-phase-3-trial-of-zanubrutinib-vs", | ||
"pdfurl" : "https://ashpublications.org/blood/article-pdf/136/18/2038/1779238/bloodbld2020006844.pdf", | "pdfurl" : "https://ashpublications.org/blood/article-pdf/136/18/2038/1779238/bloodbld2020006844.pdf", | ||
" | "title" : "ASPEN", | ||
"statusUsableDate" : "2021-11-30", | "statusUsableDate" : "2021-11-30", | ||
" | "pmid" : "32731259", | ||
"abbreviation" : "ASPEN", | "abbreviation" : "ASPEN", | ||
" | "timestamp" : "2025-06-19T18:36:44Z", | ||
" | "published" : "2020-10-29" | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "ASA probably reduces recurrent VTE", | ||
"diseases" : "Venous Thromboembolism", | |||
" | "pageName" : "ASPIRE", | ||
" | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"expansion" : "Aspirin to Prevent Recurrent Venous Thromboembolism", | |||
"citation" : "Brighton TA, <i>et al</i>. \"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 367(21):1979-1987.", | "citation" : "Brighton TA, <i>et al</i>. \"Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 367(21):1979-1987.", | ||
"pageid" : 1241, | |||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210384", | ||
"briefDesignDescription" : "Aspirin after VTE treatment", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210384", | |||
"statusUsableDate" : "2013-08-01", | "statusUsableDate" : "2013-08-01", | ||
" | "pmid" : "23121403", | ||
"title" : "Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism", | |||
"timestamp" : "2017-12-03T22:33:32Z", | |||
"published" : "2012-11-04", | "published" : "2012-11-04", | ||
"abbreviation" : "ASPIRE" | |||
"abbreviation" : "ASPIRE | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Aspirin for ASCVD 1° prevention if age >70", | "briefDesignDescription" : "Aspirin for ASCVD 1° prevention if age >70", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800722", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800722", | ||
" | "subspecialties" : "Preventive Medicine;Cardiology", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800722", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800722", | ||
" | "title" : "Effect of aspirin on disability-free survival in the healthy elderly", | ||
"pmid" : "30221596", | |||
" | |||
"statusUsableDate" : "2019-05-23", | "statusUsableDate" : "2019-05-23", | ||
" | "abbreviation" : "ASPREE", | ||
"published" : "2018-09-16", | "published" : "2018-09-16", | ||
"timestamp" : "2025-05-22T17:33:23Z", | |||
"pageName" : "ASPREE", | "pageName" : "ASPREE", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Aspirin without 1° prevention benefit in adults >70 years", | ||
" | "trainingLevel" : "Student", | ||
"expansion" : "Aspirin in Reducing Events in the Elderly", | |||
"pageid" : 3709, | |||
"citation" : "McNeil JJ, <i>et al</i>. \"Effect of aspirin on disability-free survival in the healthy elderly\". <i>The New England Journal of Medicine</i>. 2018. 379(16):1-10." | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-01-04T18:44:16Z", | "title" : "Revascularization versus medical therapy for renal-artery stenosis", | ||
"pmid" : "19907042", | |||
"statusUsableDate" : "2013-09-01", | |||
"abbreviation" : "ASTRAL", | |||
"published" : "2009-11-12", | |||
"timestamp" : "2018-01-04T18:44:16Z", | |||
"briefDesignDescription" : "Revascularization in RAS", | "briefDesignDescription" : "Revascularization in RAS", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0905368", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0905368", | ||
"subspecialties" : "Nephrology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905368", | |||
"expansion" : "Angioplasty and Stenting for Renal Artery Lesions", | |||
"pageid" : 1684, | "pageid" : 1684, | ||
"citation" : "Wheatley K, <i>et al</i>. \"Revascularization versus medical therapy for renal-artery stenosis\". <i>The New England Journal of Medicine</i>. 2009. 361(20):1953-1962.", | "citation" : "Wheatley K, <i>et al</i>. \"Revascularization versus medical therapy for renal-artery stenosis\". <i>The New England Journal of Medicine</i>. 2009. 361(20):1953-1962.", | ||
"pageName" : "ASTRAL", | "pageName" : "ASTRAL", | ||
"diseases" : "Renal Artery Stenosis;Hypertension", | "diseases" : "Renal Artery Stenosis;Hypertension", | ||
" | "briefResultsDescription" : "Revascularization no better than medical therapy alone in RAS", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Khanna A <i>et al</i>. \"Angiotensin II for the Treatment of Vasodilatory Shock\". <i>New Engl J Med</i>. 2017. 377:419-30.", | ||
"pageid" : 2950, | "pageid" : 2950, | ||
" | "expansion" : "Angiotensin II for the Treatment of High-Output Shock", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "ATHOS-3", | ||
"briefResultsDescription" : "Angiotensin II superior to placebo in vasodilatory shock", | "briefResultsDescription" : "Angiotensin II superior to placebo in vasodilatory shock", | ||
"diseases" : "Shock", | "diseases" : "Shock", | ||
"abbreviation" : "ATHOS-3", | "abbreviation" : "ATHOS-3", | ||
"timestamp" : "2019-09-11T15:27:57Z", | |||
"published" : "2017-08-03", | |||
"title" : "Angiotensin II for the Treatment of Vasodilatory Shock", | "title" : "Angiotensin II for the Treatment of Vasodilatory Shock", | ||
"pmid" : "28528561" | "pmid" : "28528561", | ||
"statusUsableDate" : "2017-08-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1704154", | |||
"briefDesignDescription" : "Angiotensin II vs. placebo in vasodilatory shock", | |||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1704154" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Fellow", | ||
" | "diseases" : "Breast Cancer", | ||
" | "briefResultsDescription" : "10 years of tamoxifen reduces recurrence and mortality", | ||
"pageName" : "ATLAS", | |||
"pageid" : 1581, | "pageid" : 1581, | ||
"citation" : "Davies C, <i>et al</i>. \"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial\". <i>The Lancet</i>. 2013. 381(9869):805-16.", | |||
"expansion" : "Adjuvant Tamoxifen: Longer Against Shorter", | |||
"pdfurl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/fulltext", | "pdfurl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/fulltext", | ||
" | "fulltexturl" : "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/", | ||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
" | "briefDesignDescription" : "10y vs. 5y tamoxifen in breast cancer", | ||
"published" : "2013-03-09", | "published" : "2013-03-09", | ||
" | "timestamp" : "2017-12-03T22:33:36Z", | ||
"abbreviation" : "ATLAS", | "abbreviation" : "ATLAS", | ||
"title" : "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial | "pmid" : "23219286", | ||
"statusUsableDate" : "2013-10-01", | |||
"title" : "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112277", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1112277", | |||
"briefDesignDescription" : "Rivaroxaban after ACS", | "briefDesignDescription" : "Rivaroxaban after ACS", | ||
" | "timestamp" : "2017-12-03T22:33:37Z", | ||
" | "published" : "2012-01-05", | ||
" | "abbreviation" : "ATLAS ACS 2-TIMI 51", | ||
"pmid" : "22077192", | |||
"statusUsableDate" : "2013-03-01", | |||
"title" : "Rivaroxaban in Patients with Recent Acute Coronary Syndrome", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Rivaroxaban reduces cardiovascular death, MI, and stroke, but increases nonfatal bleeding", | "briefResultsDescription" : "Rivaroxaban reduces cardiovascular death, MI, and stroke, but increases nonfatal bleeding", | ||
" | "diseases" : "Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction", | ||
"pageName" : "ATLAS ACS-2, TIMI 51", | "pageName" : "ATLAS ACS-2, TIMI 51", | ||
" | "citation" : "Mega JL, <i>et al</i>. \"Rivaroxaban in Patients with Recent Acute Coronary Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 366(1):9-19.", | ||
" | "pageid" : 174, | ||
" | "expansion" : "Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "Intensive RRT yields similar mortality as conventional RRT in critically ill patients with ATN", | ||
" | "diseases" : "Acute Kidney Injury;Critical Illness", | ||
"pageName" : "ATN", | |||
"citation" : "Palevsky PM, <i>et al</i>. \"Intensity of renal support in critically ill patients with acute kidney injury\". <i>The New England Journal of Medicine</i>. 2008. 359(1):7-20.", | |||
"pageid" : 2339, | "pageid" : 2339, | ||
"expansion" : "Acute Renal Failure Trial Network Study", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802639", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802639", | ||
"subspecialties" : "Nephrology;Critical Care", | "subspecialties" : "Nephrology;Critical Care", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0802639", | ||
" | "briefDesignDescription" : "RRT intensity in ATN", | ||
" | "timestamp" : "2017-12-03T22:33:39Z", | ||
"published" : "2008-07-03", | "published" : "2008-07-03", | ||
"abbreviation" : "ATN", | "abbreviation" : "ATN", | ||
"title" : "Intensity of renal support in critically ill patients with acute kidney injury | "statusUsableDate" : "2015-03-01", | ||
"pmid" : "18492867", | |||
"title" : "Intensity of renal support in critically ill patients with acute kidney injury" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805689", | ||
"briefDesignDescription" : "Tafamidis vs. placebo in amyloid cardiomyopathy", | "briefDesignDescription" : "Tafamidis vs. placebo in amyloid cardiomyopathy", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1805689", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1805689", | ||
" | "abbreviation" : "ATTR-ACT", | ||
" | "timestamp" : "2019-05-21T14:25:21Z", | ||
"published" : "2018-08-27", | |||
"title" : "Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy", | |||
"statusUsableDate" : "2018-09-05", | |||
"pmid" : "30145929", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "ATTR-ACT", | ||
"briefResultsDescription" : "Tafamidis superior to placebo in amyloid cardiomyopathy", | "briefResultsDescription" : "Tafamidis superior to placebo in amyloid cardiomyopathy", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "citation" : "Maurer MS, <i>et al</i>. \"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2018. 379(11):1007-1016.", | ||
"pageid" : 3696, | |||
" | "expansion" : "The Transthyretin Amyloidosis Cardiomyopathy Clinical Trial" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Vedantham S, <i>et al</i>. \"Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis\". <i>The New England Journal of Medicine</i>. 2017. 377(23):2240-2252.", | ||
"pageid" : 3546, | "pageid" : 3546, | ||
" | "expansion" : "Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis", | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
"briefResultsDescription" : "No difference with intervention vs. anticoagulation", | "briefResultsDescription" : "No difference with intervention vs. anticoagulation", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Post-Thrombotic Syndrome", | |||
"pageName" : "ATTRACT", | |||
"timestamp" : "2019-07-17T05:12:53Z", | |||
"published" : "2017-12-07", | "published" : "2017-12-07", | ||
"abbreviation" : "ATTRACT", | "abbreviation" : "ATTRACT", | ||
"statusUsableDate" : "2018-07-19", | |||
"pmid" : "29211671", | |||
"title" : "Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis", | "title" : "Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1615066", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1615066", | |||
"briefDesignDescription" : "Pharmacomechanical therapy vs. anticoagulation in DVT" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2019-10-17", | |||
"pmid" : "30883055", | |||
"title" : "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", | |||
"timestamp" : "2025-05-22T17:32:42Z", | "timestamp" : "2025-05-22T17:32:42Z", | ||
"published" : "2019-04-18", | |||
"abbreviation" : "AUGUSTUS", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1817083", | |||
"briefDesignDescription" : "DOAC, VKA, antiplatelets after PCI with stent and AF", | "briefDesignDescription" : "DOAC, VKA, antiplatelets after PCI with stent and AF", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817083", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817083", | ||
" | "expansion" : "An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention", | ||
"citation" : "Lopes RD, <i>et al</i>. \"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2019. 380(16):1509-1524.", | "citation" : "Lopes RD, <i>et al</i>. \"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2019. 380(16):1509-1524.", | ||
" | "pageid" : 3947, | ||
"briefResultsDescription" : "Apixaban with lower bleeding", | "briefResultsDescription" : "Apixaban with lower bleeding", | ||
" | "diseases" : "Coronary Artery Disease;Atrial Fibrillation", | ||
"pageName" : "AUGUSTUS", | "pageName" : "AUGUSTUS", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007432", | ||
"briefDesignDescription" : "Apixaban vs. ASA in AF", | "briefDesignDescription" : "Apixaban vs. ASA in AF", | ||
"subspecialties" : "Cardiology;Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1007432", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1007432", | ||
" | "abbreviation" : "AVERROES", | ||
" | "timestamp" : "2017-12-03T22:33:40Z", | ||
"published" : "2011-03-03", | |||
"title" : "Apixaban in patients with atrial fibrillation", | |||
"pmid" : "21309657", | |||
"statusUsableDate" : "2013-11-01", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "AVERROES", | ||
"briefResultsDescription" : "Apixaban better than ASA without increased bleeding in AF", | "briefResultsDescription" : "Apixaban better than ASA without increased bleeding in AF", | ||
"diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | "diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | ||
" | "citation" : "Connolly SJ, <i>et al</i>. \"Apixaban in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 364(9):806-817.", | ||
"pageid" : 1718, | |||
" | "expansion" : "Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "AVERT", | |||
"published" : "2018-12-04", | |||
"timestamp" : "2019-02-05T14:44:30Z", | "timestamp" : "2019-02-05T14:44:30Z", | ||
"briefDesignDescription" : "Apixaban for VTE prevention in cancer", | "title" : "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer", | ||
"pmid" : "30511879", | |||
"statusUsableDate" : "2019-01-31", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814468", | |||
"briefDesignDescription" : "Apixaban for VTE prevention in cancer", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1814468", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1814468", | ||
"subspecialties" : "Hematology;Oncology", | |||
"pageid" : 3752, | "pageid" : 3752, | ||
"citation" : "Carrier M, <i>et al</i>. \"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer\". <i>The New England Journal of Medicine</i>. 2018. E-pub 2018-12-04:1-8.", | "citation" : "Carrier M, <i>et al</i>. \"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer\". <i>The New England Journal of Medicine</i>. 2018. E-pub 2018-12-04:1-8.", | ||
"expansion" : "Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients", | "expansion" : "Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "AVERT", | "pageName" : "AVERT", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | "diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | ||
" | "briefResultsDescription" : "Apixaban reduces risk of VTE, increases risk of bleeding" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Comparing Oxygen with normal air in patients with ST-Segment Elevation Myocardial Infarction who are not hypoxic.", | ||
"pageid" : 2930, | "pageid" : 2930, | ||
"citation" : "Stub D, <i>et al</i>. \"Air Versus Oxygen in ST-Segment Elevation Myocardial Infarction\". <i>Circulation</i>. 2015. 131(24):2143-2150.", | "citation" : "Stub D, <i>et al</i>. \"Air Versus Oxygen in ST-Segment Elevation Myocardial Infarction\". <i>Circulation</i>. 2015. 131(24):2143-2150.", | ||
"pageName" : "AVOID", | "pageName" : "AVOID", | ||
"diseases" : "Myocardial Infarction", | "diseases" : "Myocardial Infarction", | ||
"briefResultsDescription" : "No benefit from in non-hypoxemic patients with STEMI", | |||
"trainingLevel" : "Intern", | |||
"title" : "Air Versus Oxygen in ST-Segment Elevation Myocardial Infarction", | |||
"statusUsableDate" : "2017-09-01", | |||
"pmid" : "26002889", | |||
"abbreviation" : "AVOID", | "abbreviation" : "AVOID", | ||
" | "published" : "2015-05-22", | ||
" | "timestamp" : "2017-12-03T22:33:41Z", | ||
"briefDesignDescription" : "Supplemental oxygen in STEMI", | |||
"fulltexturl" : "http://circ.ahajournals.org/content/131/24/2143", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://circ.ahajournals.org/content/131/24/2143.full.pdf" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "HIV", | ||
" | "briefResultsDescription" : "Zidovudine reduces mortality in HIV/AIDS", | ||
" | "pageName" : "AZT Trial", | ||
"trainingLevel" : "Student", | |||
"expansion" : "", | |||
"pageid" : 1775, | "pageid" : 1775, | ||
"citation" : "Fischl MA <i>et al</i>. \"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex\". <i>The New England Journal of Medicine</i>. 1987. 317(4):185-191.", | "citation" : "Fischl MA <i>et al</i>. \"The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex\". <i>The New England Journal of Medicine</i>. 1987. 317(4):185-191.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198707233170401", | |||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
" | "briefDesignDescription" : "Zidovudine in HIV/AIDS", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198707233170401", | |||
"pmid" : "3299089", | |||
"statusUsableDate" : "2014-01-01", | "statusUsableDate" : "2014-01-01", | ||
" | "title" : "The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex", | ||
"published" : "1987-07-23", | "published" : "1987-07-23", | ||
" | "timestamp" : "2017-12-03T22:33:42Z", | ||
"abbreviation" : "" | |||
"abbreviation" : " | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode", | ||
"pageid" : 4250, | "pageid" : 4250, | ||
"citation" : "Jondeau G, <i>et al</i>. \"B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode\". <i>Eur Heart J</i>. 2009. 30(18):2186-2192.", | "citation" : "Jondeau G, <i>et al</i>. \"B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode\". <i>Eur Heart J</i>. 2009. 30(18):2186-2192.", | ||
" | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Beta-blocker withdrawal not needed in ADHF", | ||
"pageName" : "B-CONVINCED", | |||
"trainingLevel" : "Student", | |||
"statusUsableDate" : "2020-08-20", | "statusUsableDate" : "2020-08-20", | ||
" | "pmid" : "19717851", | ||
"title" : "B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode", | |||
"published" : "2009-08-30", | "published" : "2009-08-30", | ||
" | "timestamp" : "2020-08-20T18:18:36Z", | ||
"abbreviation" : "B-CONVINCED", | "abbreviation" : "B-CONVINCED", | ||
" | "fulltexturl" : "https://doi.org/10.1093/eurheartj/ehp323", | ||
" | "subspecialties" : "Cardiology", | ||
"briefDesignDescription" : "Beta-blocker withdrawal in ADHF", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "CABG is superior to OMT in diabetics with CAD", | ||
" | "diseases" : "Coronary Artery Disease;Diabetes Mellitus", | ||
"pageName" : "BARI 2D", | |||
"citation" : "Frye RL, <i>et al</i>. \"A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(24):2503-2515.", | |||
"pageid" : 1471, | "pageid" : 1471, | ||
"expansion" : "Bypass Angioplasty Revascularization Investigation 2 Diabetes", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805796", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805796", | ||
"subspecialties" : "Cardiology;Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0805796", | ||
" | "briefDesignDescription" : "CABG/PCI vs. OMT in diabetes with CAD", | ||
" | "timestamp" : "2017-12-03T22:33:47Z", | ||
"published" : "2009-06-11", | "published" : "2009-06-11", | ||
"abbreviation" : "BARI 2D", | "abbreviation" : "BARI 2D", | ||
"title" : "A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease | "statusUsableDate" : "2013-06-01", | ||
"pmid" : "19502645", | |||
"title" : "A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "BASALT", | ||
"diseases" : "Asthma", | |||
"briefResultsDescription" : "Symptom-, biomarker-, and physician-based treatments are similar", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Best Adjustment Strategy for Asthma in the Long Term", | |||
"pageid" : 1864, | |||
"citation" : "Calhoun WJ, <i>et al</i>. \"Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial\". <i>Journal of the American Medical Association</i>. 2012. 308(10):987-997.", | |||
"briefDesignDescription" : "Symptom-based asthma therapy", | "briefDesignDescription" : "Symptom-based asthma therapy", | ||
"fulltexturl" : "http://bit.ly/1FNk0v0", | "fulltexturl" : "http://bit.ly/1FNk0v0", | ||
" | "subspecialties" : "Pulmonology", | ||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/24854/joc120069_987_997.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/24854/joc120069_987_997.pdf", | ||
" | "title" : "Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: The BASALT randomized controlled trial", | ||
"pmid" : "22968888", | |||
" | |||
"statusUsableDate" : "2015-03-01", | "statusUsableDate" : "2015-03-01", | ||
" | "abbreviation" : "BASALT", | ||
"published" : "2012-09-12", | "published" : "2012-09-12", | ||
" | "timestamp" : "2017-12-03T22:33:48Z" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Tisa-cel vs. ASCT in R/R DLBCL", | "briefDesignDescription" : "Tisa-cel vs. ASCT in R/R DLBCL", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2116596", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2116596", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116596", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2116596", | ||
" | "title" : "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma", | ||
"statusUsableDate" : "2023-12-14", | "statusUsableDate" : "2023-12-14", | ||
" | "pmid" : "34904798", | ||
"abbreviation" : "BELINDA", | |||
"timestamp" : "2023-12-15T03:08:03Z", | |||
"published" : "2022-02-17", | "published" : "2022-02-17", | ||
"pageName" : "BELINDA", | "pageName" : "BELINDA", | ||
"briefResultsDescription" : "CART did not improve PFS compared to ASCT", | |||
"diseases" : "Lymphoma;Aggressive B-cell lymphoma", | "diseases" : "Lymphoma;Aggressive B-cell lymphoma", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "", | ||
" | "citation" : "Bishop MR, <i>et al</i>. \"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma\". <i>The New England Journal of Medicine</i>. 2022. 368(7):629-639.", | ||
"pageid" : 4462 | |||
}, | }, | ||
{ | { | ||
"title" : "Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency", | |||
"statusUsableDate" : "2016-02-01", | |||
"pmid" : "16407508", | |||
"abbreviation" : "", | |||
"published" : "2006-01-12", | |||
"timestamp" : "2017-12-03T22:33:54Z", | "timestamp" : "2017-12-03T22:33:54Z", | ||
"briefDesignDescription" : "Benazepril in non-diabetic CKD", | "briefDesignDescription" : "Benazepril in non-diabetic CKD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa053107", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa053107", | ||
"subspecialties" : "Nephrology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa053107", | |||
"expansion" : "", | |||
"pageid" : 2674, | "pageid" : 2674, | ||
"citation" : "Hou FF, <i>et al</i>. \"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency\". <i>The New England Journal of Medicine</i>. 2006. 354(2):131-140.", | "citation" : "Hou FF, <i>et al</i>. \"Effect and Safety of Benazepril for Advanced Chronic Renal Insufficiency\". <i>The New England Journal of Medicine</i>. 2006. 354(2):131-140.", | ||
"pageName" : "Benazepril in Severe CKD", | "pageName" : "Benazepril in Severe CKD", | ||
"diseases" : "Chronic Kidney Disease", | "diseases" : "Chronic Kidney Disease", | ||
" | "briefResultsDescription" : "Benazepril improves renal outcomes in non-diabetic CKD", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "BeSt", | |||
"diseases" : "Rheumatoid Arthritis", | |||
"briefResultsDescription" : "Combination therapy produces early functional improvement than DMARD alone", | |||
"pageid" : 77, | |||
"citation" : "Goekoop-Ruiterman YP, <i>et al</i>. \"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis\". <i>Arthritis & Rheumatism</i>. 2005. 52(11):3381-3390.", | |||
"expansion" : "Behandel-Strategeieën (\"treatment strategies\" in Dutch)", | |||
"pdfurl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/pdf", | |||
"briefDesignDescription" : "DMARD ± prednisone or infliximab in RA", | "briefDesignDescription" : "DMARD ± prednisone or infliximab in RA", | ||
"fulltexturl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract", | "fulltexturl" : "http://onlinelibrary.wiley.com/doi/10.1002/art.21405/abstract", | ||
"subspecialties" : "Rheumatology", | "subspecialties" : "Rheumatology", | ||
" | "abbreviation" : "BeSt", | ||
"published" : "2005-11-01", | "published" : "2005-11-01", | ||
" | "timestamp" : "2022-04-17T20:47:43Z", | ||
"title" : "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis", | "title" : "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis", | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "16258899" | "pmid" : "16258899" | ||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "PCI inferior to CABG for multivessel disease", | |||
"diseases" : "Coronary Artery Disease", | |||
"pageName" : "BEST", | |||
"citation" : "Reardon MJ, <i>et al</i>. \"Trial of everolimus-eluting stents or bypass surgery for coronary disease\". <i>The New England Journal of Medicine</i>. 2015. 372(13):1204-12.", | "citation" : "Reardon MJ, <i>et al</i>. \"Trial of everolimus-eluting stents or bypass surgery for coronary disease\". <i>The New England Journal of Medicine</i>. 2015. 372(13):1204-12.", | ||
"pageid" : 2916, | |||
"expansion" : "The Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1415447", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1415447", | ||
" | "briefDesignDescription" : "PCI vs. CABG for multivessel disease", | ||
" | "timestamp" : "2017-12-03T22:33:49Z", | ||
"published" : "2015-03-26", | "published" : "2015-03-26", | ||
"abbreviation" : "BEST", | "abbreviation" : "BEST", | ||
"title" : "Trial of everolimus-eluting stents or bypass surgery for coronary disease | "statusUsableDate" : "2017-05-01", | ||
"pmid" : "25774645", | |||
"title" : "Trial of everolimus-eluting stents or bypass surgery for coronary disease" | |||
}, | }, | ||
{ | { | ||
"pageid" : 3721, | "pageid" : 3721, | ||
"citation" : "Jaber S, <i>et al</i>. \"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial\". <i>The Lancet</i>. 2018. 392(10141):31-40.", | "citation" : "Jaber S, <i>et al</i>. \"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial\". <i>The Lancet</i>. 2018. 392(10141):31-40.", | ||
"expansion" : "Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill: A Multiple Center Randomized Clinical Trial", | "expansion" : "Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill: A Multiple Center Randomized Clinical Trial", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Metabolic Acidosis;Critical Illness", | |||
"briefResultsDescription" : "No improvement in death with sodium bicarb in ICU patients", | "briefResultsDescription" : "No improvement in death with sodium bicarb in ICU patients", | ||
"pageName" : "BICAR-ICU", | |||
"published" : "2018-07-07", | "published" : "2018-07-07", | ||
" | "timestamp" : "2019-03-05T05:23:16Z", | ||
"abbreviation" : "BICAR-ICU", | "abbreviation" : "BICAR-ICU", | ||
"statusUsableDate" : "2019-02-28", | |||
"pmid" : "29910040", | |||
"title" : "Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial", | "title" : "Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial", | ||
" | "pdfurl" : "", | ||
"fulltexturl" : "https://doi.org/10.1016/S0140-6736(18)31080-8", | |||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "Bicarbonate in severe metabolic acidosis" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210356", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210356", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210356", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "RV pacing vs. BiV pacing in HF with AV block", | ||
"published" : "2013-04-25", | |||
"timestamp" : "2019-03-26T21:31:31Z", | |||
"abbreviation" : "BLOCK-HF", | |||
"statusUsableDate" : "2017-06-01", | "statusUsableDate" : "2017-06-01", | ||
"pmid" : "23614585", | |||
"title" : "Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block", | |||
"trainingLevel" : "resident", | |||
"diseases" : "Atrioventricular Block", | |||
"briefResultsDescription" : "Biventricular pacing superior to right ventricular pacing in patients with CHF with AV block", | "briefResultsDescription" : "Biventricular pacing superior to right ventricular pacing in patients with CHF with AV block", | ||
"pageName" : "BLOCK-HF", | "pageName" : "BLOCK-HF", | ||
" | "pageid" : 2422, | ||
" | "citation" : "Curtis A.B., <i>et al</i>. \"Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block\". <i>The New England Journal of Medicine</i>. 2013. 368(17):1585-1593.", | ||
"expansion" : "Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1717250", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1717250", | ||
" | "briefDesignDescription" : "PharmD-guided BP reduction for Black men", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1717250", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1717250", | ||
" | "pmid" : "29527973", | ||
"statusUsableDate" : "2018-04-05", | "statusUsableDate" : "2018-04-05", | ||
" | "title" : "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops", | ||
"timestamp" : "2025-07-28T00:00:39Z", | |||
"published" : "2018-04-05", | "published" : "2018-04-05", | ||
"abbreviation" : "Blood-Pressure Reduction in Black Barbershops", | |||
"briefResultsDescription" : "Pharmacist-guided BP management improves", | |||
"diseases" : "Hypertension", | |||
"pageName" : "Blood Pressure Reduction in Black Barbershops", | "pageName" : "Blood Pressure Reduction in Black Barbershops", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Blood-Pressure Reduction in Black Barbershops", | ||
" | "citation" : "Victor RG, <i>et al</i>. \"A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops\". <i>The New England Journal of Medicine</i>. 2018. 378(14):1291-1301.", | ||
" | "pageid" : 3578 | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Blood Pressure Control Target in Diabetes", | ||
" | "citation" : "Bi Y, <i>et al</i>. \"Intensive blood-pressure control in patients with type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2024. e-pub 2024-11-6:1-13.", | ||
"pageid" : 5613, | "pageid" : 5613, | ||
" | "briefResultsDescription" : "Intensive BP control had fewer CVD events in DM", | ||
"diseases" : "Diabetes Mellitus;Hypertension", | |||
"pageName" : "BPROAD", | |||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
"statusUsableDate" : "2024-11-30", | "statusUsableDate" : "2024-11-30", | ||
" | "pmid" : "39555827", | ||
"title" : "Intensive blood-pressure control in patients with type 2 diabetes", | |||
"timestamp" : "2025-06-05T17:40:19Z", | |||
"published" : "2024-11-16", | "published" : "2024-11-16", | ||
"abbreviation" : "BPROAD", | "abbreviation" : "BPROAD", | ||
" | "subspecialties" : "Cardiology;Endocrinology", | ||
" | "fulltexturl" : "", | ||
"briefDesignDescription" : "Intensive BP control in DM", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2412006" | |||
}, | }, | ||
{ | { | ||
"title" : "Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation", | |||
"pmid" : "26095867", | |||
"statusUsableDate" : "2015-07-01", | |||
"abbreviation" : "BRIDGE", | |||
"timestamp" : "2018-01-17T21:45:20Z", | "timestamp" : "2018-01-17T21:45:20Z", | ||
"published" : "2015-06-22", | |||
"briefDesignDescription" : "LMWH bridging for surgery in AF", | "briefDesignDescription" : "LMWH bridging for surgery in AF", | ||
"subspecialties" : "Cardiology;Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501035", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501035", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501035", | ||
" | "expansion" : "Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for Elective Invasive Procedure or Surgery", | ||
"citation" : "Douketis JD, <i>et al</i>. \"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2015. 373(9):823-33.", | "citation" : "Douketis JD, <i>et al</i>. \"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2015. 373(9):823-33.", | ||
" | "pageid" : 2402, | ||
"pageName" : "BRIDGE", | |||
" | |||
"briefResultsDescription" : "LMWH bridging didn't reduce VTE but increased bleeding", | "briefResultsDescription" : "LMWH bridging didn't reduce VTE but increased bleeding", | ||
"diseases" : "Atrial Fibrillation;Stroke", | "diseases" : "Atrial Fibrillation;Stroke", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103782", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103782", | ||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1103782", | ||
"briefDesignDescription" : "Vemurafenib in BRAF V600+ melanoma", | |||
"timestamp" : "2017-12-03T22:33:53Z", | |||
"published" : "2011-06-30", | |||
"abbreviation" : "BRIM-3", | |||
"pmid" : "21639808", | |||
"statusUsableDate" : "2015-07-01", | "statusUsableDate" : "2015-07-01", | ||
"title" : "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation", | |||
"trainingLevel" : "Fellow", | |||
"briefResultsDescription" : "Vemurafenib improves survival in BRAF V600-mutated melanoma", | "briefResultsDescription" : "Vemurafenib improves survival in BRAF V600-mutated melanoma", | ||
" | "diseases" : "Melanoma", | ||
"pageName" : "BRIM-3", | "pageName" : "BRIM-3", | ||
" | "citation" : "Chapman BP, <i>et al</i>. \"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2507-2516.", | ||
"pageid" : 2391, | |||
"expansion" : "BRAF Inhibitor in Melanoma 3" | |||
" | }, | ||
}, | |||
{ | { | ||
" | "pageName" : "CABANA", | ||
"briefResultsDescription" : "Catheter ablation does not reduce cardiovascular events in patients with AF", | |||
"diseases" : "Atrial Fibrillation", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation", | |||
"citation" : "Packer DL, <i>et al</i>. \"Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation\". <i>JAMA</i>. 2019. 321(13):1261-1274.", | |||
"pageid" : 3950, | |||
"briefDesignDescription" : "Catheter ablation vs. anti-arrhythmic therapy in AF", | "briefDesignDescription" : "Catheter ablation vs. anti-arrhythmic therapy in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2728676", | "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2728676", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "title" : "Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation", | ||
"statusUsableDate" : "2019-04-11", | "statusUsableDate" : "2019-04-11", | ||
" | "pmid" : "30874766", | ||
"abbreviation" : "CABANA", | "abbreviation" : "CABANA", | ||
" | "timestamp" : "2019-04-11T17:25:17Z", | ||
" | "published" : "2019-04-11" | ||
}, | }, | ||
{ | { | ||
"published" : "2014-10-30", | |||
"timestamp" : "2024-08-29T19:09:38Z", | "timestamp" : "2024-08-29T19:09:38Z", | ||
"abbreviation" : "CALORIES", | |||
"pmid" : "25271389", | |||
"statusUsableDate" : "2024-08-28", | |||
"title" : "Trial of the route of early nutritional support in critically ill adults", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1409860", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1409860", | |||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "Early parenteral vs. enteral feeds in ICU", | "briefDesignDescription" : "Early parenteral vs. enteral feeds in ICU", | ||
"pageid" : 4141, | "pageid" : 4141, | ||
"citation" : "Harvey SE, <i>et al</i>. \"Trial of the route of early nutritional support in critically ill adults\". <i>The New England Journal of Medicine</i>. 2014. 371(18):1673-1684.", | "citation" : "Harvey SE, <i>et al</i>. \"Trial of the route of early nutritional support in critically ill adults\". <i>The New England Journal of Medicine</i>. 2014. 371(18):1673-1684.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Critical Illness", | |||
"briefResultsDescription" : "No difference between parenteral and enteral feeds in ICU", | "briefResultsDescription" : "No difference between parenteral and enteral feeds in ICU", | ||
"pageName" : "CALORIES" | |||
"pageName" : "CALORIES | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://ard.bmj.com/content/66/11/1443.full.pdf", | ||
"briefDesignDescription" : "Methotrexate strategies in RA", | "briefDesignDescription" : "Methotrexate strategies in RA", | ||
"fulltexturl" : "http://ard.bmj.com/content/66/11/1443.long", | "fulltexturl" : "http://ard.bmj.com/content/66/11/1443.long", | ||
"subspecialties" : "Rheumatology", | "subspecialties" : "Rheumatology", | ||
" | "abbreviation" : "CAMERA", | ||
"published" : "2007-11-01", | |||
"timestamp" : "2017-12-04T00:13:32Z", | |||
"title" : "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)", | |||
"statusUsableDate" : "2017-11-30", | "statusUsableDate" : "2017-11-30", | ||
" | "pmid" : "17519278", | ||
" | "trainingLevel" : "Fellow", | ||
"pageName" : "CAMERA", | "pageName" : "CAMERA", | ||
"diseases" : "Rheumatoid Arthritis", | "diseases" : "Rheumatoid Arthritis", | ||
" | "briefResultsDescription" : "Intensive methotrexate dosing better than conventional", | ||
" | "pageid" : 2859, | ||
" | "citation" : "Verstappen SM, <i>et al</i>. \"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)\". <i>Annals of the Rheumatic Diseases</i>. 2007. 66(11):1443-1449.", | ||
"expansion" : "Computer Assisted Management in Early Rheumatoid Arthritis" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Light therapy vs. SSRI for SAD", | "briefDesignDescription" : "Light therapy vs. SSRI for SAD", | ||
"fulltexturl" : "http://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.5.805", | "fulltexturl" : "http://ajp.psychiatryonline.org/doi/full/10.1176/ajp.2006.163.5.805", | ||
" | "subspecialties" : "Psychiatry", | ||
"pdfurl" : "http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.5.805", | "pdfurl" : "http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2006.163.5.805", | ||
" | "title" : "The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder", | ||
"pmid" : "16648320", | |||
" | |||
"statusUsableDate" : "2015-04-01", | "statusUsableDate" : "2015-04-01", | ||
" | "abbreviation" : "Can-SAD", | ||
"published" : "2006-05-01", | "published" : "2006-05-01", | ||
"timestamp" : "2017-12-03T22:34:40Z", | |||
"pageName" : "Can-SAD", | "pageName" : "Can-SAD", | ||
"diseases" : "Seasonal Affective Disorder;Depression", | "diseases" : "Seasonal Affective Disorder;Depression", | ||
" | "briefResultsDescription" : "No difference between light therapy and SSRI in SAD", | ||
" | "trainingLevel" : "Intern", | ||
"expansion" : null, | |||
"pageid" : 2173, | |||
"citation" : "Lam RW, <i>et al</i>. \"The Can-SAD study: A randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder\". <i>The American Journal of Psychiatry</i>. 2006. 165(5):805-812." | |||
}, | }, | ||
{ | { | ||
"title" : "The Canadian CT Head Rule for patients with minor head trauma", | |||
"pmid" : "11356436", | |||
"statusUsableDate" : "2012-03-01", | |||
"abbreviation" : "", | |||
"published" : "2001-05-05", | |||
"timestamp" : "2012-06-13T05:04:26Z", | "timestamp" : "2012-06-13T05:04:26Z", | ||
"briefDesignDescription" : "CT head rules for trauma", | "briefDesignDescription" : "CT head rules for trauma", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04561-X/fulltext", | ||
"subspecialties" : "Emergency Medicine;Neurology", | |||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS014067360004561X.pdf", | |||
"expansion" : "", | |||
"pageid" : 93, | "pageid" : 93, | ||
"citation" : "Stiell IG, <i>et al</i>. \"The Canadian CT Head Rule for patients with minor head trauma\". <i>The Lancet</i>. 2001. 357(9266):1391-96.", | "citation" : "Stiell IG, <i>et al</i>. \"The Canadian CT Head Rule for patients with minor head trauma\". <i>The Lancet</i>. 2001. 357(9266):1391-96.", | ||
"pageName" : "Canadian CT Head Rule", | "pageName" : "Canadian CT Head Rule", | ||
"diseases" : "Trauma", | "diseases" : "Trauma", | ||
" | "briefResultsDescription" : "GCS score, skull fracture, emesis, age, amnesia, and mechanism predict risk", | ||
"trainingLevel" : "resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Canakinumab reduces cardiovascular events in patients with previous MI", | ||
"diseases" : "Coronary Artery Disease", | |||
" | "pageName" : "CANTOS", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)", | |||
"citation" : "Ridker PM, <i>et al</i>. \"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease\". <i>The New England Journal of Medicine</i>. 2017. 377(12):1119-1131.", | "citation" : "Ridker PM, <i>et al</i>. \"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease\". <i>The New England Journal of Medicine</i>. 2017. 377(12):1119-1131.", | ||
"pageid" : 2964, | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1707914", | ||
"briefDesignDescription" : "Canakinumab in patients with previous MI", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707914", | |||
"pmid" : "28845751", | |||
"statusUsableDate" : "2017-10-01", | "statusUsableDate" : "2017-10-01", | ||
" | "title" : "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease", | ||
"timestamp" : "2018-11-12T16:15:18Z", | |||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
"abbreviation" : "CANTOS" | |||
"abbreviation" : "CANTOS | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611925", | ||
"briefDesignDescription" : "Canagliflozin for CV outcomes in T2DM", | "briefDesignDescription" : "Canagliflozin for CV outcomes in T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611925", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611925", | ||
"subspecialties" : "Endocrinology;Cardiology;Nephrology", | "subspecialties" : "Endocrinology;Cardiology;Nephrology", | ||
" | "abbreviation" : "CANVAS", | ||
"published" : "2017-08-17", | |||
"timestamp" : "2022-10-13T17:45:18Z", | |||
"title" : "Canagliflozin and cardiovascular and renal events in type 2 diabetes", | |||
"pmid" : "28605608", | |||
"statusUsableDate" : "2017-08-01", | "statusUsableDate" : "2017-08-01", | ||
" | "trainingLevel" : "intern", | ||
"pageName" : "CANVAS", | "pageName" : "CANVAS", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Canagliflozin reduces CV events compared to placebo in patients with type 2 diabetes", | ||
" | "pageid" : 2952, | ||
" | "citation" : "Neal B, <i>et al</i>. \"Canagliflozin and cardiovascular and renal events in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2017. 377(7):644-657.", | ||
"expansion" : "Canagliflozin Cardiovascular Assessment Study" | |||
}, | }, | ||
{ | { | ||
"pageid" : 2838, | "pageid" : 2838, | ||
"citation" : "Postma DF, <i>et al</i>. \"Antibiotic treatment strategies for community-acquired pneumonia in adults\". <i>The New England Journal of Medicine</i>. 2015. 372(14):1312-1323.", | "citation" : "Postma DF, <i>et al</i>. \"Antibiotic treatment strategies for community-acquired pneumonia in adults\". <i>The New England Journal of Medicine</i>. 2015. 372(14):1312-1323.", | ||
"expansion" : "Community-Acquired Pneumonia—Study on the Initial Treatment with Antibiotics of Lower Respiratory Tract Infections", | "expansion" : "Community-Acquired Pneumonia—Study on the Initial Treatment with Antibiotics of Lower Respiratory Tract Infections", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "CAP-START", | "pageName" : "CAP-START", | ||
"diseases" : "Pneumonia", | "diseases" : "Pneumonia", | ||
"briefResultsDescription" : "Beta-lactam alone is noninferior to quinolone or beta-lactam+macrolide", | |||
"abbreviation" : "CAP-START", | "abbreviation" : "CAP-START", | ||
"published" : "2015-04-02", | |||
"timestamp" : "2018-03-08T18:31:23Z", | |||
"title" : "Antibiotic treatment strategies for community-acquired pneumonia in adults", | "title" : "Antibiotic treatment strategies for community-acquired pneumonia in adults", | ||
"pmid" : "25830421" | "pmid" : "25830421", | ||
"statusUsableDate" : "2018-03-08", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406330", | |||
"briefDesignDescription" : "Antibiotic strategies for PNA", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1406330", | |||
"subspecialties" : "Infectious Disease" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "CAPE COD", | |||
"timestamp" : "2023-04-24T20:34:11Z", | "timestamp" : "2023-04-24T20:34:11Z", | ||
"published" : "2023-03-21", | |||
"title" : "Hydrocortisone in severe community-acquired pneumonia", | |||
"statusUsableDate" : "2023-04-06", | |||
"pmid" : "36942789", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2215145", | |||
"briefDesignDescription" : "Hydrocortisone in severe CAP", | "briefDesignDescription" : "Hydrocortisone in severe CAP", | ||
"subspecialties" : "Critical Care;Pulmonology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2215145", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2215145", | ||
"citation" : "Dequin PF, <i>et al</i>. \"Hydrocortisone in severe community-acquired pneumonia\". <i>The New England Journal of Medicine</i>. 2023. Epub 2023-03-21:1-11.", | |||
"pageid" : 5318, | "pageid" : 5318, | ||
" | "expansion" : "", | ||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
" | "pageName" : "CAPE COD", | ||
"briefResultsDescription" : "Hydrocortisone lowers mortality in severe CAP", | "briefResultsDescription" : "Hydrocortisone lowers mortality in severe CAP", | ||
"diseases" : "Pneumonia" | |||
"diseases" : "Pneumonia | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
"briefResultsDescription" : "Improved mortality with carvedilol post-MI with LVEF ≤40%", | |||
"diseases" : "Acute Coronary Syndrome", | |||
"pageName" : "CAPRICORN", | |||
"citation" : "Dargie HJ, <i>et al</i>. \"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial\". <i>The Lancet</i>. 2001. 357(9266):1385-1390.", | "citation" : "Dargie HJ, <i>et al</i>. \"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial\". <i>The Lancet</i>. 2001. 357(9266):1385-1390.", | ||
" | "pageid" : 2944, | ||
"expansion" : "Carvedilol Post-Infarct Survival Control in LV Dysfunction", | "expansion" : "Carvedilol Post-Infarct Survival Control in LV Dysfunction", | ||
" | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(00)04560-8.pdf", | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)04560-8", | |||
"briefDesignDescription" : "Carvedilol post-MI with HFrEF", | |||
"timestamp" : "2019-03-15T15:10:50Z", | |||
"published" : "2001-05-01", | "published" : "2001-05-01", | ||
"abbreviation" : "CAPRICORN", | "abbreviation" : "CAPRICORN", | ||
"title" : "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial | "statusUsableDate" : "2019-03-07", | ||
"pmid" : "11356434", | |||
"title" : "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673696094573.pdf", | ||
"briefDesignDescription" : "Clopidogrel vs. aspirin in CV disease", | "briefDesignDescription" : "Clopidogrel vs. aspirin in CV disease", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09457-3/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(96)09457-3/fulltext", | ||
"subspecialties" : "Neurology;Cardiology", | "subspecialties" : "Neurology;Cardiology", | ||
" | "abbreviation" : "CAPRIE", | ||
"published" : "1996-11-16", | |||
"timestamp" : "2023-03-30T18:14:36Z", | |||
"title" : "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "8918275", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "CAPRIE", | "pageName" : "CAPRIE", | ||
"diseases" : "Stroke;Transient Ischemic Attack;Coronary Artery Disease", | "diseases" : "Stroke;Transient Ischemic Attack;Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Clopidogrel reduces risk of cardiovascular events", | ||
" | "pageid" : 7, | ||
" | "citation" : "Gent M, <i>et al</i>. \"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events\". <i>The Lancet</i>. 1996. 348(9038):1329-39.", | ||
"expansion" : "Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Agnelli G, <i>et al</i>. \"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer\". <i>The New England Journal of Medicine</i>. 2020. 382:1599-607.", | ||
"pageid" : 4265, | "pageid" : 4265, | ||
" | "expansion" : "", | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "pageName" : "CARAVAGGIO", | ||
"briefResultsDescription" : "Apixaban is noninferior to dalteparin for cancer VTE", | "briefResultsDescription" : "Apixaban is noninferior to dalteparin for cancer VTE", | ||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | "diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | ||
"abbreviation" : "CARVAGGIO", | "abbreviation" : "CARVAGGIO", | ||
"timestamp" : "2020-11-05T18:09:03Z", | |||
"published" : "2020-03-29", | |||
"title" : "Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer", | "title" : "Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer", | ||
"pmid" : "32223112" | "statusUsableDate" : "2020-10-31", | ||
"pmid" : "32223112", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915103", | |||
"briefDesignDescription" : "Apixaban vs. dalteparin in cancer VTE", | |||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1915103" | |||
}, | }, | ||
{ | { | ||
"title" : "Coronary-artery revascularization before elective major vascular surgery", | |||
"pmid" : "15625331", | |||
"statusUsableDate" : "2015-09-01", | |||
"abbreviation" : "CARP", | |||
"published" : "2004-12-30", | |||
"timestamp" : "2017-12-03T22:33:59Z", | "timestamp" : "2017-12-03T22:33:59Z", | ||
"briefDesignDescription" : "Preop coronary revascularization if stable CAD", | "briefDesignDescription" : "Preop coronary revascularization if stable CAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa041905", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa041905", | ||
"subspecialties" : "Cardiology;Preventive Medicine", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa041905", | |||
"expansion" : "", | |||
"pageid" : 1332, | "pageid" : 1332, | ||
"citation" : "McFalls EO, <i>et al</i>. \"Coronary-artery revascularization before elective major vascular surgery\". <i>The New England Journal of Medicine</i>. 2004. 351(27):2795-2804.", | "citation" : "McFalls EO, <i>et al</i>. \"Coronary-artery revascularization before elective major vascular surgery\". <i>The New England Journal of Medicine</i>. 2004. 351(27):2795-2804.", | ||
"pageName" : "CARP", | "pageName" : "CARP", | ||
"diseases" : "Coronary Artery Disease;Cardiac Risk Assessment", | "diseases" : "Coronary Artery Disease;Cardiac Risk Assessment", | ||
" | "briefResultsDescription" : "Preop coronary revascularization doesn't reduce mortality", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "Ultrafiltration worse then meds in acute HF", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "CARRESS-HF", | |||
"citation" : "Bart BA, <i>et al</i>. \"Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome\". <i>The New England Journal of Medicine</i>. 2012. 367(24):2296-2304.", | |||
"pageid" : 1356, | "pageid" : 1356, | ||
"expansion" : "Cardiorenal Rescue Study in Acute Decompensated Heart Failure", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1210357", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1210357", | ||
" | "briefDesignDescription" : "Ultrafiltration in decompensated HF", | ||
" | "timestamp" : "2017-12-03T22:34:00Z", | ||
"published" : "2012-12-13", | "published" : "2012-12-13", | ||
"abbreviation" : "CARRESS-HF", | "abbreviation" : "CARRESS-HF", | ||
" | "statusUsableDate" : "2013-05-01", | ||
"pmid" : "23131078" | "pmid" : "23131078", | ||
"title" : "Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Khorana AA, <i>et al</i>. \"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer\". <i>The New England Journal of Medicine</i>. 2019. 380(8):720-8.", | ||
"pageid" : 3945, | "pageid" : 3945, | ||
" | "expansion" : "Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Rivaroxaban did not reduce VTE", | "briefResultsDescription" : "Rivaroxaban did not reduce VTE", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | |||
"pageName" : "CASSINI", | |||
"timestamp" : "2019-05-23T17:55:30Z", | |||
"published" : "2019-02-21", | "published" : "2019-02-21", | ||
"abbreviation" : "CASSINI", | "abbreviation" : "CASSINI", | ||
"statusUsableDate" : "2019-03-07", | |||
"pmid" : "30786186", | |||
"title" : "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer", | "title" : "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814630", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1814630", | |||
"briefDesignDescription" : "Rivaroxaban for VTE prevention in cancer" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199103213241201", | |||
"briefDesignDescription" : "Antiarrhythmics post-MI", | "briefDesignDescription" : "Antiarrhythmics post-MI", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199103213241201", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199103213241201", | ||
" | "pmid" : "1900101", | ||
"statusUsableDate" : "2012-12-01", | "statusUsableDate" : "2012-12-01", | ||
"title" : "Mortality and morbidity in patients receiving encainide, flecainide, or placebo", | |||
"timestamp" : "2017-12-03T22:34:01Z", | |||
"published" : "1991-03-21", | |||
"abbreviation" : "CAST I", | |||
"briefResultsDescription" : "Antiarrhythmics increase mortality", | "briefResultsDescription" : "Antiarrhythmics increase mortality", | ||
" | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
"pageName" : "CAST I", | "pageName" : "CAST I", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Cardiac Arrhythmia Suppression Trial", | ||
" | "citation" : "Echt DS, <i>et al</i>. \"Mortality and morbidity in patients receiving encainide, flecainide, or placebo\". <i>The New England Journal of Medicine</i>. 1991. 324(12):781-788.", | ||
" | "pageid" : 1110 | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "pageName" : "CASTLE-AF", | ||
" | "briefResultsDescription" : "Catheter ablation superior to standard therapy in AF and HF", | ||
"diseases" : "Atrial Fibrillation", | |||
"citation" : "Marrouche NF, <i>et al</i>. \"Catheter Ablation for Atrial Fibrillation with Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. 378(5):417-27.", | |||
"pageid" : 3533, | "pageid" : 3533, | ||
"expansion" : "Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707855", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1707855", | ||
" | "briefDesignDescription" : "Catheter ablation vs. standard therapy in AF+HF", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1707855", | ||
" | "abbreviation" : "CASTLE-AF", | ||
" | "timestamp" : "2018-08-10T15:33:15Z", | ||
"published" : "2018-02-01", | "published" : "2018-02-01", | ||
"title" : "Catheter Ablation for Atrial Fibrillation with Heart Failure", | "title" : "Catheter Ablation for Atrial Fibrillation with Heart Failure", | ||
"statusUsableDate" : "2018-02-08", | |||
"pmid" : "29385358" | "pmid" : "29385358" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "CATIE", | |||
"published" : "2005-09-22", | |||
"timestamp" : "2017-12-03T22:34:03Z", | "timestamp" : "2017-12-03T22:34:03Z", | ||
"title" : "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", | |||
"statusUsableDate" : "2012-06-01", | |||
"pmid" : "16172203", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa051688", | |||
"briefDesignDescription" : "Antipsychotics in schizophrenia", | "briefDesignDescription" : "Antipsychotics in schizophrenia", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa051688", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa051688", | ||
"subspecialties" : "Psychiatry", | |||
"pageid" : 419, | "pageid" : 419, | ||
"citation" : "Lieberman JA, <i>et al</i>. \"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia\". <i>The New England Journal of Medicine</i>. 2005. 353(12):1209-23.", | "citation" : "Lieberman JA, <i>et al</i>. \"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia\". <i>The New England Journal of Medicine</i>. 2005. 353(12):1209-23.", | ||
"expansion" : "Clinical Antipsychotic Trials of Intervention Effectiveness", | "expansion" : "Clinical Antipsychotic Trials of Intervention Effectiveness", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "CATIE", | "pageName" : "CATIE", | ||
"diseases" : "Schizophrenia", | "diseases" : "Schizophrenia", | ||
" | "briefResultsDescription" : "Olanzapine ↓discontinuations but ↑metabolic syndrome, and perphenazine ˜ atypicals" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "CATIE-AD", | |||
"diseases" : "Dementia;Alzheimer Disease;Psychosis", | |||
"briefResultsDescription" : "Antipsychotics no better than placebo", | |||
"pageid" : 2724, | |||
"citation" : "Schneider LS, <i>et al</i>. \"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease\". <i>The New England Journal of Medicine</i>. 2006. 355(15):1525-38.", | |||
"expansion" : "Clinical Antipsychotic Trials of Intervention Effectiveness–Alzheimer's Disease", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa061240", | |||
"briefDesignDescription" : "Antipsychotics in dementia with psychosis", | "briefDesignDescription" : "Antipsychotics in dementia with psychosis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa061240", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa061240", | ||
"subspecialties" : "Psychiatry", | "subspecialties" : "Psychiatry", | ||
" | "abbreviation" : "CATIE-AD", | ||
"published" : "2006-10-12", | "published" : "2006-10-12", | ||
" | "timestamp" : "2017-12-03T22:34:04Z", | ||
"title" : "Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease", | "title" : "Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease", | ||
"statusUsableDate" : "2016-04-01", | |||
"pmid" : "17035647" | "pmid" : "17035647" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "The CATT Research Group Writers. \"Ranibizumab and bevacizumab for neovascular age-related macular degeneration\". <i>The New England Journal of Medicine</i>. 2011. 364(20):1897-1908.", | ||
"pageid" : 2250, | "pageid" : 2250, | ||
" | "expansion" : "Comparison of Age-Related Macular Degeneration Treatment Trails", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Ranibizumab vs. bevacizumab similar even when comparing monthly vs. PRN scheduling", | "briefResultsDescription" : "Ranibizumab vs. bevacizumab similar even when comparing monthly vs. PRN scheduling", | ||
"diseases" : "Macular Degeneration", | |||
"pageName" : "CATT", | |||
"timestamp" : "2017-12-03T22:34:05Z", | |||
"published" : "2011-05-19", | "published" : "2011-05-19", | ||
"abbreviation" : "CATT", | "abbreviation" : "CATT", | ||
"statusUsableDate" : "2014-10-01", | |||
"pmid" : "21526923", | |||
"title" : "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", | "title" : "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102673", | ||
"subspecialties" : "Ophthalmology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1102673", | |||
"briefDesignDescription" : "Ranibizumab vs. bevacizumab for macular degeneration" | |||
}, | }, | ||
{ | { | ||
"pageid" : 2935, | "pageid" : 2935, | ||
"citation" : "Bhatt DL, <i>et al</i>. \"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events\". <i>The New England Journal of Medicine</i>. 2013. 368(14):1303-1313.", | "citation" : "Bhatt DL, <i>et al</i>. \"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events\". <i>The New England Journal of Medicine</i>. 2013. 368(14):1303-1313.", | ||
"expansion" : "Cangrelor versus standard therapy to achieve optimal management of platelet inhibition", | "expansion" : "Cangrelor versus standard therapy to achieve optimal management of platelet inhibition", | ||
" | "trainingLevel" : "Fellow", | ||
"pageName" : "CHAMPION PHOENIX", | "pageName" : "CHAMPION PHOENIX", | ||
"diseases" : "Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction", | "diseases" : "Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction", | ||
"briefResultsDescription" : "Cangrelor reduces rate of ischemic events during PCI", | |||
"abbreviation" : "CHAMPION PHOENIX", | "abbreviation" : "CHAMPION PHOENIX", | ||
"published" : "2013-04-04", | |||
"timestamp" : "2025-07-25T00:26:24Z", | |||
"title" : "Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events", | "title" : "Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events", | ||
"pmid" : "23473369" | "statusUsableDate" : "2017-06-01", | ||
"pmid" : "23473369", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300815", | |||
"briefDesignDescription" : "Cangrelor during urgent or elective PCI", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300815", | |||
"subspecialties" : "Cardiology" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "CHANCE", | |||
"diseases" : "Stroke;Transient Ischemic Attack", | |||
"briefResultsDescription" : "ASA/clopidogrel decreases stroke rates compared to ASA alone in TIA and high-risk CVA", | |||
"pageid" : 1530, | |||
"citation" : "Wang Y, <i>et al</i>. \"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2013. 369(1):11-19.", | |||
"expansion" : "Clopidogrel in High-risk patients with Acute Nondisabling Cerebrovascular Events", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215340", | |||
"briefDesignDescription" : "ASA/clopidogrel vs. ASA in TIA/stroke", | "briefDesignDescription" : "ASA/clopidogrel vs. ASA in TIA/stroke", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1215340", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1215340", | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
" | "abbreviation" : "CHANCE", | ||
"published" : "2013-07-04", | "published" : "2013-07-04", | ||
" | "timestamp" : "2020-01-03T00:19:05Z", | ||
"title" : "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack", | "title" : "Clopidogrel with aspirin in acute minor stroke or transient ischemic attack", | ||
"statusUsableDate" : "2013-07-01", | |||
"pmid" : "23803136" | "pmid" : "23803136" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : null, | ||
"pageid" : 2126, | |||
"pageid" : 2126 | |||
"citation" : "McMurray JJ, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial\". <i>The Lancet</i>. 2003. 362(9386):767-771.", | "citation" : "McMurray JJ, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial\". <i>The Lancet</i>. 2003. 362(9386):767-771.", | ||
"pageName" : "CHARM-Added", | "pageName" : "CHARM-Added", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "Adding ARB to ACE-I reduces CV events and HF hospitalizations", | |||
"trainingLevel" : "Intern", | |||
"title" : "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial", | |||
"pmid" : "13678869", | |||
"statusUsableDate" : "2014-08-01", | |||
"abbreviation" : "Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added", | "abbreviation" : "Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Added", | ||
" | "published" : "2003-09-06", | ||
" | "timestamp" : "2017-12-03T22:34:11Z", | ||
"briefDesignDescription" : "ARB plus ACE-I in HF", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2803%2914283-3/fulltext", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603142833.pdf" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "ARBs reduce CV mortality and HF hospitalization in HFrEF", | ||
"diseases" : "Heart Failure", | |||
" | "pageName" : "CHARM-Alternative", | ||
" | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"expansion" : "", | |||
"citation" : "Granger CB, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial\". <i>The Lancet</i>. 2003. 362(9386):772-776.", | "citation" : "Granger CB, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial\". <i>The Lancet</i>. 2003. 362(9386):772-776.", | ||
"pageid" : 2416, | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://doi.org/10.1016/s0140-6736(03)14284-5", | ||
"briefDesignDescription" : "ARBs in HFrEF", | |||
"pdfurl" : "", | |||
"statusUsableDate" : "2023-03-29", | "statusUsableDate" : "2023-03-29", | ||
" | "pmid" : "13678870", | ||
"title" : "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial", | |||
"timestamp" : "2023-03-30T17:58:17Z", | |||
"published" : "2003-09-06", | "published" : "2003-09-06", | ||
"abbreviation" : "CHARM-Alternative" | |||
"abbreviation" : "CHARM-Alternative | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved", | ||
"pageid" : 2381, | "pageid" : 2381, | ||
"citation" : "Yusuf S, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial\". <i>The Lancet</i>. 2003. 362(9386):777-781.", | "citation" : "Yusuf S, <i>et al</i>. \"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial\". <i>The Lancet</i>. 2003. 362(9386):777-781.", | ||
"pageName" : "CHARM-Preserved", | "pageName" : "CHARM-Preserved", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "Candesartan modestly reduces HF admissions but does not affect CV mortality", | |||
"trainingLevel" : "Intern", | |||
"title" : "Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial", | |||
"statusUsableDate" : "2015-06-01", | |||
"pmid" : "13678871", | |||
"abbreviation" : "CHARM-Preserved", | "abbreviation" : "CHARM-Preserved", | ||
" | "published" : "2003-09-06", | ||
" | "timestamp" : "2017-12-03T22:34:16Z", | ||
"briefDesignDescription" : "ARBs in HFpEF", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14285-7/fulltext", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14285-7.pdf" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "", | |||
"published" : "2012-06-28", | |||
"timestamp" : "2017-12-03T22:34:42Z", | "timestamp" : "2017-12-03T22:34:42Z", | ||
"title" : "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", | |||
"pmid" : "22658127", | |||
"statusUsableDate" : "2014-10-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200690", | |||
"briefDesignDescription" : "Nivolumab in solid tumors", | "briefDesignDescription" : "Nivolumab in solid tumors", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200690", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200690", | ||
"subspecialties" : "Oncology", | |||
"pageid" : 2220, | "pageid" : 2220, | ||
"citation" : "Topalian SL, <i>et al</i>. \"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2443-54.", | "citation" : "Topalian SL, <i>et al</i>. \"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2443-54.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "CheckMate-003", | "pageName" : "CheckMate-003", | ||
"diseases" : "Melanoma;Lung Cancer;Renal Cell Carcinoma", | "diseases" : "Melanoma;Lung Cancer;Renal Cell Carcinoma", | ||
" | "briefResultsDescription" : "Nivolumab was well tolerated, yielded durable remissions in about 30% of patients" | ||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400506", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1400506", | ||
"subspecialties" : "Gynecology;Preventive Medicine;Obstetrics", | "subspecialties" : "Gynecology;Preventive Medicine;Obstetrics", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1400506", | ||
"briefDesignDescription" : "Free long-acting reversible contraception in teens", | |||
"timestamp" : "2017-12-03T22:34:18Z", | |||
"published" : "2014-10-02", | |||
"abbreviation" : "CHOICE", | |||
"pmid" : "25271604", | |||
"statusUsableDate" : "2014-10-01", | "statusUsableDate" : "2014-10-01", | ||
"title" : "Provision of no-cost, long-acting contraception and teenage pregnancy", | |||
"trainingLevel" : "Student", | |||
"briefResultsDescription" : "LARC reduced pregnancy, live births, and abortions", | "briefResultsDescription" : "LARC reduced pregnancy, live births, and abortions", | ||
" | "diseases" : "Unplanned Pregnancy", | ||
"pageName" : "CHOICE", | "pageName" : "CHOICE", | ||
" | "citation" : "Secura GM, <i>et al</i>. \"Provision of no-cost, long-acting contraception and teenage pregnancy\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1316-1326.", | ||
"pageid" : 2233, | |||
"expansion" : "CHOICE is not an abbreviation per a communication with the research team" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Singh AK, <i>et al</i>. \"Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease\". <i>The New England Journal of Medicine</i>. 2006. 355(20):2085-2098.", | ||
"pageid" : 422, | "pageid" : 422, | ||
" | "expansion" : "Correction of Hemoglobin and Outcomes in Renal Insufficiency", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Increased morbidity/mortality with higher hgb targets", | "briefResultsDescription" : "Increased morbidity/mortality with higher hgb targets", | ||
"diseases" : "Chronic Kidney Disease;Anemia", | |||
"pageName" : "CHOIR", | |||
"timestamp" : "2019-02-21T16:44:19Z", | |||
"published" : "2006-11-16", | "published" : "2006-11-16", | ||
"abbreviation" : "CHOIR", | "abbreviation" : "CHOIR", | ||
"pmid" : "17108343", | |||
"statusUsableDate" : "2012-05-01", | |||
"title" : "Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease", | "title" : "Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485", | ||
"subspecialties" : "Nephrology;Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa065485", | |||
"briefDesignDescription" : "EPO in CKD with anemia" | |||
}, | }, | ||
{ | { | ||
"pmid" : "10023943", | |||
"statusUsableDate" : "2023-01-30", | |||
"title" : "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial", | |||
"published" : "1999-01-02", | |||
"timestamp" : "2023-02-02T19:39:17Z", | "timestamp" : "2023-02-02T19:39:17Z", | ||
"abbreviation" : "CIBIS-II", | |||
"fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0140673698111819", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Bisoprolol in HFrEF", | "briefDesignDescription" : "Bisoprolol in HFrEF", | ||
" | "pdfurl" : "", | ||
"expansion" : "", | |||
"pageid" : 2436, | "pageid" : 2436, | ||
"citation" : "CIBIS-II Writers. \"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial\". <i>The Lancet</i>. 1999. 353(9146):9-13.", | "citation" : "CIBIS-II Writers. \"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial\". <i>The Lancet</i>. 1999. 353(9146):9-13.", | ||
" | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "Bisoprolol lowers mortality in HFrEF", | "briefResultsDescription" : "Bisoprolol lowers mortality in HFrEF", | ||
"pageName" : "CIBIS-II", | "pageName" : "CIBIS-II", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1809798", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Low-dose MTX for secondary prevention of CAD", | "briefDesignDescription" : "Low-dose MTX for secondary prevention of CAD", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1809798", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1809798", | ||
" | "pmid" : "30415610", | ||
"statusUsableDate" : "2018-11-14", | "statusUsableDate" : "2018-11-14", | ||
"title" : "Low-dose methotrexate for the prevention of atherosclerotic events", | |||
"published" : "2018-11-10", | |||
"timestamp" : "2025-05-22T17:32:54Z", | |||
"abbreviation" : "CIRT", | |||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "Low-dose methotrexate not superior to placebo for secondary prevention of CAD", | "briefResultsDescription" : "Low-dose methotrexate not superior to placebo for secondary prevention of CAD", | ||
"pageName" : "CIRT", | "pageName" : "CIRT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Cardiovascular Inflammation Reduction Trial", | ||
" | "pageid" : 3739, | ||
"citation" : "Ridker PM, <i>et al</i>. \"Low-dose methotrexate for the prevention of atherosclerotic events\". <i>The New England Journal of Medicine</i>. 2018. epub 2018-11-10:1-11." | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Fellow", | ||
" | "pageName" : "CLOSURE I", | ||
" | "briefResultsDescription" : "PFO closure does not reduce recurrent stroke", | ||
"diseases" : "Stroke;Patent Foramen Ovale;Transient Ischemic Attack", | |||
"citation" : "Furlan AJ, <i>et al</i>. \"Closure or medical therapy for cryptogenic stroke with patent foramen ovale\". <i>The New England Journal of Medicine</i>. 2012. 366(11):991-999.", | |||
"pageid" : 1093, | "pageid" : 1093, | ||
"expansion" : "Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009639", | ||
" | "briefDesignDescription" : "PFO closure in cryptogenic stroke", | ||
"subspecialties" : "Neurology;Cardiology", | "subspecialties" : "Neurology;Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009639", | ||
" | "abbreviation" : "CLOSURE I", | ||
" | "timestamp" : "2017-12-03T22:34:21Z", | ||
"published" : "2012-03-15", | "published" : "2012-03-15", | ||
"title" : "Closure or medical therapy for cryptogenic stroke with patent foramen ovale", | "title" : "Closure or medical therapy for cryptogenic stroke with patent foramen ovale", | ||
"statusUsableDate" : "2013-01-01", | |||
"pmid" : "22417252" | "pmid" : "22417252" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism", | ||
" | "citation" : "Lee AY, <i>et al</i>. \"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(2):146-53.", | ||
"pageid" : 13, | "pageid" : 13, | ||
" | "briefResultsDescription" : "LMWH reduces VTE recurrence in cancer VTE without increasing bleeding risk", | ||
"diseases" : "Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism", | |||
"pageName" : "CLOT", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "12853587", | ||
"title" : "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", | |||
"timestamp" : "2018-04-14T12:16:19Z", | |||
"published" : "2003-07-10", | "published" : "2003-07-10", | ||
"abbreviation" : "CLOT", | "abbreviation" : "CLOT", | ||
" | "subspecialties" : "Hematology;Oncology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa025313", | ||
"briefDesignDescription" : "LMWH vs. warfarin in cancer VTE", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa025313" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1806640", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Mitra Clip for HF-related MR", | "briefDesignDescription" : "Mitra Clip for HF-related MR", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806640", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1806640", | ||
" | "pmid" : "30280640", | ||
"statusUsableDate" : "2018-12-19", | "statusUsableDate" : "2018-12-19", | ||
"title" : "Transcatheter Mitral Valve Repair in Patients with Heart Failure", | |||
"published" : "2018-09-23", | |||
"timestamp" : "2021-04-29T17:37:05Z", | |||
"abbreviation" : "COAPT", | |||
"diseases" : "Mitral Regurgitation", | |||
"briefResultsDescription" : "Mitra Clip reduces HF hospitalization rate in HF-related MR", | "briefResultsDescription" : "Mitra Clip reduces HF hospitalization rate in HF-related MR", | ||
"pageName" : "COAPT", | "pageName" : "COAPT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation", | ||
" | "pageid" : 3714, | ||
"citation" : "Stone GW, <i>et al</i>. \"Transcatheter Mitral Valve Repair in Patients with Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. 379:2307-2318." | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "COGENT", | |||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "PPIs reduce bleeding but do not increase CV events when given with clopidogrel", | |||
"pageid" : 313, | |||
"citation" : "Bhatt DL, <i>et al</i>. \"Clopidogrel with or without omeprazole in coronary artery disease\". <i>The New England Journal of Medicine</i>. 2010. 363(20):1909-17.", | |||
"expansion" : "Clopidogrel and the Optimization of Gastrointestinal Events Trial", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007964", | |||
"briefDesignDescription" : "PPI plus clopidogrel in CAD", | "briefDesignDescription" : "PPI plus clopidogrel in CAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1007964", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1007964", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "COGENT", | ||
"published" : "2010-11-11", | "published" : "2010-11-11", | ||
" | "timestamp" : "2017-12-03T22:34:23Z", | ||
"title" : "Clopidogrel with or without omeprazole in coronary artery disease", | "title" : "Clopidogrel with or without omeprazole in coronary artery disease", | ||
"statusUsableDate" : "2012-04-01", | |||
"pmid" : "20925534" | "pmid" : "20925534" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2021-02-18T20:37:27Z", | "title" : "Efficacy and safety of low-dose colchicine after myocardial infarction", | ||
"statusUsableDate" : "2019-11-24", | |||
"pmid" : "31733140", | |||
"abbreviation" : "COLCOT", | |||
"published" : "2019-11-16", | |||
"timestamp" : "2021-02-18T20:37:27Z", | |||
"briefDesignDescription" : "Colchicine vs. placebo in ACS", | "briefDesignDescription" : "Colchicine vs. placebo in ACS", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1912388", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1912388", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1912388", | |||
"expansion" : "Colchicine Cardiovascular Outcomes Trial", | |||
"pageid" : 4145, | "pageid" : 4145, | ||
"citation" : "Tardif J, <i>et al</i>. \"Efficacy and safety of low-dose colchicine after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2019. 381(26):2497-2505.", | "citation" : "Tardif J, <i>et al</i>. \"Efficacy and safety of low-dose colchicine after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2019. 381(26):2497-2505.", | ||
"pageName" : "COLCOT", | "pageName" : "COLCOT", | ||
"diseases" : "Acute Coronary Syndrome", | "diseases" : "Acute Coronary Syndrome", | ||
" | "briefResultsDescription" : "Colchicine superior to placebo in ACS", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "COLONPREV", | |||
"published" : "2012-02-23", | |||
"timestamp" : "2021-09-16T13:55:19Z", | "timestamp" : "2021-09-16T13:55:19Z", | ||
"title" : "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening", | |||
"pmid" : "22356323", | |||
"statusUsableDate" : "2016-07-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1108895", | |||
"briefDesignDescription" : "FIT vs. colonoscopy for colon cancer screening", | "briefDesignDescription" : "FIT vs. colonoscopy for colon cancer screening", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1108895", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1108895", | ||
"subspecialties" : "Preventive Medicine;Gastroenterology;Oncology", | |||
"pageid" : 2393, | "pageid" : 2393, | ||
"citation" : "Quintero E, <i>et al</i>. \"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening\". <i>The New England Journal of Medicine</i>. 2012. 366(8):697-706.", | "citation" : "Quintero E, <i>et al</i>. \"Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening\". <i>The New England Journal of Medicine</i>. 2012. 366(8):697-706.", | ||
"expansion" : null, | "expansion" : null, | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "COLONPREV", | "pageName" : "COLONPREV", | ||
"diseases" : "Colorectal Cancer", | "diseases" : "Colorectal Cancer", | ||
" | "briefResultsDescription" : "FIT is noninferior to colonoscopy for detecting colon cancer" | ||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)13800-7/fulltext", | |||
"briefDesignDescription" : "Carvedilol vs. metoprolol in HFrEF", | "briefDesignDescription" : "Carvedilol vs. metoprolol in HFrEF", | ||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf", | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673603138007.pdf", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"pmid" : "12853193", | |||
"title" : "Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial", | |||
"timestamp" : "2015-08-24T04:36:50Z", | |||
"published" : "2003-07-05", | |||
"abbreviation" : "COMET", | |||
"briefResultsDescription" : "Carvedilol extends survival in HFrEF", | "briefResultsDescription" : "Carvedilol extends survival in HFrEF", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "COMET", | "pageName" : "COMET", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Carvedilol Or Metoprolol European Trial", | ||
" | "citation" : "Poole-Wilson PA, <i>et al</i>. \"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial\". <i>The Lancet</i>. 2003. 362(9377):7-13.", | ||
" | "pageid" : 121 | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Chen ZM, <i>et al</i>. \"Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial\". <i>The Lancet</i>. 2005. 366(9497):1622-1632.", | ||
"pageid" : 1451, | "pageid" : 1451, | ||
" | "expansion" : "ClOpidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "briefResultsDescription" : "High-dose IV and PO metoprolol increases cardiogenic shock", | ||
" | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "pageName" : "COMMIT", | ||
" | "timestamp" : "2018-03-08T18:56:18Z", | ||
"published" : "2005-11-05", | "published" : "2005-11-05", | ||
"abbreviation" : "COMMIT/CCS-2", | "abbreviation" : "COMMIT/CCS-2", | ||
"statusUsableDate" : "2013-05-01", | |||
"pmid" : "16271643", | |||
"title" : "Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial", | "title" : "Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial", | ||
" | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673605676611.pdf", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67661-1/fulltext", | |||
"briefDesignDescription" : "Metoprolol in acute MI" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Smits PC, <i>et al</i>. \"Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction\". <i>The New England Journal of Medicine</i>. 2017. 376(13):1234-1244.", | ||
"pageid" : 3543, | "pageid" : 3543, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "Compare-Acute", | ||
"briefResultsDescription" : "FFR-guided complete revascularization superior to infarct-related artery only PCI", | "briefResultsDescription" : "FFR-guided complete revascularization superior to infarct-related artery only PCI", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : "Compare-Acute", | "abbreviation" : "Compare-Acute", | ||
"timestamp" : "2018-03-12T00:27:10Z", | |||
"published" : "2017-03-30", | |||
"title" : "Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction", | "title" : "Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction", | ||
"pmid" : "28745981" | "statusUsableDate" : "2018-03-11", | ||
"pmid" : "28745981", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMc1706275", | |||
"briefDesignDescription" : "Multivessel PCI vs. FFR-guided complete revascularization", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMc1706275" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "Rivaroxaban + ASA superior to placebo + ASA for secondary prevention of CAD", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "COMPASS", | |||
"citation" : "Eikelboom JW <i>et al</i>. \"Rivaroxaban with or without aspirin in stable cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. 377(14):1319-1330.", | |||
"pageid" : 2955, | "pageid" : 2955, | ||
"expansion" : "Cardiovascular Outcomes for People Using Anticoagulation Stratgies", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709118", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709118", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1709118", | ||
" | "briefDesignDescription" : "Rivaroxaban, ASA, or both in stable CAD", | ||
" | "timestamp" : "2024-08-27T16:42:59Z", | ||
"published" : "2017-08-27", | "published" : "2017-08-27", | ||
"abbreviation" : "COMPASS", | "abbreviation" : "COMPASS", | ||
"title" : "Rivaroxaban with or without aspirin in stable cardiovascular disease | "pmid" : "28844192", | ||
"statusUsableDate" : "2017-09-01", | |||
"title" : "Rivaroxaban with or without aspirin in stable cardiovascular disease" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Cooperative North Scandinavian Enalapril Survival Study", | ||
" | "citation" : "CONSENSUS Trial Study Group. \"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study\". <i>The New England Journal of Medicine</i>. 1987. 316(23):1429-35.", | ||
"pageid" : 18, | "pageid" : 18, | ||
" | "briefResultsDescription" : "Enalapril ↓mortality in NYHA class IV HFrEF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "CONSENSUS", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "2883575", | ||
"title" : "Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study", | |||
"timestamp" : "2021-02-20T21:38:07Z", | |||
"published" : "1987-06-04", | "published" : "1987-06-04", | ||
"abbreviation" : "CONSENSUS", | "abbreviation" : "CONSENSUS", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198706043162301", | ||
"briefDesignDescription" : "Enalapril in severe HFrEF", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198706043162301" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
" | "briefResultsDescription" : "Carvedilol reduces mortality and HF hospitalizations in severe NYHA class III-IV HFrEF", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "COPERNICUS", | |||
"citation" : "Packer M, <i>et al</i>. \"Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure\". <i>Circulation</i>. 2002. 106(17):2194-9.", | |||
"pageid" : 42, | "pageid" : 42, | ||
"expansion" : "Carvedilol Prospective Randomized Cumulative Survival", | |||
"pdfurl" : "http://circ.ahajournals.org/content/106/17/2194.full.pdf", | "pdfurl" : "http://circ.ahajournals.org/content/106/17/2194.full.pdf", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://circ.ahajournals.org/content/106/17/2194.full", | ||
" | "briefDesignDescription" : "Carvedilol in HFrEF", | ||
" | "timestamp" : "2014-06-13T04:33:43Z", | ||
"published" : "2002-10-22", | "published" : "2002-10-22", | ||
"abbreviation" : "COPERNICUS", | "abbreviation" : "COPERNICUS", | ||
"title" : "Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure | "pmid" : "12390947", | ||
"statusUsableDate" : "2012-03-01", | |||
"title" : "Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "diseases" : "Heart Failure;Hyperlipidemia", | ||
" | "briefResultsDescription" : "Statins confer no survival benefit but may reduce hospitalizations in ischemic HFrEF", | ||
"pageName" : "CORONA", | |||
"pageid" : 524, | "pageid" : 524, | ||
"citation" : "Kjekshus J, <i>et al</i>. \"Rosuvastatin in Older Patients with Systolic Heart Failure\". <i>The New England Journal of Medicine</i>. 2007. 357(22):2248-61.", | |||
"expansion" : "Controlled Rosuvastatin Multinational Trial in Heart Failure", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706201", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0706201", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Rosuvastatin in ischemic HFrEF", | ||
"published" : "2007-11-29", | "published" : "2007-11-29", | ||
" | "timestamp" : "2017-12-03T22:34:30Z", | ||
"abbreviation" : "CORONA", | "abbreviation" : "CORONA", | ||
" | "statusUsableDate" : "2012-07-01", | ||
"pmid" : "17984166" | "pmid" : "17984166", | ||
"title" : "Rosuvastatin in Older Patients with Systolic Heart Failure" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa071366", | ||
"subspecialties" : "Critical Care;Endocrinology", | |||
"briefDesignDescription" : "Hydrocortisone in septic shock", | "briefDesignDescription" : "Hydrocortisone in septic shock", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa071366", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"pmid" : "18184957", | |||
"title" : "Hydrocortisone therapy for patients with septic shock", | |||
"published" : "2008-01-10", | |||
"timestamp" : "2018-03-03T22:13:51Z", | |||
"abbreviation" : "CORTICUS", | |||
"diseases" : "Sepsis;Shock", | |||
"briefResultsDescription" : "Improved survival of hydrocortisone in septic shock", | "briefResultsDescription" : "Improved survival of hydrocortisone in septic shock", | ||
"pageName" : "CORTICUS", | "pageName" : "CORTICUS", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "Corticosteroid Therapy of Septic Shock", | ||
" | "pageid" : 4, | ||
"citation" : "Sprung CL, <i>et al</i>. \"Hydrocortisone therapy for patients with septic shock\". <i>New England Journal of Medicine</i>. 2008. 358(2):111-24." | |||
}, | }, | ||
{ | { | ||
"title" : "Optimal medical therapy with or without PCI for stable coronary disease", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "17387127", | |||
"abbreviation" : "COURAGE", | |||
"timestamp" : "2017-12-14T14:38:53Z", | "timestamp" : "2017-12-14T14:38:53Z", | ||
"published" : "2007-04-12", | |||
"briefDesignDescription" : "PCI vs. medical therapy in CAD", | "briefDesignDescription" : "PCI vs. medical therapy in CAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa070829", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa070829", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa070829", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa070829", | ||
" | "expansion" : "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation", | ||
"citation" : "Boden WE, <i>et al</i>. \"Optimal medical therapy with or without PCI for stable coronary disease\". <i>The New England Journal of Medicine</i>. 2007. 356:1503-16.", | "citation" : "Boden WE, <i>et al</i>. \"Optimal medical therapy with or without PCI for stable coronary disease\". <i>The New England Journal of Medicine</i>. 2007. 356:1503-16.", | ||
" | "pageid" : 21, | ||
"pageName" : "COURAGE", | |||
" | |||
"briefResultsDescription" : "No difference between PCI and OMT in stable CAD", | "briefResultsDescription" : "No difference between PCI and OMT in stable CAD", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2900, | "pageid" : 2900, | ||
"citation" : "Juthani-Mehta M, <i>et al</i>. \"Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial\". <i>JAMA</i>. 2016. 316(18):1879-1887.", | "citation" : "Juthani-Mehta M, <i>et al</i>. \"Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial\". <i>JAMA</i>. 2016. 316(18):1879-1887.", | ||
"pageName" : "Cranberry for prevention of pyuria and bacteriuria", | "pageName" : "Cranberry for prevention of pyuria and bacteriuria", | ||
"diseases" : "Bacteriuria;Pyuria", | "diseases" : "Bacteriuria;Pyuria", | ||
"briefResultsDescription" : "Cranberry ineffective to prevent pyuria and bacteriuria", | |||
"trainingLevel" : "student", | |||
"title" : "Effect of cranberry capsules on bacteriuria plus pyuria among older women in nursing homes: A randomized clinical trial", | |||
"pmid" : "27787564", | |||
"statusUsableDate" : "2017-04-01", | |||
"abbreviation" : "", | "abbreviation" : "", | ||
" | "published" : "2016-11-08", | ||
" | "timestamp" : "2017-12-03T22:34:43Z", | ||
"briefDesignDescription" : "Cranberry in for prevention of pyuria and bacteriuria", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.16141", | |||
"subspecialties" : "Infectious Disease;Geriatrics", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Tranexamic acid in trauma", | "briefDesignDescription" : "Tranexamic acid in trauma", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2960835-5/fulltext", | ||
" | "subspecialties" : "Emergency Medicine;Surgery;Hematology", | ||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf", | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673610608355.pdf", | ||
" | "title" : "Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage", | ||
"pmid" : "20554319", | |||
" | |||
"statusUsableDate" : "2013-07-01", | "statusUsableDate" : "2013-07-01", | ||
" | "abbreviation" : "CRASH-2", | ||
"published" : "2010-07-03", | "published" : "2010-07-03", | ||
"timestamp" : "2022-12-01T18:56:37Z", | |||
"pageName" : "CRASH-2", | "pageName" : "CRASH-2", | ||
"diseases" : "Trauma", | "diseases" : "Trauma", | ||
" | "briefResultsDescription" : "Tranexamic acid reduces 4-week mortality", | ||
" | "trainingLevel" : "resident", | ||
"expansion" : "Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2", | |||
"pageid" : 490, | |||
"citation" : "Shakur H, <i>et al</i>. \"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage\". <i>The Lancet</i>. 2010. 376(9734):23-32." | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1817226", | ||
"subspecialties" : "Hematology;Oncology", | |||
"briefDesignDescription" : "Ide-cel CART in myeloma", | "briefDesignDescription" : "Ide-cel CART in myeloma", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817226", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817226", | ||
" | "pmid" : "31042825", | ||
"statusUsableDate" : "2022-06-16", | "statusUsableDate" : "2022-06-16", | ||
"title" : "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma", | |||
"published" : "2019-05-02", | |||
"timestamp" : "2022-06-17T05:34:20Z", | |||
"abbreviation" : "CRB-401", | |||
"diseases" : "Multiple Myeloma", | |||
"briefResultsDescription" : "CRS 76%, ORR 85%, PFS 11.8 months", | "briefResultsDescription" : "CRS 76%, ORR 85%, PFS 11.8 months", | ||
"pageName" : "CRB-401", | "pageName" : "CRB-401", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "", | ||
" | "pageid" : 4096, | ||
"citation" : "Raje N, <i>et al</i>. \"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma\". <i>The New England Journal of Medicine</i>. 2019. 380(18):1726-1737." | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "CREDENCE", | |||
"timestamp" : "2019-10-15T19:28:09Z", | "timestamp" : "2019-10-15T19:28:09Z", | ||
"published" : "2019-06-13", | |||
"title" : "Canagliflozin and renal outcomes in diabetic nephropathy", | |||
"pmid" : "30990260", | |||
"statusUsableDate" : "2019-07-31", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811744", | |||
"briefDesignDescription" : "Canagliflozin in diabetic nephropathy", | "briefDesignDescription" : "Canagliflozin in diabetic nephropathy", | ||
"subspecialties" : "Endocrinology;Nephrology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1811744", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1811744", | ||
"citation" : "Perkovic V, <i>et al</i>. \"Canagliflozin and renal outcomes in diabetic nephropathy\". <i>The New England Journal of Medicine</i>. 2019. 380(24):2295-2306.", | |||
"pageid" : 4088, | "pageid" : 4088, | ||
" | "expansion" : "Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluation", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "CREDENCE", | ||
"briefResultsDescription" : "Canagliflozin reduces renal and CVD endpoints vs. placebo", | "briefResultsDescription" : "Canagliflozin reduces renal and CVD endpoints vs. placebo", | ||
"diseases" : "Diabetes Mellitus;Diabetic Nephropathy" | |||
"diseases" : "Diabetes Mellitus;Diabetic Nephropathy | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
" | "pageName" : "CREST", | ||
" | "diseases" : "Carotid Stenosis;Stroke;Transient Ischemic Attack", | ||
"briefResultsDescription" : "No difference in stroke/MI/death; stenting ↑perioperative stroke but ↓perioperative MI", | |||
"pageid" : 492, | "pageid" : 492, | ||
"citation" : "Brott TG, <i>et al</i>. \"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis\". <i>The New England Journal of Medicine</i>. 2010. 363(1):11-23.", | "citation" : "Brott TG, <i>et al</i>. \"Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis\". <i>The New England Journal of Medicine</i>. 2010. 363(1):11-23.", | ||
"expansion" : "Carotid Revascularization Endarterectomy vs. Stenting Trial", | "expansion" : "Carotid Revascularization Endarterectomy vs. Stenting Trial", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0912321", | ||
" | "briefDesignDescription" : "Stenting vs. CEA in carotid stenosis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0912321", | |||
"subspecialties" : "Surgery;Neurology;Cardiology", | |||
"abbreviation" : "CREST", | |||
"published" : "2010-07-01", | "published" : "2010-07-01", | ||
" | "timestamp" : "2019-01-30T21:43:56Z", | ||
"title" : "Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis", | "title" : "Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis", | ||
"pmid" : "20505173" | "pmid" : "20505173", | ||
"statusUsableDate" : "2012-03-01" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://bit.ly/1kLbQWJ", | ||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "Colloids vs. crystalloids in shock", | "briefDesignDescription" : "Colloids vs. crystalloids in shock", | ||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/928522/joi130081.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/928522/joi130081.pdf", | ||
"statusUsableDate" : "2014-07-01", | "statusUsableDate" : "2014-07-01", | ||
"pmid" : "24108515", | |||
"title" : "Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock", | |||
"published" : "2013-11-06", | |||
"timestamp" : "2017-12-03T22:34:32Z", | |||
"abbreviation" : "CRISTAL", | |||
"diseases" : "Shock", | |||
"briefResultsDescription" : "Colloids no different from crystalloids in mortality", | "briefResultsDescription" : "Colloids no different from crystalloids in mortality", | ||
"pageName" : "CRISTAL", | "pageName" : "CRISTAL", | ||
" | "trainingLevel" : "resident", | ||
" | "expansion" : "Colloids Versus Crystalloids for the Resuscitation of the Critically Ill", | ||
" | "pageid" : 1768, | ||
"citation" : "Annane D, <i>et al</i>. \"Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock\". <i>The Journal of the American Medical Association</i>. 2013. 310(17):1809-1817." | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Diabetic Nephropathy;Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Captopril reduces T1DM nephropathy progression", | ||
" | "pageName" : "CSG Captopril Trial", | ||
"trainingLevel" : "Student", | |||
"expansion" : "Collaborative Study Group Captopril Trial", | |||
"pageid" : 1591, | "pageid" : 1591, | ||
"citation" : "Lewis EJ, <i>et al</i>. \"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\". <i>The New England Journal of Medicine</i>. 1993. 329(20):1456-1462.", | "citation" : "Lewis EJ, <i>et al</i>. \"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.\". <i>The New England Journal of Medicine</i>. 1993. 329(20):1456-1462.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199311113292004", | |||
"subspecialties" : "Nephrology;Endocrinology", | "subspecialties" : "Nephrology;Endocrinology", | ||
" | "briefDesignDescription" : "Captopril in T1DM nephropathy", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199311113292004", | |||
"pmid" : "8413456", | |||
"statusUsableDate" : "2013-08-01", | "statusUsableDate" : "2013-08-01", | ||
" | "title" : "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.", | ||
"published" : "1993-11-11", | "published" : "1993-11-11", | ||
" | "timestamp" : "2021-04-22T22:10:39Z", | ||
"abbreviation" : "CSG Captopril Trial" | |||
"abbreviation" : "CSG Captopril Trial | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1710261#t", | |||
"briefDesignDescription" : "Culprit-only vs. multivessel PCI in cardiogenic shock", | "briefDesignDescription" : "Culprit-only vs. multivessel PCI in cardiogenic shock", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1710261#t", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1710261#t", | ||
" | "pmid" : "29083953", | ||
"statusUsableDate" : "2017-11-01", | "statusUsableDate" : "2017-11-01", | ||
"title" : "PCI strategies in patients with acute myocardial infarction and cardiogenic shock", | |||
"timestamp" : "2018-08-28T15:50:00Z", | |||
"published" : "2017-10-30", | |||
"abbreviation" : "CULPRIT-SHOCK", | |||
"briefResultsDescription" : "Culprit-only PCI superior to multivessel PCI in cardiogenic shock", | "briefResultsDescription" : "Culprit-only PCI superior to multivessel PCI in cardiogenic shock", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "CULPRIT-SHOCK", | "pageName" : "CULPRIT-SHOCK", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock", | ||
" | "citation" : "Thiele H, <i>et al</i>. \"PCI strategies in patients with acute myocardial infarction and cardiogenic shock\". <i>New England Journal of Medicine</i>. 2017. epub 2017-10-30:1-13.", | ||
" | "pageid" : 2977 | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "CURE", | |||
"published" : "2001-08-16", | |||
"timestamp" : "2017-12-03T22:34:36Z", | "timestamp" : "2017-12-03T22:34:36Z", | ||
"title" : "Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation", | |||
"pmid" : "11519503", | |||
"statusUsableDate" : "2012-12-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010746", | |||
"briefDesignDescription" : "Clopidogrel in UA/NSTEMI", | "briefDesignDescription" : "Clopidogrel in UA/NSTEMI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010746", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010746", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 921, | "pageid" : 921, | ||
"citation" : "Yusuf S, <i>et al</i>. \"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation\". <i>The New England Journal of Medicine</i>. 2001. 345(7):494-502.", | "citation" : "Yusuf S, <i>et al</i>. \"Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation\". <i>The New England Journal of Medicine</i>. 2001. 345(7):494-502.", | ||
"expansion" : "Clopidogrel in Unstable Angina to Prevent Recurrent Events", | "expansion" : "Clopidogrel in Unstable Angina to Prevent Recurrent Events", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "CURE", | "pageName" : "CURE", | ||
"diseases" : "Acute Coronary Syndrome", | "diseases" : "Acute Coronary Syndrome", | ||
" | "briefResultsDescription" : "Clopidogrel reduces CV events but increases bleeding in UA/NSTEMI" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Culprit lesion-only vs. complete revascularization", | "briefDesignDescription" : "Culprit lesion-only vs. complete revascularization", | ||
"fulltexturl" : "http://www.onlinejacc.org/content/65/10/963", | "fulltexturl" : "http://www.onlinejacc.org/content/65/10/963", | ||
" | "subspecialties" : "Cardiology", | ||
"pdfurl" : "http://www.onlinejacc.org/content/accj/65/10/963.full.pdf?download", | "pdfurl" : "http://www.onlinejacc.org/content/accj/65/10/963.full.pdf?download", | ||
" | "title" : "Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease", | ||
"statusUsableDate" : "2017-02-01", | "statusUsableDate" : "2017-02-01", | ||
" | "pmid" : "25766941", | ||
"abbreviation" : "CvLPRIT", | |||
"published" : "2015-03-17", | "published" : "2015-03-17", | ||
"timestamp" : "2017-12-03T22:34:45Z", | |||
"pageName" : "CvLPRIT", | "pageName" : "CvLPRIT", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Complete revascularization superior to culprit lesion-only revascularization", | ||
" | "trainingLevel" : "Resident", | ||
"expansion" : "Complete Versus Lesion-Only Primary PCI Trial", | |||
"pageid" : 2880, | |||
"citation" : "Gershlick <i>et al</i>. \"Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease\". <i>J Am Coll Cardiol</i>. 2015. 65(10):963-72." | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Pulse no worse than daily cyclophosphamide", | ||
"diseases" : "Vasculitis", | |||
" | "pageName" : "CYCLOPS", | ||
" | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"expansion" : null, | |||
"citation" : "de Groot K, <i>et al</i>. \"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial\". <i>Annals of Internal Medicine</i>. 2009. 150(10):670-680.", | "citation" : "de Groot K, <i>et al</i>. \"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial\". <i>Annals of Internal Medicine</i>. 2009. 150(10):670-680.", | ||
"pageid" : 2338, | |||
"subspecialties" : "Rheumatology;Nephrology", | "subspecialties" : "Rheumatology;Nephrology", | ||
" | "fulltexturl" : null, | ||
"briefDesignDescription" : "Pulse cyclophosphamide for ANCA vasculitis", | |||
"pdfurl" : "http://annals.org/data/Journals/AIM/20182/0000605-200905190-00004.pdf", | |||
"pmid" : "19451574", | |||
"statusUsableDate" : "2015-03-01", | "statusUsableDate" : "2015-03-01", | ||
" | "title" : "Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial", | ||
"timestamp" : "2017-12-03T22:34:37Z", | |||
"published" : "2009-05-19", | "published" : "2009-05-19", | ||
"abbreviation" : "CYCLOPS" | |||
"abbreviation" : "CYCLOPS | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
" | "diseases" : "Tobacco Abuse", | ||
" | "briefResultsDescription" : "Cytisine superior to NRT for abstinence at 1 month", | ||
"pageName" : "Cytisine for Smoking Cessation", | |||
"pageid" : 2319, | "pageid" : 2319, | ||
"citation" : "Walker N, <i>et al</i>. \"Cytisine versus nicotine for smoking cessation\". <i>The New England Journal of Medicine</i>. 2014. 371(25):2353-2362.", | |||
"expansion" : null, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407764", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407764", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1407764", | ||
"subspecialties" : "Pulmonology;Preventive Medicine", | "subspecialties" : "Pulmonology;Preventive Medicine", | ||
" | "briefDesignDescription" : "Cytisine vs. NRT for tobacco abuse", | ||
"published" : "2014-12-18", | "published" : "2014-12-18", | ||
" | "timestamp" : "2018-01-13T01:32:16Z", | ||
"abbreviation" : null, | "abbreviation" : null, | ||
" | "statusUsableDate" : "2015-01-01", | ||
"pmid" : "25517706" | "pmid" : "25517706", | ||
"title" : "Cytisine versus nicotine for smoking cessation" | |||
}, | }, | ||
{ | { | ||
"title" : "Cardiovascular events and intensity of treatment in polycythemia vera", | |||
"statusUsableDate" : "2016-02-01", | |||
"pmid" : "23216616", | |||
"abbreviation" : "CYTO-PV", | |||
"published" : "2013-01-03", | |||
"timestamp" : "2017-12-03T22:34:39Z", | "timestamp" : "2017-12-03T22:34:39Z", | ||
"briefDesignDescription" : "Hematocrit thresholds in PV", | "briefDesignDescription" : "Hematocrit thresholds in PV", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208500", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208500", | ||
"subspecialties" : "Hematology;Cardiology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208500", | |||
"expansion" : "Cytoreductive Therapy in Polycythemia Vera", | |||
"pageid" : 2709, | "pageid" : 2709, | ||
"citation" : "Marchioli R, <i>et al</i>. \"Cardiovascular events and intensity of treatment in polycythemia vera\". <i>The New England Journal of Medicine</i>. 2013. 368(1):22-33.", | "citation" : "Marchioli R, <i>et al</i>. \"Cardiovascular events and intensity of treatment in polycythemia vera\". <i>The New England Journal of Medicine</i>. 2013. 368(1):22-33.", | ||
"pageName" : "CYTO-PV", | "pageName" : "CYTO-PV", | ||
"diseases" : "Polycythemia Vera;Myeloproliferative Neoplasms", | "diseases" : "Polycythemia Vera;Myeloproliferative Neoplasms", | ||
" | "briefResultsDescription" : "Fewer vascular events with hematocrit <45% compared to 45-50%", | ||
"trainingLevel" : "Fellow" | |||
" | |||
}, | }, | ||
{ | { | ||
"pageid" : 1554, | "pageid" : 1554, | ||
"citation" : "Kress JP, <i>et al</i>. \"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation\". <i>The New England Journal of Medicine</i>. 2000. 342(20):1471-1477.", | "citation" : "Kress JP, <i>et al</i>. \"Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation\". <i>The New England Journal of Medicine</i>. 2000. 342(20):1471-1477.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Respiratory Failure", | |||
"briefResultsDescription" : "Sedation holidays reduce intubated, ICU, hospital days", | "briefResultsDescription" : "Sedation holidays reduce intubated, ICU, hospital days", | ||
"pageName" : "Daily ICU Sedation Holidays", | |||
"published" : "2000-05-18", | "published" : "2000-05-18", | ||
" | "timestamp" : "2017-12-03T22:35:01Z", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
"pmid" : "10816184", | |||
"statusUsableDate" : "2013-08-01", | |||
"title" : "Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation", | "title" : "Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200005183422002", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200005183422002", | |||
"subspecialties" : "Critical Care;Pulmonology", | |||
"briefDesignDescription" : "Scheduled daily sedation holidays in intubated patients" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "pageName" : "DANAMI-3 PRIMULTI", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"briefResultsDescription" : "FFR-guided revascularization was superior to culprit-lesion only in multivessel CAD", | |||
"pageid" : 3634, | "pageid" : 3634, | ||
"citation" : "Engstrom T, <i>et al</i>. \"Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease\". <i>The Lancet</i>. 2015. 386:665-71.", | |||
"expansion" : "Third Danish Study of Optimal Acute Treatment of Patients with STEMI: Primary PCI in Multivessel Disease", | |||
"pdfurl" : "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60648-1.pdf", | "pdfurl" : "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)60648-1.pdf", | ||
" | "briefDesignDescription" : "Culprit lesion PCI vs. FFR in multivessel CAD", | ||
" | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60648-1/fulltext", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "DANAMI-3 PRIMULTI", | ||
"published" : "2015-08-15", | "published" : "2015-08-15", | ||
" | "timestamp" : "2018-05-31T17:39:19Z", | ||
"title" : "Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease", | "title" : "Complete Revascularization Versus Treatment of the Culprit Lesion Only in Patients with ST-segment Elevation Myocardial Infarction and Multivessel Disease", | ||
"statusUsableDate" : "2018-05-28", | |||
"pmid" : "26347918" | "pmid" : "26347918" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Danish–German Cardiogenic Shock", | ||
" | "citation" : "Møller JE, <i>et al</i>. \"Microaxial flow pump or standard care in infarct-related cardiogenic shock\". <i>The New England Journal of Medicine</i>. 2024. 390(15):1382-1393.", | ||
"pageid" : 5645, | "pageid" : 5645, | ||
" | "pageName" : "DanGer Shock", | ||
"briefResultsDescription" : "Impella lowers 180d mortality if STEMI w/shock", | |||
"diseases" : "Myocardial Infarction;Cardiogenic Shock", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Microaxial flow pump or standard care in infarct-related cardiogenic shock", | ||
"statusUsableDate" : "2024-12-15", | "statusUsableDate" : "2024-12-15", | ||
" | "pmid" : "38587239", | ||
"abbreviation" : "DanGer Shock", | |||
"timestamp" : "2025-01-23T17:44:24Z", | |||
"published" : "2024-04-18", | "published" : "2024-04-18", | ||
" | "briefDesignDescription" : "Impella in STEMI w/cardiogenic shock", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2312572", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312572" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "DANISH", | |||
"timestamp" : "2017-12-03T22:34:48Z", | "timestamp" : "2017-12-03T22:34:48Z", | ||
"published" : "2016-08-28", | |||
"title" : "Defibrillator implantation in patients with nonischemic systolic heart failure", | |||
"statusUsableDate" : "2016-09-01", | |||
"pmid" : "27571011", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1608029", | |||
"briefDesignDescription" : "ICD vs. standard care in NICM and LVEF ≤35%", | "briefDesignDescription" : "ICD vs. standard care in NICM and LVEF ≤35%", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1608029", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1608029", | ||
"citation" : "Kober L, <i>et al</i>. \"Defibrillator implantation in patients with nonischemic systolic heart failure\". <i>The New England Journal of Medicine</i>. 2016. epub 2016-08-28:1-10.", | |||
"pageid" : 2815, | "pageid" : 2815, | ||
" | "expansion" : "Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "DANISH", | ||
"briefResultsDescription" : "ICD not better than standard of care in NICM and LVEF ≤35%", | "briefResultsDescription" : "ICD not better than standard of care in NICM and LVEF ≤35%", | ||
"diseases" : "Ventricular Tachycardia" | |||
"diseases" : "Ventricular Tachycardia | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "DAPA-CKD", | ||
"diseases" : "Chronic Kidney Disease", | |||
"briefResultsDescription" : "Dapagliflozin in CKD reduces renal endpoints and CVD death", | |||
"trainingLevel" : "resident", | |||
"expansion" : "Dapagliflozin in Chronic Kidney Disease", | |||
"pageid" : 4363, | |||
"citation" : "Heerspink, <i>et al</i>. \"Dapagliflozin in patients with chronic kidney disease\". <i>The New England Journal of Medicine</i>. 2020. 383(13):1436-1446.", | |||
"briefDesignDescription" : "Dapagliflozin in CKD±T2DM", | "briefDesignDescription" : "Dapagliflozin in CKD±T2DM", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2024816", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2024816", | ||
" | "subspecialties" : "Nephrology;Cardiology", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024816", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024816", | ||
" | "title" : "Dapagliflozin in patients with chronic kidney disease", | ||
"pmid" : "32970396", | |||
" | |||
"statusUsableDate" : "2020-10-29", | "statusUsableDate" : "2020-10-29", | ||
" | "abbreviation" : "DAPA-CKD", | ||
"published" : "2020-10-08", | "published" : "2020-10-08", | ||
" | "timestamp" : "2021-05-28T02:47:35Z" | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Dapagliflozin reduces CV complications in HFrEF", | ||
"diseases" : "Heart Failure", | |||
" | "pageName" : "DAPA-HF", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Dapagliflozin in Heart Failure", | |||
"citation" : "McMurray JJV, <i>et al</i>. \"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2019. 381(21):1995-2008.", | "citation" : "McMurray JJV, <i>et al</i>. \"Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2019. 381(21):1995-2008.", | ||
"pageid" : 4113, | |||
"subspecialties" : "Cardiology;Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1911303", | ||
"briefDesignDescription" : "Dapagliflozin in HFrEF", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1911303", | |||
"pmid" : "31535829", | |||
"statusUsableDate" : "2019-12-12", | "statusUsableDate" : "2019-12-12", | ||
" | "title" : "Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction", | ||
"timestamp" : "2022-10-13T18:58:46Z", | |||
"published" : "2019-11-21", | "published" : "2019-11-21", | ||
"abbreviation" : "DAPA-HF" | |||
"abbreviation" : "DAPA-HF | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "DAPT", | ||
"diseases" : "Coronary Artery Disease;Myocardial Infarction;Stroke", | |||
"briefResultsDescription" : "Longer duration reduces stent thrombosis, MI, stroke, but increases mortality/bleeding", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Dual Antiplatelet Therapy", | |||
"pageid" : 2264, | |||
"citation" : "Mauri L, <i>et al</i>. \"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents\". <i>The New England Journal of Medicine</i>. 2014. 371(23):2155-2166.", | |||
"briefDesignDescription" : "Aspirin/clopidogrel duration after PCI", | "briefDesignDescription" : "Aspirin/clopidogrel duration after PCI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1409312", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1409312", | ||
" | "subspecialties" : "Cardiology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409312", | ||
" | "title" : "Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents", | ||
"pmid" : "25399658", | |||
" | |||
"statusUsableDate" : "2014-11-01", | "statusUsableDate" : "2014-11-01", | ||
" | "abbreviation" : "DAPT", | ||
"published" : "2014-11-16", | "published" : "2014-11-16", | ||
" | "timestamp" : "2017-12-03T22:34:50Z" | ||
}, | |||
}, | |||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199704173361601", | ||
"subspecialties" : "Cardiology;Nephrology", | |||
"briefDesignDescription" : "DASH diet in HTN", | "briefDesignDescription" : "DASH diet in HTN", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199704173361601", | ||
" | "pmid" : "9099655", | ||
"statusUsableDate" : "2012-04-01", | "statusUsableDate" : "2012-04-01", | ||
"title" : "A clinical trial of the effects of dietary patterns on blood pressure", | |||
"published" : "1997-04-17", | |||
"timestamp" : "2020-09-22T18:22:21Z", | |||
"abbreviation" : "DASH", | |||
"diseases" : "Hypertension", | |||
"briefResultsDescription" : "DASH diet reduces SBP and DBP", | "briefResultsDescription" : "DASH diet reduces SBP and DBP", | ||
"pageName" : "DASH", | "pageName" : "DASH", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "Dietary Approaches to Stop Hypertension", | ||
" | "pageid" : 90, | ||
"citation" : "Appel LJ, <i>et al</i>. \"A clinical trial of the effects of dietary patterns on blood pressure\". <i>The New England Journal of Medicine</i>. 1997. 336(16):1117-1124." | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Wilkoff BL, <i>et al</i>. \"Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator\". <i>Journal of the American Medical Association</i>. 2002. 288(24):3115-3123.", | ||
"pageid" : 2713, | "pageid" : 2713, | ||
" | "expansion" : "Dual-chamber pacing or ventricular backup pacing in ICD patients", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "DAVID", | ||
"briefResultsDescription" : "Ventricular backup pacemaker superior to dual-chamber pacemaker", | "briefResultsDescription" : "Ventricular backup pacemaker superior to dual-chamber pacemaker", | ||
"diseases" : "Bradycardia", | "diseases" : "Bradycardia", | ||
"abbreviation" : "DAVID", | "abbreviation" : "DAVID", | ||
"timestamp" : "2017-12-03T22:34:54Z", | |||
"published" : "2002-12-25", | |||
"title" : "Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator", | "title" : "Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator", | ||
"pmid" : "12495391" | "statusUsableDate" : "2016-08-01", | ||
"pmid" : "12495391", | |||
"pdfurl" : null, | |||
"briefDesignDescription" : "Dual-chamber vs. ventricular backup pacing in ICD patients", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://jama.jamanetwork.com/article.aspx?volume" | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2020-01-25T11:34:00Z", | "timestamp" : "2020-01-25T11:34:00Z", | ||
"published" : "2018-01-04", | |||
"abbreviation" : "DAWN", | |||
"pmid" : "29129157", | |||
"statusUsableDate" : "2020-01-23", | |||
"title" : "Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1706442", | |||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1706442", | |||
"briefDesignDescription" : "Thrombectomy 6-24 hours after stroke", | "briefDesignDescription" : "Thrombectomy 6-24 hours after stroke", | ||
" | "citation" : "Nogueira RG, <i>et al</i>. \"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct\". <i>The New England Journal of Medicine</i>. 2018. 378(1):11-21.", | ||
"pageid" : 3529, | "pageid" : 3529, | ||
" | "expansion" : "DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Thrombectomy improved 90-day outcomes compared to standard care", | "briefResultsDescription" : "Thrombectomy improved 90-day outcomes compared to standard care", | ||
"diseases" : "Stroke", | "diseases" : "Stroke", | ||
" | "pageName" : "DAWN" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Diabetes Control and Complications Trial", | ||
"pageid" : 135, | "pageid" : 135, | ||
"citation" : "DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". <i>The New England Journal of Medicine</i>. 1993. 329(14):977-986.", | "citation" : "DCCT Research Group. \"The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus\". <i>The New England Journal of Medicine</i>. 1993. 329(14):977-986.", | ||
"pageName" : "DCCT", | "pageName" : "DCCT", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
"briefResultsDescription" : "Intensive therapy delays microvascular but not macrovascular complications in T1DM", | |||
"trainingLevel" : "Student", | |||
"title" : "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus", | |||
"pmid" : "8366922", | |||
"statusUsableDate" : "2012-03-01", | |||
"abbreviation" : "DCCT", | "abbreviation" : "DCCT", | ||
" | "published" : "1993-09-30", | ||
" | "timestamp" : "2012-09-16T11:23:12Z", | ||
"briefDesignDescription" : "Intensive glycemic therapy in T1DM", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199309303291401", | |||
"subspecialties" : "Endocrinology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation", | ||
"pageid" : 84, | "pageid" : 84, | ||
"citation" : "Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.", | "citation" : "Kadish A, <i>et al</i>. \"Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy\". <i>The New England Journal of Medicine</i>. 2004. 350(21):2151-2158.", | ||
"pageName" : "DEFINITE", | "pageName" : "DEFINITE", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "ICD reduced risk of arrhythmogenic sudden death, but not overall mortality", | |||
"trainingLevel" : "Resident", | |||
"title" : "Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy", | |||
"pmid" : "15152060", | |||
"statusUsableDate" : "2012-03-01", | |||
"abbreviation" : "DEFINITE", | "abbreviation" : "DEFINITE", | ||
" | "published" : "2004-05-20", | ||
" | "timestamp" : "2014-06-13T04:45:33Z", | ||
"briefDesignDescription" : "ICD vs. medical therapy in HFrEF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa033088", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa033088" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "", | ||
"fulltexturl" : "http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1831407", | "fulltexturl" : "http://jamanetwork.com/journals/jamapsychiatry/fullarticle/1831407", | ||
"subspecialties" : "Psychiatry;Geriatrics", | "subspecialties" : "Psychiatry;Geriatrics", | ||
" | "briefDesignDescription" : "Ramelteon vs. placebo to prevent delirium", | ||
"published" : "2014-04-01", | |||
"timestamp" : "2021-10-04T20:25:15Z", | |||
"abbreviation" : "DELIRIA-J", | |||
"statusUsableDate" : "2021-09-30", | "statusUsableDate" : "2021-09-30", | ||
"pmid" : "24554232", | |||
"title" : "Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial", | |||
"trainingLevel" : "Resident", | |||
"diseases" : "Delirium", | |||
"briefResultsDescription" : "Ramelteon decreased risk of delirium in elderly patients", | "briefResultsDescription" : "Ramelteon decreased risk of delirium in elderly patients", | ||
"pageName" : "DELIRIA-J", | "pageName" : "DELIRIA-J", | ||
" | "pageid" : 2806, | ||
" | "citation" : "Hatta K, <i>et al</i>. \"Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial\". <i>JAMA Psychiatry</i>. 2014. 71(4):397-403.", | ||
"expansion" : "Delirium Intervention Research for Improving Acute phase outcomes in Japan" | |||
" | }, | ||
}, | |||
{ | { | ||
"pmid" : "36027570", | |||
"statusUsableDate" : "2022-10-13", | |||
"title" : "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction", | |||
"timestamp" : "2023-05-04T03:39:40Z", | "timestamp" : "2023-05-04T03:39:40Z", | ||
"published" : "2022-09-22", | |||
"abbreviation" : "DELIVER", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2206286", | |||
"briefDesignDescription" : "Dapagliflozin in HFmrEF or HFpEF", | "briefDesignDescription" : "Dapagliflozin in HFmrEF or HFpEF", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206286", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2206286", | ||
" | "expansion" : "Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure", | ||
"citation" : "Solomon SD, <i>et al</i>. \"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2022. 387(12):1089-1098.", | "citation" : "Solomon SD, <i>et al</i>. \"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2022. 387(12):1089-1098.", | ||
" | "pageid" : 4921, | ||
"briefResultsDescription" : "Dapagliflozin reduces HF events in HFmrEF or HFpEF", | "briefResultsDescription" : "Dapagliflozin reduces HF events in HFmrEF or HFpEF", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "DELIVER", | "pageName" : "DELIVER", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction", | ||
" | "citation" : "Hofmann R, <i>et al</i>. \"Oxygen therapy in suspected acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 2017. 377(13):1240-1249.", | ||
"pageid" : 2970, | "pageid" : 2970, | ||
" | "briefResultsDescription" : "Oxygen doesn't improve 1 year survival in MI", | ||
"diseases" : "Myocardial Infarction", | |||
"pageName" : "DETO2X-AMI", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"statusUsableDate" : "2017-10-01", | "statusUsableDate" : "2017-10-01", | ||
" | "pmid" : "28844200", | ||
"title" : "Oxygen therapy in suspected acute myocardial infarction", | |||
"timestamp" : "2018-02-01T20:15:39Z", | |||
"published" : "2017-09-28", | "published" : "2017-09-28", | ||
"abbreviation" : "DETO2X-AMI", | "abbreviation" : "DETO2X-AMI", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1706222", | ||
"briefDesignDescription" : "Oxygen for suspected MI", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1706222" | |||
}, | }, | ||
{ | { | ||
"pageid" : 89, | "pageid" : 89, | ||
"citation" : "Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.", | "citation" : "Gorlin R, <i>et al</i>. \"The effect of digoxin on mortality and morbidity in patients with heart failure\". <i>The New England Journal of Medicine</i>. 1997. 336(8):525-533.", | ||
"expansion" : "Digitalis Investigation Group", | "expansion" : "Digitalis Investigation Group", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "DIG", | "pageName" : "DIG", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "Reduced hospitalizations, no mortality benefit", | |||
"abbreviation" : "DIG", | "abbreviation" : "DIG", | ||
"published" : "1997-02-20", | |||
"timestamp" : "2014-06-13T04:50:56Z", | |||
"title" : "The effect of digoxin on mortality and morbidity in patients with heart failure", | "title" : "The effect of digoxin on mortality and morbidity in patients with heart failure", | ||
"pmid" : "9036306" | "pmid" : "9036306", | ||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199702203360801", | |||
"briefDesignDescription" : "Digoxin in HFrEF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199702203360801", | |||
"subspecialties" : "Cardiology" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa041489", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "ICD for ICM shortly after MI", | "briefDesignDescription" : "ICD for ICM shortly after MI", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa041489", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa041489", | ||
" | "pmid" : "15590950", | ||
"statusUsableDate" : "2016-04-01", | "statusUsableDate" : "2016-04-01", | ||
"title" : "Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction", | |||
"published" : "2004-12-09", | |||
"timestamp" : "2020-09-14T19:26:41Z", | |||
"abbreviation" : "DINAMIT", | |||
"diseases" : "Heart Failure;Myocardial Infarction", | |||
"briefResultsDescription" : "ICD reduces arrhythmia but not mortality", | "briefResultsDescription" : "ICD reduces arrhythmia but not mortality", | ||
"pageName" : "DINAMIT", | "pageName" : "DINAMIT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Defibrillator in Acute Myocardial Infarction Trial", | ||
" | "pageid" : 1743, | ||
"citation" : "Hohnloser SH, <i>et al</i>. \"Prophylactic use of an implantable cardioverter–defibrillator after acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 2004. 351(24):2481-2488." | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "BMS vs. DES for saphenous vein graft PCI", | "briefDesignDescription" : "BMS vs. DES for saphenous vein graft PCI", | ||
"fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30801-8/fulltext", | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30801-8/fulltext", | ||
" | "subspecialties" : "Cardiology", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "title" : "Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial", | ||
"pmid" : "29759512", | |||
" | |||
"statusUsableDate" : "2018-11-27", | "statusUsableDate" : "2018-11-27", | ||
" | "abbreviation" : "DIVA", | ||
"published" : "2018-05-19", | "published" : "2018-05-19", | ||
"timestamp" : "2019-10-17T17:40:21Z", | |||
"pageName" : "DIVA", | "pageName" : "DIVA", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "BMS noninferior to DES for saphenous vein graft PCI", | ||
" | "trainingLevel" : "Resident", | ||
"expansion" : "Rationale and design of the drug-eluting stents vs bare-metal stents in saphenous vein graft angioplasty", | |||
"pageid" : 3743, | |||
"citation" : "Brilakis ES, <i>et al</i>. \"Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial\". <i>Lancet</i>. 2018. 391(10134):1997-2007." | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Kearon C, <i>et al</i>. \"Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study\". <i>Journal of Thrombosis and Hemostasis</i>. 2019. 17(7):1144-52.", | ||
"pageid" : 4089, | "pageid" : 4089, | ||
" | "expansion" : "D-dimer Optimal Duration Study", | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pageName" : "DODS", | ||
"briefResultsDescription" : "D-dimer based discontinuation effective in women, not for men", | "briefResultsDescription" : "D-dimer based discontinuation effective in women, not for men", | ||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | "diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | ||
"abbreviation" : "DODS", | "abbreviation" : "DODS", | ||
"timestamp" : "2019-07-18T20:41:06Z", | |||
"published" : "2019-01-18", | |||
"title" : "Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study", | "title" : "Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to D-dimer results: a cohort study", | ||
"pmid" : "31033194" | "pmid" : "31033194", | ||
"statusUsableDate" : "2019-07-18", | |||
"pdfurl" : "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14458", | |||
"briefDesignDescription" : "D-dimer based anticoagulation discontinuation", | |||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14458" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Donors of Hepatitis C NAT Positive Thoracic Allografts for Transplantation Evaluation in Non-HCV Recipients", | ||
" | "citation" : "Woolley AE, <i>et al</i>. \"Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients\". <i>The New England Journal of Medicine</i>. 2019. 380(17):1606-1617.", | ||
"pageid" : 4066, | "pageid" : 4066, | ||
" | "briefResultsDescription" : "Donor HCV+ heart & lung transplant is feasible", | ||
"diseases" : "Heart Failure;Respiratory Failure", | |||
"pageName" : "DONATE-HCV", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "30946553", | ||
"statusUsableDate" : "2019-05-17", | "statusUsableDate" : "2019-05-17", | ||
" | "title" : "Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients", | ||
"timestamp" : "2019-05-23T17:58:08Z", | |||
"published" : "2019-04-25", | "published" : "2019-04-25", | ||
"abbreviation" : "DONATE HCV", | "abbreviation" : "DONATE HCV", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1812406", | ||
"briefDesignDescription" : "Donor HCV positive heart and lung transplant", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812406" | |||
}, | }, | ||
{ | { | ||
"pmid" : "21366472", | |||
"statusUsableDate" : "2013-06-01", | |||
"title" : "Diuretic strategies in patients with acute decompensated heart failure", | |||
"timestamp" : "2022-09-15T20:00:28Z", | "timestamp" : "2022-09-15T20:00:28Z", | ||
"published" : "2011-03-03", | |||
"abbreviation" : "DOSE", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1005419", | |||
"briefDesignDescription" : "Diuretic dosing in acute HF", | "briefDesignDescription" : "Diuretic dosing in acute HF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1005419", | ||
" | "expansion" : "Diuretic Optimization Strategies Evaluation", | ||
"citation" : "Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.", | "citation" : "Felker GM, <i>et al</i>. \"Diuretic strategies in patients with acute decompensated heart failure\". <i>The New England Journal of Medicine</i>. 2011. 364(9):797-805.", | ||
" | "pageid" : 1457, | ||
"briefResultsDescription" : "High-dose better than low-dose, continuous infusions no better than intermittent IV boluses", | "briefResultsDescription" : "High-dose better than low-dose, continuous infusions no better than intermittent IV boluses", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "DOSE", | "pageName" : "DOSE", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "DPP", | |||
"published" : "2002-02-07", | |||
"timestamp" : "2018-05-31T18:34:46Z", | "timestamp" : "2018-05-31T18:34:46Z", | ||
"title" : "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin", | |||
"pmid" : "11832527", | |||
"statusUsableDate" : "2018-05-31", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa012512", | |||
"briefDesignDescription" : "Metformin and intensive lifestyle in prediabetes", | "briefDesignDescription" : "Metformin and intensive lifestyle in prediabetes", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa012512", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa012512", | ||
"subspecialties" : "Endocrinology", | |||
"pageid" : 2494, | "pageid" : 2494, | ||
"citation" : "Knowler WC, <i>et al</i>. \"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin\". <i>The New England Journal of Medicine</i>. 2002. 346(6):393-403.", | "citation" : "Knowler WC, <i>et al</i>. \"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin\". <i>The New England Journal of Medicine</i>. 2002. 346(6):393-403.", | ||
"expansion" : "Diabetes Prevention Program", | "expansion" : "Diabetes Prevention Program", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "DPP", | "pageName" : "DPP", | ||
"diseases" : "Prediabetes;Diabetes Mellitus", | "diseases" : "Prediabetes;Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Metformin and intensive lifestyle reduce incidence of diabetes" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "", | |||
"published" : "2002-10-01", | |||
"timestamp" : "2017-12-03T22:35:03Z", | "timestamp" : "2017-12-03T22:35:03Z", | ||
"title" : "The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)", | |||
"statusUsableDate" : "2013-07-01", | |||
"pmid" : "12361440", | |||
"pdfurl" : "http://archpedi.jamanetwork.com/data/Journals/PEDS/5052/POA20075.pdf", | |||
"briefDesignDescription" : "Duct tape vs. cryotherapy for warts", | "briefDesignDescription" : "Duct tape vs. cryotherapy for warts", | ||
"fulltexturl" : "", | "fulltexturl" : "", | ||
"subspecialties" : "Pediatrics;Dermatology", | |||
"pageid" : 1579, | "pageid" : 1579, | ||
"citation" : "Focht DR, <i>et al</i>. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". <i>Archives of Pediatric and Adolescent Medicine</i>. 2002. 156:971-974.", | "citation" : "Focht DR, <i>et al</i>. \"The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart)\". <i>Archives of Pediatric and Adolescent Medicine</i>. 2002. 156:971-974.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "Duct Tape for Treatment of the Common Wart", | "pageName" : "Duct Tape for Treatment of the Common Wart", | ||
"diseases" : "Warts", | "diseases" : "Warts", | ||
" | "briefResultsDescription" : "Duct tape superior to cryotherapy for wart resolution" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "", | |||
"published" : "2013-01-31", | |||
"timestamp" : "2018-03-29T18:30:43Z", | "timestamp" : "2018-03-29T18:30:43Z", | ||
"title" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | |||
"statusUsableDate" : "2013-02-01", | |||
"pmid" : "23323867", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205037", | |||
"briefDesignDescription" : "Fecal transplant in C. difficile", | "briefDesignDescription" : "Fecal transplant in C. difficile", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205037", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205037", | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | |||
"pageid" : 1226, | "pageid" : 1226, | ||
"citation" : "Van Nood E, <i>et al</i>. \"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile\". <i>The New England Journal of Medicine</i>. 2013. 368(5):407-415.", | "citation" : "Van Nood E, <i>et al</i>. \"Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile\". <i>The New England Journal of Medicine</i>. 2013. 368(5):407-415.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | "pageName" : "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile", | ||
"diseases" : "Clostridium difficile", | "diseases" : "Clostridium difficile", | ||
" | "briefResultsDescription" : "Fecal transplant better than vancomycin in C. difficile" | ||
}, | }, | ||
{ | { | ||
"title" : "Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer", | |||
"pmid" : "20818875", | |||
"statusUsableDate" : "2012-06-01", | |||
"abbreviation" : null, | |||
"timestamp" : "2017-12-03T22:35:32Z", | "timestamp" : "2017-12-03T22:35:32Z", | ||
"published" : "2010-08-19", | |||
"briefDesignDescription" : "Palliative care in NSCLC", | "briefDesignDescription" : "Palliative care in NSCLC", | ||
"subspecialties" : "Oncology;Palliative Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000678", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000678", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000678", | ||
" | "expansion" : null, | ||
"citation" : "Temel JS, <i>et al</i>. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2010. 363(8):733-742.", | "citation" : "Temel JS, <i>et al</i>. \"Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2010. 363(8):733-742.", | ||
" | "pageid" : 466, | ||
"pageName" : "Early Palliative Care", | |||
" | |||
"briefResultsDescription" : "Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care", | "briefResultsDescription" : "Palliative care ↑mood, ↑QOL, ↑survival, ↓aggressive care", | ||
"diseases" : "Lung Cancer", | "diseases" : "Lung Cancer", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "Early TIPS reduces rates of treatment failure and improves 1-year survival", | ||
" | "diseases" : "Cirrhosis;Gastrointestinal Hemorrhage", | ||
"pageName" : "Early TIPS", | |||
"citation" : "García-Pagán JC, <i>et al</i>. \"Early use of TIPS in patients with cirrhosis and variceal bleeding\". <i>The New England Journal of Medicine</i>. 2010. 362(25):2370-2379.", | |||
"pageid" : 2661, | "pageid" : 2661, | ||
"expansion" : "", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910102", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910102", | ||
"subspecialties" : "Gastroenterology;Interventional Radiology", | "subspecialties" : "Gastroenterology;Interventional Radiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0910102", | ||
" | "briefDesignDescription" : "Early TIPS in high-risk cirrhotic variceal bleeding", | ||
" | "timestamp" : "2018-08-30T17:24:07Z", | ||
"published" : "2010-06-24", | "published" : "2010-06-24", | ||
"abbreviation" : "Early TIPS", | "abbreviation" : "Early TIPS", | ||
"title" : "Early use of TIPS in patients with cirrhosis and variceal bleeding | "statusUsableDate" : "2018-08-30", | ||
"pmid" : "20573925", | |||
"title" : "Early use of TIPS in patients with cirrhosis and variceal bleeding" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "EARLY-AF", | |||
"timestamp" : "2021-11-08T18:52:31Z", | "timestamp" : "2021-11-08T18:52:31Z", | ||
"published" : "2021-01-28", | |||
"title" : "Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation", | |||
"statusUsableDate" : "2021-10-14", | |||
"pmid" : "33197159", | |||
"pdfurl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2029980", | |||
"briefDesignDescription" : "Cryoablation vs. antiarrhythmics in AF", | "briefDesignDescription" : "Cryoablation vs. antiarrhythmics in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2029980", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2029980", | ||
"citation" : "Andrade J, <i>et al</i>. \"Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2021. 384(4):305-315.", | |||
"pageid" : 4406, | "pageid" : 4406, | ||
" | "expansion" : "Early Aggressive Invasive Intervention for Atrial Fibrillation", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "EARLY-AF", | ||
"briefResultsDescription" : "Cryoablation with lower tachyarrhythmia recurrence than antiarrhythmics.", | "briefResultsDescription" : "Cryoablation with lower tachyarrhythmia recurrence than antiarrhythmics.", | ||
"diseases" : "Atrial Fibrillation" | |||
"diseases" : "Atrial Fibrillation | |||
}, | }, | ||
{ | { | ||
"pmid" : "22738096", | |||
"statusUsableDate" : "2019-09-19", | |||
"title" : "Early surgery versus conventional treatment for infective endocarditis", | |||
"timestamp" : "2019-09-19T17:42:49Z", | "timestamp" : "2019-09-19T17:42:49Z", | ||
"published" : "2012-06-28", | |||
"abbreviation" : "EASE", | |||
"subspecialties" : "Cardiology;Infectious Disease;Surgery", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1112843", | |||
"briefDesignDescription" : "Early surgery in endocarditis", | "briefDesignDescription" : "Early surgery in endocarditis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112843", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1112843", | ||
" | "expansion" : "Early Surgery versus Conventional Treatment in Infective Endocarditis", | ||
"citation" : "Kang DH, <i>et al</i>. \"Early surgery versus conventional treatment for infective endocarditis\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2466-73.", | "citation" : "Kang DH, <i>et al</i>. \"Early surgery versus conventional treatment for infective endocarditis\". <i>The New England Journal of Medicine</i>. 2012. 366(26):2466-73.", | ||
" | "pageid" : 2939, | ||
"briefResultsDescription" : "Early surgery improves outcomes in infective endocarditis", | "briefResultsDescription" : "Early surgery improves outcomes in infective endocarditis", | ||
" | "diseases" : "Endocarditis", | ||
"pageName" : "EASE", | "pageName" : "EASE", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Kirchhof P, <i>et al</i>. \"Early rhythm-control therapy in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2020. 383(14):1305-1316.", | ||
"pageid" : 4399, | "pageid" : 4399, | ||
" | "expansion" : "The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "EAST-AFNET 4", | ||
"briefResultsDescription" : "Early rhythm control with fewer CVD events.", | "briefResultsDescription" : "Early rhythm control with fewer CVD events.", | ||
"diseases" : "Atrial Fibrillation", | "diseases" : "Atrial Fibrillation", | ||
"abbreviation" : "EAST-AFNET 4", | "abbreviation" : "EAST-AFNET 4", | ||
"timestamp" : "2025-05-15T20:16:15Z", | |||
"published" : "2020-10-01", | |||
"title" : "Early rhythm-control therapy in patients with atrial fibrillation", | "title" : "Early rhythm-control therapy in patients with atrial fibrillation", | ||
"pmid" : "32865375" | "statusUsableDate" : "2021-01-28", | ||
"pmid" : "32865375", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422", | |||
"briefDesignDescription" : "Early rhythm vs. rate control in AF", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2019422" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "ECASS III", | ||
"diseases" : "Stroke", | |||
"briefResultsDescription" : "Alteplase improves neurological outcomes at 3 months", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "European Cooperative Acute Stroke Study III", | |||
"pageid" : 115, | |||
"citation" : "Hacke W, <i>et al</i>. \"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(13):1317-1329.", | |||
"briefDesignDescription" : "Alteplase 3-4.5h after stroke", | "briefDesignDescription" : "Alteplase 3-4.5h after stroke", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0804656", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0804656", | ||
" | "subspecialties" : "Neurology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804656", | ||
" | "title" : "Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke", | ||
"pmid" : "18815396", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : "ECASS III", | ||
"published" : "2008-09-25", | "published" : "2008-09-25", | ||
" | "timestamp" : "2017-04-20T01:11:46Z" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Emergency treatment with Levetiracetam or Phenytoin in convulsive Status Epilepticus in children", | ||
" | "citation" : "Lyttle MD, <i>et al</i>. \"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.\". <i>Lancet</i>. 2019. 393(10186):2125-2134.", | ||
"pageid" : 4086, | "pageid" : 4086, | ||
" | "briefResultsDescription" : "Levetiracetam is non-inferior to phenytoin", | ||
"diseases" : "Status Epilepticus", | |||
"pageName" : "EcLiPSE", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2024-05-16", | "statusUsableDate" : "2024-05-16", | ||
" | "pmid" : "31005385", | ||
"title" : "Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.", | |||
"timestamp" : "2024-06-27T17:56:09Z", | |||
"published" : "2019-05-25", | "published" : "2019-05-25", | ||
"abbreviation" : "EcLiPSE", | "abbreviation" : "EcLiPSE", | ||
" | "subspecialties" : "Emergency Medicine;Pediatrics;Neurology", | ||
" | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30724-X/fulltext", | ||
"briefDesignDescription" : "Levetiracetam vs. phenytoin in status epilepticus", | |||
"pdfurl" : "https://www.thelancet.com/action/showPdf?pii" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "", | ||
"briefDesignDescription" : "CEA in symptomatic carotid stenosis", | "briefDesignDescription" : "CEA in symptomatic carotid stenosis", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2909292-1", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2897%2909292-1", | ||
"subspecialties" : "Surgery;Neurology", | "subspecialties" : "Surgery;Neurology", | ||
" | "abbreviation" : "ECST", | ||
"published" : "1998-05-09", | |||
"timestamp" : "2020-08-01T19:26:48Z", | |||
"title" : "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)", | |||
"pmid" : "9593407", | |||
"statusUsableDate" : "2015-08-01", | "statusUsableDate" : "2015-08-01", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "ECST", | "pageName" : "ECST", | ||
"diseases" : "Carotid Stenosis;Stroke", | "diseases" : "Carotid Stenosis;Stroke", | ||
" | "briefResultsDescription" : "CEA improves outcomes in patients with ≥80% symptomatic carotid stenosis", | ||
" | "pageid" : 2354, | ||
" | "citation" : "ECST Writers. \"Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)\". <i>The Lancet</i>. 1998. 351(9113):1379-1387.", | ||
"expansion" : "European Carotid Surgery Trial" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Epidemiology of Diabetes Interventions and Complications", | ||
"pageid" : 136, | "pageid" : 136, | ||
"citation" : "Nathan DM, <i>et al</i>. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". <i>The New England Journal of Medicine</i>. 2005. 353(25):2643-2653.", | "citation" : "Nathan DM, <i>et al</i>. \"Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes\". <i>The New England Journal of Medicine</i>. 2005. 353(25):2643-2653.", | ||
" | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Intensive therapy associated with fewer cardiovascular complications", | ||
"pageName" : "EDIC", | |||
"trainingLevel" : "intern", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "16371630", | ||
"title" : "Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes", | |||
"published" : "2005-12-22", | "published" : "2005-12-22", | ||
" | "timestamp" : "2013-03-12T08:18:42Z", | ||
"abbreviation" : "EDIC", | "abbreviation" : "EDIC", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052187", | ||
" | "subspecialties" : "Endocrinology", | ||
"briefDesignDescription" : "Intensive glycemic therapy in T1DM", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa052187" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Rivaroxaban after VTE treatment", | "briefDesignDescription" : "Rivaroxaban after VTE treatment", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1700518", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1700518", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700518", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700518", | ||
" | "title" : "Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism", | ||
"statusUsableDate" : "2017-07-01", | "statusUsableDate" : "2017-07-01", | ||
" | "pmid" : "28316279", | ||
"abbreviation" : "EINSTEIN CHOICE", | |||
"timestamp" : "2017-12-03T22:35:08Z", | |||
"published" : "2017-03-30", | "published" : "2017-03-30", | ||
"pageName" : "EINSTEIN CHOICE", | "pageName" : "EINSTEIN CHOICE", | ||
"briefResultsDescription" : "Rivaroxaban reduces recurrent VTE", | |||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | "diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism", | ||
" | "citation" : "Weitz JI, <i>et al</i>. \"Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2017. 376(13):1211-22.", | ||
"pageid" : 2927 | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1113572", | ||
"briefDesignDescription" : "Rivaroxaban vs. warfarin in PE", | "briefDesignDescription" : "Rivaroxaban vs. warfarin in PE", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1113572", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1113572", | ||
"subspecialties" : "Hematology;Pulmonology", | "subspecialties" : "Hematology;Pulmonology", | ||
" | "abbreviation" : "EINSTEIN-PE", | ||
"published" : "2012-04-05", | |||
"timestamp" : "2017-12-03T22:35:09Z", | |||
"title" : "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", | |||
"pmid" : "22449293", | |||
"statusUsableDate" : "2013-07-01", | "statusUsableDate" : "2013-07-01", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "EINSTEIN-PE", | "pageName" : "EINSTEIN-PE", | ||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism", | "diseases" : "Pulmonary Embolism;Venous Thromboembolism", | ||
" | "briefResultsDescription" : "Rivaroxaban is noninferior to warfarin in PE treatment", | ||
" | "pageid" : 1519, | ||
" | "citation" : "Büller HR, <i>et al</i>. \"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2012. 366(14):1287-1297.", | ||
"expansion" : "" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Daclizumab, mycophenolate, steroids, and tacrolimus beneficial", | |||
"diseases" : "Kidney Transplant", | |||
"pageName" : "ELITE-Symphony", | |||
"citation" : "Ekberg H, <i>et al</i>. \"Reduced exposure to calcineurin inhibitors in renal transplantation\". <i>The New England Journal of Medicine</i>. 2007. 357(25):2562-2575.", | "citation" : "Ekberg H, <i>et al</i>. \"Reduced exposure to calcineurin inhibitors in renal transplantation\". <i>The New England Journal of Medicine</i>. 2007. 357(25):2562-2575.", | ||
" | "pageid" : 2324, | ||
"expansion" : "Efficacy Limiting Toxicity Elimination-Symphony", | "expansion" : "Efficacy Limiting Toxicity Elimination-Symphony", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa067411", | ||
" | "subspecialties" : "Nephrology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa067411", | |||
"briefDesignDescription" : "Immunosuppression after kidney transplant", | |||
"timestamp" : "2018-05-27T16:17:38Z", | |||
"published" : "2007-12-20", | "published" : "2007-12-20", | ||
"abbreviation" : "ELITE-Symphony", | "abbreviation" : "ELITE-Symphony", | ||
"title" : "Reduced exposure to calcineurin inhibitors in renal transplantation | "pmid" : "18094377", | ||
"statusUsableDate" : "2015-02-01", | |||
"title" : "Reduced exposure to calcineurin inhibitors in renal transplantation" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event", | ||
"pageid" : 2403, | "pageid" : 2403, | ||
"citation" : "Gladstone DJ, <i>et al</i>. \"Atrial Fibrillation in Patients with Cryptogenic Stroke\". <i>The New England Journal of Medicine</i>. 2014. 370(26):2467-2477.", | "citation" : "Gladstone DJ, <i>et al</i>. \"Atrial Fibrillation in Patients with Cryptogenic Stroke\". <i>The New England Journal of Medicine</i>. 2014. 370(26):2467-2477.", | ||
"pageName" : "EMBRACE", | "pageName" : "EMBRACE", | ||
"diseases" : "Stroke;Atrial Fibrillation", | "diseases" : "Stroke;Atrial Fibrillation", | ||
"briefResultsDescription" : "Extended EKG monitoring detects AF more frequently than 24-hour monitoring", | |||
"trainingLevel" : "Resident", | |||
"title" : "Atrial Fibrillation in Patients with Cryptogenic Stroke", | |||
"statusUsableDate" : "2018-09-13", | |||
"pmid" : "24963566", | |||
"abbreviation" : "EMBRACE", | "abbreviation" : "EMBRACE", | ||
" | "published" : "2014-06-26", | ||
" | "timestamp" : "2018-09-13T17:28:08Z", | ||
"briefDesignDescription" : "Extended EKG monitoring after cryptogenic stroke", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1311376", | |||
"subspecialties" : "Neurology;Cardiology", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1311376" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1209124", | ||
"fulltexturl" : "http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124", | "fulltexturl" : "http://www.nejm.org/doi/abs/10.1056/NEJMoa1209124", | ||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
" | "briefDesignDescription" : "T-DM1 in metastatic breast cancer", | ||
"published" : "2012-11-08", | |||
"timestamp" : "2021-07-28T13:09:44Z", | |||
"abbreviation" : "EMILIA", | |||
"statusUsableDate" : "2013-04-01", | "statusUsableDate" : "2013-04-01", | ||
"pmid" : "23020162", | |||
"title" : "Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer", | |||
"trainingLevel" : "fellow", | |||
"diseases" : "Breast Cancer", | |||
"briefResultsDescription" : "T-DM1 prolongs PFS in metastatic breast cancer", | "briefResultsDescription" : "T-DM1 prolongs PFS in metastatic breast cancer", | ||
"pageName" : "EMILIA", | "pageName" : "EMILIA", | ||
" | "pageid" : 1257, | ||
" | "citation" : "Verma S, <i>et al</i>. \"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer\". <i>The New England Journal of Medicine</i>. 2012. 367(19):1783-1791.", | ||
"expansion" : "Emtansine vs. Capecitabine+Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Zinman B, <i>et al</i>. \"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2117-28.", | ||
"pageid" : 2448, | "pageid" : 2448, | ||
" | "pageName" : "EMPA-REG OUTCOME", | ||
"briefResultsDescription" : "Empagliflozin reduces mortality compared to placebo in patients with type 2 diabetes", | |||
"diseases" : "Diabetes Mellitus", | |||
"trainingLevel" : "intern", | "trainingLevel" : "intern", | ||
" | "title" : "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes", | ||
"pmid" : "26378978", | |||
"statusUsableDate" : "2015-10-01", | |||
"abbreviation" : "EMPA-REG OUTCOME", | |||
"timestamp" : "2023-12-14T18:27:14Z", | |||
"published" : "2015-09-17", | |||
"briefDesignDescription" : "Empagliflozin for CV outcomes in T2DM", | |||
"subspecialties" : "Cardiology;Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1504720", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720" | |||
" | |||
}, | }, | ||
{ | { | ||
"pmid" : "34449189", | |||
"statusUsableDate" : "2021-09-09", | |||
"title" : "Empagliflozin in Heart Failure with a Preserved Ejection Fraction", | |||
"timestamp" : "2022-10-13T18:59:03Z", | "timestamp" : "2022-10-13T18:59:03Z", | ||
"published" : "2021-08-27", | |||
"abbreviation" : "EMPEROR-Preserved", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2107038", | |||
"briefDesignDescription" : "Empagliflozin in HFmrEF and HFpEF", | "briefDesignDescription" : "Empagliflozin in HFmrEF and HFpEF", | ||
"pdfurl" : null, | "pdfurl" : null, | ||
" | "expansion" : "Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction", | ||
"citation" : "Anker S, <i>et al</i>. \"Empagliflozin in Heart Failure with a Preserved Ejection Fraction\". <i>New England Journal of Medicine</i>. 2021. epub 2021-08-27:1-11.", | "citation" : "Anker S, <i>et al</i>. \"Empagliflozin in Heart Failure with a Preserved Ejection Fraction\". <i>New England Journal of Medicine</i>. 2021. epub 2021-08-27:1-11.", | ||
" | "pageid" : 4440, | ||
"briefResultsDescription" : "Empagliflozin improved outcomes in HFpEF", | "briefResultsDescription" : "Empagliflozin improved outcomes in HFpEF", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "EMPEROR-Preserved", | "pageName" : "EMPEROR-Preserved", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "EMPHASIS-HF", | |||
"timestamp" : "2017-12-03T22:35:16Z", | "timestamp" : "2017-12-03T22:35:16Z", | ||
"published" : "2011-01-06", | |||
"title" : "Eplerenone in patients with systolic heart failure and mild symptoms", | |||
"statusUsableDate" : "2012-08-01", | |||
"pmid" : "21073363", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009492", | |||
"briefDesignDescription" : "Eplerenone in HFrEF", | "briefDesignDescription" : "Eplerenone in HFrEF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009492", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009492", | ||
"citation" : "Zannad F, <i>et al</i>. \"Eplerenone in patients with systolic heart failure and mild symptoms\". <i>The New England Journal of Medicine</i>. 2011. 364(1):11-21.", | |||
"pageid" : 120, | "pageid" : 120, | ||
" | "expansion" : "Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "EMPHASIS-HF", | ||
"briefResultsDescription" : "Eplerenone reduces CV deaths and HF hospitalizations", | "briefResultsDescription" : "Eplerenone reduces CV deaths and HF hospitalizations", | ||
"diseases" : "Heart Failure" | |||
"diseases" : "Heart Failure | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48", | ||
" | "citation" : "Guigliano RP, <i>et al</i>. \"Edoxaban versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2013. 369(22):2093-2104.", | ||
"pageid" : 2471, | "pageid" : 2471, | ||
" | "pageName" : "ENGAGE AF-TIMI 48", | ||
"briefResultsDescription" : "Edoxaban is noninferior to warfarin to prevent stroke or thromboembolism", | |||
"diseases" : "Atrial Fibrillation", | |||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "title" : "Edoxaban versus warfarin in patients with atrial fibrillation", | ||
"statusUsableDate" : "2017-02-01", | "statusUsableDate" : "2017-02-01", | ||
" | "pmid" : "24251359", | ||
"abbreviation" : "ENGAGE AF-TIMI 48", | |||
"timestamp" : "2024-10-03T18:39:58Z", | |||
"published" : "2013-11-28", | "published" : "2013-11-28", | ||
" | "briefDesignDescription" : "Edoxaban vs. warfarin in AF", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310907", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310907" | ||
}, | }, | ||
{ | { | ||
"pmid" : "29466159", | |||
"statusUsableDate" : "2018-03-29", | |||
"title" : "Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty", | |||
"timestamp" : "2019-04-18T17:47:16Z", | "timestamp" : "2019-04-18T17:47:16Z", | ||
"published" : "2018-02-22", | |||
"abbreviation" : "EPCAT II", | |||
"subspecialties" : "Orthopedics;Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1712746", | |||
"briefDesignDescription" : "Aspirin vs. rivaroxaban for postoperative VTE prophylaxis", | "briefDesignDescription" : "Aspirin vs. rivaroxaban for postoperative VTE prophylaxis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1712746", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1712746", | ||
" | "expansion" : "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty II", | ||
"citation" : "Anderson DR, <i>et al</i>. \"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty\". <i>The New England Journal of Medicine</i>. 2018. 378(8):699-707.", | "citation" : "Anderson DR, <i>et al</i>. \"Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty\". <i>The New England Journal of Medicine</i>. 2018. 378(8):699-707.", | ||
" | "pageid" : 3552, | ||
"briefResultsDescription" : "Aspirin similar to rivaroxaban for prevention of VTE", | "briefResultsDescription" : "Aspirin similar to rivaroxaban for prevention of VTE", | ||
" | "diseases" : "Deep Vein Thrombosis;Hip Fracture;Meniscal Tear;Osteoarthritis;Pulmonary Embolism;Venous Thromboembolism", | ||
"pageName" : "EPCAT II", | "pageName" : "EPCAT II", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030207", | ||
"briefDesignDescription" : "Eplerenone post-MI with HFrEF", | "briefDesignDescription" : "Eplerenone post-MI with HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030207", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030207", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "EPHESUS", | ||
"published" : "2003-04-03", | |||
"timestamp" : "2015-12-24T15:08:03Z", | |||
"title" : "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction", | |||
"pmid" : "12668699", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "EPHESUS", | "pageName" : "EPHESUS", | ||
"diseases" : "Heart Failure;Acute Coronary Syndrome;Myocardial Infarction", | "diseases" : "Heart Failure;Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "briefResultsDescription" : "Mortality benefit of eplerenone post MI with HFrEF", | ||
" | "pageid" : 16, | ||
" | "citation" : "Pitt B, <i>et al</i>. \"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2003. 348(14):1309-21.", | ||
"expansion" : "Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Choo MS, <i>et al</i>. \"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease\". <i>The New England Journal of Medicine</i>. 2024. 1-13.", | ||
"pageid" : 5576, | "pageid" : 5576, | ||
" | "expansion" : "Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease", | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "pageName" : "EPIC-CAD", | ||
"briefResultsDescription" : "Edoxaban monotherapy has lower bleeding events in AF+stable CAD", | "briefResultsDescription" : "Edoxaban monotherapy has lower bleeding events in AF+stable CAD", | ||
"diseases" : "Coronary Artery Disease;Atrial Fibrillation", | "diseases" : "Coronary Artery Disease;Atrial Fibrillation", | ||
"abbreviation" : "EPIC-CAD", | "abbreviation" : "EPIC-CAD", | ||
"timestamp" : "2024-10-03T19:17:59Z", | |||
"published" : "2024-09-01", | |||
"title" : "Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease", | "title" : "Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease", | ||
"pmid" : "39225258" | "statusUsableDate" : "2024-09-29", | ||
"pmid" : "39225258", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2407362", | |||
"briefDesignDescription" : "Edoxaban±antiplatelet in AF+stable CAD", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2407362" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Decrease in prostate cancer mortality but increased risk of overdiagnosis and overtreatment", | ||
"diseases" : "Prostate Cancer", | |||
" | "pageName" : "ERSPC", | ||
" | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"expansion" : "European Randomized Study of Screening for Prostate Cancer", | |||
"citation" : "Schröder FH, <i>et al</i>. \"Screening and Prostate-Cancer Mortality in a Randomized European Study\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1320-1328.", | "citation" : "Schröder FH, <i>et al</i>. \"Screening and Prostate-Cancer Mortality in a Randomized European Study\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1320-1328.", | ||
"pageid" : 2796, | |||
"subspecialties" : "Urology;Oncology;Preventive Medicine", | "subspecialties" : "Urology;Oncology;Preventive Medicine", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0810084", | ||
"briefDesignDescription" : "PSA for prostate cancer screening", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810084", | |||
"statusUsableDate" : "2016-07-01", | "statusUsableDate" : "2016-07-01", | ||
" | "pmid" : "19297566", | ||
"title" : "Screening and Prostate-Cancer Mortality in a Randomized European Study", | |||
"timestamp" : "2017-12-03T22:35:20Z", | |||
"published" : "2009-07-09", | "published" : "2009-07-09", | ||
"abbreviation" : "ERSPC" | |||
"abbreviation" : "ERSPC | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "ESCAPE", | ||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "Routine PA catheters no better than clinical assessment", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness", | |||
"pageid" : 1407, | |||
"citation" : "Binanay C, <i>et al</i>. \"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness\". <i>JAMA</i>. 2005. 294(13):1625-1633.", | |||
"briefDesignDescription" : "PA catheters in acute HF management", | "briefDesignDescription" : "PA catheters in acute HF management", | ||
"fulltexturl" : null, | "fulltexturl" : null, | ||
" | "subspecialties" : "Cardiology;Critical Care", | ||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4994/JOC50108.pdf", | ||
" | "title" : "Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness", | ||
"pmid" : "16204662", | |||
" | |||
"statusUsableDate" : "2013-06-01", | "statusUsableDate" : "2013-06-01", | ||
" | "abbreviation" : "ESCAPE", | ||
"published" : "2005-10-05", | "published" : "2005-10-05", | ||
" | "timestamp" : "2017-12-03T22:35:21Z" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "ESPRIT", | ||
"briefResultsDescription" : "ASA+dipyridamole better than ASA for secondary stroke prevention", | |||
"diseases" : "Stroke;Transient Ischemic Attack", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "European/Australasian Stroke Prevention in Reversible Ischaemia Trial", | |||
"citation" : "Halkes PH, <i>et al</i>. \"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial\". <i>The Lancet</i>. 2006. 367(9523):1665-1673.", | |||
"pageid" : 1726, | |||
"briefDesignDescription" : "ASA+dipyridamole in secondary stroke prevention", | "briefDesignDescription" : "ASA+dipyridamole in secondary stroke prevention", | ||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2806%2968734-5/fulltext", | ||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf", | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673606687345.pdf", | ||
" | "title" : "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomized controlled trial", | ||
"statusUsableDate" : "2013-11-01", | "statusUsableDate" : "2013-11-01", | ||
" | "pmid" : "16714187", | ||
"abbreviation" : "ESPRIT", | "abbreviation" : "ESPRIT", | ||
" | "timestamp" : "2017-12-03T22:35:22Z", | ||
" | "published" : "2006-05-20" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Cohen M, <i>et al</i>. \"A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 1997. 337(7):447-452.", | ||
"pageid" : 1443, | "pageid" : 1443, | ||
" | "expansion" : "Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "ESSENCE", | ||
"briefResultsDescription" : "LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI", | "briefResultsDescription" : "LMWH reduces 14-day mortality, MI, or recurrent angina in UA/NSTEMI", | ||
"diseases" : "Acute Coronary Syndrome", | "diseases" : "Acute Coronary Syndrome", | ||
"abbreviation" : "ESSENCE", | "abbreviation" : "ESSENCE", | ||
"timestamp" : "2017-12-03T22:35:24Z", | |||
"published" : "1997-08-14", | |||
"title" : "A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease", | "title" : "A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease", | ||
"pmid" : "9250846" | "pmid" : "9250846", | ||
"statusUsableDate" : "2013-05-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199708143370702", | |||
"briefDesignDescription" : "LMWH vs. UFH in UA/NSTEMI", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199708143370702" | |||
}, | }, | ||
{ | { | ||
"title" : "Ticagrelor versus clopidogrel in symptomatic peripheral artery disease", | |||
"statusUsableDate" : "2017-01-01", | |||
"pmid" : "27959717", | |||
"abbreviation" : "EUCLID", | |||
"timestamp" : "2021-01-25T01:47:56Z", | "timestamp" : "2021-01-25T01:47:56Z", | ||
"published" : "2017-01-05", | |||
"briefDesignDescription" : "Ticagrelor vs. clopidogrel in symptomatic PAD", | "briefDesignDescription" : "Ticagrelor vs. clopidogrel in symptomatic PAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611688", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611688", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611688", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611688", | ||
" | "expansion" : "Examining use of ticagrelor in peripheral artery disease", | ||
"citation" : "Hiatt WR <i>et al</i>. \"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease\". <i>New Engl J Med</i>. 2017. 376(1):32-40.", | "citation" : "Hiatt WR <i>et al</i>. \"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease\". <i>New Engl J Med</i>. 2017. 376(1):32-40.", | ||
" | "pageid" : 2878, | ||
"pageName" : "EUCLID (Ticagrelor)", | |||
" | |||
"briefResultsDescription" : "Ticagrelor not superior to clopidogrel in symptomatic PAD", | "briefResultsDescription" : "Ticagrelor not superior to clopidogrel in symptomatic PAD", | ||
"diseases" : "Peripheral Vascular Disease", | "diseases" : "Peripheral Vascular Disease", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14286-9/fulltext", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Perindopril in patients with stable CAD", | "briefDesignDescription" : "Perindopril in patients with stable CAD", | ||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14286-9.pdf", | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14286-9.pdf", | ||
" | "pmid" : "13678872", | ||
"statusUsableDate" : "2018-02-08", | "statusUsableDate" : "2018-02-08", | ||
" | "title" : "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease", | ||
"published" : "2003-09-06", | "published" : "2003-09-06", | ||
" | "timestamp" : "2018-02-08T17:32:01Z", | ||
"abbreviation" : "EUROPA", | |||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Perindopril reduces composite of CV mortality, MI, or cardiac arrest", | ||
" | "pageName" : "EUROPA", | ||
"trainingLevel" : "intern", | |||
"expansion" : "European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease", | |||
"pageid" : 2823, | |||
"citation" : "Fox KM, <i>et al</i>. \"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease\". <i>The Lancet</i>. 2003. 362(9386):782–788." | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "European Dexamethasone Study", | |||
"diseases" : "Meningitis", | |||
"briefResultsDescription" : "Dexamethasone reduces mortality in bacterial meningitis", | |||
"pageid" : 306, | |||
"citation" : "de Gans JD, <i>et al</i>. \"Dexamethasone in Adults with Bacterial Meningitis\". <i>The New England Journal of Medicine</i>. 2002. 347(20):1549-1556.", | |||
"expansion" : "European Dexamethasone Study", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa021334", | |||
"briefDesignDescription" : "Dexamethasone in meningitis", | "briefDesignDescription" : "Dexamethasone in meningitis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021334", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021334", | ||
"subspecialties" : "Infectious Disease;Neurology", | "subspecialties" : "Infectious Disease;Neurology", | ||
" | "abbreviation" : "EDS", | ||
"published" : "2002-11-14", | "published" : "2002-11-14", | ||
" | "timestamp" : "2017-12-03T22:35:34Z", | ||
"title" : "Dexamethasone in Adults with Bacterial Meningitis", | "title" : "Dexamethasone in Adults with Bacterial Meningitis", | ||
"pmid" : "12432041" | "pmid" : "12432041", | ||
"statusUsableDate" : "2012-04-01" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "briefResultsDescription" : "No benefit from tolvaptan when given for 60 days after acute HF episode", | ||
" | "diseases" : "Heart Failure", | ||
"pageName" : "EVEREST-Outcomes", | |||
"citation" : "Konstam MA, <i>et al</i>. \"The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure\". <i>The Journal of the American Medical Association</i>. 2007. 297(12):1319-1331.", | |||
"pageid" : 1345, | "pageid" : 1345, | ||
"expansion" : "Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan", | |||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5131/joc70029_1319_1331.pdf", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : null, | ||
" | "briefDesignDescription" : "Tolvaptan in acute HF in HFrEF", | ||
" | "timestamp" : "2017-12-03T22:35:27Z", | ||
"published" : "2007-03-28", | "published" : "2007-03-28", | ||
"abbreviation" : "EVEREST", | "abbreviation" : "EVEREST", | ||
"title" : "The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure | "statusUsableDate" : "2013-06-01", | ||
"pmid" : "17384437", | |||
"title" : "The Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Popma JJ, <i>et al</i>. \"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients\". <i>The New England Journal of Medicine</i>. 2019. 380(18):1706-1715.", | ||
"pageid" : 4061, | "pageid" : 4061, | ||
" | "briefResultsDescription" : "TAVR non-inferior to surgery at 24 months in low-risk patients", | ||
"diseases" : "Aortic Stenosis", | |||
"pageName" : "Evolut Low Risk", | |||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
"statusUsableDate" : "2024-06-27", | "statusUsableDate" : "2024-06-27", | ||
" | "pmid" : "30883053", | ||
"title" : "Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients", | |||
"timestamp" : "2024-06-27T19:03:26Z", | |||
"published" : "2019-05-02", | "published" : "2019-05-02", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1816885", | ||
"briefDesignDescription" : "TAVR in low-risk patients", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1816885" | |||
}, | }, | ||
{ | { | ||
"title" : "Everolimus-eluting stents or bypass surgery for left main coronary artery disease", | |||
"statusUsableDate" : "2016-12-01", | |||
"pmid" : "27797291", | |||
"abbreviation" : "EXCEL", | |||
"timestamp" : "2017-12-03T22:35:29Z", | "timestamp" : "2017-12-03T22:35:29Z", | ||
"published" : "2016-12-08", | |||
"briefDesignDescription" : "CABG vs. PCI in left main CAD", | "briefDesignDescription" : "CABG vs. PCI in left main CAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1610227", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1610227", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1610227", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1610227", | ||
" | "expansion" : "XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL)", | ||
"citation" : "Stone GW, <i>et al</i>. \"Everolimus-eluting stents or bypass surgery for left main coronary artery disease\". <i>The New England Journal of Medicine</i>. 2016. 375(23):2223-35.", | "citation" : "Stone GW, <i>et al</i>. \"Everolimus-eluting stents or bypass surgery for left main coronary artery disease\". <i>The New England Journal of Medicine</i>. 2016. 375(23):2223-35.", | ||
" | "pageid" : 2868, | ||
" | "pageName" : "EXCEL", | ||
"briefResultsDescription" : "PCI noninferior to CABG in left main CAD with low-intermediate anatomic complexity", | "briefResultsDescription" : "PCI noninferior to CABG in left main CAD with low-intermediate anatomic complexity", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "A Study of Omalizumab/Xolair in Subjects With Moderate to Severe Persistent Asthma", | ||
" | "citation" : "Hanania NA, <i>et al</i>. \"Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial\". <i>Annals of Internal Medicine</i>. 2011. 154(9):573-582.", | ||
"pageid" : 1434, | "pageid" : 1434, | ||
" | "pageName" : "EXTRA", | ||
"briefResultsDescription" : "Omalizumab reduces asthma exacerbations", | |||
"diseases" : "Asthma", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "title" : "Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy: A Randomized Trial", | ||
"pmid" : "21536936", | |||
" | |||
"statusUsableDate" : "2013-10-01", | "statusUsableDate" : "2013-10-01", | ||
" | "abbreviation" : "EXTRA", | ||
"timestamp" : "2017-12-03T22:35:31Z", | |||
"published" : "2011-05-03", | "published" : "2011-05-03", | ||
" | "briefDesignDescription" : "Omalizumab in severe allergic asthma", | ||
" | "subspecialties" : "Allergy and Immunology;Pulmonology;Pediatrics", | ||
" | "fulltexturl" : null, | ||
" | "pdfurl" : "http://annals.org/data/Journals/AIM/20231/0000605-201105030-00002.pdf" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa062200", | ||
"subspecialties" : "Critical Care", | |||
"briefDesignDescription" : "Fluid management in ARDS", | "briefDesignDescription" : "Fluid management in ARDS", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa062200", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa062200", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "16714767", | ||
"title" : "Comparison of two fluid-management strategies in acute lung injury", | |||
"published" : "2006-06-15", | "published" : "2006-06-15", | ||
"timestamp" : "2015-11-07T23:16:22Z", | |||
"abbreviation" : "FACTT", | |||
"diseases" : "Acute Respiratory Distress Syndrome", | |||
"briefResultsDescription" : "Mortality benefit of conservative fluid management in ALI/ARDS", | |||
"pageName" : "FACTT", | "pageName" : "FACTT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Fluids and Catheters Treatment Trial", | ||
" | "pageid" : 24, | ||
"citation" : "Wiedemann HP, <i>et al</i>. \"Comparison of two fluid-management strategies in acute lung injury\". <i>The New England Journal of Medicine</i>. 2006. 354(24):2564-75." | |||
}, | }, | ||
{ | { | ||
"pageid" : 2691, | "pageid" : 2691, | ||
"citation" : "Anker SD, <i>et al</i>. \"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency\". <i>The New England Journal of Medicine</i>. 2009. 361(25):2436-48.", | "citation" : "Anker SD, <i>et al</i>. \"Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency\". <i>The New England Journal of Medicine</i>. 2009. 361(25):2436-48.", | ||
"expansion" : "IV Iron for Symptoms in Patients with HFrEF and Iron Deficiency", | "expansion" : "IV Iron for Symptoms in Patients with HFrEF and Iron Deficiency", | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "FAIR-HF", | "pageName" : "FAIR-HF", | ||
"diseases" : "Heart Failure;Iron Deficiency Anemia", | "diseases" : "Heart Failure;Iron Deficiency Anemia", | ||
"briefResultsDescription" : "IV iron improves HFrEF symptoms in patients with HFrEF and iron deficiency", | |||
"abbreviation" : "FAIR-HF", | "abbreviation" : "FAIR-HF", | ||
"published" : "2009-12-17", | |||
"timestamp" : "2019-02-28T18:37:32Z", | |||
"title" : "Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency", | "title" : "Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency", | ||
"pmid" : "19920054" | "statusUsableDate" : "2019-03-01", | ||
"pmid" : "19920054", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0908355", | |||
"briefDesignDescription" : "Parenteral iron in HFrEF with iron deficiency", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa0908355", | |||
"subspecialties" : "Cardiology;Hematology" | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807611", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807611", | ||
"briefDesignDescription" : "FFR-guided PCI in stable CAD", | |||
"timestamp" : "2018-01-03T20:13:15Z", | |||
"published" : "2009-01-15", | |||
"abbreviation" : "FAME", | |||
"pmid" : "19144937", | |||
"statusUsableDate" : "2012-10-01", | "statusUsableDate" : "2012-10-01", | ||
"title" : "Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention", | |||
"trainingLevel" : "resident", | |||
"briefResultsDescription" : "FFR reduces composite of death, nonfatal MI, urgent revascularization", | "briefResultsDescription" : "FFR reduces composite of death, nonfatal MI, urgent revascularization", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "FAME", | "pageName" : "FAME", | ||
" | "citation" : "Tonino PAL, <i>et al</i>. \"Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention\". <i>The New England Journal of Medicine</i>. 2009. 360(3):213-224.", | ||
" | "pageid" : 998, | ||
" | "expansion" : "Fractional Flow Reserve versus Angiography for Multivessel Evaluation" | ||
}, | }, | ||
{ | { | ||
"title" : "Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease", | |||
"statusUsableDate" : "2012-11-01", | |||
"pmid" : "22924638", | |||
"abbreviation" : "FAME 2", | |||
"timestamp" : "2018-07-05T13:05:28Z", | "timestamp" : "2018-07-05T13:05:28Z", | ||
"published" : "2012-09-13", | |||
"briefDesignDescription" : "FFR-guided PCI vs. OMT in CAD", | "briefDesignDescription" : "FFR-guided PCI vs. OMT in CAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205361", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1205361", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1205361", | ||
" | "expansion" : "FFR vs. Angiographyfor Multivessel Evaluation 2", | ||
"citation" : "De Bruyne B, <i>et al</i>. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". <i>The New England Journal of Medicine</i>. 2012. 367(11):991-1001.", | "citation" : "De Bruyne B, <i>et al</i>. \"Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease\". <i>The New England Journal of Medicine</i>. 2012. 367(11):991-1001.", | ||
" | "pageid" : 1003, | ||
" | "pageName" : "FAME 2", | ||
"briefResultsDescription" : "FFR-guided PCI reduces urgent revascularization", | "briefResultsDescription" : "FFR-guided PCI reduces urgent revascularization", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "FEAST", | ||
"briefResultsDescription" : "Albumin and saline increase mortality when compared to no fluids in this patient population", | |||
"diseases" : "Shock", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Fluid Expansion as Supportive Therapy", | |||
"citation" : "Maitland K, <i>et al</i>. \"Mortality after fluid bolus in African children with severe infection\". <i>The New England Journal of Medicine</i>. 2011. 364(26):2483-2495.", | |||
"pageid" : 1860, | |||
"briefDesignDescription" : "Fluid resuscitation in Sub-Saharan Africa", | "briefDesignDescription" : "Fluid resuscitation in Sub-Saharan Africa", | ||
"subspecialties" : "Pediatrics;Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1101549", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1101549", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1101549", | ||
" | "title" : "Mortality after fluid bolus in African children with severe infection", | ||
"pmid" : "21615299", | |||
" | |||
"statusUsableDate" : "2014-11-01", | "statusUsableDate" : "2014-11-01", | ||
"abbreviation" : "FEAST", | "abbreviation" : "FEAST", | ||
" | "timestamp" : "2017-12-03T22:35:38Z", | ||
" | "published" : "2011-06-30" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Fidaxomicin in C. difficile", | "briefDesignDescription" : "Fidaxomicin in C. difficile", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0910812", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0910812", | ||
" | "subspecialties" : "Infectious Disease;Gastroenterology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0910812", | ||
" | "title" : "Fidaxomicin versus Vancomycin for Clostridium difficile Infection", | ||
"pmid" : "21288078", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : null, | ||
"published" : "2011-02-03", | "published" : "2011-02-03", | ||
"timestamp" : "2013-10-07T20:50:13Z", | |||
"pageName" : "Fidaxomicin in C. difficile Diarrhea", | "pageName" : "Fidaxomicin in C. difficile Diarrhea", | ||
"diseases" : "Clostridium difficile", | "diseases" : "Clostridium difficile", | ||
" | "briefResultsDescription" : "Fidaxomicin noninferior to vancomycin for cure, and resulted in 45% fewer recurrences", | ||
" | "trainingLevel" : "Resident", | ||
"expansion" : null, | |||
"pageid" : 255, | |||
"citation" : "Louie TJ, <i>et al</i>. \"Fidaxomicin versus Vancomycin for Clostridium difficile Infection\". <i>The New England Journal of Medicine</i>. 2011. 365(5):422-431." | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2024-10-17T17:57:15Z", | "timestamp" : "2024-10-17T17:57:15Z", | ||
"published" : "2020-10-23", | |||
"abbreviation" : "FIDELIO-DKD", | |||
"statusUsableDate" : "2024-10-17", | |||
"pmid" : "33264825", | |||
"title" : "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2025845", | |||
"subspecialties" : "Nephrology;Endocrinology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2025845", | |||
"briefDesignDescription" : "Mineralocorticoid antagonist in CKD/T2DM", | "briefDesignDescription" : "Mineralocorticoid antagonist in CKD/T2DM", | ||
" | "citation" : "Bakris GL, <i>et al</i>. \"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2020. 383(23):2219-2229.", | ||
"pageid" : 4384, | "pageid" : 4384, | ||
" | "expansion" : "Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Mineralocorticoid antagonist slows CKD progression", | "briefResultsDescription" : "Mineralocorticoid antagonist slows CKD progression", | ||
"diseases" : "Chronic Kidney Disease;Diabetes Mellitus", | "diseases" : "Chronic Kidney Disease;Diabetes Mellitus", | ||
" | "pageName" : "FIDELIO-DKD" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2776, | "pageid" : 2776, | ||
" | "citation" : "Tuomilehto J, <i>et al</i>. \"Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance\". <i>The New England Journal of Medicine</i>. 2001. 344(18):1343-1350.", | ||
"diseases" : "Diabetes Mellitus", | |||
"briefResultsDescription" : "Intensive lifestyle interventions prevent diabetes", | |||
"pageName" : "Finnish Diabetes Prevention Study", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "11333990", | ||
"statusUsableDate" : "2025-06-01", | "statusUsableDate" : "2025-06-01", | ||
" | "title" : "Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance", | ||
"published" : "2001-15-03", | "published" : "2001-15-03", | ||
" | "timestamp" : "2025-06-05T17:26:20Z", | ||
"abbreviation" : "Finnish Diabetes Prevention Study", | "abbreviation" : "Finnish Diabetes Prevention Study", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200105033441801#t", | ||
" | "subspecialties" : "Endocrinology", | ||
"briefDesignDescription" : "Lifestyle interventions to prevent diabetes", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200105033441801" | |||
}, | }, | ||
{ | { | ||
"title" : "Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation", | |||
"statusUsableDate" : "2016-07-01", | |||
"pmid" : "27042964", | |||
"abbreviation" : "FIRE AND ICE", | |||
"timestamp" : "2017-12-03T22:35:39Z", | "timestamp" : "2017-12-03T22:35:39Z", | ||
"published" : "2016-06-09", | |||
"briefDesignDescription" : "Cryoablation vs. RF ablation in pAF", | "briefDesignDescription" : "Cryoablation vs. RF ablation in pAF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602014", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602014", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602014", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602014", | ||
" | "expansion" : "", | ||
"citation" : "Kuck K, <i>et al</i>. \"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2235-45.", | "citation" : "Kuck K, <i>et al</i>. \"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2235-45.", | ||
" | "pageid" : 2795, | ||
"pageName" : "FIRE AND ICE", | |||
" | |||
"briefResultsDescription" : "Cryoablation equivalent to RF ablation in pAF", | "briefResultsDescription" : "Cryoablation equivalent to RF ablation in pAF", | ||
"diseases" : "Atrial Fibrillation", | "diseases" : "Atrial Fibrillation", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"published" : "2016-06-09", | |||
"timestamp" : "2017-12-03T22:35:41Z", | "timestamp" : "2017-12-03T22:35:41Z", | ||
"abbreviation" : "FLAME COPD", | |||
"pmid" : "27181606", | |||
"statusUsableDate" : "2017-01-01", | |||
"title" : "Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1516385", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1516385", | |||
"subspecialties" : "Pulmonology", | |||
"briefDesignDescription" : "LABA+LAMA vs. LABA+ICS in COPD", | "briefDesignDescription" : "LABA+LAMA vs. LABA+ICS in COPD", | ||
"pageid" : 2871, | "pageid" : 2871, | ||
"citation" : "Wedzicha JA, <i>et al</i>. \"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2222-2234.", | "citation" : "Wedzicha JA, <i>et al</i>. \"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD\". <i>The New England Journal of Medicine</i>. 2016. 374(23):2222-2234.", | ||
"expansion" : "Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations", | "expansion" : "Effect of Indacaterol Glycopyronium Vs. Fluticasone Salmeterol on COPD Exacerbations", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Emphysema;Chronic Bronchitis;Chronic Obstructive Pulmonary Disease", | |||
"briefResultsDescription" : "LABA+LAMA reduces COPD exacerbations", | "briefResultsDescription" : "LABA+LAMA reduces COPD exacerbations", | ||
"pageName" : "FLAME (COPD)" | |||
"pageName" : "FLAME (COPD) | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Fluoxetine for Motor Recovery after Acute Ischaemic Stroke", | ||
" | "citation" : "Chollet F, <i>et al</i>. \"Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial\". <i>The Lancet Neurology</i>. 2011. 10(2):123-130.", | ||
"pageid" : 2370, | "pageid" : 2370, | ||
" | "briefResultsDescription" : "Early fluoxetine improved motor outcomes post stroke", | ||
"diseases" : "Stroke", | |||
"pageName" : "FLAME (Stroke)", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2015-08-01", | "statusUsableDate" : "2015-08-01", | ||
" | "pmid" : "21216670", | ||
"title" : "Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial", | |||
"timestamp" : "2018-10-08T21:47:35Z", | |||
"published" : "2011-02-01", | "published" : "2011-02-01", | ||
"abbreviation" : "FLAME", | "abbreviation" : "FLAME", | ||
" | "subspecialties" : "Neurology", | ||
" | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S1474-4422(10)70314-8", | ||
"briefDesignDescription" : "SSRI after CVA for motor recovery", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2375, | "pageid" : 2375, | ||
" | "citation" : "Frat JP, <i>et al</i>. \"High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure\". <i>The New England Journal of Medicine</i>. 2015. 372(23):2185-2196.", | ||
"diseases" : "Respiratory Failure", | |||
"briefResultsDescription" : "High-flow oxygen therapy reduces intubation need", | |||
"pageName" : "FLORALI", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "25981908", | ||
"title" : "High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure", | |||
"published" : "2015-06-04", | "published" : "2015-06-04", | ||
" | "timestamp" : "2025-06-19T18:32:02Z", | ||
"abbreviation" : "FLORALI", | "abbreviation" : "FLORALI", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1503326", | ||
" | "subspecialties" : "Pulmonology;Critical Care", | ||
"briefDesignDescription" : "High-flow oxygen in respiratory failure", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1503326" | |||
}, | }, | ||
{ | { | ||
"pmid" : "22168590", | |||
"statusUsableDate" : "2017-12-14", | |||
"title" : "Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery", | |||
"timestamp" : "2017-12-14T18:13:26Z", | "timestamp" : "2017-12-14T18:13:26Z", | ||
"published" : "2011-12-29", | |||
"abbreviation" : "FOCUS", | |||
"subspecialties" : "Hematology;Surgery", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1012452", | |||
"briefDesignDescription" : "Transfusion thresholds after hip surgery", | "briefDesignDescription" : "Transfusion thresholds after hip surgery", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1012452", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1012452", | ||
" | "expansion" : "Transfusion Trigger Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair", | ||
"citation" : "Carson JL, <i>et al</i>. \"Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery\". <i>The New england Journal of Medicine</i>. 2011. 365(26):2453-62.", | "citation" : "Carson JL, <i>et al</i>. \"Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery\". <i>The New england Journal of Medicine</i>. 2011. 365(26):2453-62.", | ||
" | "pageid" : 2985, | ||
"briefResultsDescription" : "Liberal transfusions no better than restrictive", | "briefResultsDescription" : "Liberal transfusions no better than restrictive", | ||
" | "diseases" : "Hip Fracture;Anemia", | ||
"pageName" : "FOCUS", | "pageName" : "FOCUS", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"published" : "2017-03-17", | |||
"timestamp" : "2020-11-05T18:42:16Z", | "timestamp" : "2020-11-05T18:42:16Z", | ||
" | "abbreviation" : "FOURIER", | ||
"pmid" : "28304224", | |||
"statusUsableDate" : "2017-03-01", | |||
"title" : "Evolocumab and clinical outcomes in patients with cardiovascular disease", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1615664", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1615664", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1615664", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Evolocumab for CVD events if atherosclerotic disease", | |||
"pageid" : 2891, | "pageid" : 2891, | ||
"citation" : "Sabatine MS, <i>et al</i>. \"Evolocumab and clinical outcomes in patients with cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. epub 2017-03-17:1-10.", | "citation" : "Sabatine MS, <i>et al</i>. \"Evolocumab and clinical outcomes in patients with cardiovascular disease\". <i>The New England Journal of Medicine</i>. 2017. epub 2017-03-17:1-10.", | ||
"expansion" : "Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk", | "expansion" : "Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "Evolocumab reduces CV events in patients with atherosclerotic disease", | "briefResultsDescription" : "Evolocumab reduces CV events in patients with atherosclerotic disease", | ||
"pageName" : "FOURIER" | |||
"pageName" : "FOURIER | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211585", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211585", | ||
"subspecialties" : "Cardiology;Endocrinology", | "subspecialties" : "Cardiology;Endocrinology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1211585", | ||
"briefDesignDescription" : "CABG vs. PCI for CAD in T2DM", | |||
"timestamp" : "2017-12-03T22:35:45Z", | |||
"published" : "2012-12-20", | |||
"abbreviation" : "FREEDOM", | |||
"statusUsableDate" : "2016-04-01", | "statusUsableDate" : "2016-04-01", | ||
"pmid" : "23121323", | |||
"title" : "Strategies for multivessel revascularization in patients with diabetes", | |||
"trainingLevel" : "Resident", | |||
"briefResultsDescription" : "CABG reduces death and revascularization rates but causes more strokes", | "briefResultsDescription" : "CABG reduces death and revascularization rates but causes more strokes", | ||
" | "diseases" : "Coronary Artery Disease;Diabetes Mellitus", | ||
"pageName" : "FREEDOM", | "pageName" : "FREEDOM", | ||
" | "citation" : "Farkouh ME, <i>et al</i>. \"Strategies for multivessel revascularization in patients with diabetes\". <i>The New England Journal of Medicine</i>. 2012. 367(25):2375-2384.", | ||
"pageid" : 2314, | |||
" | "expansion" : "Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease" | ||
" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)07349-3/fulltext", | |||
"briefDesignDescription" : "Early invasive strategy in UA/NSTEMI", | "briefDesignDescription" : "Early invasive strategy in UA/NSTEMI", | ||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)07349-3.pdf", | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(99)07349-3.pdf", | ||
" | "pmid" : "10475181", | ||
"statusUsableDate" : "2015-11-01", | "statusUsableDate" : "2015-11-01", | ||
"title" : "Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study", | |||
"timestamp" : "2021-06-01T13:47:49Z", | |||
"published" : "1999-08-28", | |||
"abbreviation" : "FRISC-II", | |||
"briefResultsDescription" : "Fewer recurrent MIs with early invasive strategy in high-risk patients", | "briefResultsDescription" : "Fewer recurrent MIs with early invasive strategy in high-risk patients", | ||
" | "diseases" : "Coronary Artery Disease;Myocardial Infarction;Acute Coronary Syndrome", | ||
"pageName" : "FRISC-II", | "pageName" : "FRISC-II", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "FRagmin and Fast Revascularisation during InStability in Coronary artery disease-II", | ||
" | "citation" : "FRISC Investigators. \"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study\". <i>The Lancet</i>. 1999. 354(9180):708-15.", | ||
" | "pageid" : 2451 | ||
}, | }, | ||
{ | { | ||
" | "expansion" : null, | ||
"pageid" : 391, | "pageid" : 391, | ||
"citation" : "Cook DJ, <i>et al</i>. \"Risk factors for gastrointestinal bleeding in critically ill patients\". <i>The New England Journal of Medicine</i>. 1994. 330(6):337-381.", | "citation" : "Cook DJ, <i>et al</i>. \"Risk factors for gastrointestinal bleeding in critically ill patients\". <i>The New England Journal of Medicine</i>. 1994. 330(6):337-381.", | ||
"pageName" : "GI bleeding in ICU patients", | "pageName" : "GI bleeding in ICU patients", | ||
"diseases" : "Gastrointestinal Hemorrhage", | "diseases" : "Gastrointestinal Hemorrhage", | ||
"briefResultsDescription" : "Greatest risk for GI bleed with coagulopathy and mechanical ventilation", | |||
"trainingLevel" : "Intern", | |||
"title" : "Risk factors for gastrointestinal bleeding in critically ill patients", | |||
"statusUsableDate" : "2013-10-01", | |||
"pmid" : "8284001", | |||
"abbreviation" : null, | "abbreviation" : null, | ||
" | "published" : "1994-02-10", | ||
" | "timestamp" : "2017-12-03T22:35:49Z", | ||
"briefDesignDescription" : "Risk factors for GI bleeds in ICU patients", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199402103300601", | |||
"subspecialties" : "Critical Care;Gastroenterology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199402103300601" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "", | ||
"briefDesignDescription" : "Lisinopril in acute MI", | "briefDesignDescription" : "Lisinopril in acute MI", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2894%2990232-1/abstract", | ||
" | "abbreviation" : "GISSI-3", | ||
" | "timestamp" : "2014-09-24T22:28:37Z", | ||
"published" : "1994-05-07", | |||
"title" : "Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "7910229", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "GISSI-3", | ||
"briefResultsDescription" : "Lisinopril improves 6-week mortality", | "briefResultsDescription" : "Lisinopril improves 6-week mortality", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "citation" : "GISSI-3 Group. \"Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction\". <i>The Lancet</i>. 1994. 343(8906):1115-22.", | ||
"pageid" : 258, | |||
" | "expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione", | ||
"pageid" : 2824, | "pageid" : 2824, | ||
"citation" : "Tavazzi L, <i>et al</i>. \"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure\". <i>The Lancet</i>. 2008. 372(9645):1223-1230.", | "citation" : "Tavazzi L, <i>et al</i>. \"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure\". <i>The Lancet</i>. 2008. 372(9645):1223-1230.", | ||
"pageName" : "GISSI-HF", | "pageName" : "GISSI-HF", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "PUFA reduces all-cause mortality and admission for CV disease", | |||
"trainingLevel" : "intern", | |||
"title" : "Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure", | |||
"pmid" : "18757090", | |||
"statusUsableDate" : "2023-07-31", | |||
"abbreviation" : "GISSI-HF", | "abbreviation" : "GISSI-HF", | ||
" | "published" : "2008-10-04", | ||
" | "timestamp" : "2025-05-22T17:32:19Z", | ||
"briefDesignDescription" : "PUFA in patients with heart failure", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(08)61239-8.pdf" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199309023291001", | |||
"briefDesignDescription" : "tPA in ACS", | "briefDesignDescription" : "tPA in ACS", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199309023291001", | ||
"statusUsableDate" : "2014-09-01", | "statusUsableDate" : "2014-09-01", | ||
"pmid" : "8204123", | |||
"title" : "An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction", | |||
"timestamp" : "2017-12-03T22:35:51Z", | |||
"published" : "1993-09-03", | |||
"abbreviation" : "GUSTO", | |||
"briefResultsDescription" : "tPA reduces mortality in ACS", | "briefResultsDescription" : "tPA reduces mortality in ACS", | ||
" | "diseases" : "Myocardial Infarction;Acute Coronary Syndrome", | ||
"pageName" : "GUSTO", | "pageName" : "GUSTO", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries", | ||
" | "citation" : "Topol E, <i>et al</i>. \"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction\". <i>The New England Journal of Medicine</i>. 1993. 329(10):673-682.", | ||
" | "pageid" : 2177 | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Hypothermia improves neurologic outcomes and reduces mortality", | ||
"diseases" : "Cardiac Arrest", | |||
" | "pageName" : "HACA", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Hypothermia After Cardiac Arrest", | |||
"citation" : "Holzer M, <i>et al</i>. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2002. 346(8):549-556.", | "citation" : "Holzer M, <i>et al</i>. \"Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2002. 346(8):549-556.", | ||
"pageid" : 410, | |||
"subspecialties" : "Critical Care;Neurology;Cardiology", | "subspecialties" : "Critical Care;Neurology;Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/nejmoa012689", | ||
"briefDesignDescription" : "Hypothermia for cardiac arrest", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa012689", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "11856793", | ||
"title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | |||
"timestamp" : "2024-08-25T20:47:09Z", | |||
"published" : "2002-02-21", | "published" : "2002-02-21", | ||
"abbreviation" : "HACA" | |||
"abbreviation" : "HACA | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "HEAAL", | ||
"briefResultsDescription" : "High-dose losartan improves HF outcomes", | |||
"diseases" : "Heart Failure", | |||
"trainingLevel" : "resident", | |||
"expansion" : "Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan", | |||
"citation" : "Konstam MA, <i>et al</i>. \"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure\". <i>The Lancet</i>. 2009. 374(9704):1840-1848.", | |||
"pageid" : 2825, | |||
"briefDesignDescription" : "High- vs. low-dose losartan in heart failure", | "briefDesignDescription" : "High- vs. low-dose losartan in heart failure", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61913-9/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61913-9/fulltext", | ||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)61913-9.pdf", | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)61913-9.pdf", | ||
" | "title" : "Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure", | ||
"pmid" : "19922995", | |||
" | |||
"statusUsableDate" : "2025-05-12", | "statusUsableDate" : "2025-05-12", | ||
"abbreviation" : "HEAAL", | "abbreviation" : "HEAAL", | ||
" | "timestamp" : "2025-05-22T17:34:50Z", | ||
" | "published" : "2009-11-28" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "HEARTMATE II", | |||
"published" : "2009-12-03", | |||
"timestamp" : "2017-12-03T22:35:53Z", | "timestamp" : "2017-12-03T22:35:53Z", | ||
"title" : "Advanced heart failure treated with continuous-flow left ventricular assist device", | |||
"statusUsableDate" : "2016-09-01", | |||
"pmid" : "19920051", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909938", | |||
"briefDesignDescription" : "Continuous-flow LVAD in heart failure", | "briefDesignDescription" : "Continuous-flow LVAD in heart failure", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0909938#t", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0909938#t", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 2808, | "pageid" : 2808, | ||
"citation" : "Slaughter MS, <i>et al</i>. \"Advanced heart failure treated with continuous-flow left ventricular assist device\". <i>The New England Journal of Medicine</i>. 2009. 361(23):2241-2251.", | "citation" : "Slaughter MS, <i>et al</i>. \"Advanced heart failure treated with continuous-flow left ventricular assist device\". <i>The New England Journal of Medicine</i>. 2009. 361(23):2241-2251.", | ||
"expansion" : "Advanced heart failure treated with continuous-flow left ventricular assist device", | "expansion" : "Advanced heart failure treated with continuous-flow left ventricular assist device", | ||
" | "trainingLevel" : "Fellow", | ||
"pageName" : "HEARTMATE II", | "pageName" : "HEARTMATE II", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Continuous-flow LVAD improved survival free from stroke and device failure" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "Sepsis;Fever", | ||
" | "briefResultsDescription" : "Acetaminophen does not improves ICU outcomes", | ||
" | "pageName" : "HEAT", | ||
"trainingLevel" : "Intern", | |||
"expansion" : "Permissive Hyperthermia through Avoidance of Acetaminophen in Known or Suspected Infection in the Intensive Care Unit", | |||
"pageid" : 2690, | "pageid" : 2690, | ||
"citation" : "Young P, <i>et al</i>. \"Acetaminophen for Fever in Critically Ill Patients with Suspected Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2215-2224.", | "citation" : "Young P, <i>et al</i>. \"Acetaminophen for Fever in Critically Ill Patients with Suspected Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(23):2215-2224.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1508375", | |||
"subspecialties" : "Critical Care;Infectious Disease", | "subspecialties" : "Critical Care;Infectious Disease", | ||
" | "briefDesignDescription" : "Acetaminophen in febrile ICU patients", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1508375", | |||
"pmid" : "26436473", | |||
"statusUsableDate" : "2017-09-01", | "statusUsableDate" : "2017-09-01", | ||
" | "title" : "Acetaminophen for Fever in Critically Ill Patients with Suspected Infection", | ||
"published" : "2015-12-03", | "published" : "2015-12-03", | ||
" | "timestamp" : "2020-11-04T18:25:05Z", | ||
"abbreviation" : "HEAT" | |||
"abbreviation" : "HEAT | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "", | ||
"briefDesignDescription" : "Heparin vs. bivalirudin in PCI", | "briefDesignDescription" : "Heparin vs. bivalirudin in PCI", | ||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60924-7", | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60924-7", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "HEAT-PPCI", | ||
"published" : "2014-11-22", | |||
"timestamp" : "2023-02-02T19:36:38Z", | |||
"title" : "Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.", | |||
"statusUsableDate" : "2023-01-29", | "statusUsableDate" : "2023-01-29", | ||
" | "pmid" : "25002178", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "HEAT-PPCI", | "pageName" : "HEAT-PPCI", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Heparin better than bivalirudin for PCI", | ||
" | "pageid" : 2394, | ||
" | "citation" : "Shahzad A, <i>et al</i>. \"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.\". <i>The Lancet</i>. 2014. 384(9957):1849-1858.", | ||
"expansion" : "" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"diseases" : "Chronic Kidney Disease", | |||
"briefResultsDescription" : "High dialysis dose and high-flux membrane did not reduce all-cause mortality", | |||
"pageName" : "HEMO", | |||
"pageid" : 2771, | |||
"citation" : "Rose EA, <i>et al</i>. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". <i>The New England Journal of Medicine</i>. 2002. 347(25):2020-2019.", | "citation" : "Rose EA, <i>et al</i>. \"Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis\". <i>The New England Journal of Medicine</i>. 2002. 347(25):2020-2019.", | ||
"expansion" : "Hemodialysis", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa021583", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa021583", | |||
"subspecialties" : "Nephrology", | "subspecialties" : "Nephrology", | ||
" | "briefDesignDescription" : "High dialysis dose and high-flux membrane in hemodialysis", | ||
"published" : "2002-12-19", | "published" : "2002-12-19", | ||
" | "timestamp" : "2018-10-25T17:06:10Z", | ||
"abbreviation" : "HEMO", | "abbreviation" : "HEMO", | ||
"title" : "Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis | "pmid" : "12490682", | ||
"statusUsableDate" : "2018-03-15", | |||
"title" : "Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis" | |||
}, | }, | ||
{ | { | ||
"pageid" : 440, | "pageid" : 440, | ||
"citation" : "Piccart-Gebhart MJ, <i>et al</i>. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". <i>The New England Journal of Medicine</i>. 2005. 353(16):1659-72.", | "citation" : "Piccart-Gebhart MJ, <i>et al</i>. \"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer\". <i>The New England Journal of Medicine</i>. 2005. 353(16):1659-72.", | ||
"expansion" : "Herceptin Adjuvant Trial", | "expansion" : "Herceptin Adjuvant Trial", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Breast Cancer", | |||
"briefResultsDescription" : "Trastuzumab improves survival", | "briefResultsDescription" : "Trastuzumab improves survival", | ||
"pageName" : "HERA", | |||
"published" : "2005-10-20", | "published" : "2005-10-20", | ||
" | "timestamp" : "2013-10-09T17:11:02Z", | ||
"abbreviation" : "HERA", | "abbreviation" : "HERA", | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "16236737", | |||
"title" : "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer", | "title" : "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa052306", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052306", | |||
"subspecialties" : "Oncology", | |||
"briefDesignDescription" : "Trastuzumab in breast cancer" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "", | |||
"timestamp" : "2020-10-29T17:37:34Z", | "timestamp" : "2020-10-29T17:37:34Z", | ||
"published" : "2018-02-15", | |||
"title" : "Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism", | |||
"pmid" : "29231094", | |||
"statusUsableDate" : "2018-02-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711948", | |||
"briefDesignDescription" : "Edoxaban vs. LMWH in cancer VTE", | "briefDesignDescription" : "Edoxaban vs. LMWH in cancer VTE", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711948", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711948", | ||
"citation" : "Raskob GE, <i>et al</i>. \"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2018. 378(7):615-624.", | |||
"pageid" : 3509, | "pageid" : 3509, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "Hokusai-VTE", | ||
"briefResultsDescription" : "Edoxaban noninferior to dalteparin in cancer VTE", | "briefResultsDescription" : "Edoxaban noninferior to dalteparin in cancer VTE", | ||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis" | |||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis | |||
}, | }, | ||
{ | { | ||
"expansion" : "Heart Outcomes Prevention Evaluation", | |||
"citation" : "Yusuf S, <i>et al</i>. \"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients\". <i>The New England Journal of Medicine</i>. 2000. 342(3):145-153.", | |||
"pageid" : 1165, | |||
"pageName" : "HOPE", | |||
"briefResultsDescription" : "Ramipril reduces death, MI, and stroke", | |||
"diseases" : "Coronary Artery Disease;Stroke;Transient Ischemic Attack", | |||
"trainingLevel" : "intern", | |||
"title" : "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "10639539", | |||
"abbreviation" : "HOPE", | |||
"timestamp" : "2013-08-15T18:50:04Z", | "timestamp" : "2013-08-15T18:50:04Z", | ||
"published" : "2000-01-20", | |||
"briefDesignDescription" : "Ramipril in patients with high CV risk", | "briefDesignDescription" : "Ramipril in patients with high CV risk", | ||
"subspecialties" : "Cardiology;Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200001203420301", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200001203420301", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301" | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200001203420301 | |||
}, | }, | ||
{ | { | ||
"pageid" : 4382, | "pageid" : 4382, | ||
"citation" : "Vichinsky E, <i>et al</i>. \"A phase 3 randomized trial of voxelotor in sickle cell disease\". <i>The New England Journal of Medicine</i>. 2019. 381(8):509-519.", | "citation" : "Vichinsky E, <i>et al</i>. \"A phase 3 randomized trial of voxelotor in sickle cell disease\". <i>The New England Journal of Medicine</i>. 2019. 381(8):509-519.", | ||
"expansion" : "Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization", | "expansion" : "Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization", | ||
" | "trainingLevel" : "resident", | ||
"diseases" : "Sickle Cell Disease", | |||
"briefResultsDescription" : "Voxelotor increases hemoglobin and reduces evidence of hemolysis", | "briefResultsDescription" : "Voxelotor increases hemoglobin and reduces evidence of hemolysis", | ||
"pageName" : "HOPE (Sickle Cell Disease)", | |||
"published" : "2019-08-08", | "published" : "2019-08-08", | ||
" | "timestamp" : "2020-12-31T20:42:03Z", | ||
"abbreviation" : "HOPE", | "abbreviation" : "HOPE", | ||
"pmid" : "31199090", | |||
"statusUsableDate" : "2020-12-10", | |||
"title" : "A phase 3 randomized trial of voxelotor in sickle cell disease", | "title" : "A phase 3 randomized trial of voxelotor in sickle cell disease", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1903212", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa1903212", | |||
"subspecialties" : "Hematology", | |||
"briefDesignDescription" : "Voxelotor in sickle cell disease" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Osteoporosis", | ||
" | "briefResultsDescription" : "Annual zoledronate reduces fracture risk in osteoporosis", | ||
" | "pageName" : "HORIZON-PFT", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial", | |||
"pageid" : 2765, | "pageid" : 2765, | ||
"citation" : "Black DM, <i>et al</i>. \"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis\". <i>The New England Journal of Medicine</i>. 2007. 356(18):1809-22.", | "citation" : "Black DM, <i>et al</i>. \"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis\". <i>The New England Journal of Medicine</i>. 2007. 356(18):1809-22.", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa067312", | |||
"subspecialties" : "Endocrinology;Preventive Medicine", | "subspecialties" : "Endocrinology;Preventive Medicine", | ||
" | "briefDesignDescription" : "Zoledronate vs. placebo in osteoporosis", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa067312", | |||
"pmid" : "17476007", | |||
"statusUsableDate" : "2021-08-31", | "statusUsableDate" : "2021-08-31", | ||
" | "title" : "Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis", | ||
"published" : "2007-05-03", | "published" : "2007-05-03", | ||
" | "timestamp" : "2021-09-09T17:34:24Z", | ||
"abbreviation" : "HORIZON-PFT" | |||
"abbreviation" : "HORIZON-PFT | |||
}, | }, | ||
{ | { | ||
"pdfurl" : null, | "pdfurl" : null, | ||
"subspecialties" : "Infectious Disease;Hematology", | "subspecialties" : "Infectious Disease;Hematology", | ||
" | "fulltexturl" : "https://doi.org/10.1016/S2352-3026(17)30211-9", | ||
" | "briefDesignDescription" : "Duration of empiric antibiotics in ↑risk neutropenic fever", | ||
" | "timestamp" : "2024-05-02T17:49:17Z", | ||
"published" : "2017-11-15", | "published" : "2017-11-15", | ||
"abbreviation" : null, | "abbreviation" : null, | ||
"pmid" : "29153975", | |||
"statusUsableDate" : "2021-03-15", | |||
"title" : "Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial", | "title" : "Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial", | ||
" | "trainingLevel" : "Fellow", | ||
"briefResultsDescription" : "Shorter courses of antibiotics led to fewer days of antibiotics without excess harm", | |||
"diseases" : "Febrile Neutropenia", | |||
"pageName" : "How Long", | |||
"citation" : "Aguilar-Guisado M, <i>et al</i>. \"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial\". <i>Lancet Haematology</i>. 2017. 4(12):e573-e583.", | |||
"pageid" : 4119, | |||
"expansion" : null | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Landray MJ <i>et al</i>. \"Effects of extended-release niacin with laropiprant in high-risk patients\". <i>The New England Journal of Medicine</i>. 2014. 371(3):203-212.", | ||
"pageid" : 2329, | "pageid" : 2329, | ||
" | "expansion" : "Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"briefResultsDescription" : "Niacin is poorly tolerated, doesn't reduce major vascular events", | "briefResultsDescription" : "Niacin is poorly tolerated, doesn't reduce major vascular events", | ||
"diseases" : "Coronary Artery Disease;Peripheral Vascular Disease", | |||
"pageName" : "HPS2-THRIVE", | |||
"timestamp" : "2017-12-03T22:35:56Z", | |||
"published" : "2014-07-17", | "published" : "2014-07-17", | ||
"abbreviation" : "HPS2-THRIVE", | "abbreviation" : "HPS2-THRIVE", | ||
"statusUsableDate" : "2015-02-01", | |||
"pmid" : "25014686", | |||
"title" : "Effects of extended-release niacin with laropiprant in high-risk patients", | "title" : "Effects of extended-release niacin with laropiprant in high-risk patients", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300955", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300955", | |||
"briefDesignDescription" : "Niacin in atherosclerotic disease" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1105243", | ||
"subspecialties" : "Infectious Disease", | |||
"briefDesignDescription" : "Early ART in HIV", | "briefDesignDescription" : "Early ART in HIV", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243", | ||
" | "pmid" : "21767103", | ||
"statusUsableDate" : "2012-10-01", | "statusUsableDate" : "2012-10-01", | ||
"title" : "Prevention of HIV-1 Infection with Early Antiretroviral Therapy", | |||
"published" : "2011-08-11", | |||
"timestamp" : "2017-12-03T22:35:58Z", | |||
"abbreviation" : "HPTN 052", | |||
"diseases" : "HIV", | |||
"briefResultsDescription" : "Reduced morbidity and HIV transmission", | "briefResultsDescription" : "Reduced morbidity and HIV transmission", | ||
"pageName" : "HPTN 052", | "pageName" : "HPTN 052", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "HIV Prevention Trials Network 052 Study", | ||
" | "pageid" : 1010, | ||
"citation" : "Cohen MS, <i>et al</i>. \"Prevention of HIV-1 Infection with Early Antiretroviral Therapy\". <i>The New England Journal of Medicine</i>. 2011. 365(6):493-505." | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:35:59Z", | "timestamp" : "2017-12-03T22:35:59Z", | ||
"published" : "2014-06-17", | |||
"abbreviation" : null, | |||
"statusUsableDate" : "2015-03-01", | |||
"pmid" : "24694529", | |||
"title" : "Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction", | |||
"pdfurl" : null, | |||
"subspecialties" : "Emergency Medicine;Cardiology", | |||
"fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0735109714017264", | |||
"briefDesignDescription" : "High sensitivity troponin for acute chest pain", | "briefDesignDescription" : "High sensitivity troponin for acute chest pain", | ||
" | "citation" : "Bandstein N, <i>et al</i>. \"Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction\". <i>Journal of the American College of Cardiology</i>. 2014. 63(23):2569-2578.", | ||
"pageid" : 2343, | "pageid" : 2343, | ||
" | "expansion" : null, | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"briefResultsDescription" : "HS troponin-T is associated with high NPV for MI at 30 days", | "briefResultsDescription" : "HS troponin-T is associated with high NPV for MI at 30 days", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "pageName" : "HS troponin-T to rule out MI" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : null, | ||
"pageid" : 2142, | "pageid" : 2142, | ||
"citation" : "Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". <i>The New England Journal of Medicine</i>. 1992. 327(26):1832-1835.", | "citation" : "Czeizel AE and Dudas I. \"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation\". <i>The New England Journal of Medicine</i>. 1992. 327(26):1832-1835.", | ||
"pageName" : "Hungarian Prenatal Vitamin Trial", | "pageName" : "Hungarian Prenatal Vitamin Trial", | ||
"diseases" : "Neural Tube Defects", | "diseases" : "Neural Tube Defects", | ||
"briefResultsDescription" : "Perinatal vitamins reduce neural tube defects", | |||
"trainingLevel" : "Student", | |||
"title" : "Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation", | |||
"statusUsableDate" : "2014-09-01", | |||
"pmid" : "1307234", | |||
"abbreviation" : null, | "abbreviation" : null, | ||
" | "published" : "1992-12-24", | ||
" | "timestamp" : "2017-12-03T22:36:04Z", | ||
"briefDesignDescription" : "Perinatal vitamins to prevent neural tube defects", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199212243272602", | |||
"subspecialties" : "Obstetrics;Preventive Medicine", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199212243272602" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/pdf", | ||
"fulltexturl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext", | "fulltexturl" : "http://journal.chestnet.org/article/S0012-3692(16)62564-3/fulltext", | ||
"subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | "subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | ||
" | "briefDesignDescription" : "Hydrocortisone, Vit C, and thiamine in sepsis", | ||
"published" : "2017-06-01", | |||
"timestamp" : "2023-11-22T21:12:44Z", | |||
"abbreviation" : "", | |||
"pmid" : "27940189", | |||
"statusUsableDate" : "2018-08-13", | "statusUsableDate" : "2018-08-13", | ||
"title" : "Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study", | |||
"trainingLevel" : "Resident", | |||
"diseases" : "Sepsis;Shock", | |||
"briefResultsDescription" : "Pilot study with impressive findings, low-quality data", | "briefResultsDescription" : "Pilot study with impressive findings, low-quality data", | ||
"pageName" : "Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock", | "pageName" : "Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock", | ||
" | "pageid" : 2946, | ||
" | "citation" : "Marik PE, <i>et al</i>. \"Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock A Retrospective Before-After Study\". <i>Chest</i>. 2017. 151(6):1229-1238.", | ||
"expansion" : "" | |||
" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"pageName" : "HYPRESS", | |||
"briefResultsDescription" : "Hydrocortisone not superior to placebo in severe sepsis", | |||
"diseases" : "Sepsis", | |||
"citation" : "Keh D, <i>et al</i>. \"Effect of hydrocortisone on development of shock among patients with severe sepsis\". <i>Journal of the American Medical Association</i>. 2016. 316(17):1775-1785.", | "citation" : "Keh D, <i>et al</i>. \"Effect of hydrocortisone on development of shock among patients with severe sepsis\". <i>Journal of the American Medical Association</i>. 2016. 316(17):1775-1785.", | ||
" | "pageid" : 2860, | ||
"expansion" : "", | "expansion" : "", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMsa1410639", | ||
" | "briefDesignDescription" : "Hydrocortisone in severe sepsis", | ||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMsa1410639", | |||
"abbreviation" : "HYPRESS", | |||
"timestamp" : "2018-02-08T17:14:46Z", | |||
"published" : "2016-10-03", | "published" : "2016-10-03", | ||
"title" : "Effect of hydrocortisone on development of shock among patients with severe sepsis", | "title" : "Effect of hydrocortisone on development of shock among patients with severe sepsis", | ||
"statusUsableDate" : "2016-11-01", | |||
"pmid" : "27695824" | "pmid" : "27695824" | ||
}, | }, | ||
{ | { | ||
"published" : "2008-05-01", | |||
"timestamp" : "2018-01-11T18:14:28Z", | "timestamp" : "2018-01-11T18:14:28Z", | ||
"abbreviation" : "HYVET", | |||
"statusUsableDate" : "2015-04-01", | |||
"pmid" : "18378519", | |||
"title" : "Treatment of hypertension in patients 80 years of age or older", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0801369", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0801369", | |||
"subspecialties" : "Nephrology;Cardiology;Geriatrics", | |||
"briefDesignDescription" : "Elderly HTN treatment", | "briefDesignDescription" : "Elderly HTN treatment", | ||
"pageid" : 2349, | "pageid" : 2349, | ||
"citation" : "Beckett NS, <i>et al</i>. \"Treatment of hypertension in patients 80 years of age or older\". <i>The New England Journal of Medicine</i>. 2008. 358(18):1887-1898.", | "citation" : "Beckett NS, <i>et al</i>. \"Treatment of hypertension in patients 80 years of age or older\". <i>The New England Journal of Medicine</i>. 2008. 358(18):1887-1898.", | ||
"expansion" : "Hypertension in the Very Elderly Trial", | "expansion" : "Hypertension in the Very Elderly Trial", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Hypertension", | |||
"briefResultsDescription" : "Trend towards reduction in stroke with treatment (P", | "briefResultsDescription" : "Trend towards reduction in stroke with treatment (P", | ||
"pageName" : "HYVET" | |||
"pageName" : "HYVET | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Intraaortic Balloon Pump in Cardiogenic Shock II", | ||
"pageid" : 1065, | "pageid" : 1065, | ||
" | "citation" : "Thiele H, <i>et al</i>. \"Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 2012. 367(14):1287-1296.", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction;Shock", | |||
"briefResultsDescription" : "IABP did not reduce mortality at 30 days", | |||
"pageName" : "IABP-SHOCK II", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "22920912", | ||
"title" : "Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock", | |||
"published" : "2012-10-10", | "published" : "2012-10-10", | ||
" | "timestamp" : "2017-09-24T13:54:35Z", | ||
"abbreviation" : "IABP-SHOCK II", | "abbreviation" : "IABP-SHOCK II", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208410", | ||
" | "subspecialties" : "Cardiology;Critical Care", | ||
"briefDesignDescription" : "IABP in MI and cardiogenic shock", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208410" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "IALT", | |||
"timestamp" : "2019-05-23T17:29:10Z", | "timestamp" : "2019-05-23T17:29:10Z", | ||
"published" : "2004-01-22", | |||
"title" : "Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer", | |||
"pmid" : "14736927", | |||
"statusUsableDate" : "2019-05-23", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa031644", | |||
"briefDesignDescription" : "Adjuvant cisplatin in resected NSCLC", | "briefDesignDescription" : "Adjuvant cisplatin in resected NSCLC", | ||
"subspecialties" : "Oncology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa031644", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa031644", | ||
"citation" : "Arriagada R, <i>et al</i>. \"Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer\". <i>The New England Journal of Medicine</i>. 2004. 350(4):351-360.", | |||
"pageid" : 2503, | "pageid" : 2503, | ||
" | "expansion" : "International Adjuvant Lung Cancer Trial", | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pageName" : "IALT", | ||
"briefResultsDescription" : "Adjuvant cisplatin improves 5-year OS in resected NSCLC", | "briefResultsDescription" : "Adjuvant cisplatin improves 5-year OS in resected NSCLC", | ||
"diseases" : "Lung Cancer" | |||
"diseases" : "Lung Cancer | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501548", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501548", | ||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501548", | ||
"briefDesignDescription" : "Second-line ibrutinib in WM", | |||
"timestamp" : "2021-11-04T17:33:05Z", | |||
"published" : "2015-04-09", | |||
"abbreviation" : null, | |||
"pmid" : "25853747", | |||
"statusUsableDate" : "2015-12-01", | "statusUsableDate" : "2015-12-01", | ||
"title" : "Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia", | |||
"trainingLevel" : "Fellow", | |||
"briefResultsDescription" : "Ibrutinib is safe and effective in previously treated WM", | "briefResultsDescription" : "Ibrutinib is safe and effective in previously treated WM", | ||
" | "diseases" : "Lymphoma;Waldenström Macroglobulinemia", | ||
"pageName" : "Ibrutinib in Waldenstrom macroglobulinemia", | "pageName" : "Ibrutinib in Waldenstrom macroglobulinemia", | ||
" | "citation" : "Treon SP, <i>et al</i>. \"Ibrutinib in Previously Treated Waldenstrom Macroglobulinemia\". <i>The New England Journal of Medicine</i>. 2015. 372(15):1430-1440.", | ||
"pageid" : 2660, | |||
"expansion" : null | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Fellow", | ||
" | "pageName" : "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", | ||
" | "briefResultsDescription" : "IR improved survival over FCR in untreated CLL", | ||
"diseases" : "Chronic Lymphocytic Leukemia;Small Lymphocytic Lymphoma", | |||
"citation" : "Shanafelt TD, <i>et al</i>. \"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia\". <i>The New England Journal of Medicine</i>. 2019. 381(5):432-43.", | |||
"pageid" : 4175, | "pageid" : 4175, | ||
"expansion" : "", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1817073", | ||
" | "briefDesignDescription" : "Ibrutinib-rituximab vs. FCR in untreated CLL", | ||
"subspecialties" : "Hematology;Oncology", | "subspecialties" : "Hematology;Oncology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1817073", | ||
" | "abbreviation" : "E1912", | ||
" | "timestamp" : "2020-02-10T07:03:58Z", | ||
"published" : "2019-08-01", | "published" : "2019-08-01", | ||
"title" : "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", | "title" : "Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia", | ||
"statusUsableDate" : "2020-02-09", | |||
"pmid" : "31365801" | "pmid" : "31365801" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-10-16T05:02:38Z", | "timestamp" : "2018-10-16T05:02:38Z", | ||
" | "published" : "2013-10-17", | ||
"abbreviation" : "ICAP", | |||
"pmid" : "23992557", | |||
"statusUsableDate" : "2014-01-01", | |||
"title" : "A Randomized Trial of Colchicine for Acute Pericarditis", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1208536", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208536", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1208536", | ||
"briefDesignDescription" : "Colchicine in the first episode of acute pericarditis", | |||
"citation" : "Imazio M, <i>et al</i>. \"A Randomized Trial of Colchicine for Acute Pericarditis\". <i>The New England Journal of Medicine</i>. 2013. 369(16):1522-1528.", | |||
"pageid" : 1729, | "pageid" : 1729, | ||
" | "expansion" : "Evaluation of additive benefit of colchicine to conventional therapy in acute pericarditis", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"briefResultsDescription" : "Colchicine reduces incessant or recurrent acute pericarditis when used in first episode", | "briefResultsDescription" : "Colchicine reduces incessant or recurrent acute pericarditis when used in first episode", | ||
"diseases" : "Pericarditis", | "diseases" : "Pericarditis", | ||
" | "pageName" : "ICAP" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1000552", | ||
"briefDesignDescription" : "Early vs. late dialysis in CKD", | "briefDesignDescription" : "Early vs. late dialysis in CKD", | ||
"subspecialties" : "Nephrology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000552", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1000552", | ||
" | "abbreviation" : "IDEAL", | ||
" | "timestamp" : "2017-12-03T22:36:07Z", | ||
"published" : "2010-08-12", | |||
"title" : "A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis", | |||
"pmid" : "20581422", | |||
"statusUsableDate" : "2012-10-01", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "IDEAL", | ||
"briefResultsDescription" : "No difference in survival or clinical outcomes", | "briefResultsDescription" : "No difference in survival or clinical outcomes", | ||
"diseases" : "Chronic Kidney Disease", | "diseases" : "Chronic Kidney Disease", | ||
" | "citation" : "Cooper BA, <i>et al</i>. \"A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis\". <i>The New England Journal of Medicine</i>. 2010. 363(7):609-619.", | ||
"pageid" : 1020, | |||
" | "expansion" : "Initiating Dialysis Early and Late" | ||
}, | }, | ||
{ | { | ||
"pmid" : "30304656", | |||
"statusUsableDate" : "2019-03-27", | |||
"title" : "Timing of renal-replacement therapy in patients with acute kidney injury and sepsis", | |||
"timestamp" : "2025-06-19T18:33:35Z", | "timestamp" : "2025-06-19T18:33:35Z", | ||
"published" : "2018-10-11", | |||
"abbreviation" : "IDEAL-ICU", | |||
"subspecialties" : "Critical Care;Nephrology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1803213", | |||
"briefDesignDescription" : "Early vs. delayed RRT in septic shock", | "briefDesignDescription" : "Early vs. delayed RRT in septic shock", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803213", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803213", | ||
" | "expansion" : "Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit", | ||
"citation" : "Barbar SD, <i>et al</i>. \"Timing of renal-replacement therapy in patients with acute kidney injury and sepsis\". <i>The New England Journal of Medicine</i>. 2018. 379(15):1431-1442.", | "citation" : "Barbar SD, <i>et al</i>. \"Timing of renal-replacement therapy in patients with acute kidney injury and sepsis\". <i>The New England Journal of Medicine</i>. 2018. 379(15):1431-1442.", | ||
" | "pageid" : 3746, | ||
"briefResultsDescription" : "No benefit from early initiated RRT in septic shock", | "briefResultsDescription" : "No benefit from early initiated RRT in septic shock", | ||
" | "diseases" : "Acute Kidney Injury;Shock;Sepsis", | ||
"pageName" : "IDEAL-ICU", | "pageName" : "IDEAL-ICU", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "IDNT", | ||
"diseases" : "Diabetic Nephropathy;Diabetes Mellitus", | |||
"briefResultsDescription" : "ARBs prevent progression of T2DM nephropathy", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Irbesartan Diabetic Nephropathy Trial", | |||
"pageid" : 2670, | |||
"citation" : "Lewis EJ, <i>et al</i>. \"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes\". <i>The New England Journal of Medicine</i>. 2001. 345(12):851-860.", | |||
"briefDesignDescription" : "ARBs in diabetic nephropathy", | "briefDesignDescription" : "ARBs in diabetic nephropathy", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011303", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011303", | ||
" | "subspecialties" : "Nephrology;Endocrinology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011303", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011303", | ||
" | "title" : "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", | ||
"statusUsableDate" : "2016-01-01", | "statusUsableDate" : "2016-01-01", | ||
" | "pmid" : "11565517", | ||
"abbreviation" : "IDNT", | |||
"published" : "2001-09-20", | "published" : "2001-09-20", | ||
" | "timestamp" : "2017-12-03T22:36:08Z" | ||
}, | }, | ||
{ | { | ||
"published" : "2017-05-11", | |||
"timestamp" : "2017-12-03T22:36:10Z", | "timestamp" : "2017-12-03T22:36:10Z", | ||
"abbreviation" : "iFR-SWEDEHEART", | |||
"statusUsableDate" : "2017-05-01", | |||
"pmid" : "28317438", | |||
"title" : "Spontaneous wave-free ratio versus fractional flow reserve to guide PCI", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1616540", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1616540", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "iFR vs. FFR for PCI", | "briefDesignDescription" : "iFR vs. FFR for PCI", | ||
"pageid" : 2926, | "pageid" : 2926, | ||
"citation" : "Gotberg M, <i>et al</i>. \"Spontaneous wave-free ratio versus fractional flow reserve to guide PCI\". <i>The New England Journal of Medicine</i>. 2017. 376(19):1813-1823.", | "citation" : "Gotberg M, <i>et al</i>. \"Spontaneous wave-free ratio versus fractional flow reserve to guide PCI\". <i>The New England Journal of Medicine</i>. 2017. 376(19):1813-1823.", | ||
"expansion" : "Instantaneous Wave-free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome", | "expansion" : "Instantaneous Wave-free Ratio versus Fractional Flow Reserve in Patients with Stable Angina Pectoris or Acute Coronary Syndrome", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "iFR noninferior to FFR for PCI", | "briefResultsDescription" : "iFR noninferior to FFR for PCI", | ||
"pageName" : "IFR-SWEDEHEART" | |||
"pageName" : "IFR-SWEDEHEART | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "IMProved Reduction of Outcomes: Vytorin Efficacy International Trial", | ||
"pageid" : 2369, | "pageid" : 2369, | ||
" | "citation" : "Cannon CP, <i>et al</i>. \"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2015. 375(25):2387-2397.", | ||
"diseases" : "Hyperlipidemia;Acute Coronary Syndrome;Myocardial Infarction", | |||
"briefResultsDescription" : "Ezetimibe improves CV outcomes when added to statin", | |||
"pageName" : "IMPROVE-IT", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"statusUsableDate" : "2015-06-01", | "statusUsableDate" : "2015-06-01", | ||
" | "pmid" : "26039521", | ||
"title" : "Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes", | |||
"published" : "2015-06-18", | "published" : "2015-06-18", | ||
" | "timestamp" : "2017-12-14T19:46:19Z", | ||
"abbreviation" : "IMPROVE-IT", | "abbreviation" : "IMPROVE-IT", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1410489", | ||
" | "subspecialties" : "Cardiology", | ||
"briefDesignDescription" : "Ezetimibe+simvastatin after ACS", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410489" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2934, | "pageid" : 2934, | ||
"citation" : "Richeldi L, <i>et al</i>. \"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2071-2082.", | "citation" : "Richeldi L, <i>et al</i>. \"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis\". <i>The New England Journal of Medicine</i>. 2014. 370(22):2071-2082.", | ||
"pageName" : "INPULSIS Trials", | "pageName" : "INPULSIS Trials", | ||
"diseases" : "Idiopathic Pulmonary Fibrosis", | "diseases" : "Idiopathic Pulmonary Fibrosis", | ||
"briefResultsDescription" : "Nintedanib slows progression of IPF", | |||
"trainingLevel" : "Resident", | |||
"title" : "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", | |||
"statusUsableDate" : "2018-03-30", | |||
"pmid" : "24836310", | |||
"abbreviation" : "INPULSIS I and II", | "abbreviation" : "INPULSIS I and II", | ||
" | "published" : "2014-05-29", | ||
" | "timestamp" : "2018-03-30T14:11:39Z", | ||
"briefDesignDescription" : "Nintedanib in IPF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1402584", | |||
"subspecialties" : "Pulmonology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402584" | |||
}, | }, | ||
{ | { | ||
"title" : "Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection", | |||
"statusUsableDate" : "2016-01-01", | |||
"pmid" : "26192873", | |||
"abbreviation" : "START", | |||
"published" : "2015-08-27", | |||
"timestamp" : "2017-12-03T22:36:12Z", | "timestamp" : "2017-12-03T22:36:12Z", | ||
"briefDesignDescription" : "Early vs. delayed ART in HIV", | "briefDesignDescription" : "Early vs. delayed ART in HIV", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1506816", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1506816", | ||
"subspecialties" : "Infectious Disease", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506816", | |||
"expansion" : null, | |||
"pageid" : 2468, | "pageid" : 2468, | ||
"citation" : "INSIGHT START Writers. \"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(9):795-807.", | "citation" : "INSIGHT START Writers. \"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection\". <i>The New England Journal of Medicine</i>. 2015. 373(9):795-807.", | ||
"pageName" : "INSIGHT START", | "pageName" : "INSIGHT START", | ||
"diseases" : "HIV", | "diseases" : "HIV", | ||
" | "briefResultsDescription" : "Less complications with early ART", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "IPrEx", | ||
"diseases" : "HIV", | |||
"briefResultsDescription" : "ART reduces tranmission of HIV among MSM", | |||
"trainingLevel" : "intern", | |||
"expansion" : "Iniciativa Profilaxis Pre Exposicion (\"Preexposure Prophylaxis Initiative\")", | |||
"pageid" : 1100, | |||
"citation" : "Grant RM, <i>et al</i>. \"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men\". <i>The New England Journal of Medicine</i>. 2010. 363(27):2587-2599.", | |||
"briefDesignDescription" : "ART in primary HIV prevention", | "briefDesignDescription" : "ART in primary HIV prevention", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1011205", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1011205", | ||
" | "subspecialties" : "Infectious Disease;Preventive Medicine", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011205", | ||
" | "title" : "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men", | ||
"statusUsableDate" : "2013-02-01", | "statusUsableDate" : "2013-02-01", | ||
" | "pmid" : "21091279", | ||
"abbreviation" : "iPrEx", | |||
"published" : "2010-12-30", | "published" : "2010-12-30", | ||
" | "timestamp" : "2017-12-03T22:36:14Z" | ||
}, | }, | ||
{ | { | ||
"expansion" : "International Randomized Study of Interferon and STI571", | |||
"citation" : "O'Brien SG, <i>et al</i>. \"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia\". <i>The New England Journal of Medicine</i>. 2003. 384(11):994-1004.", | |||
"pageid" : 1076, | |||
"pageName" : "IRIS", | |||
"briefResultsDescription" : "Imatinib delays disease progression", | |||
"diseases" : "Chronic Myeloid Leukemia;Myeloproliferative Neoplasms", | |||
"trainingLevel" : "Student", | |||
"title" : "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia", | |||
"pmid" : "12637609", | |||
"statusUsableDate" : "2012-11-01", | |||
"abbreviation" : "IRIS", | |||
"timestamp" : "2017-12-03T22:36:15Z", | "timestamp" : "2017-12-03T22:36:15Z", | ||
"published" : "2003-03-13", | |||
"briefDesignDescription" : "Imatinib vs. IFNα/cytarabine in CML", | "briefDesignDescription" : "Imatinib vs. IFNα/cytarabine in CML", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa022457", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa022457", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457" | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa022457 | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Litton E, <i>et al</i>. \"Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial\". <i>Intensive Care Med</i>. 2016. 42:1715-1722.", | ||
"pageid" : 3651, | "pageid" : 3651, | ||
" | "pageName" : "IRONMAN", | ||
"briefResultsDescription" : "IV iron did not reduce transfusion requirements", | |||
"diseases" : "Anemia;Critical Illness", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "title" : "Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial", | ||
"statusUsableDate" : "2024-04-30", | "statusUsableDate" : "2024-04-30", | ||
" | "pmid" : "27686346", | ||
"abbreviation" : "IRONMAN", | |||
"timestamp" : "2024-05-20T13:33:05Z", | |||
"published" : "2016-11-01", | "published" : "2016-11-01", | ||
" | "briefDesignDescription" : "IV iron in critical illness", | ||
" | "subspecialties" : "Critical Care;Hematology", | ||
" | "fulltexturl" : "https://link.springer.com/article/10.1007%2Fs00134-016-4465-6", | ||
" | "pdfurl" : "https://link.springer.com/content/pdf/10.1007/s00134-016-4465-6.pdf" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Oral iron not superior to placebo in HFrEF", | ||
"pageName" : "IRONOUT-HF", | |||
"pageid" : 2941, | "pageid" : 2941, | ||
"citation" : "Lewis GD, <i>et al</i>. \"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency\". <i>JAMA</i>. 2017. 317(19):1958-66.", | |||
"expansion" : "Iron Repletion Effects on Oxygen Uptake in Heart Failure", | |||
"pdfurl" : "http://jamanetwork.com/journals/jama/article-abstract/2626574", | "pdfurl" : "http://jamanetwork.com/journals/jama/article-abstract/2626574", | ||
" | "fulltexturl" : "http://jamanetwork.com/journals/jama/article-abstract/2626574", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Oral iron vs. placebo in HFrEF and iron deficiency", | ||
"published" : "2017-07-09", | "published" : "2017-07-09", | ||
" | "timestamp" : "2017-12-03T22:36:17Z", | ||
"abbreviation" : "IRONOUT-HF", | "abbreviation" : "IRONOUT-HF", | ||
"title" : "Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency | "statusUsableDate" : "2017-07-01", | ||
"pmid" : "28510680", | |||
"title" : "Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency" | |||
}, | }, | ||
{ | { | ||
"pmid" : "31475799", | |||
"statusUsableDate" : "2019-10-17", | |||
"title" : "Ticagrelor or prasugrel in patients with acute coronary syndromes", | |||
"published" : "2019-09-01", | |||
"timestamp" : "2019-10-17T17:39:50Z", | "timestamp" : "2019-10-17T17:39:50Z", | ||
" | "abbreviation" : "ISAR-REACT 5", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1908973", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1908973", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Ticagrelor vs. prasugrel in ACS", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908973", | |||
"expansion" : "Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 Trial", | |||
"pageid" : 4100, | "pageid" : 4100, | ||
"citation" : "Schupke S <i>et al</i>. \"Ticagrelor or prasugrel in patients with acute coronary syndromes\". <i>New Engl J Med</i>. 2019. 1-11.", | "citation" : "Schupke S <i>et al</i>. \"Ticagrelor or prasugrel in patients with acute coronary syndromes\". <i>New Engl J Med</i>. 2019. 1-11.", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"briefResultsDescription" : "Prasugrel superior to ticagrelor in acute coronary syndromes", | "briefResultsDescription" : "Prasugrel superior to ticagrelor in acute coronary syndromes", | ||
"pageName" : "ISAR-REACT 5", | "pageName" : "ISAR-REACT 5", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://content.onlinejacc.org/article.aspx?articleID", | |||
"briefDesignDescription" : "Triple therapy for 6w vs. 6m after DES", | "briefDesignDescription" : "Triple therapy for 6w vs. 6m after DES", | ||
"pdfurl" : "https://www.jacc.org/doi/pdf/10.1016/j.jacc.2015.02.050", | "pdfurl" : "https://www.jacc.org/doi/pdf/10.1016/j.jacc.2015.02.050", | ||
"statusUsableDate" : "2016-10-01", | "statusUsableDate" : "2016-10-01", | ||
"pmid" : "25908066", | |||
"title" : "Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation", | |||
"timestamp" : "2021-01-30T20:57:06Z", | |||
"published" : "2015-04-28", | |||
"abbreviation" : "ISAR-TRIPLE", | |||
"briefResultsDescription" : "Triple therapy for 6 weeks not superior to 6 months in regards to net clinical outcome", | "briefResultsDescription" : "Triple therapy for 6 weeks not superior to 6 months in regards to net clinical outcome", | ||
" | "diseases" : "Coronary Artery Disease;Atrial Fibrillation", | ||
"pageName" : "ISAR-TRIPLE", | "pageName" : "ISAR-TRIPLE", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "Triple therapy in Patients who Require Oral Anticoagulation After Drug-Eluting Stent Implantation", | ||
" | "citation" : "Fiedler KA <i>et al</i>. \"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation\". <i>J Am Coll Cardiol</i>. 2015. 65(16):1619-30.", | ||
" | "pageid" : 2812 | ||
}, | }, | ||
{ | { | ||
"title" : "Initial Invasive or Conservative Strategy for Stable Coronary Disease", | |||
"statusUsableDate" : "2021-01-28", | |||
"pmid" : "32227755", | |||
"abbreviation" : "ISCHEMIA", | |||
"published" : "2020-04-09", | |||
"timestamp" : "2021-04-07T17:13:36Z", | "timestamp" : "2021-04-07T17:13:36Z", | ||
"briefDesignDescription" : "PCI/CABG vs. medical therapy in stable CAD", | "briefDesignDescription" : "PCI/CABG vs. medical therapy in stable CAD", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1915922", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1915922", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915922", | |||
"expansion" : "International Study of Comparative Health Effectiveness with Medical and Invasive Approaches", | |||
"pageid" : 4153, | "pageid" : 4153, | ||
"citation" : "Maron DJ, <i>et al</i>. \"Initial Invasive or Conservative Strategy for Stable Coronary Disease\". <i>The New England Journal of Medicine</i>. 2020. 382(15):1395-1407.", | "citation" : "Maron DJ, <i>et al</i>. \"Initial Invasive or Conservative Strategy for Stable Coronary Disease\". <i>The New England Journal of Medicine</i>. 2020. 382(15):1395-1407.", | ||
"pageName" : "ISCHEMIA", | "pageName" : "ISCHEMIA", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "No difference between PCI/CABG and medical therapy in stable CAD with moderate-severe ischemia", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Second International Study of Infarct Survival", | ||
" | "citation" : "ISIS-2 Collaborative Group. \"Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction\". <i>The Lancet</i>. 1988. 332(8607):349-360.", | ||
"pageid" : 133, | "pageid" : 133, | ||
" | "briefResultsDescription" : "Mortality benefit of aspirin within 24 hours of acute MI", | ||
" | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "pageName" : "ISIS-2", | ||
" | "trainingLevel" : "Resident", | ||
" | "pmid" : "2899772", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither among 17187 Cases of Suspected Acute Myocardial Infarction", | ||
"timestamp" : "2017-12-20T19:04:02Z", | |||
"published" : "1988-08-13", | "published" : "1988-08-13", | ||
"abbreviation" : "ISIS-2", | "abbreviation" : "ISIS-2", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)92833-4/abstract", | ||
"briefDesignDescription" : "Aspirin ± streptokinase in acute MI", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "International Stroke Trial", | ||
" | "citation" : "IST Collaborative Group. \"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke\". <i>The Lancet</i>. 1997. 349(9065):1569-1581.", | ||
"pageid" : 132, | "pageid" : 132, | ||
" | "pageName" : "IST", | ||
"briefResultsDescription" : "Mortality benefit with aspirin", | |||
"diseases" : "Stroke", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "title" : "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "9174558", | ||
"abbreviation" : "IST", | |||
"timestamp" : "2016-03-07T04:46:48Z", | |||
"published" : "1997-05-31", | "published" : "1997-05-31", | ||
" | "briefDesignDescription" : "Aspirin in acute ischemic stroke", | ||
" | "subspecialties" : "Neurology", | ||
" | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)04011-7/fulltext", | ||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673697040117.pdf" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807646", | ||
"briefDesignDescription" : "Rosuvastatin for primary CV prevention", | "briefDesignDescription" : "Rosuvastatin for primary CV prevention", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807646", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807646", | ||
"subspecialties" : "Cardiology;Preventive Medicine", | "subspecialties" : "Cardiology;Preventive Medicine", | ||
" | "abbreviation" : "JUPITER", | ||
"published" : "2008-11-20", | |||
"timestamp" : "2017-12-03T22:36:21Z", | |||
"title" : "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", | |||
"statusUsableDate" : "2012-06-01", | "statusUsableDate" : "2012-06-01", | ||
" | "pmid" : "18997196", | ||
" | "trainingLevel" : "resident", | ||
"pageName" : "JUPITER", | "pageName" : "JUPITER", | ||
"diseases" : "Hyperlipidemia;Coronary Artery Disease;Stroke;Transient Ischemic Attack", | "diseases" : "Hyperlipidemia;Coronary Artery Disease;Stroke;Transient Ischemic Attack", | ||
" | "briefResultsDescription" : "Rosuvastatin delays major CV events", | ||
" | "pageid" : 445, | ||
" | "citation" : "Ridker PM, <i>et al</i>. \"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein\". <i>The New England Journal of Medicine</i>. 2008. 359(21):2195-2207.", | ||
"expansion" : "Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Reck M, <i>et al</i>. \"Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer\". <i>The New England Journal of Medicine</i>. 2016. 375(19):1824-1833.", | ||
"pageid" : 2846, | "pageid" : 2846, | ||
" | "pageName" : "KEYNOTE-024", | ||
"briefResultsDescription" : "Pembrolizumab improves survival in advanced NSCLC over chemotherapy", | |||
"diseases" : "Lung Cancer", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer", | ||
"pmid" : "27718847", | |||
" | |||
"statusUsableDate" : "2016-11-01", | "statusUsableDate" : "2016-11-01", | ||
" | "abbreviation" : "KEYNOTE-024", | ||
"timestamp" : "2017-12-03T22:36:23Z", | |||
"published" : "2016-11-10", | "published" : "2016-11-10", | ||
" | "briefDesignDescription" : "Pembrolizumab vs. chemotherapy in NSCLC", | ||
" | "subspecialties" : "Oncology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1606774", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1606774" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "LAAOS III", | |||
"timestamp" : "2025-05-15T20:40:37Z", | "timestamp" : "2025-05-15T20:40:37Z", | ||
"published" : "2021-06-03", | |||
"title" : "Left atrial appendage occlusion during cardiac surgery to prevent stroke", | |||
"statusUsableDate" : "2025-04-19", | |||
"pmid" : "33999547", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101897", | |||
"briefDesignDescription" : "Surgical LAA occlusion in AF", | "briefDesignDescription" : "Surgical LAA occlusion in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2101897", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2101897", | ||
"citation" : "Whitlock RP, <i>et al</i>. \"Left atrial appendage occlusion during cardiac surgery to prevent stroke\". <i>The New England Journal of Medicine</i>. 2021. 384(22):2081-2091.", | |||
"pageid" : 4425, | "pageid" : 4425, | ||
" | "expansion" : "Left Atrial Appendage Occlusion Study III", | ||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "pageName" : "LAAOS III", | ||
"briefResultsDescription" : "Surgical LAA associated with fewer AF events", | "briefResultsDescription" : "Surgical LAA associated with fewer AF events", | ||
"diseases" : "Atrial Fibrillation" | |||
"diseases" : "Atrial Fibrillation | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1300439", | ||
"briefDesignDescription" : "Lenalidomide/dexamethasone in smoldering MM", | "briefDesignDescription" : "Lenalidomide/dexamethasone in smoldering MM", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1300439", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1300439", | ||
"subspecialties" : "Hematology;Oncology", | "subspecialties" : "Hematology;Oncology", | ||
" | "abbreviation" : "", | ||
"published" : "2013-08-01", | |||
"timestamp" : "2018-10-25T17:05:24Z", | |||
"title" : "Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma", | |||
"statusUsableDate" : "2018-10-25", | "statusUsableDate" : "2018-10-25", | ||
" | "pmid" : "23902483", | ||
" | "trainingLevel" : "Fellow", | ||
"pageName" : "LenDex in High-Risk Smoldering Myeloma", | "pageName" : "LenDex in High-Risk Smoldering Myeloma", | ||
"diseases" : "Multiple Myeloma", | "diseases" : "Multiple Myeloma", | ||
" | "briefResultsDescription" : "In flawed trial, LenDex improved OS compared to observation", | ||
" | "pageid" : 3706, | ||
" | "citation" : "Mateos MV, <i>et al</i>. \"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma\". <i>The New England Journal of Medicine</i>. 2013. 369(5):438-47.", | ||
"expansion" : "" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2014-07-01", | |||
"pmid" : "24988555", | |||
"title" : "A randomized trial of epidural glucocorticoid injections for spinal stenosis", | |||
"timestamp" : "2017-12-03T22:36:26Z", | "timestamp" : "2017-12-03T22:36:26Z", | ||
"published" : "2014-07-03", | |||
"abbreviation" : "LESS", | |||
"subspecialties" : "Pain Medicine;Physical Medicine and Rehabilitation;Radiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1313265", | |||
"briefDesignDescription" : "Epidural steroids in spinal stenosis", | "briefDesignDescription" : "Epidural steroids in spinal stenosis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313265", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313265", | ||
" | "expansion" : "Lumbar Epidural Steroid Injections for Spinal Stenosis", | ||
"citation" : "Friedly JL, <i>et al</i>. \"A randomized trial of epidural glucocorticoid injections for spinal stenosis\". <i>The New England Journal of Medicine</i>. 2014. 371(1):11-21.", | "citation" : "Friedly JL, <i>et al</i>. \"A randomized trial of epidural glucocorticoid injections for spinal stenosis\". <i>The New England Journal of Medicine</i>. 2014. 371(1):11-21.", | ||
" | "pageid" : 1883, | ||
"briefResultsDescription" : "Epidural steroids don't improve pain or disability at six weeks", | "briefResultsDescription" : "Epidural steroids don't improve pain or disability at six weeks", | ||
" | "diseases" : "Spinal Stenosis", | ||
"pageName" : "LESS", | "pageName" : "LESS", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Intensive glycemic therapy in the surgical ICU", | "briefDesignDescription" : "Intensive glycemic therapy in the surgical ICU", | ||
"subspecialties" : "Critical Care;Endocrinology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011300", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011300", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011300", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011300", | ||
" | "title" : "Intensive Insulin Therapy in Critically Ill Patients", | ||
"pmid" : "11794168", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : "Leuven Surgical Trial", | ||
"timestamp" : "2017-01-19T20:18:41Z", | |||
"published" : "2001-11-08", | "published" : "2001-11-08", | ||
"pageName" : "Leuven Surgical Trial", | "pageName" : "Leuven Surgical Trial", | ||
"briefResultsDescription" : "Intensive glycemic control reduces mortality", | |||
"diseases" : "Stress Hyperglycemia", | "diseases" : "Stress Hyperglycemia", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "", | ||
" | "citation" : "Van den Berghe G, <i>et al</i>. \"Intensive Insulin Therapy in Critically Ill Patients\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1359-1367.", | ||
"pageid" : 139 | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300874", | ||
"briefDesignDescription" : "ATRA-ATO vs. ATRA-chemotherapy in APL", | "briefDesignDescription" : "ATRA-ATO vs. ATRA-chemotherapy in APL", | ||
"subspecialties" : "Hematology;Oncology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300874", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300874", | ||
" | "abbreviation" : "", | ||
" | "timestamp" : "2017-12-03T22:36:27Z", | ||
"published" : "2013-07-11", | |||
"title" : "Retinoic acid and arsenic trioxide for acute promyelocytic leukemia", | |||
"pmid" : "23841729", | |||
"statusUsableDate" : "2014-12-01", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pageName" : "Lo-Coco 2013", | ||
"briefResultsDescription" : "ATRA-ATO is noninferior, possibly superior to ATRA-chemotherapy in APL", | "briefResultsDescription" : "ATRA-ATO is noninferior, possibly superior to ATRA-chemotherapy in APL", | ||
"diseases" : "Leukemia", | "diseases" : "Leukemia", | ||
" | "citation" : "Lo-Coco F, <i>et al</i>. \"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia\". <i>The New England Journal of Medicine</i>. 2013. 369(2):111-21.", | ||
"pageid" : 2285, | |||
" | "expansion" : "" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "LoDoCo", | |||
"published" : "2013-01-29", | |||
"timestamp" : "2021-02-18T20:36:25Z", | "timestamp" : "2021-02-18T20:36:25Z", | ||
"title" : "Low-dose colchicine for secondary prevention of cardiovascular disease", | |||
"pmid" : "23265346", | |||
"statusUsableDate" : "2013-08-01", | |||
"pdfurl" : null, | |||
"briefDesignDescription" : "Colchicine for stable CAD", | "briefDesignDescription" : "Colchicine for stable CAD", | ||
"fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0735109712054782", | "fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0735109712054782", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 1583, | "pageid" : 1583, | ||
"citation" : "Nidorf SM, <i>et al</i>. \"Low-dose colchicine for secondary prevention of cardiovascular disease\". <i>Journal of the American College of Cardiology</i>. 2013. 61(4):404-410.", | "citation" : "Nidorf SM, <i>et al</i>. \"Low-dose colchicine for secondary prevention of cardiovascular disease\". <i>Journal of the American College of Cardiology</i>. 2013. 61(4):404-410.", | ||
"expansion" : "Low-Dose Colchicine", | "expansion" : "Low-Dose Colchicine", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "LoDoCo", | "pageName" : "LoDoCo", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Colcicine may reduce complications in stable CAD" | ||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2021-02-18", | |||
"pmid" : "32865380", | |||
"title" : "Colchicine in patients with chronic coronary disease", | |||
"timestamp" : "2024-08-08T17:36:48Z", | "timestamp" : "2024-08-08T17:36:48Z", | ||
"published" : "2020-11-05", | |||
"abbreviation" : "LoDoCo2", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2021372", | |||
"briefDesignDescription" : "Colchicine in stable CAD", | "briefDesignDescription" : "Colchicine in stable CAD", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021372", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021372", | ||
" | "expansion" : "Low Dose Colchicine 2", | ||
"citation" : "Nidorf SM, <i>et al</i>. \"Colchicine in patients with chronic coronary disease\". <i>The New England Journal of Medicine</i>. 2020. 383(19):1838-1847.", | "citation" : "Nidorf SM, <i>et al</i>. \"Colchicine in patients with chronic coronary disease\". <i>The New England Journal of Medicine</i>. 2020. 383(19):1838-1847.", | ||
" | "pageid" : 4359, | ||
"briefResultsDescription" : "Colchicine with fewer CV events", | "briefResultsDescription" : "Colchicine with fewer CV events", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "LoDoCo2", | "pageName" : "LoDoCo2", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "LOVIT", | ||
"briefResultsDescription" : "Vitamin C associated with greater risk of poor ICU outcomes", | |||
"diseases" : "Sepsis;Shock", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Lessening Organ Dysfunction with Vitamin C", | |||
"citation" : "Lamontagne, F, <i>et al</i>. \"Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit\". <i>New England Journal of Medicine</i>. 2022. 386(25):2387-2398.", | |||
"pageid" : 5147, | |||
"briefDesignDescription" : "Vitamin C in sepsis", | "briefDesignDescription" : "Vitamin C in sepsis", | ||
"subspecialties" : "Critical Care;Infectious Disease", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2200644", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2200644", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200644", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2200644", | ||
" | "title" : "Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit", | ||
"statusUsableDate" : "2023-10-28", | "statusUsableDate" : "2023-10-28", | ||
" | "pmid" : "35704292", | ||
"abbreviation" : "LOVIT", | "abbreviation" : "LOVIT", | ||
" | "timestamp" : "2025-06-19T18:33:56Z", | ||
" | "published" : "2022-06-23" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906431", | ||
"briefDesignDescription" : "CRT in HFrEF with QRS ≥130 msec and mild symptoms", | "briefDesignDescription" : "CRT in HFrEF with QRS ≥130 msec and mild symptoms", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906431", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906431", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "MADIT-CRT", | ||
"published" : "2009-10-01", | "published" : "2009-10-01", | ||
"pageName" : "MADIT-CRT", | "timestamp" : "2017-12-03T22:37:23Z", | ||
"title" : "Cardiac-resynchronization therapy for the prevention of heart-failure events", | |||
"pmid" : "19723701", | |||
"statusUsableDate" : "2014-04-01", | |||
"trainingLevel" : "Resident", | |||
"pageName" : "MADIT-CRT", | |||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "CRT reduces mortality or HF complications in mildly symptomatic HFrEF with prolonged QRS", | ||
" | "pageid" : 1780, | ||
" | "citation" : "Moss AJ, <i>et al</i>. \"Cardiac-resynchronization therapy for the prevention of heart-failure events\". <i>The New England Journal of Medicine</i>. 2009. 361(14):1329-1338.", | ||
"expansion" : "Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "MADIT-II", | ||
"briefResultsDescription" : "ICD improves survival in post-MI patients with LVEF≤30%", | |||
"diseases" : "Heart Failure;Acute Coronary Syndrome;Myocardial Infarction", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Multicenter Automatic Defibrillator Implantation Trial II", | |||
"citation" : "Moss AJ, <i>et al</i>. \"Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction\". <i>The New England Journal of Medicine</i>. 2002. 346(12):877-883.", | |||
"pageid" : 385, | |||
"briefDesignDescription" : "ICD post-MI with HFrEF", | "briefDesignDescription" : "ICD post-MI with HFrEF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013474", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013474", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013474", | ||
" | "title" : "Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction", | ||
"pmid" : "11907286", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"abbreviation" : "MADIT-II", | "abbreviation" : "MADIT-II", | ||
" | "timestamp" : "2019-03-07T17:25:42Z", | ||
" | "published" : "2002-03-21" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin", | ||
" | "citation" : "Cohen AT, <i>et al</i>. \"Rivaroxaban for thromboprophylaxis in acutely ill medical patients\". <i>The New England Journal of Medicine</i>. 2013. 368(6):513-523.", | ||
"pageid" : 1272, | "pageid" : 1272, | ||
" | "pageName" : "MAGELLAN", | ||
"briefResultsDescription" : "Rivaroxaban similar to LMWH for prophylaxis, caused more bleeding", | |||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Rivaroxaban for thromboprophylaxis in acutely ill medical patients", | ||
" | "pmid" : "23388003", | ||
"statusUsableDate" : "2013-10-01", | "statusUsableDate" : "2013-10-01", | ||
" | "abbreviation" : "MAGELLAN", | ||
"timestamp" : "2017-12-03T22:37:25Z", | |||
"published" : "2013-02-07", | "published" : "2013-02-07", | ||
" | "briefDesignDescription" : "Rivaroxaban vs. LMWH for VTE prophylaxis", | ||
" | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1111096", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1111096" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018-10-08T21:48:25Z", | "timestamp" : "2018-10-08T21:48:25Z", | ||
"published" : "2017-08-27", | |||
"abbreviation" : "MARINER", | |||
"statusUsableDate" : "2018-09-13", | |||
"pmid" : "30145946", | |||
"title" : "Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805090", | |||
"subspecialties" : "Hematology;Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1805090", | |||
"briefDesignDescription" : "Rivaroxaban VTE ppx after medical admission", | "briefDesignDescription" : "Rivaroxaban VTE ppx after medical admission", | ||
" | "citation" : "Spyropoulos AC, <i>et al</i>. \"Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness\". <i>The New England Journal of Medicine</i>. 2018. e-published 2018-08-26:1-10.", | ||
"pageid" : 3699, | "pageid" : 3699, | ||
" | "expansion" : "Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Rivaroxaban does not prevent VTE in medically ill patients", | "briefResultsDescription" : "Rivaroxaban does not prevent VTE in medically ill patients", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | "diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | ||
" | "pageName" : "MARINER" | ||
}, | }, | ||
{ | { | ||
"title" : "Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study", | |||
"pmid" : "19553269", | |||
"statusUsableDate" : "2015-10-01", | |||
"abbreviation" : "MASS", | |||
"published" : "2009-06-24", | |||
"timestamp" : "2017-12-03T22:37:27Z", | "timestamp" : "2017-12-03T22:37:27Z", | ||
"briefDesignDescription" : "US screening for AAA in men", | "briefDesignDescription" : "US screening for AAA in men", | ||
"fulltexturl" : "http://www.bmj.com/content/338/bmj.b2307.long", | "fulltexturl" : "http://www.bmj.com/content/338/bmj.b2307.long", | ||
"subspecialties" : "Preventive Medicine;Radiology", | |||
"pdfurl" : "http://www.bmj.com/content/338/bmj.b2307.full.pdf", | |||
"expansion" : "Multicentre Aneurysm Screening Study", | |||
"pageid" : 2397, | "pageid" : 2397, | ||
"citation" : "Thompson SG, <i>et al</i>. \"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study\". <i>BMJ</i>. 2009. 338:b2307.", | "citation" : "Thompson SG, <i>et al</i>. \"Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study\". <i>BMJ</i>. 2009. 338:b2307.", | ||
"pageName" : "MASS", | "pageName" : "MASS", | ||
"diseases" : "Abdominal Aortic Aneurysm", | "diseases" : "Abdominal Aortic Aneurysm", | ||
" | "briefResultsDescription" : "US screening reduces AAA mortality in men", | ||
"trainingLevel" : "Intern" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "resident", | ||
"pageName" : "MASTER DAPT", | |||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "Abbreviated DAPT non-inferior or superior for CVD and/or bleeding events", | |||
"pageid" : 4443, | |||
"citation" : "Valgimigli M, <i>et al</i>. \"Dual antiplatelet therapy after PCI in patients at high bleeding risk\". <i>The New England Journal of Medicine</i>. 2021. 385(18):1643-1655.", | |||
"expansion" : "Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation with an Abbreviated versus Standard DAPT Regimen", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2108749", | |||
"briefDesignDescription" : "Abbreviated DAPT in high-risk bleeding", | "briefDesignDescription" : "Abbreviated DAPT in high-risk bleeding", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2108749", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2108749", | ||
"subspecialties" : "Cardiology;Hematology", | "subspecialties" : "Cardiology;Hematology", | ||
" | "abbreviation" : "MASTER DAPT", | ||
"published" : "2021-10-28", | "published" : "2021-10-28", | ||
" | "timestamp" : "2021-11-06T00:38:08Z", | ||
"title" : "Dual antiplatelet therapy after PCI in patients at high bleeding risk", | "title" : "Dual antiplatelet therapy after PCI in patients at high bleeding risk", | ||
"pmid" : "34449185" | "pmid" : "34449185", | ||
"statusUsableDate" : "2021-10-31" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "student", | ||
" | "pageName" : "MATCH", | ||
" | "diseases" : "Stroke", | ||
"briefResultsDescription" : "More major bleeding but no greater efficacy with combination therapy", | |||
"pageid" : 1125, | "pageid" : 1125, | ||
"citation" : "Diener HC, <i>et al</i>. \"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial\". <i>The Lancet</i>. 2004. 364(9431):331-337.", | "citation" : "Diener HC, <i>et al</i>. \"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial\". <i>The Lancet</i>. 2004. 364(9431):331-337.", | ||
"expansion" : "Management of Atherothrombosis with Clopidogrel in High-risk patients", | "expansion" : "Management of Atherothrombosis with Clopidogrel in High-risk patients", | ||
" | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673604167214.pdf", | ||
" | "briefDesignDescription" : "ASA/clopidogrel vs. clopidogrel in stroke", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16721-4/fulltext", | |||
"subspecialties" : "Neurology", | |||
"abbreviation" : "MATCH", | |||
"published" : "2004-07-24", | "published" : "2004-07-24", | ||
" | "timestamp" : "2017-12-03T22:37:28Z", | ||
"title" : "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial", | "title" : "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial", | ||
"pmid" : "15276392" | "pmid" : "15276392", | ||
"statusUsableDate" : "2013-04-01" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "MATRIX Antithrombin", | |||
"timestamp" : "2023-08-03T18:17:01Z", | "timestamp" : "2023-08-03T18:17:01Z", | ||
"published" : "2015-09-10", | |||
"title" : "Bivalirudin or unfractionated heparin in acute coronary syndromes", | |||
"pmid" : "26324049", | |||
"statusUsableDate" : "2023-07-29", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1507854", | |||
"briefDesignDescription" : "Heparin vs. bivalirudin in PCI", | "briefDesignDescription" : "Heparin vs. bivalirudin in PCI", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1507854", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1507854", | ||
"citation" : "Valgimigli M, <i>et al</i>. \"Bivalirudin or unfractionated heparin in acute coronary syndromes\". <i>New England Journal of Medicine</i>. 2015. 373(11):997-1009.", | |||
"pageid" : 2485, | "pageid" : 2485, | ||
" | "expansion" : "Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX)", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "MATRIX Antithrombin", | ||
"briefResultsDescription" : "Bivalirudin equivalent to heparin for PCI", | "briefResultsDescription" : "Bivalirudin equivalent to heparin for PCI", | ||
"diseases" : "Coronary Artery Disease" | |||
"diseases" : "Coronary Artery Disease | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Harris PNA, <i>et al</i>. \"Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae Bloodstream Infection and ceftriaxone resistance: A randomized clinical trial\". <i>JAMA</i>. 2018. 320(10):984-994.", | ||
"pageid" : 4422, | "pageid" : 4422, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Piperacillin-tazobactam is inferior to meropenem for ESBL bacteremia", | "briefResultsDescription" : "Piperacillin-tazobactam is inferior to meropenem for ESBL bacteremia", | ||
"diseases" : "ESBL Bacteremia", | |||
"pageName" : "MERINO", | |||
"timestamp" : "2022-04-21T19:13:41Z", | |||
"published" : "2018-09-11", | "published" : "2018-09-11", | ||
"abbreviation" : "MERINO", | "abbreviation" : "MERINO", | ||
"statusUsableDate" : "2022-04-21", | |||
"pmid" : "30208454", | |||
"title" : "Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae Bloodstream Infection and ceftriaxone resistance: A randomized clinical trial", | "title" : "Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae Bloodstream Infection and ceftriaxone resistance: A randomized clinical trial", | ||
" | "pdfurl" : "", | ||
"subspecialties" : "Infectious Disease", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2702145", | |||
"briefDesignDescription" : "Piperacillin-tazobactam for ESBL bacteremia" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "MERIT-HF", | |||
"published" : "1999-06-12", | |||
"timestamp" : "2015-08-24T03:51:03Z", | "timestamp" : "2015-08-24T03:51:03Z", | ||
"title" : "Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure", | |||
"pmid" : "10376614", | |||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : "", | |||
"briefDesignDescription" : "Metoprolol in HFrEF", | "briefDesignDescription" : "Metoprolol in HFrEF", | ||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402", | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140673699044402", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 130, | "pageid" : 130, | ||
"citation" : "Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.", | "citation" : "Fagerberg B, <i>et al</i>. \"Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure\". <i>The Lancet</i>. 1999. 353(9169):2001-7.", | ||
"expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure", | "expansion" : "Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "MERIT-HF", | "pageName" : "MERIT-HF", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Metoprolol improves survival in NYHA II-IV HFrEF" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Surgery vs. PT in OA with meniscal tear", | "briefDesignDescription" : "Surgery vs. PT in OA with meniscal tear", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1301408", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1301408", | ||
" | "subspecialties" : "Surgery;Physical Medicine and Rehabilitation", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301408", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301408", | ||
" | "title" : "Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis", | ||
"statusUsableDate" : "2013-09-01", | "statusUsableDate" : "2013-09-01", | ||
" | "pmid" : "23506518", | ||
"abbreviation" : "METEOR", | |||
"published" : "2013-05-02", | "published" : "2013-05-02", | ||
"timestamp" : "2017-12-03T22:37:29Z", | |||
"pageName" : "METEOR", | "pageName" : "METEOR", | ||
"diseases" : "Meniscal Tear;Osteoarthritis", | "diseases" : "Meniscal Tear;Osteoarthritis", | ||
" | "briefResultsDescription" : "Surgery no better than PT alone", | ||
" | "trainingLevel" : "Student", | ||
"expansion" : "Meniscal Tear in Osteoarthritis Research", | |||
"pageid" : 1429, | |||
"citation" : "Katz JN, <i>et al</i>. \"Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis\". <i>The New England Journal of Medicine</i>. 2013. 368(18):1675-1684." | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Early surgery for MR", | "briefDesignDescription" : "Early surgery for MR", | ||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/927436/joi130034.pdf", | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/927436/joi130034.pdf", | ||
"statusUsableDate" : "2014-02-01", | "statusUsableDate" : "2014-02-01", | ||
"pmid" : "23942679", | |||
"title" : "Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets", | |||
"published" : "2013-08-14", | |||
"timestamp" : "2017-12-03T22:37:31Z", | |||
"abbreviation" : "MIDA", | |||
"diseases" : "Mitral Regurgitation", | |||
"briefResultsDescription" : "Early surgery reduces mortality in MR", | "briefResultsDescription" : "Early surgery reduces mortality in MR", | ||
"pageName" : "MIDA", | "pageName" : "MIDA", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Mitral Regurgitation International Database", | ||
" | "pageid" : 1787, | ||
"citation" : "Suri RM, <i>et al</i>. \"Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets\". <i>JAMA</i>. 2013. 310(6):609-616." | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Modifying the Impact of ICU-Associated Neurological Dysfunction–USA", | ||
" | "citation" : "Girard TD, <i>et al</i>. \"Haloperidol and ziprasidone for treatment of delirium in critical illness\". <i>The New England Journal of Medicine</i>. 2018. ePub 2018-10-22:1-12.", | ||
"pageid" : 3741, | "pageid" : 3741, | ||
" | "pageName" : "MIND-USA", | ||
"briefResultsDescription" : "Antipsychotics don't reduce days without delirium or coma in ICU", | |||
"diseases" : "Delirium;Critical Illness", | |||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "title" : "Haloperidol and ziprasidone for treatment of delirium in critical illness", | ||
"pmid" : "30346242", | |||
" | |||
"statusUsableDate" : "2018-11-30", | "statusUsableDate" : "2018-11-30", | ||
" | "abbreviation" : "MIND-USA", | ||
"timestamp" : "2022-11-02T14:33:46Z", | |||
"published" : "2018-10-22", | "published" : "2018-10-22", | ||
" | "briefDesignDescription" : "Antipsychotics in ICU delirium", | ||
" | "subspecialties" : "Psychiatry;Critical Care", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1808217", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1808217" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2020-10-29T17:14:07Z", | "timestamp" : "2020-10-29T17:14:07Z", | ||
"published" : "2001-04-04", | |||
"abbreviation" : "MIRACL", | |||
"pmid" : "11277825", | |||
"statusUsableDate" : "2012-03-01", | |||
"title" : "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes", | |||
"pdfurl" : "http://jama.ama-assn.org/content/285/13/1711.full.pdf", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://jama.ama-assn.org/content/285/13/1711.long", | |||
"briefDesignDescription" : "Atorvastatin in UA/NSTEMI", | "briefDesignDescription" : "Atorvastatin in UA/NSTEMI", | ||
" | "citation" : "Schwartz GG, <i>et al</i>. \"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes\". <i>Journal of the American Medical Association</i>. 2001. 285(13):1711-1718.", | ||
"pageid" : 432, | "pageid" : 432, | ||
" | "expansion" : "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Atorvastatin reduced rate of CV events after UA/NSTEMI", | "briefResultsDescription" : "Atorvastatin reduced rate of CV events after UA/NSTEMI", | ||
"diseases" : "Coronary Artery Disease;Acute Coronary Syndrome;Hyperlipidemia", | "diseases" : "Coronary Artery Disease;Acute Coronary Syndrome;Hyperlipidemia", | ||
" | "pageName" : "MIRACL" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "tPA and/or DNase for pleural infection", | "briefDesignDescription" : "tPA and/or DNase for pleural infection", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1012740", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1012740", | ||
" | "subspecialties" : "Pulmonology;Infectious Disease", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1012740", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1012740", | ||
" | "title" : "Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection", | ||
"statusUsableDate" : "2020-12-31", | "statusUsableDate" : "2020-12-31", | ||
" | "pmid" : "21830966", | ||
"abbreviation" : "MIST2", | |||
"published" : "2011-08-11", | "published" : "2011-08-11", | ||
"timestamp" : "2021-01-06T13:53:52Z", | |||
"pageName" : "MIST2", | "pageName" : "MIST2", | ||
"diseases" : "Pleural Infection", | "diseases" : "Pleural Infection", | ||
" | "briefResultsDescription" : "tPA+DNase with greatest reduction in size of effusion", | ||
" | "trainingLevel" : "Fellow", | ||
"expansion" : "Second MIST trial", | |||
"pageid" : 3757, | |||
"citation" : "Rahman NM, <i>et al</i>. \"Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection\". <i>The New England Journal of Medicine</i>. 2011. 365(6):518-526." | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "MITIGATE", | |||
"diseases" : "Acute Respiratory Infection", | |||
"briefResultsDescription" : "Antibiotic stewardship reduced unnecessary prescriptions", | |||
"pageid" : 4102, | |||
"citation" : "Yadav K, <i>et al</i>. \"A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings\". <i>Academic Emergency Medicine</i>. 2019. 26(7):719-731.", | |||
"expansion" : "A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings", | |||
"pdfurl" : "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acem.13690?download", | |||
"briefDesignDescription" : "Antibiotic stewardship in respiratory infections", | "briefDesignDescription" : "Antibiotic stewardship in respiratory infections", | ||
"fulltexturl" : "https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.13690", | "fulltexturl" : "https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.13690", | ||
"subspecialties" : "Emergency Medicine;Infectious Disease", | "subspecialties" : "Emergency Medicine;Infectious Disease", | ||
" | "abbreviation" : "MITIGATE", | ||
"published" : "2019-07-01", | "published" : "2019-07-01", | ||
" | "timestamp" : "2024-05-18T01:31:16Z", | ||
"title" : "A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings", | "title" : "A Multifaceted Intervention Improves Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings", | ||
"statusUsableDate" : "2024-04-29", | |||
"pmid" : "31215721" | "pmid" : "31215721" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "MODIFY I and II", | |||
"published" : "2017-01-26", | |||
"timestamp" : "2023-04-12T13:12:04Z", | "timestamp" : "2023-04-12T13:12:04Z", | ||
"briefDesignDescription" : "Bezlotoxumab for C. diff recurrence prevention", | "title" : "Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection", | ||
"statusUsableDate" : "2017-05-01", | |||
"pmid" : "28121498", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602615", | |||
"briefDesignDescription" : "Bezlotoxumab for C. diff recurrence prevention", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602615", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602615", | ||
"subspecialties" : "Gastroenterology;Infectious Disease", | |||
"pageid" : 2931, | "pageid" : 2931, | ||
"citation" : "Wilcox MH, <i>et al</i>. \"Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection\". <i>New England Journal of Medicine</i>. 2017. 376(4):305-317.", | "citation" : "Wilcox MH, <i>et al</i>. \"Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection\". <i>New England Journal of Medicine</i>. 2017. 376(4):305-317.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "MODIFY I and II", | "pageName" : "MODIFY I and II", | ||
"diseases" : "Clostridium difficile", | "diseases" : "Clostridium difficile", | ||
" | "briefResultsDescription" : "Bezlotoxumab lowers recurrence rate of C. diff infection" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Mehra MR, <i>et al</i>. \"Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. 378(15):1386-95.", | ||
"pageid" : 3605, | "pageid" : 3605, | ||
" | "expansion" : "Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Centrifugal-flow LVAD superior to axial-flow LVAD in advanced HF", | "briefResultsDescription" : "Centrifugal-flow LVAD superior to axial-flow LVAD in advanced HF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "MOMENTUM 3", | |||
"timestamp" : "2018-06-29T18:08:40Z", | |||
"published" : "2018-04-12", | "published" : "2018-04-12", | ||
"abbreviation" : "MOMENTUM 3", | "abbreviation" : "MOMENTUM 3", | ||
"statusUsableDate" : "2018-06-29", | |||
"pmid" : "29526139", | |||
"title" : "Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure", | "title" : "Two-year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800866", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800866", | |||
"briefDesignDescription" : "Centrifugal-flow LVAD vs. axial-flow LVAD in advanced HF" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "MOPETT", | ||
"briefResultsDescription" : "Low-dose tPA reduces pulmonary HTN in submassive PE", | |||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Moderate Pulmonary Embolism Treated with Thrombolysis", | |||
"citation" : "Sharifi M, <i>et al</i>. \"Moderate pulmonary embolism treated with thrombolysis\". <i>The American Journal of Cardiology</i>. 2013. 111(2):273-277.", | |||
"pageid" : 1785, | |||
"briefDesignDescription" : "Low-dose tPA for submassive PE", | "briefDesignDescription" : "Low-dose tPA for submassive PE", | ||
"subspecialties" : "Critical Care;Pulmonology;Cardiology", | |||
"fulltexturl" : "http://www.ajconline.org/article/S0002-9149%2812%2902205-9/fulltext", | "fulltexturl" : "http://www.ajconline.org/article/S0002-9149%2812%2902205-9/fulltext", | ||
"pdfurl" : "http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914912022059.pdf", | "pdfurl" : "http://download.journals.elsevierhealth.com/pdfs/journals/0002-9149/PIIS0002914912022059.pdf", | ||
" | "title" : "Moderate pulmonary embolism treated with thrombolysis", | ||
"pmid" : "23102885", | |||
" | |||
"statusUsableDate" : "2014-02-01", | "statusUsableDate" : "2014-02-01", | ||
"abbreviation" : "MOPETT", | "abbreviation" : "MOPETT", | ||
" | "timestamp" : "2017-12-03T22:37:34Z", | ||
" | "published" : "2013-01-15" | ||
}, | }, | ||
{ | { | ||
"pageid" : 1055, | "pageid" : 1055, | ||
"citation" : "Moseley JB, <i>et al</i>. \"A controlled trial of arthroscopic surgery for osteoarthritis of the knee\". <i>The New England Journal of Medicine</i>. 2002. 347(2):81-88.", | "citation" : "Moseley JB, <i>et al</i>. \"A controlled trial of arthroscopic surgery for osteoarthritis of the knee\". <i>The New England Journal of Medicine</i>. 2002. 347(2):81-88.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Osteoarthritis", | |||
"briefResultsDescription" : "No difference between groups at 2 years", | "briefResultsDescription" : "No difference between groups at 2 years", | ||
"pageName" : "Moseley Trial", | |||
"published" : "2002-07-11", | "published" : "2002-07-11", | ||
" | "timestamp" : "2017-12-03T22:37:42Z", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
"statusUsableDate" : "2012-11-01", | |||
"pmid" : "12110735", | |||
"title" : "A controlled trial of arthroscopic surgery for osteoarthritis of the knee", | "title" : "A controlled trial of arthroscopic surgery for osteoarthritis of the knee", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013259", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013259", | |||
"subspecialties" : "Surgery;Physical Medicine and Rehabilitation", | |||
"briefDesignDescription" : "Arthroscopy in knee OA" | |||
}, | }, | ||
{ | { | ||
"pmid" : "12063369", | |||
"statusUsableDate" : "2023-03-30", | |||
"title" : "Ventricular pacing or dual-chamber pacing for sinus-node dysfunction", | |||
"timestamp" : "2023-03-30T22:49:47Z", | "timestamp" : "2023-03-30T22:49:47Z", | ||
"published" : "2002-06-13", | |||
"abbreviation" : "MOST", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa013040", | |||
"briefDesignDescription" : "Dual- vs. single-chamber pacing in bradycardia", | "briefDesignDescription" : "Dual- vs. single-chamber pacing in bradycardia", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013040", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa013040", | ||
" | "expansion" : "Ventricular pacing or dual-chamber pacing for sinus-node dysfunction", | ||
"citation" : "Lamas GA, <i>et al</i>. \"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction\". <i>The New England Journal of Medicine</i>. 2002. 346(24):1854-62.", | "citation" : "Lamas GA, <i>et al</i>. \"Ventricular pacing or dual-chamber pacing for sinus-node dysfunction\". <i>The New England Journal of Medicine</i>. 2002. 346(24):1854-62.", | ||
" | "pageid" : 2710, | ||
"briefResultsDescription" : "Dual-chamber pacing superior to single-chamber ventricular pacing", | "briefResultsDescription" : "Dual-chamber pacing superior to single-chamber ventricular pacing", | ||
" | "diseases" : "Bradycardia", | ||
"pageName" : "MOST", | "pageName" : "MOST", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"pageid" : 2816, | "pageid" : 2816, | ||
"citation" : "Von Hoff DD, <i>et al</i>. \"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine\". <i>The New England Journal of Medicine</i>. 2013. 369(18):1691-1703.", | "citation" : "Von Hoff DD, <i>et al</i>. \"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine\". <i>The New England Journal of Medicine</i>. 2013. 369(18):1691-1703.", | ||
"expansion" : "Metastatic Pancreatic Adenocarcinoma Clinical Trial", | "expansion" : "Metastatic Pancreatic Adenocarcinoma Clinical Trial", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Pancreatic Cancer", | |||
"briefResultsDescription" : "Gemcicabine/nab-paclitaxel improves OS in metastatic pancreatic cancer compared to gemcitabine", | "briefResultsDescription" : "Gemcicabine/nab-paclitaxel improves OS in metastatic pancreatic cancer compared to gemcitabine", | ||
"pageName" : "MPACT", | |||
"published" : "2013-10-31", | "published" : "2013-10-31", | ||
" | "timestamp" : "2017-12-03T22:37:36Z", | ||
"abbreviation" : "MPACT", | "abbreviation" : "MPACT", | ||
"statusUsableDate" : "2016-08-01", | |||
"pmid" : "24131140", | |||
"title" : "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", | "title" : "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1304369", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1304369", | |||
"subspecialties" : "Oncology", | |||
"briefDesignDescription" : "Gemcitabine/nab-paclitaxel in pancreatic cancer" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "MR CLEAN", | |||
"timestamp" : "2016-03-10T04:00:44Z", | "timestamp" : "2016-03-10T04:00:44Z", | ||
"published" : "2015-01-01", | |||
"title" : "A randomized trial of intraarterial treatment for acute ischemic stroke", | |||
"pmid" : "25517348", | |||
"statusUsableDate" : "2012-03-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411587", | |||
"briefDesignDescription" : "IA therapy for proximal large artery strokes", | "briefDesignDescription" : "IA therapy for proximal large artery strokes", | ||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1411587", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1411587", | ||
"citation" : "Berkhemer OA, <i>et al</i>. \"A randomized trial of intraarterial treatment for acute ischemic stroke\". <i>The New England Journal of Medicine</i>. 2015. 372(1):11-20.", | |||
"pageid" : 2373, | "pageid" : 2373, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "MR CLEAN", | ||
"briefResultsDescription" : "IA therapy improves outcome without increased mortality or ICH", | "briefResultsDescription" : "IA therapy improves outcome without increased mortality or ICH", | ||
"diseases" : "Stroke" | |||
}, | |||
"diseases" : "Stroke | |||
}, | |||
{ | { | ||
"title" : "A trial of imaging selection and endovascular treatment for ischemic stroke", | |||
"statusUsableDate" : "2015-05-01", | |||
"pmid" : "23394476", | |||
"abbreviation" : "MR RESCUE", | |||
"published" : "2013-03-07", | |||
"timestamp" : "2017-12-03T22:37:37Z", | "timestamp" : "2017-12-03T22:37:37Z", | ||
"briefDesignDescription" : "Thrombectomy vs. standard care in stroke", | "briefDesignDescription" : "Thrombectomy vs. standard care in stroke", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1212793", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1212793", | ||
"subspecialties" : "Neurology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212793", | |||
"expansion" : "", | |||
"pageid" : 2363, | "pageid" : 2363, | ||
"citation" : "Kidwell CS, <i>et al</i>. \"A trial of imaging selection and endovascular treatment for ischemic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(10):914-923.", | "citation" : "Kidwell CS, <i>et al</i>. \"A trial of imaging selection and endovascular treatment for ischemic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(10):914-923.", | ||
"pageName" : "MR RESCUE", | "pageName" : "MR RESCUE", | ||
"diseases" : "Stroke", | "diseases" : "Stroke", | ||
" | "briefResultsDescription" : "Imaging did not id pts who would benefit from endovascular thrombectomy for acute ischemic stroke.", | ||
"trainingLevel" : "Fellow" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology;Preventive Medicine", | ||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/377969", | |||
"briefDesignDescription" : "CHD risk modification for CHD mortality prevention", | "briefDesignDescription" : "CHD risk modification for CHD mortality prevention", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "pmid" : "7050440", | ||
"statusUsableDate" : "2021-06-24", | "statusUsableDate" : "2021-06-24", | ||
"title" : "Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group", | |||
"timestamp" : "2021-06-25T23:51:15Z", | |||
"published" : "1982-09-24", | |||
"abbreviation" : "MRFIT", | |||
"briefResultsDescription" : "CHD risk modification did not lower 7 year mortality", | "briefResultsDescription" : "CHD risk modification did not lower 7 year mortality", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "MRFIT", | "pageName" : "MRFIT", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "Multiple Risk Factor Intervention Trial", | ||
" | "citation" : "MRFIT Writers. \"Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group\". <i>JAMA</i>. 1982. 248(12):1465-1477.", | ||
" | "pageid" : 2455 | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Multicenter Study of Hydroxyurea in Sickle-Cell Anemia", | ||
" | "citation" : "Charache S, <i>et al</i>. \"Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia\". <i>The New England Journal of Medicine</i>. 1995. 332(20):1317-1322.", | ||
"pageid" : 2797, | "pageid" : 2797, | ||
" | "briefResultsDescription" : "Hydroxyurea ↓frequency of painful crises in SCD", | ||
"diseases" : "Sickle Cell Disease", | |||
"pageName" : "MSH", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "pmid" : "7715639", | ||
"statusUsableDate" : "2016-07-01", | "statusUsableDate" : "2016-07-01", | ||
" | "title" : "Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle-Cell Anemia", | ||
"timestamp" : "2021-01-05T21:08:12Z", | |||
"published" : "1995-05-18", | "published" : "1995-05-18", | ||
"abbreviation" : "MSH", | "abbreviation" : "MSH", | ||
" | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199505183322001", | ||
"briefDesignDescription" : "Hydroxyurea in sickle-cell disease", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199505183322001" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1310460", | ||
"subspecialties" : "Surgery;Oncology", | |||
"briefDesignDescription" : "SLNB vs. surveillance in melanoma", | "briefDesignDescription" : "SLNB vs. surveillance in melanoma", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1310460", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1310460", | ||
"statusUsableDate" : "2024-03-28", | "statusUsableDate" : "2024-03-28", | ||
"pmid" : "24521106", | |||
"title" : "Multicenter Selective Lymphadenectomy Trial", | |||
"published" : "2014-02-13", | |||
"timestamp" : "2024-03-28T20:26:52Z", | |||
"abbreviation" : "MSLT-I", | |||
"diseases" : "Melanoma", | |||
"briefResultsDescription" : "SLBN did not improve melanoma-specific survival compared to observation", | "briefResultsDescription" : "SLBN did not improve melanoma-specific survival compared to observation", | ||
"pageName" : "MSLT-1", | "pageName" : "MSLT-1", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma", | ||
" | "pageid" : 3521, | ||
"citation" : "Morton DL, <i>et al</i>. \"Multicenter Selective Lymphadenectomy Trial\". <i>The New England Journal of Medicine</i>. 2014. 370(7):599-609." | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "ICD placement better than antiarrhythmics in mild HF with NSVT", | ||
"diseases" : "Ventricular Tachycardia", | |||
" | "pageName" : "MUSTT", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Multicenter Unsustained Tachycardia Trial", | |||
"citation" : "Buxton AE <i>et al</i>. \"A randomized study of the prevention of sudden death in patients with coronary artery disease\". <i>New Engl J Med</i>. 1999. 341(25):1882-90.", | "citation" : "Buxton AE <i>et al</i>. \"A randomized study of the prevention of sudden death in patients with coronary artery disease\". <i>New Engl J Med</i>. 1999. 341(25):1882-90.", | ||
"pageid" : 2872, | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199912163412503", | ||
"briefDesignDescription" : "ICD and antiarrhythmics in mild HFrEF and NSVT", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199912163412503", | |||
"pmid" : "10601507", | |||
"statusUsableDate" : "2016-12-01", | "statusUsableDate" : "2016-12-01", | ||
" | "title" : "A randomized study of the prevention of sudden death in patients with coronary artery disease", | ||
"timestamp" : "2022-12-01T19:00:15Z", | |||
"published" : "1999-12-16", | "published" : "1999-12-16", | ||
"abbreviation" : "MUSTT" | |||
"abbreviation" : "MUSTT | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "NA-ACCORD", | |||
"published" : "2009-04-30", | |||
"timestamp" : "2017-12-03T22:37:44Z", | "timestamp" : "2017-12-03T22:37:44Z", | ||
"title" : "Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival", | |||
"pmid" : "19339714", | |||
"statusUsableDate" : "2014-11-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807252", | |||
"briefDesignDescription" : "Early vs. delayed ART in HIV", | "briefDesignDescription" : "Early vs. delayed ART in HIV", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807252", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807252", | ||
"subspecialties" : "Infectious Disease", | |||
"pageid" : 1039, | "pageid" : 1039, | ||
"citation" : "Kitahata MM, <i>et al</i>. \"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival\". <i>The New England Journal of Medicine</i>. 2009. 360(18):1815-1826.", | "citation" : "Kitahata MM, <i>et al</i>. \"Effect of Early vs. Deferred Antiretroviral therapy for HIV on Survival\". <i>The New England Journal of Medicine</i>. 2009. 360(18):1815-1826.", | ||
"expansion" : "North American AIDS Cohort Collaboration on Research and Design", | "expansion" : "North American AIDS Cohort Collaboration on Research and Design", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "NA-ACCORD", | "pageName" : "NA-ACCORD", | ||
"diseases" : "HIV", | "diseases" : "HIV", | ||
" | "briefResultsDescription" : "Early ART in HIV improves survival" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "pageid" : 4063, | ||
" | "citation" : "Wong A. \"The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose\". <i>Hepatology</i>. 2019. 69(2):774-784.", | ||
" | "diseases" : "Acetaminophen Overdose", | ||
" | "briefResultsDescription" : "No difference between 12 vs. 20 hours of NAC for APAP overdose", | ||
"pageName" : "NACSTOP", | |||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
"statusUsableDate" : "2022-07-15", | "statusUsableDate" : "2022-07-15", | ||
" | "pmid" : "30125376", | ||
"title" : "The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose", | |||
"published" : "2019-02-02", | "published" : "2019-02-02", | ||
" | "timestamp" : "2022-07-29T01:52:18Z", | ||
"abbreviation" : "NACSTOP", | "abbreviation" : "NACSTOP", | ||
" | "fulltexturl" : "https://doi.org/10.1002/hep.30224", | ||
" | "subspecialties" : "Emergency Medicine;Critical Care", | ||
"briefDesignDescription" : "12 vs. 20 hours of NAC in APAP overdose", | |||
"pdfurl" : "https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30224" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "CEA in symptomatic carotid stenosis", | "briefDesignDescription" : "CEA in symptomatic carotid stenosis", | ||
"subspecialties" : "Surgery;Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199811123392002", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199811123392002", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199811123392002", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199811123392002", | ||
" | "title" : "Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis", | ||
"pmid" : "9811916", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : "NASCET", | ||
"timestamp" : "2020-08-01T21:47:56Z", | |||
"published" : "1998-11-12", | "published" : "1998-11-12", | ||
"pageName" : "NASCET", | "pageName" : "NASCET", | ||
"briefResultsDescription" : "CEA reduces the risk of death or stroke in symptomatic 50-69% carotid stenosis", | |||
"diseases" : "Carotid Stenosis;Stroke", | "diseases" : "Carotid Stenosis;Stroke", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "North American Symptomatic Carotid Endarterectomy Trial", | ||
" | "citation" : "Barnett HJ, <i>et al</i>. \"Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis\". <i>The New England Journal of Medicine</i>. 1998. 339(20):1415-25.", | ||
"pageid" : 128 | |||
}, | }, | ||
{ | { | ||
"timestamp" : "2022-10-19T13:06:44Z", | "timestamp" : "2022-10-19T13:06:44Z", | ||
"published" : "2018-06-07", | |||
"abbreviation" : "NAVIGATE ESUS", | |||
"statusUsableDate" : "2022-07-28", | |||
"pmid" : "29766772", | |||
"title" : "Rivaroxaban for stroke prevention after embolic stroke of undetermined source", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1802686", | |||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1802686", | |||
"briefDesignDescription" : "Rivaroxaban vs. ASA for ESUS (stroke)", | "briefDesignDescription" : "Rivaroxaban vs. ASA for ESUS (stroke)", | ||
" | "citation" : "Hart RG, <i>et al</i>. \"Rivaroxaban for stroke prevention after embolic stroke of undetermined source\". <i>The New England Journal of Medicine</i>. 2018. 378(23):2191-2201.", | ||
"pageid" : 3665, | "pageid" : 3665, | ||
" | "expansion" : "New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source\nof Undetermined Source", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Rivaroxaban is not superior to ASA for stroke", | "briefResultsDescription" : "Rivaroxaban is not superior to ASA for stroke", | ||
"diseases" : "Stroke", | "diseases" : "Stroke", | ||
" | "pageName" : "NAVIGATE ESUS" | ||
}, | }, | ||
{ | { | ||
"published" : "1981-11-12", | |||
"timestamp" : "2017-12-03T22:37:45Z", | "timestamp" : "2017-12-03T22:37:45Z", | ||
" | "abbreviation" : "NCDS", | ||
"pmid" : "7027040", | |||
"statusUsableDate" : "2013-07-01", | |||
"title" : "Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198111123052003", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198111123052003", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198111123052003", | ||
"subspecialties" : "Nephrology", | |||
"briefDesignDescription" : "Dialysis prescriptions in ESRD", | |||
"pageid" : 504, | "pageid" : 504, | ||
"citation" : "Lowrie EG, <i>et al</i>. \"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study\". <i>The New England Journal of Medicine</i>. 1981. 305(20):1176-1181.", | "citation" : "Lowrie EG, <i>et al</i>. \"Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study\". <i>The New England Journal of Medicine</i>. 1981. 305(20):1176-1181.", | ||
"expansion" : "The National Cooperative Dialysis Study", | "expansion" : "The National Cooperative Dialysis Study", | ||
" | "trainingLevel" : "Fellow", | ||
"diseases" : "Chronic Kidney Disease", | |||
"briefResultsDescription" : "Low BUN better tolerated, fewer hospitalizations", | "briefResultsDescription" : "Low BUN better tolerated, fewer hospitalizations", | ||
"pageName" : "NCDS" | |||
"pageName" : "NCDS | |||
}, | }, | ||
{ | { | ||
"published" : "2015-12-10", | |||
"timestamp" : "2017-12-03T22:37:47Z", | "timestamp" : "2017-12-03T22:37:47Z", | ||
"abbreviation" : "NEAT-HFpEF", | |||
"pmid" : "26549714", | |||
"statusUsableDate" : "2016-04-01", | |||
"title" : "Isosorbide mononitrate in heart failure with preserved ejection fraction", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1510774", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1510774", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Nitrates for activity tolerance in HFpEF", | "briefDesignDescription" : "Nitrates for activity tolerance in HFpEF", | ||
"pageid" : 2668, | "pageid" : 2668, | ||
"citation" : "Redfield MM, <i>et al</i>. \"Isosorbide mononitrate in heart failure with preserved ejection fraction\". <i>New England Journal of Medicine</i>. 2015. 373(24):2314-2324.", | "citation" : "Redfield MM, <i>et al</i>. \"Isosorbide mononitrate in heart failure with preserved ejection fraction\". <i>New England Journal of Medicine</i>. 2015. 373(24):2314-2324.", | ||
"expansion" : "Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction", | "expansion" : "Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "Nitrates do not improve activity tolerance in HFpEF", | "briefResultsDescription" : "Nitrates do not improve activity tolerance in HFpEF", | ||
"pageName" : "NEAT-HFpEF" | |||
"pageName" : "NEAT-HFpEF | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "National Emphysema Treatment Trial", | ||
"pageid" : 1604, | "pageid" : 1604, | ||
" | "citation" : "Fishman A, <i>et al</i>. \"A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema\". <i>The New England Journal of Medicine</i>. 2003. 348(21):2059-2073.", | ||
"diseases" : "Chronic Obstructive Pulmonary Disease;Emphysema", | |||
"briefResultsDescription" : "LVRS benefits apical emphysema and those with low exercise function", | |||
"pageName" : "NETT", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "12759479", | ||
"statusUsableDate" : "2013-08-01", | "statusUsableDate" : "2013-08-01", | ||
" | "title" : "A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema", | ||
"published" : "2003-05-22", | "published" : "2003-05-22", | ||
" | "timestamp" : "2017-12-03T22:37:49Z", | ||
"abbreviation" : "NETT", | "abbreviation" : "NETT", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030287", | ||
" | "subspecialties" : "Surgery;Pulmonology", | ||
"briefDesignDescription" : "Lung volume reduction in COPD", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030287" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Increased mortality targeting euglycemia", | ||
" | "diseases" : "Stress Hyperglycemia", | ||
" | "pageName" : "NICE-SUGAR", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"expansion" : "Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation", | |||
"citation" : "Finfer S, <i>et al</i>. \"Intensive versus conventional glucose control in critically ill patients\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1283-1297.", | "citation" : "Finfer S, <i>et al</i>. \"Intensive versus conventional glucose control in critically ill patients\". <i>The New England Journal of Medicine</i>. 2009. 360(13):1283-1297.", | ||
"pageid" : 26, | |||
"subspecialties" : "Critical Care;Endocrinology", | "subspecialties" : "Critical Care;Endocrinology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0810625", | ||
"briefDesignDescription" : "Intensive glycemic therapy in ICU", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0810625", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "19318384", | ||
"title" : "Intensive versus conventional glucose control in critically ill patients", | |||
"timestamp" : "2020-02-06T15:48:50Z", | |||
"published" : "2009-03-26", | "published" : "2009-03-26", | ||
"abbreviation" : "NICE-SUGAR" | |||
"abbreviation" : "NICE-SUGAR | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199512143332401", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199512143332401", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199512143332401", | ||
"subspecialties" : "Neurology;Critical Care", | "subspecialties" : "Neurology;Critical Care", | ||
" | "briefDesignDescription" : "tPA in ischemic stroke", | ||
"published" : "1995-12-14", | |||
"timestamp" : "2015-08-24T19:41:34Z", | |||
"abbreviation" : "NINDS", | |||
"pmid" : "7477192", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"title" : "Tissue Plasminogen Activator for Acute Ischemic Stroke", | |||
"trainingLevel" : "MedicalStudent", | |||
"diseases" : "Stroke", | |||
"briefResultsDescription" : "tPA within 3 hours improved outcomes", | "briefResultsDescription" : "tPA within 3 hours improved outcomes", | ||
"pageName" : "NINDS", | "pageName" : "NINDS", | ||
" | "pageid" : 131, | ||
" | "citation" : "Marler JR, <i>et al</i>. \"Tissue Plasminogen Activator for Acute Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 1995. 333(24):1581-1587.", | ||
"expansion" : "National Institute of Neurological Disorders and Stroke rt-PA Stroke Study" | |||
" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "CT vs. CXR in lung cancer screening", | "briefDesignDescription" : "CT vs. CXR in lung cancer screening", | ||
"subspecialties" : "Pulmonology;Oncology;Preventive Medicine", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1102873", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1102873", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102873", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1102873", | ||
" | "title" : "Reduced lung cancer mortality with low-dose computed tomographic screening", | ||
"pmid" : "21714641", | |||
" | |||
"statusUsableDate" : "2012-10-01", | "statusUsableDate" : "2012-10-01", | ||
" | "abbreviation" : "NLST", | ||
"timestamp" : "2017-12-03T22:37:50Z", | |||
"published" : "2011-08-04", | "published" : "2011-08-04", | ||
"pageName" : "NLST", | "pageName" : "NLST", | ||
"briefResultsDescription" : "Low-dose CT reduces lung cancer mortality compared to CXR", | |||
"diseases" : "Lung Cancer", | "diseases" : "Lung Cancer", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "National Lung Screening Trial", | ||
" | "citation" : "Berg CD, <i>et al</i>. \"Reduced lung cancer mortality with low-dose computed tomographic screening\". <i>The New England Journal of Medicine</i>. 2011. 365(5):395-409.", | ||
"pageid" : 980 | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2208375", | ||
"subspecialties" : "Preventive Medicine", | |||
"briefDesignDescription" : "Invitations for screening colonoscopy", | "briefDesignDescription" : "Invitations for screening colonoscopy", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208375", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2208375", | ||
"statusUsableDate" : "2022-10-14", | "statusUsableDate" : "2022-10-14", | ||
" | "pmid" : "36214590", | ||
"title" : "Effect of colonoscopy screening on risks of colorectal cancer and related death", | |||
"published" : "2022-10-09", | "published" : "2022-10-09", | ||
" | "timestamp" : "2022-12-01T20:16:39Z", | ||
"abbreviation" : "NordICC", | |||
"diseases" : "Colorectal Cancer", | "diseases" : "Colorectal Cancer", | ||
" | "briefResultsDescription" : "Invitations for screening colonoscopy don't lower mortality", | ||
" | "pageName" : "NordICC", | ||
"trainingLevel" : "resident", | |||
"expansion" : "Nordic-European Initiative on Colorectal Cancer", | |||
"pageid" : 5065, | |||
"citation" : "Bretthauer M, <i>et al</i>. \"Effect of colonoscopy screening on risks of colorectal cancer and related death\". <i>The New England Journal of Medicine</i>. 2022. 1-10." | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Cardiology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1607991", | |||
"briefDesignDescription" : "Drug-eluting stent vs. bare-metal stent in CAD", | "briefDesignDescription" : "Drug-eluting stent vs. bare-metal stent in CAD", | ||
"pdfurl" : "http://www.nejm.org/pdf/full/10.1056/NEJMoa1607991", | "pdfurl" : "http://www.nejm.org/pdf/full/10.1056/NEJMoa1607991", | ||
" | "pmid" : "27572953", | ||
"statusUsableDate" : "2016-10-01", | "statusUsableDate" : "2016-10-01", | ||
"title" : "Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease", | |||
"timestamp" : "2021-01-30T21:12:28Z", | |||
"published" : "2016-08-30", | |||
"abbreviation" : "NORSTENT", | |||
"briefResultsDescription" : "Drug-eluting stent superior to bare-metal stent in CAD", | "briefResultsDescription" : "Drug-eluting stent superior to bare-metal stent in CAD", | ||
" | "diseases" : "Coronary Artery Disease", | ||
"pageName" : "NORSTENT", | "pageName" : "NORSTENT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Drug-Eluting or Bare-Metal Stents for Percutaneous Coronary Intervention in Stable or Unstable Coronary Artery Disease", | ||
" | "citation" : "Bonaa KH, <i>et al</i>. \"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2016. 375:1242-1252.", | ||
" | "pageid" : 2832 | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Student", | ||
" | "diseases" : "Chronic Obstructive Pulmonary Disease", | ||
" | "briefResultsDescription" : "Continuous oxygen reduces mortality in COPD with hypoxemia", | ||
"pageName" : "NOTT", | |||
"pageid" : 1788, | "pageid" : 1788, | ||
"citation" : "NOTT Group. \"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group\". <i>Annals of Internal Medicine</i>. 1980. 93(3):91-398.", | |||
"expansion" : "Nocturnal Oxygen Therapy Trial", | |||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "fulltexturl" : "http://annals.org/article.aspx?articleid", | ||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
" | "briefDesignDescription" : "Continuous vs. nocturnal oxygen in COPD", | ||
"published" : "1980-09-01", | "published" : "1980-09-01", | ||
" | "timestamp" : "2017-12-03T22:37:53Z", | ||
"abbreviation" : "NOTT", | "abbreviation" : "NOTT", | ||
"title" : "Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group | "statusUsableDate" : "2014-01-01", | ||
"pmid" : "6776858", | |||
"title" : "Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Nocturnal Oxygen Therapy Trial Group" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "Novel START", | ||
"briefResultsDescription" : "ICS+LABA PRN with fewer overall, but more severe exacerbations", | |||
"diseases" : "Asthma", | |||
"trainingLevel" : "resident", | |||
"expansion" : "Novel Symbicort Turbuhaler Asthma Reliever Therapy", | |||
"citation" : "Beasley R, <i>et al</i>. \"Controlled trial of budesonide+formoterol as needed for mild asthma\". <i>The New England Journal of Medicine</i>. 2019. 380(21):2020-2030.", | |||
"pageid" : 4142, | |||
"briefDesignDescription" : "ICS+LABA PRN in mild asthma", | "briefDesignDescription" : "ICS+LABA PRN in mild asthma", | ||
"subspecialties" : "Pulmonology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1901963", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1901963", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901963", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901963", | ||
" | "title" : "Controlled trial of budesonide+formoterol as needed for mild asthma", | ||
"pmid" : "31112386", | |||
" | |||
"statusUsableDate" : "2021-05-20", | "statusUsableDate" : "2021-05-20", | ||
"abbreviation" : "Novel START", | "abbreviation" : "Novel START", | ||
" | "timestamp" : "2021-05-31T17:57:36Z", | ||
" | "published" : "2019-05-23" | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Sentinel lymph node biopsy is equally efficacious but has fewer side effects than ALND", | ||
"diseases" : "Breast Cancer", | |||
" | "pageName" : "NSABP B-32", | ||
" | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"expansion" : "National Surgical Adjuvant Breast and Bowel Project Trial B-32", | |||
"citation" : "Krag DN, <i>et al</i>. \"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial\". <i>Lancet Oncology</i>. 2010. 11(10):927-933.", | "citation" : "Krag DN, <i>et al</i>. \"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial\". <i>Lancet Oncology</i>. 2010. 11(10):927-933.", | ||
"pageid" : 1167, | |||
"subspecialties" : "Oncology", | "subspecialties" : "Oncology", | ||
" | "fulltexturl" : "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/", | ||
"briefDesignDescription" : "Sentinel LN biopsy in breast cancer", | |||
"pdfurl" : "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041644/pdf/nihms-250175.pdf", | |||
"statusUsableDate" : "2013-02-01", | "statusUsableDate" : "2013-02-01", | ||
" | "pmid" : "20863759", | ||
"title" : "Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial", | |||
"timestamp" : "2018-09-06T17:17:20Z", | |||
"published" : "2010-10-01", | "published" : "2010-10-01", | ||
"abbreviation" : "NSABP B-32" | |||
"abbreviation" : "NSABP B-32 | |||
}, | }, | ||
{ | { | ||
"published" : "1998-09-16", | |||
"timestamp" : "2017-12-03T22:37:56Z", | "timestamp" : "2017-12-03T22:37:56Z", | ||
"abbreviation" : "NSABP P-1", | |||
"pmid" : "9747868", | |||
"statusUsableDate" : "2012-10-01", | |||
"title" : "Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study", | |||
"pdfurl" : "http://jnci.oxfordjournals.org/content/90/18/1371.full.pdf+html", | |||
"fulltexturl" : "http://jnci.oxfordjournals.org/content/90/18/1371.long", | |||
"subspecialties" : "Oncology;Preventive Medicine", | |||
"briefDesignDescription" : "Tamoxifen in breast cancer prevention", | "briefDesignDescription" : "Tamoxifen in breast cancer prevention", | ||
"pageid" : 1049, | "pageid" : 1049, | ||
"citation" : "Fisher B, <i>et al</i>. \"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study\". <i>Journal of the National Cancer Institute</i>. 1998. 90(18):1371-1388.", | "citation" : "Fisher B, <i>et al</i>. \"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study\". <i>Journal of the National Cancer Institute</i>. 1998. 90(18):1371-1388.", | ||
"expansion" : "National Surgical Adjuvant Breast and Bowel Project, Prevention-1", | "expansion" : "National Surgical Adjuvant Breast and Bowel Project, Prevention-1", | ||
" | "trainingLevel" : "resident", | ||
"diseases" : "Breast Cancer", | |||
"briefResultsDescription" : "Tamoxifen reduces breast cancer incidence by 48%", | "briefResultsDescription" : "Tamoxifen reduces breast cancer incidence by 48%", | ||
"pageName" : "NSABP P-1" | |||
"pageName" : "NSABP P-1 | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Fondaparinux vs. enoxaparin in NSTE-ACS", | "briefDesignDescription" : "Fondaparinux vs. enoxaparin in NSTE-ACS", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa055443", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa055443", | ||
" | "subspecialties" : "Cardiology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa055443", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa055443", | ||
" | "title" : "Comparison of fondaparinux and enoxaparin in acute coronary syndromes", | ||
"pmid" : "16537663", | |||
" | |||
"statusUsableDate" : "2018-04-27", | "statusUsableDate" : "2018-04-27", | ||
" | "abbreviation" : "OASIS-5", | ||
"published" : "2006-04-06", | "published" : "2006-04-06", | ||
"timestamp" : "2018-04-26T20:18:28Z", | |||
"pageName" : "OASIS-5", | "pageName" : "OASIS-5", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | "diseases" : "Acute Coronary Syndrome;Myocardial Infarction", | ||
" | "briefResultsDescription" : "Fondaparinux is non-inferior to enoxaparin in NSTE-ACS", | ||
" | "trainingLevel" : "intern", | ||
"expansion" : "Fifth Organization to Assess Strategies in Acute Ischemic Syndromes", | |||
"pageid" : 2484, | |||
"citation" : "Yusuf S, <i>et al</i>. \"Comparison of fondaparinux and enoxaparin in acute coronary syndromes\". <i>The New England Journal of Medicine</i>. 2006. 354(14):1464-1476." | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Occluded Artery Trial", | ||
" | "citation" : "Hochman J.S., <i>et al</i>. \"Coronary Intervention for Persistent Occlusion after Myocardial Infarction\". <i>The New England Journal of Medicine</i>. 2006. 355(23):2395-2407.", | ||
"pageid" : 2676, | "pageid" : 2676, | ||
" | "briefResultsDescription" : "PCI+OMT no better than OMT 3-28 days after MI", | ||
"diseases" : "Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction", | |||
"pageName" : "OAT", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pmid" : "17105759", | ||
"statusUsableDate" : "2016-06-01", | "statusUsableDate" : "2016-06-01", | ||
" | "title" : "Coronary Intervention for Persistent Occlusion after Myocardial Infarction", | ||
"timestamp" : "2020-09-14T19:27:00Z", | |||
"published" : "2006-12-07", | "published" : "2006-12-07", | ||
"abbreviation" : "OAT", | "abbreviation" : "OAT", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa066139", | ||
"briefDesignDescription" : "PCI+OMT vs. OMT 3-28 days after MI", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa066139" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1501031", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501031", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1501031", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "PCSK9 inhibitor alirocumab for HLD", | ||
"published" : "2015-04-16", | |||
"timestamp" : "2017-12-14T19:48:32Z", | |||
"abbreviation" : "ODYSSEY LONG TERM", | |||
"statusUsableDate" : "2015-09-01", | "statusUsableDate" : "2015-09-01", | ||
"pmid" : "25773378", | |||
"title" : "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", | |||
"trainingLevel" : "Student", | |||
"diseases" : "Hyperlipidemia", | |||
"briefResultsDescription" : "Alirocumab lowers LDL, reduces non-fatal MI", | "briefResultsDescription" : "Alirocumab lowers LDL, reduces non-fatal MI", | ||
"pageName" : "ODYSSEY LONG TERM", | "pageName" : "ODYSSEY LONG TERM", | ||
" | "pageid" : 2423, | ||
" | "citation" : "Robinson JG, <i>et al</i>. \"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events\". <i>The New England Journal of Medicine</i>. 2015. 372(16):1489-1499.", | ||
"expansion" : "Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not\nAdequately Controlled with Their Lipid Modifying Therapy" | |||
" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "IV PPI for GI bleeds", | "briefDesignDescription" : "IV PPI for GI bleeds", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200008033430501", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200008033430501", | ||
" | "subspecialties" : "Gastroenterology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200008033430501", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200008033430501", | ||
" | "title" : "Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer", | ||
"pmid" : "10922420", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : null, | ||
"published" : "2000-08-03", | "published" : "2000-08-03", | ||
"timestamp" : "2016-04-01T23:27:21Z", | |||
"pageName" : "Omeprazole in Peptic Ulcer Bleeding", | "pageName" : "Omeprazole in Peptic Ulcer Bleeding", | ||
"diseases" : "Gastrointestinal Hemorrhage", | "diseases" : "Gastrointestinal Hemorrhage", | ||
" | "briefResultsDescription" : "IV omeprazole reduced 30-day rebleeding", | ||
" | "trainingLevel" : "Resident", | ||
"expansion" : null, | |||
"pageid" : 247, | |||
"citation" : "Lau JYW, <i>et al</i>. \"Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcer\". <i>The New England Journal of Medicine</i>. 2000. 343(5):310-316." | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Wazni OM, <i>et al</i>. \"Left atrial appendage closure after ablation for atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2025. 392(13):1277-1287.", | ||
"pageid" : 5693, | "pageid" : 5693, | ||
" | "expansion" : "cOmParison of anTIcoagulation with left atrial appendage clOsure after atrial fibrillation ablatioN", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"briefResultsDescription" : "LAA closure non-inferior or superior for AF outcomes vs. anticoagulation", | "briefResultsDescription" : "LAA closure non-inferior or superior for AF outcomes vs. anticoagulation", | ||
"diseases" : "Atrial Fibrillation", | |||
"pageName" : "OPTION", | |||
"timestamp" : "2025-05-16T15:04:11Z", | |||
"published" : "2025-04-03", | "published" : "2025-04-03", | ||
"abbreviation" : "OPTION", | "abbreviation" : "OPTION", | ||
"statusUsableDate" : "2025-04-20", | |||
"pmid" : "39555822", | |||
"title" : "Left atrial appendage closure after ablation for atrial fibrillation", | "title" : "Left atrial appendage closure after ablation for atrial fibrillation", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2408308", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2408308", | |||
"briefDesignDescription" : "LAA closure vs. anticoagulation in AF" | |||
}, | }, | ||
{ | { | ||
"title" : "Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry", | |||
"pmid" : "23861512", | |||
"statusUsableDate" : "2014-06-01", | |||
"abbreviation" : "ORBIT-AF", | |||
"published" : "2013-08-13", | |||
"timestamp" : "2019-04-23T20:57:22Z", | "timestamp" : "2019-04-23T20:57:22Z", | ||
"briefDesignDescription" : "ASA/warfarin vs. warfarin in AF", | "briefDesignDescription" : "ASA/warfarin vs. warfarin in AF", | ||
"fulltexturl" : "http://circ.ahajournals.org/content/128/7/721.long", | "fulltexturl" : "http://circ.ahajournals.org/content/128/7/721.long", | ||
"subspecialties" : "Cardiology;Neurology", | |||
"pdfurl" : "http://circ.ahajournals.org/content/128/7/721.full.pdf", | |||
"expansion" : "Outcomes Registry for Better Informed Treatment of Atrial Fibrillation", | |||
"pageid" : 1769, | "pageid" : 1769, | ||
"citation" : "Steinberg BA, <i>et al</i>. \"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry\". <i>Circulation</i>. 2013. 128(7):721-8.", | "citation" : "Steinberg BA, <i>et al</i>. \"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry\". <i>Circulation</i>. 2013. 128(7):721-8.", | ||
"pageName" : "ORBIT-AF", | "pageName" : "ORBIT-AF", | ||
"diseases" : "Atrial Fibrillation;Stroke", | "diseases" : "Atrial Fibrillation;Stroke", | ||
" | "briefResultsDescription" : "ASA/warfarin associated with more bleeding, fewer CV events", | ||
"trainingLevel" : "Fellow" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Coronary Artery Disease", | ||
" | "briefResultsDescription" : "PCI not superior to medical therapy in stable angina", | ||
" | "pageName" : "ORBITA", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina", | |||
"pageid" : 3499, | "pageid" : 3499, | ||
"citation" : "Al-Lamee R, <i>et al</i>. \"Percutaneous coronary intervention in stable angina\". <i>Lancet</i>. 2017. epub 2017-11-02:1-11.", | "citation" : "Al-Lamee R, <i>et al</i>. \"Percutaneous coronary intervention in stable angina\". <i>Lancet</i>. 2017. epub 2017-11-02:1-11.", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32714-9/fulltext", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "PCI vs. medical therapy in stable angina", | ||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32714-9.pdf", | |||
"statusUsableDate" : "2017-12-14", | "statusUsableDate" : "2017-12-14", | ||
" | "pmid" : "29103656", | ||
"title" : "Percutaneous coronary intervention in stable angina", | |||
"published" : "2017-11-02", | "published" : "2017-11-02", | ||
" | "timestamp" : "2018-03-08T17:42:17Z", | ||
"abbreviation" : "ORBITA" | |||
"abbreviation" : "ORBITA | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Oscillation for Acute Respiratory Distress Syndrome Treated Early", | ||
" | "citation" : "Ferguson ND, <i>et al</i>. \"High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(9):795-805.", | ||
"pageid" : 1254, | "pageid" : 1254, | ||
" | "pageName" : "OSCILLATE", | ||
"briefResultsDescription" : "High-frequency oscillatory vent may harm in early ARDS", | |||
"diseases" : "Acute Respiratory Distress Syndrome", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome", | ||
" | "pmid" : "23339639", | ||
"statusUsableDate" : "2013-09-01", | "statusUsableDate" : "2013-09-01", | ||
" | "abbreviation" : "Oscillate", | ||
"timestamp" : "2017-12-03T22:38:05Z", | |||
"published" : "2013-02-28", | "published" : "2013-02-28", | ||
" | "briefDesignDescription" : "High-frequency oscillatory vent in early ARDS", | ||
" | "subspecialties" : "Critical Care;Pulmonology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1215554", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215554" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "OVIVA", | |||
"timestamp" : "2019-10-08T15:46:44Z", | "timestamp" : "2019-10-08T15:46:44Z", | ||
"published" : "2019-01-31", | |||
"title" : "Oral versus Intravenous Antibiotics for Bone and Joint Infection", | |||
"statusUsableDate" : "2019-04-11", | |||
"pmid" : "30699315", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1710926", | |||
"briefDesignDescription" : "PO vs. IV antibiotics for bone/joint infection", | "briefDesignDescription" : "PO vs. IV antibiotics for bone/joint infection", | ||
"subspecialties" : "Infectious Disease", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1710926", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1710926", | ||
"citation" : "Li HK, <i>et al</i>. \"Oral versus Intravenous Antibiotics for Bone and Joint Infection\". <i>The New England Journal of Medicine</i>. 2019. 380(5):425-436.", | |||
"pageid" : 3542, | "pageid" : 3542, | ||
" | "expansion" : "Oral versus Intravenous Antibiotics for Bone and Joint Infection", | ||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
" | "pageName" : "OVIVA", | ||
"briefResultsDescription" : "PO non-inferior to IV antibiotics for selected bone/joint infections", | "briefResultsDescription" : "PO non-inferior to IV antibiotics for selected bone/joint infections", | ||
"diseases" : "Osteomyelitis" | |||
"diseases" : "Osteomyelitis | |||
}, | }, | ||
{ | { | ||
"pmid" : "28885881", | |||
"statusUsableDate" : "2025-06-12", | |||
"title" : "Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer", | |||
"published" : "2017-09-08", | |||
"timestamp" : "2025-06-05T18:03:47Z", | "timestamp" : "2025-06-05T18:03:47Z", | ||
"abbreviation" : "PACIFIC", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1709937", | |||
"subspecialties" : "Oncology;Radiation Oncology", | |||
"briefDesignDescription" : "Durvalumab vs. placebo as consolidation in NSCLC", | "briefDesignDescription" : "Durvalumab vs. placebo as consolidation in NSCLC", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1709937", | ||
"expansion" : "", | |||
"pageid" : 2969, | "pageid" : 2969, | ||
"citation" : "Antonia SJ <i>et al</i>. \"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2017. 377(20):1919-1929.", | "citation" : "Antonia SJ <i>et al</i>. \"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer\". <i>The New England Journal of Medicine</i>. 2017. 377(20):1919-1929.", | ||
" | "diseases" : "Lung Cancer", | ||
"briefResultsDescription" : "Durvalumab increases PFS in NSCLC", | "briefResultsDescription" : "Durvalumab increases PFS in NSCLC", | ||
"pageName" : "PACIFIC", | "pageName" : "PACIFIC", | ||
" | "trainingLevel" : "Fellow" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2806976/jamainternal_copaescu_2023_oi_230043_1693517098.10841.pdf", | ||
"subspecialties" : "Infectious Disease", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2806976", | |||
"briefDesignDescription" : "Penicillin allergy rule-out", | "briefDesignDescription" : "Penicillin allergy rule-out", | ||
" | "timestamp" : "2025-01-30T20:34:51Z", | ||
" | "published" : "2023-09-01", | ||
" | "abbreviation" : "PALACE", | ||
"statusUsableDate" : "2025-01-29", | |||
"pmid" : "37459086", | |||
"title" : "Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy", | |||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
"briefResultsDescription" : "Penicillin 1-step rule out noninferior to 2-step", | "briefResultsDescription" : "Penicillin 1-step rule out noninferior to 2-step", | ||
" | "diseases" : "Penicillin Allergy", | ||
"pageName" : "PALACE", | "pageName" : "PALACE", | ||
" | "citation" : "Copaescu AM, <i>et al</i>. \"Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy\". <i>JAMA Internal Med</i>. 2023. 183(9):944-952.", | ||
"pageid" : 5406, | |||
"expansion" : "The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0908821", | ||
"subspecialties" : "Surgery;Gastroenterology", | |||
"briefDesignDescription" : "Step-up approach to pancreatitis", | "briefDesignDescription" : "Step-up approach to pancreatitis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0908821", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0908821", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"pmid" : "20410514", | |||
"title" : "A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis", | |||
"published" : "2010-04-22", | |||
"timestamp" : "2019-08-31T19:06:09Z", | |||
"abbreviation" : "PANTER", | |||
"diseases" : "Pancreatitis", | |||
"briefResultsDescription" : "Step-up approach reduces major complications and death", | "briefResultsDescription" : "Step-up approach reduces major complications and death", | ||
"pageName" : "PANTER", | "pageName" : "PANTER", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "Minimally Invasive Step Up Approach versus Maximal Necrosectomy in Patients with Acute Necrotising Pancreatitis", | ||
" | "pageid" : 398, | ||
"citation" : "van Santvoort HC, <i>et al</i>. \"A Step-up Approach or Open Necrosectomy for Necrotizing Pancreatitis\". <i>The New England Journal of Medicine</i>. 2010. 362(16):1491-502." | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1409077", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "ARNI vs. enalapril in HFrEF", | "briefDesignDescription" : "ARNI vs. enalapril in HFrEF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409077", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1409077", | ||
" | "pmid" : "25176015", | ||
"statusUsableDate" : "2014-09-01", | "statusUsableDate" : "2014-09-01", | ||
"title" : "Angiotensin-neprilysin inhibition versus enalapril in heart failure", | |||
"published" : "2014-08-30", | |||
"timestamp" : "2021-07-28T06:20:24Z", | |||
"abbreviation" : "PARADIGM-HF", | |||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "ARNI reduces mortality in HFrEF", | "briefResultsDescription" : "ARNI reduces mortality in HFrEF", | ||
"pageName" : "PARADIGM-HF", | "pageName" : "PARADIGM-HF", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure", | ||
" | "pageid" : 2163, | ||
"citation" : "McMurray JJV, <i>et al</i>. \"Angiotensin-neprilysin inhibition versus enalapril in heart failure\". <i>The New England Journal of Medicine</i>. 2014. 371(11):993-1004." | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908655", | ||
"briefDesignDescription" : "ARNI in symptomatic HFpEF", | "briefDesignDescription" : "ARNI in symptomatic HFpEF", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1908655", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1908655", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "PARAGON-HF", | ||
"published" : "2019-10-24", | |||
"timestamp" : "2020-07-02T17:06:36Z", | |||
"title" : "Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction", | |||
"statusUsableDate" : "2020-07-02", | "statusUsableDate" : "2020-07-02", | ||
" | "pmid" : "32187481", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "PARAGON-HF", | "pageName" : "PARAGON-HF", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "No benefit from ARNI in HFpEF", | ||
" | "pageid" : 4184, | ||
" | "citation" : "Solomon SD, <i>et al</i>. \"Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2019. 381(17):1609-1620.", | ||
"expansion" : "Prospective Comparison of ARNI Global Outcomes in HF with Preserved Ejection Fraction" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Paz-Ares LG, <i>et al</i>. \"PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer\". <i>Journal of Clinical Oncology</i>. 2013. 31(23):2895-902.", | ||
"pageid" : 1606, | "pageid" : 1606, | ||
" | "pageName" : "PARAMOUNT", | ||
"briefResultsDescription" : "Maintenance pemetrexed improves PFS and OS following induction with cisplatin/pemetrexed", | |||
"diseases" : "Lung Cancer", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "title" : "PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer", | ||
"statusUsableDate" : "2014-01-01", | "statusUsableDate" : "2014-01-01", | ||
" | "pmid" : "23835707", | ||
"abbreviation" : "PARAMOUNT", | |||
"timestamp" : "2017-12-03T22:38:08Z", | |||
"published" : "2013-08-10", | "published" : "2013-08-10", | ||
" | "briefDesignDescription" : "Maintenance pemetrexed in lung cancer", | ||
" | "subspecialties" : "Oncology", | ||
" | "fulltexturl" : "http://jco.ascopubs.org/content/31/23/2895.long", | ||
" | "pdfurl" : "http://jco.ascopubs.org/content/31/23/2895.full.pdf" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1514616", | ||
"briefDesignDescription" : "TAVI for AS in intermediate-risk surgical candidates", | "briefDesignDescription" : "TAVI for AS in intermediate-risk surgical candidates", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1514616", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1514616", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "PARTNER 2", | ||
"published" : "2016-04-28", | |||
"timestamp" : "2017-12-03T22:38:09Z", | |||
"title" : "Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients", | |||
"statusUsableDate" : "2016-05-01", | "statusUsableDate" : "2016-05-01", | ||
" | "pmid" : "27040324", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "PARTNER 2", | "pageName" : "PARTNER 2", | ||
"diseases" : "Aortic Stenosis", | "diseases" : "Aortic Stenosis", | ||
" | "briefResultsDescription" : "TAVI noninferior to surgical AVR in intermediate-risk surgical candidates", | ||
" | "pageid" : 2753, | ||
" | "citation" : "Leon MB, <i>et al</i>. \"Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients\". <i>The New England Journal of Medicine</i>. 2016. 374(17):1609-20.", | ||
"expansion" : "Placement of Aortic Transcatheter Valves, Cohort A" | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814052", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1814052", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1814052", | ||
"briefDesignDescription" : "TAVR for AS in low-risk surgical candidates", | |||
"timestamp" : "2019-10-17T18:34:54Z", | |||
"published" : "2019-03-16", | |||
"abbreviation" : "PARTNER 3", | |||
"pmid" : "30883058", | |||
"statusUsableDate" : "2019-10-16", | "statusUsableDate" : "2019-10-16", | ||
"title" : "Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients", | |||
"trainingLevel" : "Resident", | |||
"briefResultsDescription" : "TAVR superior to surgical AVR in low-risk surgical candidates", | "briefResultsDescription" : "TAVR superior to surgical AVR in low-risk surgical candidates", | ||
" | "diseases" : "Aortic Stenosis", | ||
"pageName" : "PARTNER 3", | "pageName" : "PARTNER 3", | ||
" | "citation" : "Mack MJ, <i>et al</i>. \"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients\". <i>The New England Journal of Medicine</i>. 2019. 380(18):1695-1705.", | ||
"pageid" : 3949, | |||
"expansion" : "Placement of Aortic Transcatheter Valves 3" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1103510", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1103510", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1103510", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "TAVI for AS in high-risk surgical candidates", | ||
"published" : "2011-06-09", | |||
"timestamp" : "2017-12-03T22:38:10Z", | |||
"abbreviation" : "PARTNER A", | |||
"statusUsableDate" : "2016-05-01", | "statusUsableDate" : "2016-05-01", | ||
"pmid" : "21639811", | |||
"title" : "Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients", | |||
"trainingLevel" : "Intern", | |||
"diseases" : "Aortic Stenosis", | |||
"briefResultsDescription" : "TAVI noninferior to surgical AVR in high-risk surgical candidates", | "briefResultsDescription" : "TAVI noninferior to surgical AVR in high-risk surgical candidates", | ||
"pageName" : "PARTNER A", | "pageName" : "PARTNER A", | ||
" | "pageid" : 2741, | ||
" | "citation" : "Smith CR, <i>et al</i>. \"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients\". <i>The New England Journal of Medicine</i>. 2011. 364(23):2187-98.", | ||
"expansion" : "Placement of Aortic Transcatheter Valves, Cohort A" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008232", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1008232", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1008232", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "TAVI for AS in poor surgical candidates", | ||
"published" : "2010-10-21", | "published" : "2010-10-21", | ||
" | "timestamp" : "2017-12-03T22:38:12Z", | ||
"abbreviation" : "PARTNER B", | "abbreviation" : "PARTNER B", | ||
"statusUsableDate" : "2013-12-01", | |||
"pmid" : "20961243", | |||
"title" : "Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery", | "title" : "Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Aortic Stenosis", | |||
"briefResultsDescription" : "TAVI reduces all-cause mortality ± rehospitalization, increased stroke", | |||
"pageName" : "PARTNER B", | |||
"pageid" : 1674, | |||
"citation" : "Leon MB, <i>et al</i>. \"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery\". <i>The New England Journal of Medicine</i>. 2010. 363(17):1597-1607.", | |||
"expansion" : "Placement of Aortic Transcatheter Valves, Cohort B" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)00257-3", | ||
"subspecialties" : "Cardiology;Nephrology;Preventive Medicine", | |||
"briefDesignDescription" : "Spironolactone for resistant HTN", | "briefDesignDescription" : "Spironolactone for resistant HTN", | ||
"pdfurl" : "http://bit.ly/pathway-2-pdf", | "pdfurl" : "http://bit.ly/pathway-2-pdf", | ||
" | "pmid" : "26414968", | ||
"statusUsableDate" : "2021-02-11", | "statusUsableDate" : "2021-02-11", | ||
"title" : "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial", | |||
"published" : "2015-11-21", | |||
"timestamp" : "2021-02-12T16:58:50Z", | |||
"abbreviation" : "PATHWAY-2", | |||
"diseases" : "Hypertension", | |||
"briefResultsDescription" : "Spironolactone improved BP control compared to placebo, doxazosin, or bisoprolol", | "briefResultsDescription" : "Spironolactone improved BP control compared to placebo, doxazosin, or bisoprolol", | ||
"pageName" : "PATHWAY-2", | "pageName" : "PATHWAY-2", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Prevention and Treatment of Hypertension with Algorithm-Based Therapy (PATHWAY)", | ||
" | "pageid" : 2733, | ||
"citation" : "Williams B, <i>et al</i>. \"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial\". <i>The Lancet</i>. 2015. 386(10008):2059-2068." | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Perioperative Anticoagulation Use for Surgery Evaluation", | ||
"pageid" : 4421, | "pageid" : 4421, | ||
"citation" : "Douketis JD, <i>et al</i>. \"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant\". <i>JAMA Internal Medicine</i>. 2019. 179(11):1469-1478.", | "citation" : "Douketis JD, <i>et al</i>. \"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant\". <i>JAMA Internal Medicine</i>. 2019. 179(11):1469-1478.", | ||
"pageName" : "PAUSE", | "pageName" : "PAUSE", | ||
"diseases" : "Atrial Fibrillation", | "diseases" : "Atrial Fibrillation", | ||
"briefResultsDescription" : "Holding DOAC by this protocol has little bleeding and events", | |||
"trainingLevel" : "fellow", | |||
"title" : "Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant", | |||
"pmid" : "31380891", | |||
"statusUsableDate" : "2021-04-29", | |||
"abbreviation" : "PAUSE", | "abbreviation" : "PAUSE", | ||
" | "published" : "2019-08-05", | ||
" | "timestamp" : "2021-05-12T12:54:33Z", | ||
"briefDesignDescription" : "Perioperative DOAC holding protocols in AF", | |||
"fulltexturl" : "https://doi.org/10.1001/jamainternmed.2019.2431", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Prostate Cancer Prevention Trial", | ||
"pageid" : 1786, | "pageid" : 1786, | ||
"citation" : "Thompson IM, <i>et al</i>. \"The influence of finasteride on the development of prostate cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(3):215-224.", | "citation" : "Thompson IM, <i>et al</i>. \"The influence of finasteride on the development of prostate cancer\". <i>The New England Journal of Medicine</i>. 2003. 349(3):215-224.", | ||
" | "diseases" : "Prostate Cancer", | ||
"briefResultsDescription" : "Finasteride reduces all-grade prostate cancer risk, increases high-grade disease", | "briefResultsDescription" : "Finasteride reduces all-grade prostate cancer risk, increases high-grade disease", | ||
"pageName" : "PCPT", | "pageName" : "PCPT", | ||
" | "trainingLevel" : "Intern", | ||
" | "statusUsableDate" : "2014-02-01", | ||
"pmid" : "12824459", | |||
"title" : "The influence of finasteride on the development of prostate cancer", | "title" : "The influence of finasteride on the development of prostate cancer", | ||
" | "published" : "2003-07-13", | ||
"timestamp" : "2017-12-03T22:38:13Z", | |||
"abbreviation" : "PCPT", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa030660", | |||
"subspecialties" : "Urology;Oncology", | |||
"briefDesignDescription" : "Finasteride for prostate cancer prophylaxis", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa030660" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "PEGASUS-TIMI 54", | |||
"diseases" : "Coronary Artery Disease;Acute Coronary Syndrome;Myocardial Infarction", | |||
"briefResultsDescription" : "Extended ticagrelor+ASA reduces CVD events after MI", | |||
"pageid" : 2469, | |||
"citation" : "Bonaca MP, <i>et al</i>. \"Long-term use of ticagrelor in patients with prior myocardial infarction\". <i>The New England Journal of Medicine</i>. 2015. 372(19):1791-1800.", | |||
"expansion" : "", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500857", | |||
"briefDesignDescription" : "Extended ticagrelor+ASA after MI", | "briefDesignDescription" : "Extended ticagrelor+ASA after MI", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1500857", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1500857", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "PEGASUS-TIMI 54", | ||
"published" : "2015-05-07", | "published" : "2015-05-07", | ||
" | "timestamp" : "2020-09-14T19:27:22Z", | ||
"title" : "Long-term use of ticagrelor in patients with prior myocardial infarction", | "title" : "Long-term use of ticagrelor in patients with prior myocardial infarction", | ||
"statusUsableDate" : "2015-12-01", | |||
"pmid" : "25773268" | "pmid" : "25773268" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "tPA for submassive PE", | "briefDesignDescription" : "tPA for submassive PE", | ||
"subspecialties" : "Critical Care;Pulmonology;Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1302097", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1302097", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302097", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1302097", | ||
" | "title" : "Fibrinolysis for patients with intermediate-risk pulmonary embolism", | ||
"statusUsableDate" : "2014-04-01", | "statusUsableDate" : "2014-04-01", | ||
" | "pmid" : "24716681", | ||
"abbreviation" : "PEITHO", | |||
"timestamp" : "2021-06-08T19:31:33Z", | |||
"published" : "2014-04-10", | "published" : "2014-04-10", | ||
"pageName" : "PEITHO", | "pageName" : "PEITHO", | ||
"briefResultsDescription" : "tPA reduces hemodynamic decomp, not mortality, also increases bleeding in submassive PE", | |||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism", | "diseases" : "Pulmonary Embolism;Venous Thromboembolism", | ||
" | "trainingLevel" : "resident", | ||
" | "expansion" : "Pulmonary Embolism Thrombolysis trial", | ||
" | "citation" : "Meyer G, <i>et al</i>. \"Fibrinolysis for patients with intermediate-risk pulmonary embolism\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1402-1411.", | ||
"pageid" : 1778 | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Akriviadis E, <i>et al</i>. \"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial\". <i>Gastroenterology</i>. 2000. 119(6):1637-48.", | ||
"pageid" : 53, | "pageid" : 53, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis", | "briefResultsDescription" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis", | ||
"diseases" : "Alcoholic Hepatitis", | |||
"pageName" : "Pentoxifylline in Severe Alcoholic Hepatitis", | |||
"timestamp" : "2015-07-06T21:57:52Z", | |||
"published" : "2000-12-20", | "published" : "2000-12-20", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "11113085", | |||
"title" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial", | "title" : "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial", | ||
" | "pdfurl" : "http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508500511834.pdf", | ||
"subspecialties" : "Gastroenterology", | |||
"fulltexturl" : "http://www.gastrojournal.org/article/S0016-5085(00)51183-4/fulltext", | |||
"briefDesignDescription" : "Pentoxifylline in alcoholic hepatitis" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Pulmonary Embolism Rule-Out Criteria", | ||
"pageid" : 2657, | "pageid" : 2657, | ||
"citation" : "Kline JA, <i>et al</i>. \"Prospective multicenter evaluation of the pulmonary embolism rule-out criteria\". <i>J Thromb Haemost</i>. 2008. 6(5):772-780.", | "citation" : "Kline JA, <i>et al</i>. \"Prospective multicenter evaluation of the pulmonary embolism rule-out criteria\". <i>J Thromb Haemost</i>. 2008. 6(5):772-780.", | ||
"pageName" : "PERC", | "pageName" : "PERC", | ||
"diseases" : "Pulmonary Embolism", | "diseases" : "Pulmonary Embolism", | ||
"briefResultsDescription" : "Low probability of PE mortality with low PERC probability", | |||
"trainingLevel" : "Resident", | |||
"title" : "Prospective multicenter evaluation of the pulmonary embolism rule-out criteria", | |||
"pmid" : "18318689", | |||
"statusUsableDate" : "2021-05-20", | |||
"abbreviation" : "PERC", | "abbreviation" : "PERC", | ||
" | "published" : "2008-05-06", | ||
" | "timestamp" : "2021-05-31T17:58:55Z", | ||
"briefDesignDescription" : "PE rule-out criteria", | |||
"fulltexturl" : "http://dx.doi.org/10.1111/j.1538-7836.2008.02944.x", | |||
"subspecialties" : "Emergency Medicine;Pulmonology;Hematology", | |||
"pdfurl" : "http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2008.02944.x/epdf" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Pulmonary Embolism in Syncope Italian Trial", | ||
" | "citation" : "Prandoni P, <i>et al</i>. \"Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope\". <i>The New England Journal of Medicine</i>. 2016. 375(16):1524-31.", | ||
"pageid" : 2843, | "pageid" : 2843, | ||
" | "briefResultsDescription" : "PE found in 1 of 6 patients with syncope", | ||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism;Syncope", | |||
"pageName" : "PESIT", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2016-11-01", | "statusUsableDate" : "2016-11-01", | ||
" | "pmid" : "27797317", | ||
"title" : "Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope", | |||
"timestamp" : "2017-12-03T22:38:18Z", | |||
"published" : "2016-10-20", | "published" : "2016-10-20", | ||
"abbreviation" : "PESIT", | "abbreviation" : "PESIT", | ||
" | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602172", | ||
"briefDesignDescription" : "Prevalence of PE in syncope", | |||
"pdfurl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1602172" | |||
}, | }, | ||
{ | { | ||
"pageid" : 2861, | "pageid" : 2861, | ||
"citation" : "Gibson CM, <i>et al</i>. \"Prevention of bleeding in patients with AF undergoing PCI\". <i>The New England Journal of Medicine</i>. 2016. epub 2016-11-14:1-12.", | "citation" : "Gibson CM, <i>et al</i>. \"Prevention of bleeding in patients with AF undergoing PCI\". <i>The New England Journal of Medicine</i>. 2016. epub 2016-11-14:1-12.", | ||
"expansion" : "Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with AF who Undergo Percutaneous Coronary Intervention", | "expansion" : "Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with AF who Undergo Percutaneous Coronary Intervention", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction", | |||
"briefResultsDescription" : "Rivaroxaban with lower bleeding", | "briefResultsDescription" : "Rivaroxaban with lower bleeding", | ||
"pageName" : "PIONEER AF-PCI", | |||
"published" : "2016-11-14", | "published" : "2016-11-14", | ||
" | "timestamp" : "2017-12-03T22:38:19Z", | ||
"abbreviation" : "PIONEER AF-PCI", | "abbreviation" : "PIONEER AF-PCI", | ||
"statusUsableDate" : "2016-12-01", | |||
"pmid" : "27959713", | |||
"title" : "Prevention of bleeding in patients with AF undergoing PCI", | "title" : "Prevention of bleeding in patients with AF undergoing PCI", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611594", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611594", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "DOAC, VKA, antiplatelets after PCI with stent" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Sacubitril-valsartan reduces NT-ProBNP", | ||
" | "pageName" : "PIONEER-HF", | ||
"trainingLevel" : "Student", | |||
"expansion" : "comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode", | |||
"pageid" : 3740, | "pageid" : 3740, | ||
"citation" : "Velazquez EJ, <i>et al</i>. \"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. ePub 2018-11-11:1-10.", | "citation" : "Velazquez EJ, <i>et al</i>. \"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure\". <i>The New England Journal of Medicine</i>. 2018. ePub 2018-11-11:1-10.", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1812851", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "ARNI started in ADHF hospitalization", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812851", | |||
"pmid" : "30415601", | |||
"statusUsableDate" : "2019-01-31", | "statusUsableDate" : "2019-01-31", | ||
" | "title" : "Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure", | ||
"published" : "2018-11-11", | "published" : "2018-11-11", | ||
" | "timestamp" : "2019-02-14T22:49:17Z", | ||
"abbreviation" : "PIONEER-HF" | |||
"abbreviation" : "PIONEER-HF | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "CT sensitive and specific in detecting acute PE", | ||
"diseases" : "Pulmonary Embolism;Venous Thromboembolism", | |||
" | "pageName" : "PIOPED II", | ||
" | |||
"trainingLevel" : "MedicalStudent", | "trainingLevel" : "MedicalStudent", | ||
"expansion" : "Prospective Investigation of Pulmonary Embolism Diagnosis II", | |||
"citation" : "Stein PD, <i>et al</i>. \"Multidetector Computed Tomography for Acute Pulmonary Embolism\". <i>The New England Journal of Medicine</i>. 2006. 354(22):2317-2327.", | "citation" : "Stein PD, <i>et al</i>. \"Multidetector Computed Tomography for Acute Pulmonary Embolism\". <i>The New England Journal of Medicine</i>. 2006. 354(22):2317-2327.", | ||
"pageid" : 161, | |||
"subspecialties" : "Pulmonology;Hematology", | "subspecialties" : "Pulmonology;Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa052367#t", | ||
"briefDesignDescription" : "Accuracy of CT for PE", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa052367#t", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "16738268", | ||
"title" : "Multidetector Computed Tomography for Acute Pulmonary Embolism", | |||
"timestamp" : "2016-04-05T13:46:19Z", | |||
"published" : "2006-06-01", | "published" : "2006-06-01", | ||
"abbreviation" : "PIOPED II" | |||
"abbreviation" : "PIOPED II | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Allen SJ, <i>et al</i>. \"Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial\". <i>The Lancet</i>. 2013. 382(9900):1249-1257.", | ||
"pageid" : 1770, | "pageid" : 1770, | ||
" | "briefResultsDescription" : "Probiotics do not reduce diarrhea including C. diff with antibiotics", | ||
"diseases" : "Clostridium difficile", | |||
"pageName" : "PLACIDE", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2014-05-01", | "statusUsableDate" : "2014-05-01", | ||
" | "pmid" : "23932219", | ||
"title" : "Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial", | |||
"timestamp" : "2019-12-20T10:41:43Z", | |||
"published" : "2013-10-12", | "published" : "2013-10-12", | ||
"abbreviation" : "PLACIDE", | "abbreviation" : "PLACIDE", | ||
" | "subspecialties" : "Gastroenterology;Infectious Disease;Preventive Medicine", | ||
" | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961218-0/abstract", | ||
"briefDesignDescription" : "Probiotics to prevent CDAD", | |||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673613612180.pdf" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Ticagrelor vs. clopidogrel in ACS", | "briefDesignDescription" : "Ticagrelor vs. clopidogrel in ACS", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0904327", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0904327", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904327", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904327", | ||
" | "title" : "Ticagrelor versus clopidogrel in patients with acute coronary syndromes", | ||
"statusUsableDate" : "2013-09-01", | "statusUsableDate" : "2013-09-01", | ||
" | "pmid" : "19717846", | ||
"abbreviation" : "PLATO", | |||
"timestamp" : "2017-12-03T22:38:22Z", | |||
"published" : "2009-09-10", | "published" : "2009-09-10", | ||
"pageName" : "PLATO", | "pageName" : "PLATO", | ||
"briefResultsDescription" : "Ticagrelor reduces mortality, increases bleeding", | |||
"diseases" : "Acute Coronary Syndrome;Coronary Artery Disease", | "diseases" : "Acute Coronary Syndrome;Coronary Artery Disease", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Platelet Inhibition and Patient Outcomes", | ||
" | "citation" : "Wallentin L, <i>et al</i>. \"Ticagrelor versus clopidogrel in patients with acute coronary syndromes\". <i>The New England Journal of Medicine</i>. 2009. 361(11):1045-1057.", | ||
"pageid" : 1629 | |||
}, | }, | ||
{ | { | ||
"title" : "Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial", | |||
"pmid" : "14625336", | |||
"statusUsableDate" : "2012-03-01", | |||
"abbreviation" : "PneumA", | |||
"published" : "2003-11-19", | |||
"timestamp" : "2012-05-07T02:36:42Z", | "timestamp" : "2012-05-07T02:36:42Z", | ||
"briefDesignDescription" : "8 vs. 15 days of antibiotics in VAP", | "briefDesignDescription" : "8 vs. 15 days of antibiotics in VAP", | ||
"fulltexturl" : "http://jama.ama-assn.org/content/290/19/2588.long", | "fulltexturl" : "http://jama.ama-assn.org/content/290/19/2588.long", | ||
"subspecialties" : "Critical Care;Infectious Disease;Pulmonology", | |||
"pdfurl" : "http://jama.ama-assn.org/content/290/19/2588.full.pdf", | |||
"expansion" : "", | |||
"pageid" : 118, | "pageid" : 118, | ||
"citation" : "Chastre J. \"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial\". <i>Journal of the American Medical Association</i>. 2003. 290(19):2588-98.", | "citation" : "Chastre J. \"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial\". <i>Journal of the American Medical Association</i>. 2003. 290(19):2588-98.", | ||
"pageName" : "PneumA", | "pageName" : "PneumA", | ||
"diseases" : "Pneumonia", | "diseases" : "Pneumonia", | ||
" | "briefResultsDescription" : "8 days of antibiotics are equivalent to 15 days", | ||
"trainingLevel" : "Intern" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Student", | ||
" | "briefResultsDescription" : "PO abx after IV abx non-inferior to IV abx only", | ||
" | "diseases" : "Endocarditis", | ||
"pageName" : "POET", | |||
"citation" : "Iversen K, <i>et al</i>. \"Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis\". <i>The New England Journal of Medicine</i>. 2019. 380(5):415-424.", | |||
"pageid" : 3722, | "pageid" : 3722, | ||
"expansion" : "Partial Oral Treatment of Endocarditis", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1808312", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1808312", | ||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1808312", | ||
" | "briefDesignDescription" : "PO abx after 10d IV abx for left-sided endocarditis", | ||
" | "timestamp" : "2019-08-26T14:27:41Z", | ||
"published" : "2019-01-31", | "published" : "2019-01-31", | ||
"abbreviation" : "POET", | "abbreviation" : "POET", | ||
" | "statusUsableDate" : "2019-04-10", | ||
"pmid" : "30152252" | "pmid" : "30152252", | ||
"title" : "Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "POINT", | ||
" | "diseases" : "Stroke;Transient Ischemic Attack", | ||
" | "briefResultsDescription" : "Aspirin/clopidogrel reduces stroke recurrence, increases bleeding compared to aspirin", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial", | |||
"pageid" : 3659, | |||
"citation" : "Johnston SC, <i>et al</i>. \"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA\". <i>The New England Journal of Medicine</i>. 2018. 379(3):215-225.", | "citation" : "Johnston SC, <i>et al</i>. \"Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA\". <i>The New England Journal of Medicine</i>. 2018. 379(3):215-225.", | ||
"briefDesignDescription" : "Aspirin/clopidogrel vs. aspirin in stroke/TIA", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800410", | |||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800410", | ||
"title" : "Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA", | |||
"pmid" : "29766750", | |||
"statusUsableDate" : "2018-08-09", | "statusUsableDate" : "2018-08-09", | ||
" | "abbreviation" : "POINT", | ||
"published" : "2018-05-16", | "published" : "2018-05-16", | ||
" | "timestamp" : "2018-11-07T06:34:44Z" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2024-10-23T13:45:05Z", | "timestamp" : "2024-10-23T13:45:05Z", | ||
"published" : "2008-05-31", | |||
"abbreviation" : "POISE", | |||
"pmid" : "18479744", | |||
"statusUsableDate" : "2012-03-01", | |||
"title" : "Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial", | |||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673608606017.pdf", | |||
"subspecialties" : "Surgery;Cardiology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60601-7/fulltext", | |||
"briefDesignDescription" : "Perioperative metoprolol", | "briefDesignDescription" : "Perioperative metoprolol", | ||
" | "citation" : "Devereaux PJ, <i>et al</i>. \"Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery: a Randomised Controlled Trial\". <i>The Lancet</i>. 2008. 371(9627):1839-1847.", | ||
"pageid" : 173, | "pageid" : 173, | ||
" | "expansion" : "PeriOperative ISchemic Evaluation", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"briefResultsDescription" : "Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke", | "briefResultsDescription" : "Perioperative metoprolol reduces MI risk but increases risk of mortality and stroke", | ||
"diseases" : "Cardiac Risk Assessment;Coronary Artery Disease", | "diseases" : "Cardiac Risk Assessment;Coronary Artery Disease", | ||
" | "pageName" : "POISE" | ||
}, | }, | ||
{ | { | ||
"pageid" : 1777, | "pageid" : 1777, | ||
"citation" : "Devereaux PJ, <i>et al</i>. \"Aspirin in patients undergoing noncardiac surgery\". <i>The New England Journal of Medicine</i>. 2014. 370(16):1494-1503.", | "citation" : "Devereaux PJ, <i>et al</i>. \"Aspirin in patients undergoing noncardiac surgery\". <i>The New England Journal of Medicine</i>. 2014. 370(16):1494-1503.", | ||
"expansion" : "Perioperative ischemic evaluation 2 aspirin arm", | "expansion" : "Perioperative ischemic evaluation 2 aspirin arm", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Cardiac Risk Assessment", | |||
"briefResultsDescription" : "Perioperative ASA doesn't modify MI rates but increases major bleeding", | "briefResultsDescription" : "Perioperative ASA doesn't modify MI rates but increases major bleeding", | ||
"pageName" : "POISE-2 ASA", | |||
"published" : "2014-03-31", | "published" : "2014-03-31", | ||
" | "timestamp" : "2017-12-03T22:38:24Z", | ||
"abbreviation" : "POISE-2 ASA", | "abbreviation" : "POISE-2 ASA", | ||
"pmid" : "24679062", | |||
"statusUsableDate" : "2014-04-01", | |||
"title" : "Aspirin in patients undergoing noncardiac surgery", | "title" : "Aspirin in patients undergoing noncardiac surgery", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401105", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1401105", | |||
"subspecialties" : "Cardiology;Surgery", | |||
"briefDesignDescription" : "Perioperative ASA" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "POP-UP", | ||
"diseases" : "Stress Ulcer", | |||
"briefResultsDescription" : "PPIs do not reduce risk of stress ulcer bleeding in enterally fed patients", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Pantoprazole or Placebo for Stress Ulcer Prophylaxis", | |||
"pageid" : 2866, | |||
"citation" : "Selvanderan SP, <i>et al</i>. \"Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study\". <i>Critical Care Medicine</i>. 2016. 44(10):1842-1850.", | |||
"briefDesignDescription" : "PPIs for stress ulcer prophylaxis", | "briefDesignDescription" : "PPIs for stress ulcer prophylaxis", | ||
"fulltexturl" : "https://dx.doi.org/10.1097/CCM.0000000000001819", | "fulltexturl" : "https://dx.doi.org/10.1097/CCM.0000000000001819", | ||
" | "subspecialties" : "Critical Care", | ||
"pdfurl" : "http://ovidsp.tx.ovid.com/sp-3.26.1a/ovidweb.cgi?&S", | "pdfurl" : "http://ovidsp.tx.ovid.com/sp-3.26.1a/ovidweb.cgi?&S", | ||
" | "title" : "Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study", | ||
"pmid" : "27635481", | |||
" | |||
"statusUsableDate" : "2017-09-01", | "statusUsableDate" : "2017-09-01", | ||
" | "abbreviation" : "POP-UP", | ||
"published" : "2016-10-01", | "published" : "2016-10-01", | ||
" | "timestamp" : "2017-12-03T22:38:25Z" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "PRAETORIAN", | |||
"published" : "2020-08-06", | |||
"timestamp" : "2021-01-11T18:51:08Z", | "timestamp" : "2021-01-11T18:51:08Z", | ||
"title" : "Subcutaneous or Transvenous Defibrillator Therapy", | |||
"pmid" : "32757521", | |||
"statusUsableDate" : "2021-01-08", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915932", | |||
"briefDesignDescription" : "Transvenous vs. subq ICD to prevent sudden cardiac death", | "briefDesignDescription" : "Transvenous vs. subq ICD to prevent sudden cardiac death", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1915932", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1915932", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 4394, | "pageid" : 4394, | ||
"citation" : "Knops RE, <i>et al</i>. \"Subcutaneous or Transvenous Defibrillator Therapy\". <i>The New England Journal of Medicine</i>. 2020. 383(6):526-36.", | "citation" : "Knops RE, <i>et al</i>. \"Subcutaneous or Transvenous Defibrillator Therapy\". <i>The New England Journal of Medicine</i>. 2020. 383(6):526-36.", | ||
"expansion" : "Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy", | "expansion" : "Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "PRAETORIAN", | "pageName" : "PRAETORIAN", | ||
"diseases" : "Unstable Arrhythmia", | "diseases" : "Unstable Arrhythmia", | ||
" | "briefResultsDescription" : "Subcutaneous ICD non-inferior to transvenous ICD" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Preventative Angioplasty in Acute Myocardial Infarction", | ||
" | "citation" : "Wald DS, <i>et al</i>. \"Randomized trial of preventative angioplasty in myocardial infarction\". <i>The New England Journal of Medicine</i>. 2013. 369(12):1115-1123.", | ||
"pageid" : 1748, | "pageid" : 1748, | ||
" | "pageName" : "PRAMI", | ||
"briefResultsDescription" : "PCI to high-risk non infarct arteries in STEMI improves CV outcomes", | |||
"diseases" : "Myocardial Infarction", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Randomized trial of preventative angioplasty in myocardial infarction", | ||
"statusUsableDate" : "2013-11-01", | "statusUsableDate" : "2013-11-01", | ||
" | "pmid" : "23991625", | ||
"abbreviation" : "PRAMI", | |||
"timestamp" : "2018-11-18T20:26:21Z", | |||
"published" : "2013-09-19", | "published" : "2013-09-19", | ||
" | "briefDesignDescription" : "PCI to high-risk non-infarct arteries in STEMI", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1305520", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1305520" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "PRECISION", | ||
"diseases" : "Coronary Artery Disease;Rheumatoid Arthritis;Osteoarthritis;Stroke", | |||
"briefResultsDescription" : "Celecoxib noninferior to ibuprofen or naproxen with regard to CV safety", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen", | |||
"pageid" : 2888, | |||
"citation" : "Nissen SE, <i>et al</i>. \"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis\". <i>The New England Journal of Medicine</i>. 2016. 375(26):2519-2529.", | |||
"briefDesignDescription" : "Celecoxib, naproxen, or ibuprofen for CV safety in arthritis", | "briefDesignDescription" : "Celecoxib, naproxen, or ibuprofen for CV safety in arthritis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611593", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1611593", | ||
" | "subspecialties" : "Cardiology;Rheumatology;Neurology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611593", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611593", | ||
" | "title" : "Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis", | ||
"statusUsableDate" : "2017-03-01", | "statusUsableDate" : "2017-03-01", | ||
" | "pmid" : "27959716", | ||
"abbreviation" : "PRECISION", | |||
"published" : "2016-12-29", | "published" : "2016-12-29", | ||
" | "timestamp" : "2018-06-01T20:19:38Z" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Mediterranean diet in CVD prevention", | "briefDesignDescription" : "Mediterranean diet in CVD prevention", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200303", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200303", | ||
" | "subspecialties" : "Cardiology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200303", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200303", | ||
" | "title" : "Primary prevention of cardiovascular disease with a mediterranean diet", | ||
"pmid" : "23432189", | |||
" | |||
"statusUsableDate" : "2013-06-01", | "statusUsableDate" : "2013-06-01", | ||
" | "abbreviation" : "PREDIMED", | ||
"published" : "2013-02-25", | "published" : "2013-02-25", | ||
"timestamp" : "2018-06-14T20:17:40Z", | |||
"pageName" : "PREDIMED", | "pageName" : "PREDIMED", | ||
"diseases" : "Coronary Artery Disease;Stroke;Transient Ischemic Attack", | "diseases" : "Coronary Artery Disease;Stroke;Transient Ischemic Attack", | ||
" | "briefResultsDescription" : "Mediterranean diet reduces composite rate of MI/CVA/CV death", | ||
" | "trainingLevel" : "Student", | ||
"expansion" : "Prevención con Dieta Mediterránea", | |||
"pageid" : 1247, | |||
"citation" : "Estruch R, <i>et al</i>. \"Primary prevention of cardiovascular disease with a mediterranean diet\". <i>The New England Journal of Medicine</i>. 2013. 368(14):1279-1290." | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199202203260802", | ||
"subspecialties" : "Gastroenterology", | |||
"briefDesignDescription" : "Prednisolone vs. placebo in alcoholic hepatitis", | "briefDesignDescription" : "Prednisolone vs. placebo in alcoholic hepatitis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199202203260802", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199202203260802", | ||
" | "pmid" : "1531090", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"title" : "A randomized trial of prednisolone in patients with severe alcoholic hepatitis", | |||
"published" : "1992-02-20", | |||
"timestamp" : "2015-07-06T21:57:28Z", | |||
"abbreviation" : "", | |||
"diseases" : "Alcoholic Hepatitis", | |||
"briefResultsDescription" : "Prednisolone improves short-term survival", | "briefResultsDescription" : "Prednisolone improves short-term survival", | ||
"pageName" : "Prednisolone in Severe Alcoholic Hepatitis", | "pageName" : "Prednisolone in Severe Alcoholic Hepatitis", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "", | ||
" | "pageid" : 1113, | ||
"citation" : "Ramond MJ, <i>et al</i>. \"A randomized trial of prednisolone in patients with severe alcoholic hepatitis\". <i>The New England Journal of Medicine</i>. 1992. 362(8):507-512." | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "PREPIC", | ||
"diseases" : "Deep Vein Thrombosis;Venous Thromboembolism;Pulmonary Embolism", | |||
"briefResultsDescription" : "IVC filters reduce future PE risk but increase DVT risk", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group", | |||
"pageid" : 2697, | |||
"citation" : "Decousus H, <i>et al</i>. \"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis\". <i>The New England Journal of Medicine</i>. 1998. 338(7):409-416.", | |||
"briefDesignDescription" : "IVC filters for proximal DVT", | "briefDesignDescription" : "IVC filters for proximal DVT", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199802123380701", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199802123380701", | ||
" | "subspecialties" : "Pulmonology;Hematology;Interventional Radiology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199802123380701", | ||
" | "title" : "A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis", | ||
"statusUsableDate" : "2016-03-01", | "statusUsableDate" : "2016-03-01", | ||
" | "pmid" : "9459643", | ||
"abbreviation" : "PREPIC", | |||
"published" : "1998-02-12", | "published" : "1998-02-12", | ||
" | "timestamp" : "2017-12-03T22:38:31Z" | ||
}, | |||
}, | |||
{ | { | ||
" | "citation" : "Mismetti P, <i>et al</i>. \"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial\". <i>The Journal of the American Medical Association</i>. 2015. 313(16):1627-35.", | ||
"pageid" : 2405, | "pageid" : 2405, | ||
" | "expansion" : "Prevention du Risque d'Embolie Pulmonaire par Interruption Cave 2", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "PREPIC 2", | ||
"briefResultsDescription" : "IVC filters do not improve outcomes in acute high-risk PE", | "briefResultsDescription" : "IVC filters do not improve outcomes in acute high-risk PE", | ||
"diseases" : "Venous Thromboembolism", | "diseases" : "Venous Thromboembolism", | ||
"abbreviation" : "PREPIC 2", | "abbreviation" : "PREPIC 2", | ||
"timestamp" : "2017-12-03T22:38:33Z", | |||
"published" : "2015-04-28", | |||
"title" : "Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial", | "title" : "Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial", | ||
"pmid" : "25919526" | "pmid" : "25919526", | ||
"statusUsableDate" : "2015-07-01", | |||
"pdfurl" : "http://bit.ly/1ONs0iA", | |||
"briefDesignDescription" : "IVC filters for high-risk PE", | |||
"subspecialties" : "Hematology;Pulmonology;Interventional Radiology", | |||
"fulltexturl" : "http://bit.ly/1Jti6Ct" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "PREVAIL", | ||
"briefResultsDescription" : "LAA noninferior to warfarin in AF", | |||
"diseases" : "Atrial Fibrillation", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy", | |||
"citation" : "Holmes DR, <i>et al</i>. \"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial\". <i>Journal of the American College of Cardiology</i>. 2014. 64(1):1-12.", | |||
"pageid" : 3535, | |||
"briefDesignDescription" : "LAA closure vs. warfarin in AF", | "briefDesignDescription" : "LAA closure vs. warfarin in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02341-9", | "fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(14)02341-9", | ||
"pdfurl" : "https://www.sciencedirect.com/science/article/pii/S0735109714023419/pdfft?download", | "pdfurl" : "https://www.sciencedirect.com/science/article/pii/S0735109714023419/pdfft?download", | ||
" | "title" : "Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial", | ||
"statusUsableDate" : "2021-07-29", | "statusUsableDate" : "2021-07-29", | ||
" | "pmid" : "24998121", | ||
"abbreviation" : "PREVAIL", | "abbreviation" : "PREVAIL", | ||
" | "timestamp" : "2021-07-30T04:27:31Z", | ||
" | "published" : "2014-07-08" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1104875", | ||
"briefDesignDescription" : "Rifapentine/isoniazid in latent TB", | "briefDesignDescription" : "Rifapentine/isoniazid in latent TB", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1104875", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1104875", | ||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
" | "abbreviation" : "PREVENT TB", | ||
"published" : "2011-12-08", | |||
"timestamp" : "2017-12-03T22:38:34Z", | |||
"title" : "Three months of rifapentine and isoniazid for latent tuberculosis infection.", | |||
"pmid" : "22150035", | |||
"statusUsableDate" : "2012-08-01", | "statusUsableDate" : "2012-08-01", | ||
" | "trainingLevel" : "fellow", | ||
"pageName" : "PREVENT TB", | "pageName" : "PREVENT TB", | ||
"diseases" : "Tuberculosis", | "diseases" : "Tuberculosis", | ||
" | "briefResultsDescription" : "Rifapentine/isoniazid x3 months is noninferior to isoniazid x9 months", | ||
" | "pageid" : 928, | ||
" | "citation" : "Sterling TR, <i>et al</i>. \"Three months of rifapentine and isoniazid for latent tuberculosis infection.\". <i>The New England Journal of Medicine</i>. 2011. 365(23):2155-66.", | ||
"expansion" : null | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "ProCESS", | |||
"timestamp" : "2017-12-03T22:38:46Z", | "timestamp" : "2017-12-03T22:38:46Z", | ||
"published" : "2014-05-01", | |||
"title" : "A randomized trial of protocol-based care for early septic shock", | |||
"pmid" : "24635773", | |||
"statusUsableDate" : "2014-03-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401602", | |||
"briefDesignDescription" : "EGDT in septic shock", | "briefDesignDescription" : "EGDT in septic shock", | ||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1401602", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1401602", | ||
"citation" : "Angus DC, <i>et al</i>. \"A randomized trial of protocol-based care for early septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(10):1683-1693.", | |||
"pageid" : 1782, | "pageid" : 1782, | ||
" | "expansion" : "Protocolized Care for Early Septic Shock", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "ProCESS", | ||
"briefResultsDescription" : "No difference for EGDT vs. standard protocol vs. usual care for septic shock", | "briefResultsDescription" : "No difference for EGDT vs. standard protocol vs. usual care for septic shock", | ||
"diseases" : "Sepsis" | |||
"diseases" : "Sepsis | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Conroy T, <i>et al</i>. \"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer\". <i>The New England Journal of Medicine</i>. 2011. 364(19):1817-1825.", | ||
"pageid" : 2819, | "pageid" : 2819, | ||
" | "expansion" : "PRODIGE 4 Actions concertées dans les Cancers COloRectaux et Digestifs", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "PRODIGE 4 ACCORD 11", | ||
"briefResultsDescription" : "FOLFIRINOX improves OS in metastatic pancreatic cancer compared to gemcitabine", | "briefResultsDescription" : "FOLFIRINOX improves OS in metastatic pancreatic cancer compared to gemcitabine", | ||
"diseases" : "Pancreatic Cancer", | "diseases" : "Pancreatic Cancer", | ||
"abbreviation" : "PRODIGE 4 ACCORD 11", | "abbreviation" : "PRODIGE 4 ACCORD 11", | ||
"timestamp" : "2017-12-03T22:38:35Z", | |||
"published" : "2011-05-12", | |||
"title" : "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer", | "title" : "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer", | ||
"pmid" : "21561347" | "statusUsableDate" : "2016-09-01", | ||
"pmid" : "21561347", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1011923", | |||
"briefDesignDescription" : "FOLFIRINOX in pancreatic cancer", | |||
"subspecialties" : "Oncology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1011923" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "pageName" : "PRoFESS", | ||
" | "briefResultsDescription" : "Similar efficacy but less bleeding with clopidogrel", | ||
"diseases" : "Stroke", | |||
"citation" : "Sacco RL, <i>et al</i>. \"Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke\". <i>The New England Journal of Medicine</i>. 2008. 359(12):1238-1251.", | |||
"pageid" : 1082, | "pageid" : 1082, | ||
"expansion" : "Prevention Regimen for Effectively Avoiding Second Strokes", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805002", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805002", | ||
" | "briefDesignDescription" : "ASA-dipyridamole vs. clopidogrel in stroke", | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0805002", | ||
" | "abbreviation" : "PROFESS", | ||
" | "timestamp" : "2017-12-03T22:38:44Z", | ||
"published" : "2008-09-18", | "published" : "2008-09-18", | ||
"title" : "Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke", | "title" : "Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke", | ||
"pmid" : "18753638" | "pmid" : "18753638", | ||
"statusUsableDate" : "2012-11-01" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Protection Against Recurrent Stroke Study", | ||
"pageid" : 2450, | "pageid" : 2450, | ||
" | "citation" : "PROGRESS Collaborative Group. \"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack\". <i>Lancet</i>. 2001. 358(9287):1033–1041.", | ||
"diseases" : "Stroke;Hypertension", | |||
"briefResultsDescription" : "Perindopril+indapamide lowers recurrent stroke risk among those with prior stroke", | |||
"pageName" : "PROGRESS", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"statusUsableDate" : "2023-01-21", | "statusUsableDate" : "2023-01-21", | ||
" | "pmid" : "11589932", | ||
"title" : "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack", | |||
"published" : "2001-09-29", | "published" : "2001-09-29", | ||
" | "timestamp" : "2023-07-20T03:15:45Z", | ||
"abbreviation" : "PROGRESS", | "abbreviation" : "PROGRESS", | ||
" | "fulltexturl" : "https://doi.org/10.1016/S0140-6736(01)06178-5", | ||
" | "subspecialties" : "Neurology", | ||
"briefDesignDescription" : "Perindopril±indapamide after stroke", | |||
"pdfurl" : "" | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa054444", | ||
"subspecialties" : "Hematology", | |||
"briefDesignDescription" : "D-Dimer testing after VTE", | "briefDesignDescription" : "D-Dimer testing after VTE", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa054444", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa054444", | ||
"statusUsableDate" : "2017-10-01", | "statusUsableDate" : "2017-10-01", | ||
"pmid" : "17065639", | |||
"title" : "d-Dimer Testing to Determine the Duration of Anticoagulation Therapy", | |||
"published" : "2006-10-26", | |||
"timestamp" : "2017-12-03T22:38:37Z", | |||
"abbreviation" : "PROLONG", | |||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | |||
"briefResultsDescription" : "Abnormal D-dimer predicts VTE recurrence", | "briefResultsDescription" : "Abnormal D-dimer predicts VTE recurrence", | ||
"pageName" : "PROLONG", | "pageName" : "PROLONG", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "", | ||
" | "pageid" : 2967, | ||
"citation" : "Palareti G, <i>et al</i>. \"d-Dimer Testing to Determine the Duration of Anticoagulation Therapy\". <i>The New England Journal of Medicine</i>. 2006. 355(17):1780-1789." | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
"pageid" : 2385, | "pageid" : 2385, | ||
"citation" : "Mouncey PR, <i>et al</i>. \"Trial of early, goal-directed resuscitation for septic shock\". <i>The New England Journal of Medicine</i>. 2015. 372(14):1301-1311.", | "citation" : "Mouncey PR, <i>et al</i>. \"Trial of early, goal-directed resuscitation for septic shock\". <i>The New England Journal of Medicine</i>. 2015. 372(14):1301-1311.", | ||
" | "diseases" : "Sepsis;Shock", | ||
"briefResultsDescription" : "Multicenter trial shows no benefit to EGDT in severe sepsis", | "briefResultsDescription" : "Multicenter trial shows no benefit to EGDT in severe sepsis", | ||
"pageName" : "ProMISe", | "pageName" : "ProMISe", | ||
" | "trainingLevel" : "Resident", | ||
" | "pmid" : "25776532", | ||
"statusUsableDate" : "2019-02-27", | |||
"title" : "Trial of early, goal-directed resuscitation for septic shock", | "title" : "Trial of early, goal-directed resuscitation for septic shock", | ||
"pmid" : " | "published" : "2015-04-02", | ||
"timestamp" : "2019-02-28T18:12:36Z", | |||
"abbreviation" : "ProMISe", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1500896", | |||
"subspecialties" : "Critical Care;Emergency Medicine", | |||
"briefDesignDescription" : "Multicenter EGDT trial in severe sepsis", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1500896" | |||
}, | |||
{ | |||
"title" : "Outcomes of anatomical versus functional testing for coronary artery disease", | |||
"pmid" : "25773919", | |||
"statusUsableDate" : "2024-08-05", | |||
"abbreviation" : "PROMISE", | |||
"published" : "2015-04-02", | |||
"timestamp" : "2025-08-07T19:37:56Z", | |||
"briefDesignDescription" : "Coronary CT for chest pain", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1415516", | |||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1415516", | |||
"expansion" : "Prospective Multicenter Imaging Study for Evaluation of Chest Pain", | |||
"pageid" : 3720, | |||
"citation" : "Douglas PS, <i>et al</i>. \"Outcomes of anatomical versus functional testing for coronary artery disease\". <i>The New England Journal of Medicine</i>. 2015. 372(14):1291-1300.", | |||
"pageName" : "PROMISE", | |||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "Coronary CT no different from other modalities", | |||
"trainingLevel" : "Resident" | |||
}, | }, | ||
{ | { | ||
"pageid" : 3548, | "pageid" : 3548, | ||
"citation" : "Freund Y, <i>et al</i>. \"Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial\". <i>Journal of the American Medical Association</i>. 2018. 319(6):559-566.", | "citation" : "Freund Y, <i>et al</i>. \"Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial\". <i>Journal of the American Medical Association</i>. 2018. 319(6):559-566.", | ||
"expansion" : "Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients", | "expansion" : "Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "PROPER", | "pageName" : "PROPER", | ||
"diseases" : "Pulmonary Embolism", | "diseases" : "Pulmonary Embolism", | ||
"briefResultsDescription" : "PERC score excludes PE in low-risk patients", | |||
"abbreviation" : "PROPER", | "abbreviation" : "PROPER", | ||
"published" : "2018-02-13", | |||
"timestamp" : "2023-04-21T16:19:29Z", | |||
"title" : "Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial", | "title" : "Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial", | ||
"pmid" : "29450523" | "pmid" : "29450523", | ||
"statusUsableDate" : "2023-04-20", | |||
"pdfurl" : null, | |||
"briefDesignDescription" : "Validation of PERC score in PE", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/article-abstract/2672630", | |||
"subspecialties" : "Emergency Medicine" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Emergency Medicine;Critical Care;Hematology", | ||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/2107789", | |||
"briefDesignDescription" : "Transfusion ratios in hemorrhagic shock", | "briefDesignDescription" : "Transfusion ratios in hemorrhagic shock", | ||
"pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/2107789/joi150002.pdf", | "pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/2107789/joi150002.pdf", | ||
"statusUsableDate" : "2023-09-28", | "statusUsableDate" : "2023-09-28", | ||
"pmid" : "25647203", | |||
"title" : "Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial", | |||
"timestamp" : "2023-09-28T19:19:28Z", | |||
"published" : "2015-02-03", | |||
"abbreviation" : "PROPPR", | |||
"briefResultsDescription" : "1:1:1 ratio of FFP:PLT:RBC no better than 1:1:2", | "briefResultsDescription" : "1:1:1 ratio of FFP:PLT:RBC no better than 1:1:2", | ||
" | "diseases" : "Hemorrhage;Trauma;Shock", | ||
"pageName" : "PROPPR", | "pageName" : "PROPPR", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Pragmatic, Randomized Optimal Platelet and Plasma Ratios", | ||
" | "citation" : "Holcomb JB, <i>et al</i>. \"Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial\". <i>JAMA</i>. 2015. 313(5):471-482.", | ||
" | "pageid" : 2504 | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "PRORATA", | ||
"briefResultsDescription" : "Procalcitonin noninferior and led to fewer days on antibiotics", | |||
"diseases" : "Critical Illness", | |||
"trainingLevel" : "resident", | |||
"expansion" : "Procalcitonin to Reduce Antibiotic Treatments in Acutely ill patients", | |||
"citation" : "Bouadma L, <i>et al</i>. \"Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units\". <i>The Lancet</i>. 2010. 375(9713):463-74.", | |||
"pageid" : 434, | |||
"briefDesignDescription" : "Procalcitonin-guided antibiotics", | "briefDesignDescription" : "Procalcitonin-guided antibiotics", | ||
"subspecialties" : "Critical Care;Infectious Disease", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61879-1/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61879-1/fulltext", | ||
"pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673609618791.pdf", | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673609618791.pdf", | ||
" | "title" : "Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "20097417", | ||
"abbreviation" : "PRORATA", | "abbreviation" : "PRORATA", | ||
" | "timestamp" : "2017-08-06T02:15:05Z", | ||
" | "published" : "2010-02-06" | ||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Critical Care", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1214103", | |||
"briefDesignDescription" : "Prone ventilation in ARDS", | "briefDesignDescription" : "Prone ventilation in ARDS", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214103", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214103", | ||
" | "pmid" : "23688302", | ||
"statusUsableDate" : "2013-06-01", | "statusUsableDate" : "2013-06-01", | ||
"title" : "Prone positioning in severe acute respiratory distress syndrome", | |||
"timestamp" : "2020-11-12T18:32:26Z", | |||
"published" : "2013-06-06", | |||
"abbreviation" : "PROSEVA", | |||
"briefResultsDescription" : "Intermittent prone positioning improves survival in severe ARDS", | "briefResultsDescription" : "Intermittent prone positioning improves survival in severe ARDS", | ||
" | "diseases" : "Acute Respiratory Distress Syndrome", | ||
"pageName" : "PROSEVA", | "pageName" : "PROSEVA", | ||
" | "trainingLevel" : "fellow", | ||
" | "expansion" : "Proning Severe ARDS Patients", | ||
" | "citation" : "Guérin C, <i>et al</i>. \"Prone positioning in severe acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2013. 368(23):2159-2168.", | ||
" | "pageid" : 1479 | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "PROTECT AF", | |||
"timestamp" : "2025-05-15T20:05:21Z", | "timestamp" : "2025-05-15T20:05:21Z", | ||
"published" : "2009-11-07", | |||
"title" : "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial", | |||
"pmid" : "19683639", | |||
"statusUsableDate" : "2018-01-18", | |||
"pdfurl" : "", | |||
"briefDesignDescription" : "LAA closure vs. warfarin in AF", | "briefDesignDescription" : "LAA closure vs. warfarin in AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61343-X/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61343-X/fulltext", | ||
"citation" : "Holmes DR, <i>et al</i>. \"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial\". <i>Lancet</i>. 2009. 374(9689):534-42.", | |||
"pageid" : 2459, | "pageid" : 2459, | ||
" | "expansion" : "WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "PROTECT AF", | ||
"briefResultsDescription" : "LAA closure was noninferior to warfarin therapy", | "briefResultsDescription" : "LAA closure was noninferior to warfarin therapy", | ||
"diseases" : "Atrial Fibrillation;Stroke" | |||
"diseases" : "Atrial Fibrillation;Stroke | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa040583", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa040583", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa040583", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Pravastatin vs. atorvastatin after ACS", | ||
"published" : "2004-04-08", | "published" : "2004-04-08", | ||
" | "timestamp" : "2017-12-14T19:39:45Z", | ||
"abbreviation" : "PROVE IT-TIMI 22", | "abbreviation" : "PROVE IT-TIMI 22", | ||
"statusUsableDate" : "2013-04-01", | |||
"pmid" : "15007110", | |||
"title" : "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes", | "title" : "Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Acute Coronary Syndrome;Hyperlipidemia", | |||
"briefResultsDescription" : "High-dose atorvastatin is superior to moderate-dose pravastatin at reducing CV events after ACS", | |||
"pageName" : "PROVE IT-TIMI 22", | |||
"pageid" : 1338, | |||
"citation" : "Cannon CP, <i>et al</i>. \"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2004. 350(15):1495-1504.", | |||
"expansion" : "Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200103083441001", | ||
"briefDesignDescription" : "Activated protein C in severe sepsis", | "briefDesignDescription" : "Activated protein C in severe sepsis", | ||
"subspecialties" : "Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200103083441001", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200103083441001", | ||
" | "abbreviation" : "PROWESS", | ||
" | "timestamp" : "2017-12-03T22:38:41Z", | ||
"published" : "2001-03-08", | |||
"title" : "Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis", | |||
"statusUsableDate" : "2012-09-01", | |||
"pmid" : "11236773", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "PROWESS", | ||
"briefResultsDescription" : "Improved survival with APC but not seen in subsequent larger PROWESS-SHOCK trial", | "briefResultsDescription" : "Improved survival with APC but not seen in subsequent larger PROWESS-SHOCK trial", | ||
"diseases" : "Sepsis;Shock", | "diseases" : "Sepsis;Shock", | ||
" | "citation" : "Bernard GR, <i>et al</i>. \"Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis\". <i>The New England Journal of Medicine</i>. 2001. 344(10):699-709.", | ||
"pageid" : 983, | |||
" | "expansion" : "Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "pageName" : "PROWESS-SHOCK", | ||
" | "briefResultsDescription" : "No survival benefit at 28 or 90 days, in contrast to PROWESS", | ||
"diseases" : "Sepsis;Shock", | |||
"citation" : "Ranieri VM, <i>et al</i>. \"Drotrecogin Alfa (Activated) in Adults with Septic Shock\". <i>The New England Journal of Medicine</i>. 2012. 366(22):2055-2064.", | |||
"pageid" : 977, | "pageid" : 977, | ||
"expansion" : "Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1202290", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1202290", | ||
" | "briefDesignDescription" : "Activated protein C in septic shock", | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1202290", | ||
" | "abbreviation" : "PROWESS-SHOCK", | ||
" | "timestamp" : "2017-12-03T22:38:43Z", | ||
"published" : "2012-05-31", | "published" : "2012-05-31", | ||
"title" : "Drotrecogin Alfa (Activated) in Adults with Septic Shock", | "title" : "Drotrecogin Alfa (Activated) in Adults with Septic Shock", | ||
"statusUsableDate" : "2012-09-01", | |||
"pmid" : "22616830" | "pmid" : "22616830" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "RABBIT 2", | |||
"timestamp" : "2018-12-24T16:50:42Z", | "timestamp" : "2018-12-24T16:50:42Z", | ||
"published" : "2007-09-30", | |||
"title" : "Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)", | |||
"pmid" : "17513708", | |||
"statusUsableDate" : "2018-06-14", | |||
"pdfurl" : "http://care.diabetesjournals.org/content/30/9/2181.full-text.pdf", | |||
"briefDesignDescription" : "Basal-bolus insulin in inpatients with DM", | "briefDesignDescription" : "Basal-bolus insulin in inpatients with DM", | ||
"subspecialties" : "Critical Care;Endocrinology", | |||
"fulltexturl" : "http://bit.ly/29xvPia", | "fulltexturl" : "http://bit.ly/29xvPia", | ||
"citation" : "Umpierrez GE, <i>et al</i>. \"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)\". <i>Diabetes Care</i>. 2007. 30(9):2181-2186.", | |||
"pageid" : 2720, | "pageid" : 2720, | ||
" | "expansion" : "Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "RABBIT 2", | ||
"briefResultsDescription" : "Basal-bolus more effective for glycemic control compared to sliding-scale insulin", | "briefResultsDescription" : "Basal-bolus more effective for glycemic control compared to sliding-scale insulin", | ||
"diseases" : "Diabetes Mellitus" | |||
"diseases" : "Diabetes Mellitus | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See", | ||
" | "citation" : "Pluymaekers NAHA, <i>et al</i>. \"Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2019. 380(16):1499-1508.", | ||
"pageid" : 4062, | "pageid" : 4062, | ||
" | "pageName" : "RACE 7 ACWAS", | ||
"briefResultsDescription" : "Delayed is noninferior to early cardioversion in obtaining sinus rhythm", | |||
"diseases" : "Atrial Fibrillation", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation", | ||
"statusUsableDate" : "2025-05-25", | "statusUsableDate" : "2025-05-25", | ||
" | "pmid" : "30883054", | ||
"abbreviation" : "RACE 7 ACWAS", | |||
"timestamp" : "2025-05-22T17:30:01Z", | |||
"published" : "2019-04-18", | "published" : "2019-04-18", | ||
" | "briefDesignDescription" : "Delayed vs. early cardioversion in AF", | ||
" | "subspecialties" : "Emergency Medicine;Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1900353", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1900353" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "Atrial Fibrillation", | ||
" | "briefResultsDescription" : "Lenient rate control is as effective as strict rate control", | ||
" | "pageName" : "RACE II", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II", | |||
"pageid" : 181, | "pageid" : 181, | ||
"citation" : "Van Gelder IC, <i>et al</i>. \"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1363-73.", | "citation" : "Van Gelder IC, <i>et al</i>. \"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1363-73.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1001337", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Lenient vs. strict rate control in AF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001337", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "20231232", | ||
"title" : "Lenient versus Strict Rate Control in Patients with Atrial Fibrillation", | |||
"published" : "2010-04-15", | "published" : "2010-04-15", | ||
" | "timestamp" : "2025-05-15T20:17:08Z", | ||
"abbreviation" : "RACE II" | |||
"abbreviation" : "RACE II | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"pageName" : "Radiograph vs. MRI for low back pain", | |||
"diseases" : "Low Back Pain", | |||
"briefResultsDescription" : "No differences in pain or disability related to back pain, possibly more surgeries in MRI group", | |||
"pageid" : 2665, | |||
"citation" : "Jarvik JG, <i>et al</i>. \"Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.\". <i>The Journal of the American Medical Association</i>. 2003. 289(21):2810-8.", | "citation" : "Jarvik JG, <i>et al</i>. \"Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.\". <i>The Journal of the American Medical Association</i>. 2003. 289(21):2810-8.", | ||
"expansion" : "", | |||
"pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/196680/joc22401.pdf", | |||
"briefDesignDescription" : "Radiograph vs. MRI for low back pain", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/196680", | |||
"subspecialties" : "Physical Medicine and Rehabilitation", | "subspecialties" : "Physical Medicine and Rehabilitation", | ||
" | "abbreviation" : "Radiograph vs. MRI for low back pain", | ||
"published" : "2003-06-04", | "published" : "2003-06-04", | ||
" | "timestamp" : "2025-06-19T18:35:37Z", | ||
"title" : "Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.", | "title" : "Rapid magnetic resonance imaging vs. radiographs for patients with low back pain: a randomized controlled trial.", | ||
"statusUsableDate" : "2018-10-31", | |||
"pmid" : "12783911" | "pmid" : "12783911" | ||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009540", | ||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "CRT+ICD for mild-moderate HFrEF", | "briefDesignDescription" : "CRT+ICD for mild-moderate HFrEF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009540", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009540", | ||
"statusUsableDate" : "2016-09-01", | "statusUsableDate" : "2016-09-01", | ||
"pmid" : "21073365", | |||
"title" : "Cardiac-resynchronization therapy for mild-to-moderate heart failure", | |||
"published" : "2010-12-16", | |||
"timestamp" : "2017-12-03T22:38:47Z", | |||
"abbreviation" : "RAFT", | |||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "CRT+ICD reduces mortality but increased the rate of adverse events", | "briefResultsDescription" : "CRT+ICD reduces mortality but increased the rate of adverse events", | ||
"pageName" : "RAFT", | "pageName" : "RAFT", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Resynchronization–Defibrillation for Ambulatory Heart Failure", | ||
" | "pageid" : 2731, | ||
"citation" : "Tang AS, <i>et al</i>. \"Cardiac-resynchronization therapy for mild-to-moderate heart failure\". <i>The New England Journal of Medicine</i>. 2010. 363(25):2385-2395." | |||
}, | }, | ||
{ | { | ||
"title" : "The effect of spironolactone on morbidity and mortality in patients with severe heart failure", | |||
"pmid" : "10471456", | |||
"statusUsableDate" : "2012-03-01", | |||
"abbreviation" : "RALES", | |||
"published" : "1999-09-02", | |||
"timestamp" : "2015-08-24T04:40:44Z", | "timestamp" : "2015-08-24T04:40:44Z", | ||
"briefDesignDescription" : "Spironolactone in HFrEF", | "briefDesignDescription" : "Spironolactone in HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199909023411001", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199909023411001", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199909023411001", | |||
"expansion" : "Randomized Aldactone Evaluation Study", | |||
"pageid" : 11, | "pageid" : 11, | ||
"citation" : "Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341(10):709-717.", | "citation" : "Pitt B, <i>et al</i>. \"The effect of spironolactone on morbidity and mortality in patients with severe heart failure\". <i>New England Journal of Medicine</i>. 1999. 341(10):709-717.", | ||
"pageName" : "RALES", | "pageName" : "RALES", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
" | "briefResultsDescription" : "Spironolactone reduces all-cause mortality by 30% in severe HFrEF", | ||
"trainingLevel" : "Intern" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Silbergleit R, <i>et al</i>. \"Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus\". <i>The New England Journal of Medicine</i>. 2012. 366(7):591-600.", | ||
"pageid" : 2505, | "pageid" : 2505, | ||
" | "expansion" : "Rapid Anticonvulsant Medication Prior to Arrival Trial", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "RAMPART", | ||
"briefResultsDescription" : "IM midazolam is as safe and efficacious as IV lorazepam", | "briefResultsDescription" : "IM midazolam is as safe and efficacious as IV lorazepam", | ||
"diseases" : "Epilepsy;Seizure", | "diseases" : "Epilepsy;Seizure", | ||
"abbreviation" : "RAMPART", | "abbreviation" : "RAMPART", | ||
"timestamp" : "2021-08-12T22:54:12Z", | |||
"published" : "2012-02-22", | |||
"title" : "Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus", | "title" : "Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus", | ||
"pmid" : "22335736" | "pmid" : "22335736", | ||
"statusUsableDate" : "2019-08-31", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1107494", | |||
"briefDesignDescription" : "Midazolam vs. lorazepam for status epilepticus", | |||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1107494" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Chemo-RT vs. chemo in rectal cancer", | "briefDesignDescription" : "Chemo-RT vs. chemo in rectal cancer", | ||
"subspecialties" : "Oncology", | |||
"fulltexturl" : "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext", | "fulltexturl" : "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext", | ||
"pdfurl" : "https://www.thelancet.com/action/showPdf?pii", | "pdfurl" : "https://www.thelancet.com/action/showPdf?pii", | ||
" | "title" : "Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial", | ||
"statusUsableDate" : "2025-05-22", | "statusUsableDate" : "2025-05-22", | ||
" | "pmid" : "33301740", | ||
"abbreviation" : "RAPIDO", | |||
"timestamp" : "2025-05-22T17:14:03Z", | |||
"published" : "2021-01-01", | "published" : "2021-01-01", | ||
"pageName" : "RAPIDO", | "pageName" : "RAPIDO", | ||
"briefResultsDescription" : "Fewer treatment failures with chemo-RT", | |||
"diseases" : "Colorectal Cancer", | "diseases" : "Colorectal Cancer", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "Rectal Cancer and Preoperative Induction Therapy Followed by Dedicated Operation Trial", | ||
" | "citation" : "Bahadoer RR, <i>et al</i>. \"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial\". <i>The Lancet Oncology</i>. 2021. 22(1):29-42.", | ||
"pageid" : 5600 | |||
}, | }, | ||
{ | { | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0909905", | ||
"subspecialties" : "Rheumatology", | |||
"briefDesignDescription" : "Rituximab vs. cyclophosphamide in ANCA-associated vasculitis", | "briefDesignDescription" : "Rituximab vs. cyclophosphamide in ANCA-associated vasculitis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909905", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0909905", | ||
" | "pmid" : "20647199", | ||
"statusUsableDate" : "2013-02-01", | "statusUsableDate" : "2013-02-01", | ||
"title" : "Rituximab versus cyclophosphamide for ANCA-associated vasculitis", | |||
"published" : "2010-07-15", | |||
"timestamp" : "2017-12-03T22:38:49Z", | |||
"abbreviation" : "RAVE", | |||
"diseases" : "Vasculitis", | |||
"briefResultsDescription" : "Rituximab noninferior to cyclophosphamide in ANCA-associated vasculitis", | "briefResultsDescription" : "Rituximab noninferior to cyclophosphamide in ANCA-associated vasculitis", | ||
"pageName" : "RAVE", | "pageName" : "RAVE", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "Rituximab in ANCA-Associated Vasculitis", | ||
" | "pageid" : 1214, | ||
"citation" : "Stone JH, <i>et al</i>. \"Rituximab versus cyclophosphamide for ANCA-associated vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):221-232." | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Dabigatran has more thromboembolism and bleeding than warfarin", | ||
"diseases" : "Valvular Disease", | |||
" | "pageName" : "RE-ALIGN", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement", | |||
"citation" : "Eikelboom JW, <i>et al</i>. \"Dabigatran versus warfarin in patients with mechanical heart valves\". <i>The New England Journal of Medicine</i>. 2013. 369(13):1206-1214.", | "citation" : "Eikelboom JW, <i>et al</i>. \"Dabigatran versus warfarin in patients with mechanical heart valves\". <i>The New England Journal of Medicine</i>. 2013. 369(13):1206-1214.", | ||
"pageid" : 1707, | |||
"subspecialties" : "Cardiology;Hematology", | "subspecialties" : "Cardiology;Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1300615", | ||
"briefDesignDescription" : "Dabigatran in mechanical heart valves", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1300615", | |||
"pmid" : "23991661", | |||
"statusUsableDate" : "2013-10-01", | "statusUsableDate" : "2013-10-01", | ||
" | "title" : "Dabigatran versus warfarin in patients with mechanical heart valves", | ||
"timestamp" : "2017-12-03T22:38:51Z", | |||
"published" : "2013-09-26", | "published" : "2013-09-26", | ||
"abbreviation" : "RE-ALIGN" | |||
"abbreviation" : "RE-ALIGN | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "RE-COVER", | |||
"timestamp" : "2017-12-03T22:38:52Z", | "timestamp" : "2017-12-03T22:38:52Z", | ||
"published" : "2009-12-10", | |||
"title" : "Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism", | |||
"statusUsableDate" : "2012-08-01", | |||
"pmid" : "19966341", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0906598", | |||
"briefDesignDescription" : "Dabigatran vs. warfarin in VTE", | "briefDesignDescription" : "Dabigatran vs. warfarin in VTE", | ||
"subspecialties" : "Hematology;Pulmonology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906598", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0906598", | ||
"citation" : "Schulman S, <i>et al</i>. \"Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism\". <i>New England Journal of Medicine</i>. 2009. 361(24):2342-52.", | |||
"pageid" : 973, | "pageid" : 973, | ||
" | "expansion" : "Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism", | ||
"trainingLevel" : "fellow", | "trainingLevel" : "fellow", | ||
" | "pageName" : "RE-COVER", | ||
"briefResultsDescription" : "Dabigatran non-inferior to warfarin for VTE recurrence, but dabigatran yielded less bleeding", | "briefResultsDescription" : "Dabigatran non-inferior to warfarin for VTE recurrence, but dabigatran yielded less bleeding", | ||
"diseases" : "Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism" | |||
"diseases" : "Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "RE-DUAL", | ||
"briefResultsDescription" : "Aspirin and dabigatran nonferior to triple therapy in patients with AF undergoing PCI", | |||
"diseases" : "Coronary Artery Disease", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Randomized evaluation of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin in patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention", | |||
"citation" : "Cannon CP, <i>et al</i>. \"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2017. 377(16):1513-1524.", | |||
"pageid" : 3527, | |||
"briefDesignDescription" : "Triple therapy vs. ASA+dabigatran in PCI if AF", | "briefDesignDescription" : "Triple therapy vs. ASA+dabigatran in PCI if AF", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1708454", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1708454", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1708454", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1708454", | ||
" | "title" : "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", | ||
"statusUsableDate" : "2018-01-29", | "statusUsableDate" : "2018-01-29", | ||
" | "pmid" : "28844193", | ||
"abbreviation" : "RE-DUAL PCI", | "abbreviation" : "RE-DUAL PCI", | ||
" | "timestamp" : "2018-01-30T17:09:14Z", | ||
" | "published" : "2017-10-19" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Connolly SJ, <i>et al</i>. \"Dabigatran versus warfarin in patients with atrial fibrillation\". <i>The New England Journal of Medicine</i>. 2009. 361(12):1139-51.", | ||
"pageid" : 178, | "pageid" : 178, | ||
" | "expansion" : "Randomized Evaluation of Long-Term Anticoagulation Therapy", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation", | "briefResultsDescription" : "High-dose dabigatran reduces stroke risk without increasing major bleeding in atrial fibrillation", | ||
" | "diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | ||
"pageName" : "RE-LY", | "pageName" : "RE-LY", | ||
" | "timestamp" : "2015-04-18T21:22:31Z", | ||
"published" : "2009-09-17", | |||
"abbreviation" : "RE-LY", | "abbreviation" : "RE-LY", | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "19717844", | |||
"title" : "Dabigatran versus warfarin in patients with atrial fibrillation", | "title" : "Dabigatran versus warfarin in patients with atrial fibrillation", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0905561", | ||
"subspecialties" : "Cardiology;Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0905561", | |||
"briefDesignDescription" : "Dabigatran vs. warfarin in AF" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1502000", | ||
"briefDesignDescription" : "Idarucizumab for dabigatran reversal", | "briefDesignDescription" : "Idarucizumab for dabigatran reversal", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1502000", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1502000", | ||
" | "abbreviation" : "RE-VERSE AD", | ||
" | "timestamp" : "2017-12-03T22:38:54Z", | ||
"published" : "2015-08-06", | |||
"title" : "Idarucizumab for Dabigatran Reversal", | |||
"statusUsableDate" : "2016-01-01", | |||
"pmid" : "26095746", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "RE-VERSE AD", | ||
"briefResultsDescription" : "Idarucizumab reversed the dabigatran effect in minutes", | "briefResultsDescription" : "Idarucizumab reversed the dabigatran effect in minutes", | ||
"diseases" : "Hemorrhage", | "diseases" : "Hemorrhage", | ||
" | "citation" : "Pollack CV, <i>et al</i>. \"Idarucizumab for Dabigatran Reversal\". <i>The New England Journal of Medicine</i>. 2015. 373(6):511-520.", | ||
" | "pageid" : 2421, | ||
" | "expansion" : "" | ||
}, | }, | ||
{ | { | ||
"pageid" : 4431, | "pageid" : 4431, | ||
"citation" : "Ducrocq G, <i>et al</i>. \"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia\". <i>Journal of the American Medical Association</i>. 2021. 325(6):552-560.", | "citation" : "Ducrocq G, <i>et al</i>. \"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia\". <i>Journal of the American Medical Association</i>. 2021. 325(6):552-560.", | ||
"expansion" : "Restrictive and Liberal Transfusion Strategies in Patients With Acute Myocardial Infarction trial", | "expansion" : "Restrictive and Liberal Transfusion Strategies in Patients With Acute Myocardial Infarction trial", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Acute Coronary Syndrome", | |||
"briefResultsDescription" : "Restrictive threshold non-inferior to liberal transfusion threshold", | "briefResultsDescription" : "Restrictive threshold non-inferior to liberal transfusion threshold", | ||
"pageName" : "REALITY", | |||
"published" : "2021-02-09", | "published" : "2021-02-09", | ||
" | "timestamp" : "2021-08-05T18:21:13Z", | ||
"abbreviation" : "REALITY", | "abbreviation" : "REALITY", | ||
"statusUsableDate" : "2021-07-31", | |||
"pmid" : "33560322", | |||
"title" : "Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia", | "title" : "Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia", | ||
" | "pdfurl" : null, | ||
"fulltexturl" : "https://doi.org/10.1001/jama.2021.0135", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Transfusion thresholds in MI" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "RECOVERY (Covid-19)", | |||
"diseases" : "Covid-19", | |||
"briefResultsDescription" : "Dexamethasone improved survival in a subset of patients with Covid-19", | |||
"pageid" : 4273, | |||
"citation" : "Horby P, <i>et al</i>. \"Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report\". <i>The New England Journal of Medicine</i>. 2020. e-pub 2020-07-17:1-11.", | |||
"expansion" : "Randomized Evaluation of Covid-19 Therapy", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2021436", | |||
"briefDesignDescription" : "Dexamethasone vs. usual care in Covid-19", | "briefDesignDescription" : "Dexamethasone vs. usual care in Covid-19", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2021436", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2021436", | ||
"subspecialties" : "Infectious Disease", | "subspecialties" : "Infectious Disease", | ||
" | "abbreviation" : "RECOVERY", | ||
"published" : "2020-07-17", | "published" : "2020-07-17", | ||
" | "timestamp" : "2020-10-29T17:10:25Z", | ||
"title" : "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report", | "title" : "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report", | ||
"statusUsableDate" : "2020-08-20", | |||
"pmid" : "32678530" | "pmid" : "32678530" | ||
}, | }, | ||
{ | { | ||
"pmid" : "23473338", | |||
"statusUsableDate" : "2014-06-01", | |||
"title" : "Treatment of anemia with darbepoetin alfa in systolic heart failure", | |||
"published" : "2013-03-28", | |||
"timestamp" : "2017-12-03T22:38:55Z", | "timestamp" : "2017-12-03T22:38:55Z", | ||
"abbreviation" : "RED-HF", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1214865", | |||
"subspecialties" : "Cardiology;Hematology", | |||
"briefDesignDescription" : "Darbepoetin in HFrEF", | "briefDesignDescription" : "Darbepoetin in HFrEF", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214865", | ||
"expansion" : "Reduction of Events by Darbepoetin Alfa in Heart Failure", | |||
"pageid" : 1842, | "pageid" : 1842, | ||
"citation" : "Swedberg K, <i>et al</i>. \"Treatment of anemia with darbepoetin alfa in systolic heart failure\". <i>The New England Journal of Medicine</i>. 2013. 368(13):1210-9.", | "citation" : "Swedberg K, <i>et al</i>. \"Treatment of anemia with darbepoetin alfa in systolic heart failure\". <i>The New England Journal of Medicine</i>. 2013. 368(13):1210-9.", | ||
" | "diseases" : "Heart Failure;Anemia", | ||
"briefResultsDescription" : "Darbepoetin does not improve clinical outcomes in HF with anemia", | "briefResultsDescription" : "Darbepoetin does not improve clinical outcomes in HF with anemia", | ||
"pageName" : "RED-HF", | "pageName" : "RED-HF", | ||
" | "trainingLevel" : "Fellow" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Reduction in the Use of Corticosteroids in Exacerbated COPD", | ||
"pageid" : 1615, | "pageid" : 1615, | ||
" | "citation" : "Leuppi JD, <i>et al</i>. \"Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial\". <i>JAMA</i>. 2013. 309(21):2223-2231.", | ||
"diseases" : "Chronic Obstructive Pulmonary Disease", | |||
"briefResultsDescription" : "5d steroids noninferior to 14d in acute COPD", | |||
"pageName" : "REDUCE", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"statusUsableDate" : "2013-09-01", | "statusUsableDate" : "2013-09-01", | ||
" | "pmid" : "23695200", | ||
"title" : "Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial", | |||
"published" : "2013-06-05", | "published" : "2013-06-05", | ||
" | "timestamp" : "2017-12-03T22:38:56Z", | ||
"abbreviation" : "REDUCE", | "abbreviation" : "REDUCE", | ||
" | "fulltexturl" : "http://bit.ly/1BQhpuy", | ||
" | "subspecialties" : "Pulmonology", | ||
"briefDesignDescription" : "5d vs. 14d steroids in acute COPD", | |||
"pdfurl" : null | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Yndigegn T, <i>et al</i>. \"Beta-blockers after myocardial infarction and preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2024. 390(15):1372-1381.", | ||
"pageid" : 5504, | "pageid" : 5504, | ||
" | "briefResultsDescription" : "Beta-Blockers no better than no beta-blockers in MI with normal LVEF", | ||
"diseases" : "Myocardial Infarction", | |||
"pageName" : "REDUCE-AMI", | |||
"trainingLevel" : "students", | "trainingLevel" : "students", | ||
"statusUsableDate" : "2024-05-16", | "statusUsableDate" : "2024-05-16", | ||
" | "pmid" : "38587241", | ||
"title" : "Beta-blockers after myocardial infarction and preserved ejection fraction", | |||
"timestamp" : "2024-05-16T18:52:20Z", | |||
"published" : "2024-04-18", | "published" : "2024-04-18", | ||
"abbreviation" : "REDUCE-AMI", | "abbreviation" : "REDUCE-AMI", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2401479", | ||
"briefDesignDescription" : "Beta-blockers if post-AMI LVEF ≥50%", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401479" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial", | ||
" | "citation" : "Bhatt DL, <i>et al</i>. \"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia\". <i>The New England Journal of Medicine</i>. 2018. epub 2018-11-10:1-12.", | ||
"pageid" : 3748, | "pageid" : 3748, | ||
" | "pageName" : "REDUCE-IT", | ||
"briefResultsDescription" : "Icosapent ethyl superior to placebo in CAD with hypertriglyceridemia", | |||
"diseases" : "Coronary Artery Disease", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia", | ||
"statusUsableDate" : "2018-12-27", | "statusUsableDate" : "2018-12-27", | ||
" | "pmid" : "30415628", | ||
"abbreviation" : "REDUCE-IT", | |||
"timestamp" : "2019-10-17T17:47:07Z", | |||
"published" : "2018-11-10", | "published" : "2018-11-10", | ||
" | "briefDesignDescription" : "Icosapent ethyl in CAD", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1812792", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1812792" | ||
}, | }, | ||
{ | { | ||
"pageid" : 2973, | "pageid" : 2973, | ||
"citation" : "Redfield MM, <i>et al</i>. \"Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction\". <i>JAMA</i>. 2013. 309(12):1268-1277.", | "citation" : "Redfield MM, <i>et al</i>. \"Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction\". <i>JAMA</i>. 2013. 309(12):1268-1277.", | ||
"expansion" : "Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction", | "expansion" : "Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "RELAX", | "pageName" : "RELAX", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"briefResultsDescription" : "Sildenafil not superior to placebo in HFpEF", | |||
"abbreviation" : "RELAX", | "abbreviation" : "RELAX", | ||
"published" : "2013-03-11", | |||
"timestamp" : "2017-12-03T22:38:58Z", | |||
"title" : "Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction", | "title" : "Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction", | ||
"pmid" : "23478662" | "pmid" : "23478662", | ||
"statusUsableDate" : "2017-10-01", | |||
"pdfurl" : "https://jamanetwork.com/journals/jama/articlepdf/1663257/joc130025_1268_1277.pdf", | |||
"briefDesignDescription" : "Sildenafil vs. placebo in HFpEF", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/1663257", | |||
"subspecialties" : "Cardiology" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"pageName" : "REMATCH", | |||
"briefResultsDescription" : "LVAD reduced all-cause mortality in end-stage heart failure", | |||
"diseases" : "Heart Failure", | |||
"citation" : "Rose EA, <i>et al</i>. \"Long-term use of a left ventricular assist device for end-stage heart failure\". <i>The New England Journal of Medicine</i>. 2001. 345(20):1435-43.", | "citation" : "Rose EA, <i>et al</i>. \"Long-term use of a left ventricular assist device for end-stage heart failure\". <i>The New England Journal of Medicine</i>. 2001. 345(20):1435-43.", | ||
" | "pageid" : 2822, | ||
"expansion" : "Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure", | "expansion" : "Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa012175", | ||
" | "briefDesignDescription" : "Destination LVAD in end-stage heart failure", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa012175", | ||
"abbreviation" : "REMATCH", | "abbreviation" : "REMATCH", | ||
"timestamp" : "2019-04-11T17:01:50Z", | |||
"published" : "2001-11-15", | |||
"title" : "Long-term use of a left ventricular assist device for end-stage heart failure", | "title" : "Long-term use of a left ventricular assist device for end-stage heart failure", | ||
"pmid" : "11794191" | "pmid" : "11794191", | ||
"statusUsableDate" : "2019-04-11" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "RENAAL", | ||
"briefResultsDescription" : "ARBs reduce progression to", | |||
"diseases" : "Diabetes Mellitus;Chronic Kidney Disease", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan", | |||
"citation" : "Brenner BM, <i>et al</i>. \"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy\". <i>The New England Journal of Medicine</i>. 2001. 345(12):861-869.", | |||
"pageid" : 1030, | |||
"briefDesignDescription" : "ARBs in diabetic nephropathy", | "briefDesignDescription" : "ARBs in diabetic nephropathy", | ||
"subspecialties" : "Endocrinology;Nephrology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011161", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011161", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011161", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011161", | ||
" | "title" : "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", | ||
"statusUsableDate" : "2013-01-01", | "statusUsableDate" : "2013-01-01", | ||
" | "pmid" : "11565518", | ||
"abbreviation" : "RENAAL", | "abbreviation" : "RENAAL", | ||
" | "timestamp" : "2017-12-03T22:38:59Z", | ||
" | "published" : "2001-09-20" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "RESCUEicp", | ||
"briefResultsDescription" : "Craniectomy reduced mortality by 22% compared to usual care", | |||
"diseases" : "Intracranial Hypertension;Traumatic Brain Injury", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of Intracranial Pressure", | |||
"citation" : "Hutchinson PJ, <i>et al</i>. \"Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension\". <i>The New England Journal of Medicine</i>. 2016. 375(12):1119-30.", | |||
"pageid" : 3596, | |||
"briefDesignDescription" : "Craniectomy vs. medical care for intracranial hypertension", | "briefDesignDescription" : "Craniectomy vs. medical care for intracranial hypertension", | ||
"subspecialties" : "Surgery;Neurology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1605215", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1605215", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1605215", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1605215", | ||
" | "title" : "Trial of Decompressive Craniectomy for Traumatic Intracranial Hypertension", | ||
"statusUsableDate" : "2018-07-19", | "statusUsableDate" : "2018-07-19", | ||
" | "pmid" : "27602507", | ||
"abbreviation" : "RESCUEicp", | "abbreviation" : "RESCUEicp", | ||
" | "timestamp" : "2018-07-22T21:45:32Z", | ||
" | "published" : "2016-09-22" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "RESPECT", | |||
"timestamp" : "2017-12-03T22:39:00Z", | "timestamp" : "2017-12-03T22:39:00Z", | ||
"published" : "2013-03-21", | |||
"title" : "Closure of patent foramen ovale versus medical therapy after cryptogenic stroke", | |||
"statusUsableDate" : "2013-05-01", | |||
"pmid" : "23514286", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1301440", | |||
"briefDesignDescription" : "PFO closure in cryptogenic stroke", | "briefDesignDescription" : "PFO closure in cryptogenic stroke", | ||
"subspecialties" : "Neurology;Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1301440", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1301440", | ||
"citation" : "Carroll JD, <i>et al</i>. \"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke\". <i>The New England Journal of Medicine</i>. 2013. 368(12):1092-1100.", | |||
"pageid" : 1334, | "pageid" : 1334, | ||
" | "expansion" : "Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "RESPECT", | ||
"briefResultsDescription" : "PFO closure does not reduce recurrent CVA after cryptogenic CVA", | "briefResultsDescription" : "PFO closure does not reduce recurrent CVA after cryptogenic CVA", | ||
"diseases" : "Stroke;Patent Foramen Ovale;Transient Ischemic Attack" | |||
"diseases" : "Stroke;Patent Foramen Ovale;Transient Ischemic Attack | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nature.com/ajg/journal/v108/n9/pdf/ajg2013219a.pdf", | ||
"fulltexturl" : "http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html", | "fulltexturl" : "http://www.nature.com/ajg/journal/v108/n9/full/ajg2013219a.html", | ||
"subspecialties" : "Gastroenterology", | "subspecialties" : "Gastroenterology", | ||
" | "briefDesignDescription" : "Rifaximin/lactulose vs. lactulose for acute HE", | ||
"published" : "2013-09-01", | |||
"timestamp" : "2017-12-03T22:39:03Z", | |||
"abbreviation" : "", | |||
"statusUsableDate" : "2014-03-01", | "statusUsableDate" : "2014-03-01", | ||
"pmid" : "23877348", | |||
"title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", | |||
"trainingLevel" : "Intern", | |||
"diseases" : "Hepatic Encephalopathy", | |||
"briefResultsDescription" : "Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS", | "briefResultsDescription" : "Rifaximin/lactulose improved rates of HE reversal and survival, reduced hospital LOS", | ||
"pageName" : "Rifaximin and Lactulose for HE", | "pageName" : "Rifaximin and Lactulose for HE", | ||
" | "pageid" : 1784, | ||
" | "citation" : "Sharma BC, <i>et al</i>. \"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy\". <i>The American Journal of Gastroenterology</i>. 2013. 108(9):1458-1463.", | ||
"expansion" : "" | |||
" | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169", | ||
"subspecialties" : "Rheumatology;Nephrology", | "subspecialties" : "Rheumatology;Nephrology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa0909169", | ||
"briefDesignDescription" : "Rituximab in ANCA-Renal Vasculitis", | |||
"timestamp" : "2022-03-10T21:09:46Z", | |||
"published" : "2010-07-15", | |||
"abbreviation" : "RITUXVAS", | |||
"statusUsableDate" : "2022-03-10", | "statusUsableDate" : "2022-03-10", | ||
"pmid" : "20647198", | |||
"title" : "Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis", | |||
"trainingLevel" : "fellow", | |||
"briefResultsDescription" : "Rituximab not superior to cyclophosphamide", | "briefResultsDescription" : "Rituximab not superior to cyclophosphamide", | ||
" | "diseases" : "Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis", | ||
"pageName" : "RITUXVAS", | "pageName" : "RITUXVAS", | ||
" | "citation" : "Jones RB, <i>et al</i>. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):211-232.", | ||
"pageid" : 4459, | |||
" | "expansion" : "" | ||
" | |||
}, | }, | ||
{ | { | ||
"title" : "Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "11794169", | |||
"abbreviation" : "", | |||
"published" : "2001-11-08", | |||
"timestamp" : "2022-04-19T13:00:26Z", | "timestamp" : "2022-04-19T13:00:26Z", | ||
"briefDesignDescription" : "Early goal-directed therapy in sepsis", | "briefDesignDescription" : "Early goal-directed therapy in sepsis", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010307", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010307", | ||
" | "subspecialties" : "Critical Care;Emergency Medicine", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010307", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010307", | ||
" | "expansion" : "", | ||
"pageid" : 60, | |||
"citation" : "Rivers E, <i>et al</i>. \"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1368-1377.", | "citation" : "Rivers E, <i>et al</i>. \"Early Goal Directed Therapy in the Treatment of Severe Sepsis and Septic Shock\". <i>The New England Journal of Medicine</i>. 2001. 345(19):1368-1377.", | ||
"pageName" : "Rivers Trial", | "pageName" : "Rivers Trial", | ||
"diseases" : "Sepsis;Shock", | "diseases" : "Sepsis;Shock", | ||
" | "briefResultsDescription" : "Early goal-directed therapy decreased mortality and morbiditiy in sepsis", | ||
"trainingLevel" : "Student" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1009638", | ||
"briefDesignDescription" : "Rivaroxaban vs. warfarin in AF", | "briefDesignDescription" : "Rivaroxaban vs. warfarin in AF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009638", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1009638", | ||
"subspecialties" : "Cardiology;Neurology", | "subspecialties" : "Cardiology;Neurology", | ||
" | "abbreviation" : "ROCKET AF", | ||
"published" : "2011-09-08", | |||
"timestamp" : "2017-12-03T22:39:02Z", | |||
"title" : "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation", | |||
"statusUsableDate" : "2013-04-01", | "statusUsableDate" : "2013-04-01", | ||
" | "pmid" : "21830957", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "ROCKET AF", | "pageName" : "ROCKET AF", | ||
"diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | "diseases" : "Atrial Fibrillation;Stroke;Transient Ischemic Attack", | ||
" | "briefResultsDescription" : "Rivaroxaban is noninferior to warfarin for stroke/embolization prevention in nonvalvular AF", | ||
" | "pageid" : 1358, | ||
" | "citation" : "Patel MR, <i>et al</i>. \"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2011. 365(10):883-891.", | ||
"expansion" : "Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Reevaluation of Systemic Early Neuromuscular Blockade", | ||
"pageid" : 4070, | "pageid" : 4070, | ||
"citation" : "National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. \"Early neuromuscular blockade in the acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2019. 380(21):1997-2008.", | "citation" : "National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. \"Early neuromuscular blockade in the acute respiratory distress syndrome\". <i>The New England Journal of Medicine</i>. 2019. 380(21):1997-2008.", | ||
"pageName" : "ROSE", | "pageName" : "ROSE", | ||
"diseases" : "Acute Respiratory Distress Syndrome", | "diseases" : "Acute Respiratory Distress Syndrome", | ||
"briefResultsDescription" : "Cisatracurium blockade doesn't improve outcomes in ARDS", | |||
"trainingLevel" : "Resident", | |||
"title" : "Early neuromuscular blockade in the acute respiratory distress syndrome", | |||
"pmid" : "31112383", | |||
"statusUsableDate" : "2019-06-14", | |||
"abbreviation" : "ROSE", | "abbreviation" : "ROSE", | ||
" | "published" : "2019-05-23", | ||
" | "timestamp" : "2020-07-12T00:30:51Z", | ||
"briefDesignDescription" : "Cisatracurium NM blockade in ARDS", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1901686", | |||
"subspecialties" : "Critical Care", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901686" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Infectious Disease;Urology;Gynecology", | ||
"fulltexturl" : "https://doi.org/10.1001/jamainternmed.2018.4204", | |||
"briefDesignDescription" : "Water intake to prevent UTI", | "briefDesignDescription" : "Water intake to prevent UTI", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "pmid" : "30285042", | ||
"statusUsableDate" : "2019-09-15", | "statusUsableDate" : "2019-09-15", | ||
" | "title" : "Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections", | ||
"timestamp" : "2022-12-01T20:14:11Z", | |||
"published" : "2018-10-01", | "published" : "2018-10-01", | ||
"abbreviation" : "", | |||
"briefResultsDescription" : "Drinking more water reduces recurrent UTIs in premenopausal women", | |||
"diseases" : "Urinary Tract Infections", | |||
"pageName" : "S-HYDRACYST", | "pageName" : "S-HYDRACYST", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "", | ||
" | "citation" : "Hooton TM, <i>et al</i>. \"Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections\". <i>JAMA Internal Medicine</i>. 2018. 178(11):1509-1515.", | ||
" | "pageid" : 4072 | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Sertraline Antidepressant Heart Attack Randomized Trial", | ||
" | "citation" : "Glassman AH, <i>et al</i>. \"Sertraline treatment of major depression in patients with acute MI or unstable angina\". <i>Journal of the American Medical Association</i>. 2002. 288(6):701-709.", | ||
"pageid" : 423, | "pageid" : 423, | ||
" | "pageName" : "SADHART", | ||
"briefResultsDescription" : "Sertraline improves symptoms without adverse CV effects", | |||
"diseases" : "Depression;Acute Coronary Syndrome", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Sertraline treatment of major depression in patients with acute MI or unstable angina", | ||
"statusUsableDate" : "2012-05-01", | "statusUsableDate" : "2012-05-01", | ||
" | "pmid" : "12169073", | ||
"abbreviation" : "SADHAT", | |||
"timestamp" : "2018-09-04T17:00:07Z", | |||
"published" : "2002-08-14", | "published" : "2002-08-14", | ||
" | "briefDesignDescription" : "Sertraline for depression post-ACS", | ||
" | "subspecialties" : "Psychiatry;Cardiology", | ||
" | "fulltexturl" : "http://jama.ama-assn.org/content/288/6/701.full", | ||
" | "pdfurl" : "http://jama.ama-assn.org/content/288/6/701.full.pdf" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "SAFE", | ||
"diseases" : "Critical Illness", | |||
"briefResultsDescription" : "No mortality difference (except worse mortality with albumin for TBI)", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Saline versus Albumin Fluid Evaluation", | |||
"pageid" : 285, | |||
"citation" : "Finfer S, <i>et al</i>. \"A comparison of albumin and saline for fluid resuscitation in the intensive care unit\". <i>The New England Journal of Medicine</i>. 2004. 350(22):2247-2256.", | |||
"briefDesignDescription" : "Albumin vs. saline in ICU", | "briefDesignDescription" : "Albumin vs. saline in ICU", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa040232", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa040232", | ||
" | "subspecialties" : "Critical Care", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa040232", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa040232", | ||
" | "title" : "A comparison of albumin and saline for fluid resuscitation in the intensive care unit", | ||
"pmid" : "15163774", | |||
" | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "abbreviation" : "SAFE", | ||
"published" : "2004-05-27", | "published" : "2004-05-27", | ||
" | "timestamp" : "2017-01-19T20:07:27Z" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Saline Against Lactated Ringer's or Plasma-Lyte in the Emergency Department", | ||
"pageid" : 3556, | "pageid" : 3556, | ||
"citation" : "Self WH, <i>et al</i>. \"Balanced crystalloids versus saline in noncritically ill adults\". <i>The New England Journal of Medicine</i>. 2018. 378(10):819-828.", | "citation" : "Self WH, <i>et al</i>. \"Balanced crystalloids versus saline in noncritically ill adults\". <i>The New England Journal of Medicine</i>. 2018. 378(10):819-828.", | ||
" | "pageName" : "SALT-ED", | ||
" | "diseases" : "Hypovolemia;Acute Kidney Injury", | ||
"briefResultsDescription" : "Balanced crystalloids result in fewer renal abnormalities", | |||
"trainingLevel" : "Student", | |||
"title" : "Balanced crystalloids versus saline in noncritically ill adults", | |||
"pmid" : "29485926", | |||
"statusUsableDate" : "2018-04-05", | "statusUsableDate" : "2018-04-05", | ||
" | "abbreviation" : "SALT-ED", | ||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
" | "timestamp" : "2018-04-05T18:17:47Z", | ||
" | "briefDesignDescription" : "Balanced crystalloids vs. NS in non-critical ED patients", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711586", | ||
" | "subspecialties" : "Critical Care;Nephrology", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711586" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Stenting in intracranial stenosis", | "briefDesignDescription" : "Stenting in intracranial stenosis", | ||
"subspecialties" : "Neurology;Interventional Radiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335", | "fulltexturl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/nejmoa1105335", | ||
" | "title" : "Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis", | ||
"pmid" : "24168957", | |||
" | |||
"statusUsableDate" : "2016-03-01", | "statusUsableDate" : "2016-03-01", | ||
" | "abbreviation" : "SAMMPRIS", | ||
"timestamp" : "2019-06-27T16:40:34Z", | |||
"published" : "2011-09-15", | "published" : "2011-09-15", | ||
"pageName" : "SAMMPRIS", | "pageName" : "SAMMPRIS", | ||
"briefResultsDescription" : "Medical therapy superior to stenting in IC stenosis", | |||
"diseases" : "Stroke", | "diseases" : "Stroke", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "", | ||
" | "citation" : "Chimowitz MI, <i>et al</i>. \"Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis\". <i>The New England Journal of Medicine</i>. 2015. 365(11):993-1003.", | ||
"pageid" : 2420 | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Survival and Ventricular Enlargement Trial", | ||
"pageid" : 150, | "pageid" : 150, | ||
" | "citation" : "Pfeffer MA, <i>et al</i>. \"Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial\". <i>The New England Journal of Medicine</i>. 1992. 327(10):669-677.", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction;Heart Failure", | |||
"briefResultsDescription" : "Captopril improves survival", | |||
"pageName" : "SAVE", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pmid" : "1386652", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial", | ||
"published" : "1992-09-03", | "published" : "1992-09-03", | ||
" | "timestamp" : "2015-08-24T04:52:18Z", | ||
"abbreviation" : "SAVE", | "abbreviation" : "SAVE", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199209033271001", | ||
" | "subspecialties" : "Cardiology", | ||
"briefDesignDescription" : "Captopril in MI with LV dysfunction", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199209033271001" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Sudden Cardiac Death in Heart Failure Trial", | ||
" | "citation" : "Bardy GH, <i>et al</i>. \"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure\". <i>The New England Journal of Medicine</i>. 2005. 252(3):225-37.", | ||
"pageid" : 40, | "pageid" : 40, | ||
" | "briefResultsDescription" : "ICD reduces mortality by 23% in class II-III HFrEF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "SCD-HeFT", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "15659722", | ||
" | "title" : "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", | ||
" | "timestamp" : "2019-05-16T20:18:55Z", | ||
"published" : "2005-01-20", | "published" : "2005-01-20", | ||
"abbreviation" : "SCD-HeFT", | "abbreviation" : "SCD-HeFT", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa043399", | ||
"briefDesignDescription" : "Amiodarone or ICD in severe HFrEF", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043399" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Dexmedetomidine vs. midazolam for sedation", | "briefDesignDescription" : "Dexmedetomidine vs. midazolam for sedation", | ||
"fulltexturl" : "http://jama.ama-assn.org/content/301/5/489.long", | "fulltexturl" : "http://jama.ama-assn.org/content/301/5/489.long", | ||
" | "subspecialties" : "Critical Care", | ||
"pdfurl" : "http://jama.ama-assn.org/content/301/5/489.full.pdf", | "pdfurl" : "http://jama.ama-assn.org/content/301/5/489.full.pdf", | ||
" | "title" : "Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients", | ||
"pmid" : "19188334", | |||
" | |||
"statusUsableDate" : "2012-04-01", | "statusUsableDate" : "2012-04-01", | ||
" | "abbreviation" : "SEDCOM", | ||
"published" : "2009-02-04", | "published" : "2009-02-04", | ||
"timestamp" : "2021-02-14T17:21:07Z", | |||
"pageName" : "SEDCOM", | "pageName" : "SEDCOM", | ||
"diseases" : "Critical Illness", | "diseases" : "Critical Illness", | ||
" | "briefResultsDescription" : "↓ delirium, ↓ ventilator days with dexmedetomidine", | ||
" | "trainingLevel" : "Resident", | ||
"expansion" : "Safety and Efficacy of Dexmedetomidine Compared with Midazolam", | |||
"pageid" : 353, | |||
"citation" : "Riker RR, <i>et al</i>. \"Dexmedetomidine vs. Midazolam for Sedation of Critically Ill Patients\". <i>Journal of American Medical Association</i>. 2009. 301(5):489-499." | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Rivaroxaban noninferior to dalteparin in cancer VTE", | ||
"diseases" : "Venous Thromboembolism;Pulmonary Embolism;Deep Vein Thrombosis", | |||
" | "pageName" : "SELECT-D", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism", | |||
"citation" : "Young AM, <i>et al</i>. \"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)\". <i>Journal of Clinical Oncology</i>. 2018. 36(20):2017-23.", | "citation" : "Young AM, <i>et al</i>. \"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)\". <i>Journal of Clinical Oncology</i>. 2018. 36(20):2017-23.", | ||
"pageid" : 3717, | |||
"subspecialties" : "Hematology;Oncology", | "subspecialties" : "Hematology;Oncology", | ||
" | "fulltexturl" : "http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8034", | ||
"briefDesignDescription" : "Rivaroxaban vs. LMWH in cancer VTE", | |||
"pdfurl" : "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.78.8034", | |||
"pmid" : "29746227", | |||
"statusUsableDate" : "2018-12-20", | "statusUsableDate" : "2018-12-20", | ||
" | "title" : "Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)", | ||
"timestamp" : "2024-08-29T19:21:15Z", | |||
"published" : "2018-07-10", | "published" : "2018-07-10", | ||
"abbreviation" : "SELECT-D" | |||
"abbreviation" : "SELECT-D | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Critical Care", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1312173", | |||
"briefDesignDescription" : "MAP 65-70 vs. 80-85 mmHg in sepsis", | "briefDesignDescription" : "MAP 65-70 vs. 80-85 mmHg in sepsis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1312173", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1312173", | ||
" | "pmid" : "24635770", | ||
"statusUsableDate" : "2014-04-01", | "statusUsableDate" : "2014-04-01", | ||
" | "title" : "High versus low blood-pressure target in patients with septic shock", | ||
"timestamp" : "2019-04-24T01:13:29Z", | |||
"published" : "2014-04-23", | "published" : "2014-04-23", | ||
"abbreviation" : "SEPSISPAM", | |||
"briefResultsDescription" : "No difference for higher MAP in sepsis except renal protection in vascular disease", | |||
"diseases" : "Sepsis;Shock", | |||
"pageName" : "SEPSISPAM", | "pageName" : "SEPSISPAM", | ||
" | "trainingLevel" : "Resident", | ||
" | "expansion" : "Sepsis and Mean Arterial Pressure", | ||
" | "citation" : "Asfar P, <i>et al</i>. \"High versus low blood-pressure target in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2014. 370(17):1583-1593.", | ||
" | "pageid" : 1779 | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Swedberg K <i>et al</i>. \"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study\". <i>Lancet</i>. 2010. 376(10):875-885.", | ||
"pageid" : 2735, | "pageid" : 2735, | ||
" | "expansion" : "Systolic Heart failure treatment with the If inhibitor ivabradine Trial", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "Ivabradine improves mortality and heart failure hospitalization in HFrEF", | "briefResultsDescription" : "Ivabradine improves mortality and heart failure hospitalization in HFrEF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "SHIFT", | |||
"timestamp" : "2017-12-03T22:39:10Z", | |||
"published" : "2010-09-11", | "published" : "2010-09-11", | ||
"abbreviation" : "SHIFT", | "abbreviation" : "SHIFT", | ||
"pmid" : "20801500", | |||
"statusUsableDate" : "2016-05-01", | |||
"title" : "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study", | "title" : "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study", | ||
" | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(10)61198-1.pdf", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0140673610611981", | |||
"briefDesignDescription" : "Ivabradine in HFrEF" | |||
}, | }, | ||
{ | { | ||
"pageid" : 388, | "pageid" : 388, | ||
"citation" : "Hochman JS, <i>et al</i>. \"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 1999. 341(9):625-634.", | "citation" : "Hochman JS, <i>et al</i>. \"Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock\". <i>The New England Journal of Medicine</i>. 1999. 341(9):625-634.", | ||
"expansion" : "SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK", | "expansion" : "SHould we emergently revascularize Occluded Coronaries for Cardiogenic shocK", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Acute Coronary Syndrome;Myocardial Infarction;Shock", | |||
"briefResultsDescription" : "Early PCI/CABG improves survival in acute MI and cardiogenic shock", | "briefResultsDescription" : "Early PCI/CABG improves survival in acute MI and cardiogenic shock", | ||
"pageName" : "SHOCK", | |||
"published" : "1999-08-26", | "published" : "1999-08-26", | ||
" | "timestamp" : "2017-12-03T22:39:12Z", | ||
"abbreviation" : "SHOCK", | "abbreviation" : "SHOCK", | ||
"statusUsableDate" : "2012-04-01", | |||
"pmid" : "10460813", | |||
"title" : "Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock", | "title" : "Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199908263410901", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199908263410901", | |||
"subspecialties" : "Cardiology;Critical Care", | |||
"briefDesignDescription" : "Early PCI/CABG in MI + shock" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Salmeterol increases death in subgroups", | ||
"diseases" : "Asthma", | |||
" | "pageName" : "SMART", | ||
" | |||
"trainingLevel" : "intern", | "trainingLevel" : "intern", | ||
"expansion" : "Salmeterol Multicenter Asthma Research Trial", | |||
"citation" : "Nelson HS, <i>et al</i>. \"The salmeterol multicenter asthma research trial\". <i>Chest</i>. 2006. 129(1):15-26.", | "citation" : "Nelson HS, <i>et al</i>. \"The salmeterol multicenter asthma research trial\". <i>Chest</i>. 2006. 129(1):15-26.", | ||
"pageid" : 512, | |||
"subspecialties" : "Pulmonology", | "subspecialties" : "Pulmonology", | ||
" | "fulltexturl" : "http://bit.ly/1VSBfoL", | ||
"briefDesignDescription" : "Salmeterol in asthma", | |||
"pdfurl" : "http://journal.publications.chestnet.org/data/Journals/CHEST/22038/15.pdf", | |||
"pmid" : "16424409", | |||
"statusUsableDate" : "2012-08-01", | "statusUsableDate" : "2012-08-01", | ||
" | "title" : "The salmeterol multicenter asthma research trial", | ||
"timestamp" : "2017-12-03T22:39:13Z", | |||
"published" : "2006-01-01", | "published" : "2006-01-01", | ||
"abbreviation" : "SMART" | |||
"abbreviation" : "SMART | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "NS vs. balanced crystalloids in ICU", | "briefDesignDescription" : "NS vs. balanced crystalloids in ICU", | ||
"subspecialties" : "Critical Care;Nephrology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711584", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711584", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711584", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711584", | ||
" | "title" : "Balanced Crystalloids versus Saline in Critically Ill Adults", | ||
"statusUsableDate" : "2018-04-05", | "statusUsableDate" : "2018-04-05", | ||
" | "pmid" : "29485925", | ||
"abbreviation" : "SMART", | |||
"timestamp" : "2018-04-05T17:39:53Z", | |||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
"pageName" : "SMART-MED and SMART-SURG", | "pageName" : "SMART-MED and SMART-SURG", | ||
"briefResultsDescription" : "Balanced crystalloids slightly reduced composite rate of death, RRT, or CKD", | |||
"diseases" : "Critical Illness", | "diseases" : "Critical Illness", | ||
" | "trainingLevel" : "student", | ||
" | "expansion" : "Isotonic Solutions and Major Adverse Renal Events Trial", | ||
" | "citation" : "Semler MW, <i>et al</i>. \"Balanced Crystalloids versus Saline in Critically Ill Adults\". <i>The New England Journal of Medicine</i>. 2018. 378(9):829-839.", | ||
"pageid" : 3555 | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "20200382", | |||
"title" : "Comparison of dopamine and norepinephrine in the treatment of shock", | |||
"timestamp" : "2017-01-19T19:50:29Z", | "timestamp" : "2017-01-19T19:50:29Z", | ||
"published" : "2010-03-04", | |||
"abbreviation" : "SOAP II", | |||
"subspecialties" : "Critical Care;Emergency Medicine", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0907118", | |||
"briefDesignDescription" : "Dopamine vs. norepinephrine in shock", | "briefDesignDescription" : "Dopamine vs. norepinephrine in shock", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907118", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907118", | ||
" | "expansion" : "Sepsis Occurrence in Acutely Ill Patients II", | ||
"citation" : "De Backer D, <i>et al</i>. \"Comparison of dopamine and norepinephrine in the treatment of shock\". <i>The New England Journal of Medicine</i>. 2010. 362(9):779-89.", | "citation" : "De Backer D, <i>et al</i>. \"Comparison of dopamine and norepinephrine in the treatment of shock\". <i>The New England Journal of Medicine</i>. 2010. 362(9):779-89.", | ||
" | "pageid" : 113, | ||
"briefResultsDescription" : "Norepinephrine reduces mortality", | "briefResultsDescription" : "Norepinephrine reduces mortality", | ||
" | "diseases" : "Sepsis;Shock", | ||
"pageName" : "SOAP II", | "pageName" : "SOAP II", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2016-10-01", | |||
"pmid" : "27160892", | |||
"title" : "Ticagrelor versus aspirin in acute stroke or transient ischemic attack", | |||
"timestamp" : "2017-12-03T22:39:15Z", | "timestamp" : "2017-12-03T22:39:15Z", | ||
"published" : "2016-07-07", | |||
"abbreviation" : "SOCRATES", | |||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1603060", | |||
"briefDesignDescription" : "Ticagrelor vs. aspirin in acute stroke or TIA", | "briefDesignDescription" : "Ticagrelor vs. aspirin in acute stroke or TIA", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603060", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1603060", | ||
" | "expansion" : "Ticagrelor versus aspirin in stroke/TIA", | ||
"citation" : "Johnston SC, <i>et al</i>. \"Ticagrelor versus aspirin in acute stroke or transient ischemic attack\". <i>New Engl J Med</i>. 2016. 365(1):35-43.", | "citation" : "Johnston SC, <i>et al</i>. \"Ticagrelor versus aspirin in acute stroke or transient ischemic attack\". <i>New Engl J Med</i>. 2016. 365(1):35-43.", | ||
" | "pageid" : 2809, | ||
"briefResultsDescription" : "Ticagrelor not superior to aspirin in acute stroke or TIA", | "briefResultsDescription" : "Ticagrelor not superior to aspirin in acute stroke or TIA", | ||
" | "diseases" : "Stroke", | ||
"pageName" : "SOCRATES", | "pageName" : "SOCRATES", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"pageid" : 394, | "pageid" : 394, | ||
"citation" : "Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.", | "citation" : "Yusuf S, <i>et al</i>. \"Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):293-302.", | ||
"expansion" : "Studies of Left Ventricular Dysfunction", | "expansion" : "Studies of Left Ventricular Dysfunction", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "Enalapril reduces mortality and HF hospitalizations in HFrEF", | "briefResultsDescription" : "Enalapril reduces mortality and HF hospitalizations in HFrEF", | ||
"pageName" : "SOLVD", | |||
"published" : "1991-08-01", | "published" : "1991-08-01", | ||
" | "timestamp" : "2017-12-03T22:39:16Z", | ||
"abbreviation" : "SOLVD", | "abbreviation" : "SOLVD", | ||
"statusUsableDate" : "2012-04-01", | |||
"pmid" : "2057034", | |||
"title" : "Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure", | "title" : "Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250501", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199108013250501", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Enalapril in moderate-severe HFrEF" | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "No benefit over age-appropriate screening", | ||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | |||
" | "pageName" : "SOME", | ||
" | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"expansion" : "", | |||
"citation" : "Carrier M, <i>et al</i>. \"Screening for Occult Cancer in Unprovoked Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2015. 373(8):697-704.", | "citation" : "Carrier M, <i>et al</i>. \"Screening for Occult Cancer in Unprovoked Venous Thromboembolism\". <i>The New England Journal of Medicine</i>. 2015. 373(8):697-704.", | ||
"pageid" : 2498, | |||
"subspecialties" : "Oncology;Hematology", | "subspecialties" : "Oncology;Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1506623", | ||
"briefDesignDescription" : "Occult cancer screening in unprovoked VTE", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1506623", | |||
"statusUsableDate" : "2018-08-30", | "statusUsableDate" : "2018-08-30", | ||
" | "pmid" : "26095467", | ||
"title" : "Screening for Occult Cancer in Unprovoked Venous Thromboembolism", | |||
"timestamp" : "2018-08-30T18:21:05Z", | |||
"published" : "2015-08-20", | "published" : "2015-08-20", | ||
"abbreviation" : "SOME" | |||
"abbreviation" : "SOME | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Gastroenterology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0904492", | |||
"briefDesignDescription" : "Infliximab ± azathioprine induction in Crohn disease", | "briefDesignDescription" : "Infliximab ± azathioprine induction in Crohn disease", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904492", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0904492", | ||
"statusUsableDate" : "2014-07-01", | "statusUsableDate" : "2014-07-01", | ||
"pmid" : "20393175", | |||
"title" : "Infliximab, azathioprine, or combination therapy for Crohn's disease", | |||
"timestamp" : "2017-12-03T22:39:17Z", | |||
"published" : "2010-04-15", | |||
"abbreviation" : "SONIC", | |||
"briefResultsDescription" : "Combination therapy better than infliximab or azathioprine for Crohn disease induction therapy", | "briefResultsDescription" : "Combination therapy better than infliximab or azathioprine for Crohn disease induction therapy", | ||
" | "diseases" : "Inflammatory Bowel Disease;Crohn Disease", | ||
"pageName" : "SONIC", | "pageName" : "SONIC", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease", | ||
" | "citation" : "Colombel JF, <i>et al</i>. \"Infliximab, azathioprine, or combination therapy for Crohn's disease\". <i>The New England Journal of Medicine</i>. 2010. 362(15):1383-1395.", | ||
" | "pageid" : 1863 | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Opioids without benefit over non-opioid management for chronic MSK pain", | ||
"diseases" : "Chronic Pain", | |||
" | "pageName" : "SPACE", | ||
" | |||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
"expansion" : "Strategies for Prescribing Analgesics Comparative Effectiveness", | |||
"citation" : "Krebs EE, <i>et al</i>. \"Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain\". <i>JAMA</i>. 2018. 319(9):872-882.", | "citation" : "Krebs EE, <i>et al</i>. \"Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain\". <i>JAMA</i>. 2018. 319(9):872-882.", | ||
"pageid" : 3620, | |||
"subspecialties" : "Emergency Medicine;Pain Medicine", | "subspecialties" : "Emergency Medicine;Pain Medicine", | ||
" | "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2018.0899", | ||
"briefDesignDescription" : "Opioids vs. non-opioids in chronic MSK pain", | |||
"pdfurl" : "", | |||
"pmid" : "29509867", | |||
"statusUsableDate" : "2019-06-27", | "statusUsableDate" : "2019-06-27", | ||
" | "title" : "Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain", | ||
"timestamp" : "2019-06-28T16:43:02Z", | |||
"published" : "2018-06-03", | "published" : "2018-06-03", | ||
"abbreviation" : "SPACE" | |||
"abbreviation" : "SPACE | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://circ.ahajournals.org/content/84/2/527.full.pdf", | ||
"briefDesignDescription" : "Aspirin and warfarin in AF", | "briefDesignDescription" : "Aspirin and warfarin in AF", | ||
"fulltexturl" : "http://circ.ahajournals.org/content/84/2/527.long", | "fulltexturl" : "http://circ.ahajournals.org/content/84/2/527.long", | ||
"subspecialties" : "Cardiology;Neurology", | "subspecialties" : "Cardiology;Neurology", | ||
" | "abbreviation" : "SPAF", | ||
"published" : "1991-08-01", | |||
"timestamp" : "2017-12-03T22:39:18Z", | |||
"title" : "Stroke Prevention in Atrial Fibrillation Study. Final results", | |||
"pmid" : "1860198", | |||
"statusUsableDate" : "2016-08-01", | "statusUsableDate" : "2016-08-01", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "SPAF", | "pageName" : "SPAF", | ||
"diseases" : "Atrial Fibrillation;Stroke", | "diseases" : "Atrial Fibrillation;Stroke", | ||
" | "briefResultsDescription" : "Aspirin and warfarin reduce stroke incidence in AF", | ||
" | "pageid" : 2340, | ||
" | "citation" : "SPAF Investigators. \"Stroke Prevention in Atrial Fibrillation Study. Final results\". <i>Circulation</i>. 1991. 84(2):527-39.", | ||
"expansion" : "Stroke Prevention in Atrial Fibrillation" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "intern", | ||
" | "pageName" : "SPARCL", | ||
" | "briefResultsDescription" : "Atorvastatin ↓stroke risk in general but slightly ↑hemorrhagic strokes", | ||
"diseases" : "Stroke;Hyperlipidemia;Transient Ischemic Attack", | |||
"citation" : "Amarenco P, <i>et al</i>. \"High-dose atorvastatin after stroke or transient ischemic attack\". <i>The New England Journal of Medicine</i>. 2006. 355(6):549-559.", | |||
"pageid" : 461, | "pageid" : 461, | ||
"expansion" : "Stroke Prevention by Aggressive Reduction in Cholesterol Levels", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa061894", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa061894", | ||
" | "briefDesignDescription" : "Atorvastatin after stroke", | ||
"subspecialties" : "Neurology", | "subspecialties" : "Neurology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa061894", | ||
" | "abbreviation" : "SPARCL", | ||
" | "timestamp" : "2017-12-03T22:39:20Z", | ||
"published" : "2006-08-10", | "published" : "2006-08-10", | ||
"title" : "High-dose atorvastatin after stroke or transient ischemic attack", | "title" : "High-dose atorvastatin after stroke or transient ischemic attack", | ||
"statusUsableDate" : "2012-06-01", | |||
"pmid" : "16899775" | "pmid" : "16899775" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Sedation Practice in Intensive Care Evaluation", | ||
" | "citation" : "Shehabi Y, <i>et al</i>. \"Early Sedation with Dexmedetomidine in Critically Ill Patients\". <i>The New England Journal of Medicine</i>. 2019. 380(26):2506-2517.", | ||
"pageid" : 4073, | "pageid" : 4073, | ||
" | "briefResultsDescription" : "Dexmedetomidine with more adverse events vs. usual care", | ||
"diseases" : "Sedation;Delirium", | |||
"pageName" : "SPICE III", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pmid" : "31112380", | ||
"statusUsableDate" : "2020-05-14", | "statusUsableDate" : "2020-05-14", | ||
" | "title" : "Early Sedation with Dexmedetomidine in Critically Ill Patients", | ||
"timestamp" : "2021-10-26T13:55:55Z", | |||
"published" : "2019-05-19", | "published" : "2019-05-19", | ||
"abbreviation" : "SPICE III", | "abbreviation" : "SPICE III", | ||
" | "subspecialties" : "Critical Care", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1904710", | ||
"briefDesignDescription" : "Dexmedetomidine in ICU sedation", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1904710?articleTools" | |||
}, | }, | ||
{ | { | ||
"pmid" : "26551272", | |||
"statusUsableDate" : "2015-11-01", | |||
"title" : "A randomized trial of intensive versus standard blood-pressure control", | |||
"published" : "2015-11-09", | |||
"timestamp" : "2024-12-12T20:30:17Z", | "timestamp" : "2024-12-12T20:30:17Z", | ||
"abbreviation" : "SPRINT", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1511939", | |||
"subspecialties" : "Cardiology;Preventive Medicine", | |||
"briefDesignDescription" : "BP targets in high-risk patients", | "briefDesignDescription" : "BP targets in high-risk patients", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1511939", | ||
"expansion" : "Systolic Blood Pressure Intervention Trial", | |||
"pageid" : 2487, | "pageid" : 2487, | ||
"citation" : "The SPRINT Research Group. \"A randomized trial of intensive versus standard blood-pressure control\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2103-2116.", | "citation" : "The SPRINT Research Group. \"A randomized trial of intensive versus standard blood-pressure control\". <i>The New England Journal of Medicine</i>. 2015. 373(22):2103-2116.", | ||
" | "diseases" : "Hypertension", | ||
"briefResultsDescription" : "SBP <120 improves CV outcomes with increased risks", | "briefResultsDescription" : "SBP <120 improves CV outcomes with increased risks", | ||
"pageName" : "SPRINT", | "pageName" : "SPRINT", | ||
" | "trainingLevel" : "Student" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "SPS3-Clopidogrel+ASA", | |||
"timestamp" : "2017-12-03T22:39:22Z", | "timestamp" : "2017-12-03T22:39:22Z", | ||
"published" : "2012-08-30", | |||
"title" : "Effects of clopidogrel added to aspirin in patients with recent lacunar stroke", | |||
"pmid" : "22931315", | |||
"statusUsableDate" : "2016-06-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1204133", | |||
"briefDesignDescription" : "Clopidogrel+ASA for lacunar strokes", | "briefDesignDescription" : "Clopidogrel+ASA for lacunar strokes", | ||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1204133", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1204133", | ||
"citation" : "SPS3 Study Group writers. \"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke\". <i>New England Journal of Medicine</i>. 2012. 367(9):817-825.", | |||
"pageid" : 2678, | "pageid" : 2678, | ||
" | "expansion" : "Secondary Prevention of Small Subcortical Strokes clopidogrel+ASA", | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "SPS3 Clopidogrel-ASA", | ||
"briefResultsDescription" : "Clopidogrel+ASA increased all cause mortality compared to ASA alone", | "briefResultsDescription" : "Clopidogrel+ASA increased all cause mortality compared to ASA alone", | ||
"diseases" : "Stroke;Transient Ischemic Attack" | |||
"diseases" : "Stroke;Transient Ischemic Attack | |||
}, | }, | ||
{ | { | ||
"published" : "2013-05-29", | |||
"timestamp" : "2017-12-03T22:39:24Z", | "timestamp" : "2017-12-03T22:39:24Z", | ||
" | "abbreviation" : "SPS3-BP", | ||
"statusUsableDate" : "2016-01-01", | |||
"pmid" : "23726159", | |||
"title" : "Blood-pressure targets in patients with recent lacunar stroke", | |||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(13)60852-1.pdf", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60852-1/abstract", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60852-1/abstract", | ||
"subspecialties" : "Neurology", | |||
"briefDesignDescription" : "SBP <130 vs. SBP 130-150 after lacunar strokes", | |||
"pageid" : 2671, | "pageid" : 2671, | ||
"citation" : "SPS3 Study Group. \"Blood-pressure targets in patients with recent lacunar stroke\". <i>The Lancet</i>. 2013. 382(9891):507-515.", | "citation" : "SPS3 Study Group. \"Blood-pressure targets in patients with recent lacunar stroke\". <i>The Lancet</i>. 2013. 382(9891):507-515.", | ||
"expansion" : "Secondary Prevention of Small Subcortical Strokes-Blood Pressure", | "expansion" : "Secondary Prevention of Small Subcortical Strokes-Blood Pressure", | ||
" | "trainingLevel" : "Intern", | ||
"diseases" : "Stroke", | |||
"briefResultsDescription" : "No significant difference in all stroke types between two groups", | "briefResultsDescription" : "No significant difference in all stroke types between two groups", | ||
"pageName" : "SPS3-BP" | |||
"pageName" : "SPS3-BP | |||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Renal denervation+meds is superior to medical therapy alone in resistant hypertension", | ||
"diseases" : "Hypertension", | |||
" | "pageName" : "SPYRAL HTN-ON MED", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy", | |||
"citation" : "Kandazi DE, <i>et al</i>. \"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs\". <i>The Lancet</i>. 2018. 391:2346-55.", | "citation" : "Kandazi DE, <i>et al</i>. \"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs\". <i>The Lancet</i>. 2018. 391:2346-55.", | ||
"pageid" : 3642, | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30951-6/fulltext", | ||
"briefDesignDescription" : "Renal denervation in resistant hypertension", | |||
"pdfurl" : "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(18)30951-6.pdf", | |||
"statusUsableDate" : "2018-06-12", | "statusUsableDate" : "2018-06-12", | ||
" | "pmid" : "29803589", | ||
"title" : "Effect of renal denervation on blood pressure in the presence of antihypertensive drugs", | |||
"timestamp" : "2018-06-29T18:11:38Z", | |||
"published" : "2018-06-09", | "published" : "2018-06-09", | ||
"abbreviation" : "SPYRAL HTN-ON MED" | |||
"abbreviation" : "SPYRAL HTN-ON MED | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "STAMPEDE", | ||
"diseases" : "Diabetes Mellitus;Obesity", | |||
"briefResultsDescription" : "Bypass plus medical therapy is superior to medical therapy alone", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently", | |||
"pageid" : 2266, | |||
"citation" : "Schauer PR, <i>et al</i>. \"Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes\". <i>The New England Journal of Medicine</i>. 2012. 366(17):1567-76.", | |||
"briefDesignDescription" : "Gastric bypass vs. medical therapy for T2DM", | "briefDesignDescription" : "Gastric bypass vs. medical therapy for T2DM", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200225", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1200225", | ||
" | "subspecialties" : "Endocrinology;Surgery", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200225", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1200225", | ||
" | "title" : "Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes", | ||
"statusUsableDate" : "2015-01-01", | "statusUsableDate" : "2015-01-01", | ||
" | "pmid" : "22449319", | ||
"abbreviation" : "STAMPEDE", | |||
"published" : "2012-04-26", | "published" : "2012-04-26", | ||
" | "timestamp" : "2017-12-03T22:39:25Z" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Study of Tamoxifen and Raloxifene (NSABP P-2)", | ||
"pageid" : 963, | "pageid" : 963, | ||
" | "citation" : "Vogel VG, <i>et al</i>. \"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes\". <i>Journal of the American Medical Association</i>. 2006. 295(23):2727-2741.", | ||
"diseases" : "Breast Cancer", | |||
"briefResultsDescription" : "Similar reduction in breast cancer risk but fewer adverse effects with raloxifene", | |||
"pageName" : "STAR", | |||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"statusUsableDate" : "2012-08-01", | "statusUsableDate" : "2012-08-01", | ||
" | "pmid" : "16754727", | ||
"title" : "Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes", | |||
"published" : "2006-06-21", | "published" : "2006-06-21", | ||
" | "timestamp" : "2017-12-03T22:39:26Z", | ||
"abbreviation" : "STAR", | "abbreviation" : "STAR", | ||
" | "fulltexturl" : "http://jama.jamanetwork.com/article.aspx?articleid", | ||
" | "subspecialties" : "Oncology", | ||
"briefDesignDescription" : "Tamoxifen vs. raloxifene in breast cancer prevention", | |||
"pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/5028/JOC60074.pdf" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Sequenced Treatment Alternatives to Relieve Depression", | ||
" | "citation" : "Rush AJ <i>et al</i>. \"Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report\". <i>The American Journal of Psychiatry</i>. 2006. 163(11):1905-1917.", | ||
"pageid" : 1564, | "pageid" : 1564, | ||
" | "briefResultsDescription" : "Most patients achieved remission in first two steps", | ||
"diseases" : "Depression", | |||
"pageName" : "STAR-D", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2013-09-01", | "statusUsableDate" : "2013-09-01", | ||
" | "pmid" : "17074942", | ||
"title" : "Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report", | |||
"timestamp" : "2017-12-03T22:39:27Z", | |||
"published" : "2006-11-01", | "published" : "2006-11-01", | ||
"abbreviation" : "STAR-D", | "abbreviation" : "STAR-D", | ||
" | "subspecialties" : "Psychiatry", | ||
" | "fulltexturl" : "", | ||
"briefDesignDescription" : "Tiered approach for depression", | |||
"pdfurl" : "http://ajp.psychiatryonline.org/data/Journals/AJP/3782/06aj1905.PDF" | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients", | ||
" | "citation" : "Zhang W, <i>et al</i>. \"Trial of intensive blood-pressure control in older patients with hypertension\". <i>The New England Journal of Medicine</i>. 2021. 385(14):1268-1279.", | ||
"pageid" : 4446, | "pageid" : 4446, | ||
" | "pageName" : "STEP", | ||
"briefResultsDescription" : "Intensive BP control lowers CVD events", | |||
"diseases" : "Hypertension", | |||
"trainingLevel" : "student", | "trainingLevel" : "student", | ||
" | "title" : "Trial of intensive blood-pressure control in older patients with hypertension", | ||
"statusUsableDate" : "2021-11-30", | "statusUsableDate" : "2021-11-30", | ||
" | "pmid" : "34491661", | ||
"abbreviation" : "STEP", | |||
"timestamp" : "2023-02-04T04:10:40Z", | |||
"published" : "2021-09-30", | "published" : "2021-09-30", | ||
" | "briefDesignDescription" : "Intensive BP control hypertension", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2111437", | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2111437" | ||
}, | }, | ||
{ | { | ||
"title" : "Once-Weekly Semaglutide in Adults with Overweight or Obesity", | |||
"statusUsableDate" : "2021-04-22", | |||
"pmid" : "33567185", | |||
"abbreviation" : "STEP 1", | |||
"timestamp" : "2023-11-11T23:27:35Z", | "timestamp" : "2023-11-11T23:27:35Z", | ||
"published" : "2021-03-18", | |||
"briefDesignDescription" : "Semaglutide in obesity without diabetes", | "briefDesignDescription" : "Semaglutide in obesity without diabetes", | ||
"subspecialties" : "Endocrinology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2032183", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2032183", | ||
" | "expansion" : "Semaglutide Treatment Effect in People with Obesity 1", | ||
"citation" : "Wilding JPH, <i>et al</i>. \"Once-Weekly Semaglutide in Adults with Overweight or Obesity\". <i>The New England Journal of Medicine</i>. 2021. 384(11):989-1002.", | "citation" : "Wilding JPH, <i>et al</i>. \"Once-Weekly Semaglutide in Adults with Overweight or Obesity\". <i>The New England Journal of Medicine</i>. 2021. 384(11):989-1002.", | ||
" | "pageid" : 4407, | ||
" | "pageName" : "STEP 1", | ||
"briefResultsDescription" : "Semaglutide led to significant weight loss vs. placebo", | "briefResultsDescription" : "Semaglutide led to significant weight loss vs. placebo", | ||
"diseases" : "Obesity;Overweight", | "diseases" : "Obesity;Overweight", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "HFpEF;Obesity", | ||
" | "briefResultsDescription" : "Semaglutide better than placebo for HF events in HFpEF+obesity", | ||
" | "pageName" : "STEP-HFpEF", | ||
"trainingLevel" : "student", | |||
"expansion" : "Semaglutide Treatment Effect in People with Heart Failure with Preserved Ejection Fraction", | |||
"pageid" : 5605, | "pageid" : 5605, | ||
"citation" : "Kosiborod MN, <i>et al</i>. \"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity\". <i>The New England Journal of Medicine</i>. 2023. 389(12):1069-1084.", | "citation" : "Kosiborod MN, <i>et al</i>. \"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity\". <i>The New England Journal of Medicine</i>. 2023. 389(12):1069-1084.", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2306963", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Semaglutide in HFpEF+obesity but no DM", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2306963", | |||
"pmid" : "37622681", | |||
"statusUsableDate" : "2025-06-19", | "statusUsableDate" : "2025-06-19", | ||
" | "title" : "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity", | ||
"published" : "2023-08-25", | "published" : "2023-08-25", | ||
" | "timestamp" : "2025-06-19T18:47:05Z", | ||
"abbreviation" : "STEP-HFpEF" | |||
"abbreviation" : "STEP-HFpEF | |||
}, | }, | ||
{ | { | ||
"pmid" : "21463150", | |||
"statusUsableDate" : "2012-12-01", | |||
"title" : "Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction", | |||
"timestamp" : "2017-12-03T22:39:28Z", | "timestamp" : "2017-12-03T22:39:28Z", | ||
"published" : "2011-04-28", | |||
"abbreviation" : "STICH", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1100356", | |||
"briefDesignDescription" : "CABG in ischemic HFrEF", | "briefDesignDescription" : "CABG in ischemic HFrEF", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1100356", | ||
" | "expansion" : "Surgical Treatment for Ischemic Heart Failure", | ||
"citation" : "Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.", | "citation" : "Velazquez EJ, <i>et al</i>. \"Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction\". <i>The New England Journal of Medicine</i>. 2011. 354(17):1607-1616.", | ||
" | "pageid" : 471, | ||
"briefResultsDescription" : "No mortality benefit with CABG vs. OMT though improved CV outcomes", | "briefResultsDescription" : "No mortality benefit with CABG vs. OMT though improved CV outcomes", | ||
" | "diseases" : "Heart Failure;Coronary Artery Disease", | ||
"pageName" : "STICH", | "pageName" : "STICH", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"pageid" : 1664, | "pageid" : 1664, | ||
" | "citation" : "Rummel MJ, <i>et al</i>. \"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial\". <i>The Lancet</i>. 2013. 381(9873):1203-10.", | ||
"expansion" : "Study Group Indolent Lymphomas", | |||
"trainingLevel" : "fellow", | "trainingLevel" : "fellow", | ||
"pageName" : "StiL", | "pageName" : "StiL", | ||
"diseases" : "Lymphoma", | "diseases" : "Lymphoma", | ||
"briefResultsDescription" : "BR superior to R-CHOP in PFS, similar in OS, less toxic", | |||
"abbreviation" : "StiL", | "abbreviation" : "StiL", | ||
"published" : "2013-04-03", | |||
"timestamp" : "2017-12-03T22:39:35Z", | |||
"title" : "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial", | "title" : "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial", | ||
"pmid" : "23433739" | "statusUsableDate" : "2014-06-01", | ||
"pmid" : "23433739", | |||
"pdfurl" : "http://bit.ly/1owpykX", | |||
"briefDesignDescription" : "BR vs. R-CHOP for indolent lymphomas", | |||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61763-2", | |||
"subspecialties" : "Oncology;Hematology" | |||
}, | }, | ||
{ | { | ||
"title" : "Trial of short-course antimicrobial therapy for intraabdominal infection", | |||
"statusUsableDate" : "2020-01-25", | |||
"pmid" : "25992746", | |||
"abbreviation" : "STOP-IT", | |||
"timestamp" : "2020-01-25T15:49:52Z", | "timestamp" : "2020-01-25T15:49:52Z", | ||
"published" : "2015-05-21", | |||
"briefDesignDescription" : "Duration of abx in intraabdominal infection", | "briefDesignDescription" : "Duration of abx in intraabdominal infection", | ||
"subspecialties" : "Infectious Disease", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1411162", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1411162", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411162", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411162", | ||
" | "expansion" : "Study to Optimize Peritoneal Infection Therapy", | ||
"citation" : "Sawyer RG, <i>et al</i>. \"Trial of short-course antimicrobial therapy for intraabdominal infection\". <i>The New England Journal of Medicine</i>. 2015. 372(21):1996-2005.", | "citation" : "Sawyer RG, <i>et al</i>. \"Trial of short-course antimicrobial therapy for intraabdominal infection\". <i>The New England Journal of Medicine</i>. 2015. 372(21):1996-2005.", | ||
" | "pageid" : 2424, | ||
" | "pageName" : "STOP-IT", | ||
"briefResultsDescription" : "Short duration non-inferior to longer duration in intraabdominal infection", | "briefResultsDescription" : "Short duration non-inferior to longer duration in intraabdominal infection", | ||
"diseases" : "Intraabdominal Infection", | "diseases" : "Intraabdominal Infection", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(02)08905-5.pdf", | ||
"briefDesignDescription" : "Acarbose to prevent diabetes in high-risk patients", | "briefDesignDescription" : "Acarbose to prevent diabetes in high-risk patients", | ||
"fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08905-5/fulltext", | "fulltexturl" : "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)08905-5/fulltext", | ||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
" | "abbreviation" : "STOP-NIDDM", | ||
"published" : "2002-06-15", | |||
"timestamp" : "2023-08-03T18:09:18Z", | |||
"title" : "Acarbose for prevention of type 2 diabetes mellitus", | |||
"pmid" : "12086760", | |||
"statusUsableDate" : "2023-08-03", | "statusUsableDate" : "2023-08-03", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "STOP-NIDDM", | "pageName" : "STOP-NIDDM", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Acarbose reduced the risk of diabetes", | ||
" | "pageid" : 2754, | ||
" | "citation" : "Chiasson JL, <i>et al</i>. \"Acarbose for prevention of type 2 diabetes mellitus\". <i>The Lancet</i>. 2005. 359(9323):2072-2077.", | ||
"expansion" : "Study to Prevent NIDDM" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Gastroenterology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1412278", | |||
"briefDesignDescription" : "Prednisolone vs. pentoxifylline in alcoholic hepatitis", | "briefDesignDescription" : "Prednisolone vs. pentoxifylline in alcoholic hepatitis", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412278", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1412278", | ||
"statusUsableDate" : "2016-03-01", | "statusUsableDate" : "2016-03-01", | ||
"pmid" : "25901427", | |||
"title" : "Prednisolone or pentoxifylline for alcoholic hepatitis", | |||
"timestamp" : "2023-11-13T16:15:41Z", | |||
"published" : "2015-04-23", | |||
"abbreviation" : "STOPAH", | |||
"briefResultsDescription" : "No difference between groups", | "briefResultsDescription" : "No difference between groups", | ||
" | "diseases" : "Alcoholic Hepatitis", | ||
"pageName" : "STOPAH", | "pageName" : "STOPAH", | ||
" | "trainingLevel" : "Intern", | ||
" | "expansion" : "Steroids or Pentoxifylline for Alcoholic Hepatitis", | ||
" | "citation" : "Thursz MR, <i>et al</i>. \"Prednisolone or pentoxifylline for alcoholic hepatitis\". <i>The New England Journal of Medicine</i>. 2015. 372(17):1619-1628.", | ||
" | "pageid" : 2365 | ||
}, | }, | ||
{ | { | ||
"pageid" : 2432, | "pageid" : 2432, | ||
"citation" : "Kutner JS, <i>et al</i>. \"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial\". <i>JAMA Internal Medicine</i>. 2015. 175(5):691-700.", | "citation" : "Kutner JS, <i>et al</i>. \"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial\". <i>JAMA Internal Medicine</i>. 2015. 175(5):691-700.", | ||
"expansion" : "", | "expansion" : "", | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Hyperlipidemia", | |||
"briefResultsDescription" : "Discontinuing statin doesn't change 60 day all-cause mortality", | "briefResultsDescription" : "Discontinuing statin doesn't change 60 day all-cause mortality", | ||
"pageName" : "Stopping Statins at the End of Life", | |||
"published" : "2015-05-01", | "published" : "2015-05-01", | ||
" | "timestamp" : "2017-12-03T22:39:36Z", | ||
"abbreviation" : "", | "abbreviation" : "", | ||
"statusUsableDate" : "2015-09-01", | |||
"pmid" : "25798575", | |||
"title" : "Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial", | "title" : "Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial", | ||
" | "pdfurl" : "", | ||
"fulltexturl" : "http://bit.ly/1LOZfB6", | |||
"subspecialties" : "Palliative Care;Cardiology", | |||
"briefDesignDescription" : "Palliative statin discontinuation" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "SUP-ICU", | |||
"published" : "2018-10-24", | |||
"timestamp" : "2025-06-19T18:34:51Z", | "timestamp" : "2025-06-19T18:34:51Z", | ||
"title" : "Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU", | |||
"statusUsableDate" : "2018-11-01", | |||
"pmid" : "30354950", | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1714919", | |||
"briefDesignDescription" : "Routine PPI use in the ICU", | "briefDesignDescription" : "Routine PPI use in the ICU", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1714919", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1714919", | ||
"subspecialties" : "Critical Care", | |||
"pageid" : 3725, | "pageid" : 3725, | ||
"citation" : "Krag M, <i>et al</i>. \"Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU\". <i>The New England Journal of Medicine</i>. 2018. 379:2199-2208.", | "citation" : "Krag M, <i>et al</i>. \"Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU\". <i>The New England Journal of Medicine</i>. 2018. 379:2199-2208.", | ||
"expansion" : "Stress Ulcer Prophylaxis in the Intensive Care Unit", | "expansion" : "Stress Ulcer Prophylaxis in the Intensive Care Unit", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "SUP-ICU", | "pageName" : "SUP-ICU", | ||
"diseases" : "Stress Ulcer", | "diseases" : "Stress Ulcer", | ||
" | "briefResultsDescription" : "PPI doesn't reduce mortality, it reduces bleeding" | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2017-12-03T22:39:31Z", | "timestamp" : "2017-12-03T22:39:31Z", | ||
"published" : "2017-03-17", | |||
"abbreviation" : "SURTAVI", | |||
"pmid" : "28304219", | |||
"statusUsableDate" : "2017-04-01", | |||
"title" : "Surgical or transcatheter aortic-valve replacement in intermediate-risk patients", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1700456", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1700456", | |||
"briefDesignDescription" : "TAVI for AS in intermediate-risk surgical candidates", | "briefDesignDescription" : "TAVI for AS in intermediate-risk surgical candidates", | ||
" | "citation" : "Reardon MJ, <i>et al</i>. \"Surgical or transcatheter aortic-valve replacement in intermediate-risk patients\". <i>The New England Journal of Medicine</i>. 2017. epub 2017-03-17:1-11.", | ||
"pageid" : 2895, | "pageid" : 2895, | ||
" | "expansion" : "Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement", | ||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"briefResultsDescription" : "TAVI noninferior to surgical AVR in intermediate-risk surgical candidates", | "briefResultsDescription" : "TAVI noninferior to surgical AVR in intermediate-risk surgical candidates", | ||
"diseases" : "Aortic Stenosis", | "diseases" : "Aortic Stenosis", | ||
" | "pageName" : "SURTAVI" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Crizanlizumab vs. placebo in SCD", | "briefDesignDescription" : "Crizanlizumab vs. placebo in SCD", | ||
"subspecialties" : "Hematology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1611770", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1611770", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611770", | ||
" | "title" : "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease", | ||
"statusUsableDate" : "2020-12-31", | "statusUsableDate" : "2020-12-31", | ||
" | "pmid" : "27959701", | ||
"abbreviation" : "SUSTAIN", | |||
"timestamp" : "2021-01-05T21:10:45Z", | |||
"published" : "2017-02-02", | "published" : "2017-02-02", | ||
"pageName" : "SUSTAIN", | "pageName" : "SUSTAIN", | ||
"briefResultsDescription" : "Crizanlizumab reduces painful crises", | |||
"diseases" : "Sickle Cell Disease", | "diseases" : "Sickle Cell Disease", | ||
" | "trainingLevel" : "Fellow", | ||
" | "expansion" : "", | ||
" | "citation" : "Ataga KI, <i>et al</i>. \"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease\". <i>The New England Journal of Medicine</i>. 2017. 376(5):429-439.", | ||
"pageid" : 4387 | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Tabar L, <i>et al</i>. \"Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades\". <i>Radiology</i>. 2011. 260(3):658-663.", | ||
"pageid" : 2435, | "pageid" : 2435, | ||
" | "briefResultsDescription" : "Breast cancer screening with mammogram lowers cancer mortality", | ||
"diseases" : "Breast Cancer", | |||
"pageName" : "Swedish Two-County Trial", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"statusUsableDate" : "2023-02-16", | "statusUsableDate" : "2023-02-16", | ||
" | "pmid" : "21712474", | ||
"title" : "Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades", | |||
"timestamp" : "2023-02-16T20:42:11Z", | |||
"published" : "2011-09-01", | "published" : "2011-09-01", | ||
"abbreviation" : "Swedish Two-County Trial", | "abbreviation" : "Swedish Two-County Trial", | ||
" | "subspecialties" : "Oncology;Preventive Medicine", | ||
" | "fulltexturl" : "http://pubs.rsna.org/doi/10.1148/radiol.11110469", | ||
"briefDesignDescription" : "Mammogram screening 29y follow-up", | |||
"pdfurl" : "http://pubs.rsna.org/doi/pdf/10.1148/radiol.11110469" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Flanigan RC, <i>et al</i>. \"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer\". <i>The New England Journal of Medicine</i>. 2001. 345(23):1655-9.", | ||
"pageid" : 1845, | "pageid" : 1845, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"briefResultsDescription" : "Cytoreductive nephrectomy improves survival in mRCC", | "briefResultsDescription" : "Cytoreductive nephrectomy improves survival in mRCC", | ||
"diseases" : "Renal Cell Carcinoma", | |||
"pageName" : "SWOG 8949", | |||
"timestamp" : "2024-10-03T23:36:53Z", | |||
"published" : "2001-12-06", | "published" : "2001-12-06", | ||
"abbreviation" : "SWOG 8949", | "abbreviation" : "SWOG 8949", | ||
"pmid" : "11759643", | |||
"statusUsableDate" : "2014-06-01", | |||
"title" : "Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer", | "title" : "Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa003013", | ||
"subspecialties" : "Oncology;Surgery;Urology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa003013", | |||
"briefDesignDescription" : "Cytoreductive nephrectomy in metastatic RCC" | |||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
"pageName" : "Symptom-Triggered Benzodiazepines in Alcohol Withdrawal", | |||
"briefResultsDescription" : "Symptom-triggered therapy reduces length of hospitalization without increasing adverse event risk", | |||
"diseases" : "Alcohol Withdrawal", | |||
"citation" : "Daeppen JB, <i>et al</i>. \"Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial\". <i>Archives of Internal Medicine</i>. 2002. 162(10):1117-21.", | "citation" : "Daeppen JB, <i>et al</i>. \"Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial\". <i>Archives of Internal Medicine</i>. 2002. 162(10):1117-21.", | ||
"pageid" : 116, | |||
"expansion" : "", | |||
"pdfurl" : "http://archinte.ama-assn.org/cgi/reprint/162/10/1117.pdf", | |||
"briefDesignDescription" : "Symptom-triggered therapy in alcohol withdrawal", | |||
"subspecialties" : "Psychiatry", | "subspecialties" : "Psychiatry", | ||
" | "fulltexturl" : "http://archinte.ama-assn.org/cgi/content/full/162/10/1117", | ||
" | "abbreviation" : "", | ||
" | "timestamp" : "2013-03-05T21:40:49Z", | ||
"published" : "2002-05-27", | "published" : "2002-05-27", | ||
"title" : "Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial", | "title" : "Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial", | ||
"pmid" : "12020181" | "pmid" : "12020181", | ||
"statusUsableDate" : "2012-03-01" | |||
}, | }, | ||
{ | { | ||
"title" : "Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease", | |||
"pmid" : "19228612", | |||
"statusUsableDate" : "2012-06-01", | |||
"abbreviation" : "SYNTAX", | |||
"timestamp" : "2017-12-03T22:39:33Z", | "timestamp" : "2017-12-03T22:39:33Z", | ||
"published" : "2009-03-05", | |||
"briefDesignDescription" : "PCI vs. CABG in severe CAD", | "briefDesignDescription" : "PCI vs. CABG in severe CAD", | ||
"subspecialties" : "Cardiology;Surgery", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0804626", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0804626", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804626", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0804626", | ||
" | "expansion" : "Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery", | ||
"citation" : "Serruys PW, <i>et al</i>. \"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(10):961-972.", | "citation" : "Serruys PW, <i>et al</i>. \"Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease\". <i>The New England Journal of Medicine</i>. 2009. 360(10):961-972.", | ||
" | "pageid" : 525, | ||
"pageName" : "SYNTAX", | |||
" | |||
"briefResultsDescription" : "CABG reduces major CV events with 3VD or LM disease", | "briefResultsDescription" : "CABG reduces major CV events with 3VD or LM disease", | ||
"diseases" : "Coronary Artery Disease", | "diseases" : "Coronary Artery Disease", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban", | ||
" | "citation" : "Cannon CP, <i>et al</i>. \"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban\". <i>New England Journal of Medicine</i>. 2001. 344(25):1879-1887.", | ||
"pageid" : 2656, | "pageid" : 2656, | ||
" | "pageName" : "TACTICS-TIMI 18", | ||
"briefResultsDescription" : "Early PCI improves outcomes in high-risk patients", | |||
"diseases" : "Coronary Artery Disease", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban", | ||
" | "pmid" : "11419424", | ||
"statusUsableDate" : "2016-05-01", | "statusUsableDate" : "2016-05-01", | ||
" | "abbreviation" : "TACTICS-TIMI 18", | ||
"timestamp" : "2020-04-01T00:34:11Z", | |||
"published" : "2001-06-21", | "published" : "2001-06-21", | ||
" | "briefDesignDescription" : "Early vs. Delayed PCI for UA-NSTEMI", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200106213442501", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200106213442501" | |||
" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2015-01-01", | |||
"pmid" : "20979471", | |||
"title" : "Tiotropium bromide step-up therapy for adults with uncontrolled asthma", | |||
"timestamp" : "2017-12-03T22:39:38Z", | "timestamp" : "2017-12-03T22:39:38Z", | ||
" | "published" : "2010-10-28", | ||
"abbreviation" : "TALC", | |||
"subspecialties" : "Pulmonology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1008770", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1008770", | ||
" | "briefDesignDescription" : "Tiotropium vs. others in asthma", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008770", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1008770", | ||
" | "expansion" : "Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid", | ||
"citation" : "Peters SP, <i>et al</i>. \"Tiotropium bromide step-up therapy for adults with uncontrolled asthma\". <i>The New England Journal of Medicine</i>. 2010. 363(18):1715-1726.", | "citation" : "Peters SP, <i>et al</i>. \"Tiotropium bromide step-up therapy for adults with uncontrolled asthma\". <i>The New England Journal of Medicine</i>. 2010. 363(18):1715-1726.", | ||
" | "pageid" : 2267, | ||
"briefResultsDescription" : "Adding tiotropium improves peak expiratory flow better than doubling the ICS dose", | "briefResultsDescription" : "Adding tiotropium improves peak expiratory flow better than doubling the ICS dose", | ||
" | "diseases" : "Asthma", | ||
"pageName" : "TALC", | "pageName" : "TALC", | ||
" | "trainingLevel" : "Fellow" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "", | ||
"briefDesignDescription" : "Intensive vs. standard treatment in early RA", | "briefDesignDescription" : "Intensive vs. standard treatment in early RA", | ||
"fulltexturl" : "https://doi.org/10.1016/s0140-6736(04)16676-2", | "fulltexturl" : "https://doi.org/10.1016/s0140-6736(04)16676-2", | ||
"subspecialties" : "Rheumatology", | "subspecialties" : "Rheumatology", | ||
" | "abbreviation" : "TICORA", | ||
"published" : "2004-07-17", | |||
"timestamp" : "2022-08-25T20:01:42Z", | |||
"title" : "Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial", | |||
"statusUsableDate" : "2022-08-25", | "statusUsableDate" : "2022-08-25", | ||
" | "pmid" : "15262104", | ||
" | "trainingLevel" : "resident", | ||
"pageName" : "TICORA", | "pageName" : "TICORA", | ||
"diseases" : "Rheumatoid Arthritis", | "diseases" : "Rheumatoid Arthritis", | ||
" | "briefResultsDescription" : "Intensive treatment with better disease control than late RA", | ||
" | "pageid" : 2722, | ||
" | "citation" : "Grigor C, <i>et al</i>. \"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial\". <i>The Lancet</i>. 2004. 364(9430):263-269.", | ||
"expansion" : "Tight Control of Rheumatoid Arthritis" | |||
}, | }, | ||
{ | { | ||
"pmid" : "19458363", | |||
"statusUsableDate" : "2018-05-31", | |||
"title" : "Early versus Delayed Invasive Intervention in Acute Coronary Syndromes", | |||
"published" : "2009-05-21", | |||
"timestamp" : "2023-09-21T17:41:32Z", | "timestamp" : "2023-09-21T17:41:32Z", | ||
"abbreviation" : "TIMACS", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0807986", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Early vs. delayed PCI in NSTEMI and UA", | "briefDesignDescription" : "Early vs. delayed PCI in NSTEMI and UA", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0807986", | ||
"expansion" : "The Timing of Intervention in Acute Coronary Syndromes", | |||
"pageid" : 2867, | "pageid" : 2867, | ||
"citation" : "Mehta SR, <i>et al</i>. \"Early versus Delayed Invasive Intervention in Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2009. 360:2165-2175.", | "citation" : "Mehta SR, <i>et al</i>. \"Early versus Delayed Invasive Intervention in Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2009. 360:2165-2175.", | ||
" | "diseases" : "Acute Coronary Syndrome;Coronary Artery Disease;Myocardial Infarction", | ||
"briefResultsDescription" : "Early PCI doesn't provide additional benefit over delayed PCI in NSTEMI and UA", | "briefResultsDescription" : "Early PCI doesn't provide additional benefit over delayed PCI in NSTEMI and UA", | ||
"pageName" : "TIMACS", | "pageName" : "TIMACS", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
" | "pageName" : "TIPPS", | ||
"briefResultsDescription" : "Dalteparin did not reduce rate of pregnancy complications", | "briefResultsDescription" : "Dalteparin did not reduce rate of pregnancy complications", | ||
"diseases" : "Thrombophilia;Pregnancy;Venous Thromboembolism", | "diseases" : "Thrombophilia;Pregnancy;Venous Thromboembolism", | ||
"citation" : "Rodger MA, <i>et al</i>. \"Antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia\". <i>Lancet</i>. 2014. 384(9955):1673-1683.", | |||
"pageid" : 3718, | |||
"expansion" : "Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia", | |||
"pdfurl" : "https://reader.elsevier.com/reader/sd/pii/S0140673614607935", | |||
"briefDesignDescription" : "Dalteparin in pregnant woman with thrombophilias", | |||
"subspecialties" : "Hematology;Obstetrics", | |||
"fulltexturl" : "https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(14)60793-5", | |||
"abbreviation" : "TIPPS", | "abbreviation" : "TIPPS", | ||
"timestamp" : "2019-06-20T18:30:08Z", | |||
"published" : "2014-11-08", | |||
"title" : "Antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia", | "title" : "Antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia", | ||
"pmid" : "25066248" | "pmid" : "25066248", | ||
"statusUsableDate" : "2019-06-20" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "TNT", | ||
"briefResultsDescription" : "Atorvastatin 80 mg better than 10 mg for major CV events in stable CAD", | |||
"diseases" : "Coronary Artery Disease;Hyperlipidemia", | |||
"trainingLevel" : "Student", | |||
"expansion" : "Treating to New Targets", | |||
"citation" : "LaRosa JC, <i>et al</i>. \"Intensive lipid lowering with atorvastatin in patients with stable coronary disease\". <i>The New England Journal of Medicine</i>. 2005. 352(14):1425-1435.", | |||
"pageid" : 1762, | |||
"briefDesignDescription" : "Atorvastatin in stable CAD", | "briefDesignDescription" : "Atorvastatin in stable CAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa050461", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa050461", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa050461", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa050461", | ||
" | "title" : "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", | ||
"pmid" : "15755765", | |||
" | |||
"statusUsableDate" : "2013-12-01", | "statusUsableDate" : "2013-12-01", | ||
"abbreviation" : "TNT", | "abbreviation" : "TNT", | ||
" | "timestamp" : "2017-12-14T19:37:07Z", | ||
" | "published" : "2005-04-07" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "Hypertension", | ||
" | "briefResultsDescription" : "Na reduction and weight loss are effective means for hypertension control in the elderly", | ||
" | "pageName" : "TONE", | ||
"trainingLevel" : "Student", | |||
"expansion" : "Trial of Nonpharmacologic Interventions in the Elderly", | |||
"pageid" : 2990, | "pageid" : 2990, | ||
"citation" : "Whelton PK, <i>et al</i>. \"Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group\". <i>JAMA</i>. 1998. 279(11):839-846.", | "citation" : "Whelton PK, <i>et al</i>. \"Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group\". <i>JAMA</i>. 1998. 279(11):839-846.", | ||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/vol/279/pg/839", | |||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "briefDesignDescription" : "Na reduction and weight loss for HTN control in elderly", | ||
"pdfurl" : "", | |||
"statusUsableDate" : "2017-12-14", | "statusUsableDate" : "2017-12-14", | ||
" | "pmid" : "9515998", | ||
"title" : "Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group", | |||
"published" : "1998-03-18", | "published" : "1998-03-18", | ||
" | "timestamp" : "2017-12-14T19:36:29Z", | ||
"abbreviation" : "TONE" | |||
"abbreviation" : "TONE | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist", | ||
" | "citation" : "Pitt B, <i>et al</i>. \"Spironolactone for heart failure with preserved ejection fraction\". <i>The New England Journal of Medicine</i>. 2014. 370(15):1383-1392.", | ||
"pageid" : 1797, | "pageid" : 1797, | ||
" | "pageName" : "TOPCAT", | ||
"briefResultsDescription" : "Spironolactone doesn't reduce CV mortality, aborted cardiac arrest or HF hospitalizations in HFpEF", | |||
"diseases" : "Heart Failure", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "title" : "Spironolactone for heart failure with preserved ejection fraction", | ||
" | "pmid" : "24716680", | ||
"statusUsableDate" : "2014-05-01", | "statusUsableDate" : "2014-05-01", | ||
" | "abbreviation" : "TOPCAT", | ||
"timestamp" : "2024-10-23T14:44:07Z", | |||
"published" : "2014-04-20", | "published" : "2014-04-20", | ||
" | "briefDesignDescription" : "Spironolactone for HFpEF", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1313731", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313731" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Trial of Prophylactic Platelets", | ||
" | "citation" : "Stanworth S, <i>et al</i>. \"A no-prophylaxis platelet-transfusion strategy for hematologic cancers\". <i>The New England Journal of Medicine</i>. 2013. 368(19):1771-1780.", | ||
"pageid" : 2794, | "pageid" : 2794, | ||
" | "briefResultsDescription" : "Prophylactic platelet transfusions lower bleeding events", | ||
"diseases" : "Thrombocytopenia", | |||
"pageName" : "TOPPS", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2023-09-22", | "statusUsableDate" : "2023-09-22", | ||
" | "pmid" : "23656642", | ||
"title" : "A no-prophylaxis platelet-transfusion strategy for hematologic cancers", | |||
"timestamp" : "2023-09-21T18:44:50Z", | |||
"published" : "2013-05-09", | "published" : "2013-05-09", | ||
"abbreviation" : "TOPPS", | "abbreviation" : "TOPPS", | ||
" | "subspecialties" : "Oncology;Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1212772", | ||
"briefDesignDescription" : "Platelet transfusions in blood cancers", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1212772" | |||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Pulmonology", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa063070", | |||
"briefDesignDescription" : "Salmeterol/fluticasone in COPD", | "briefDesignDescription" : "Salmeterol/fluticasone in COPD", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa063070", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa063070", | ||
" | "pmid" : "17314337", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"title" : "Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease", | |||
"timestamp" : "2015-05-29T16:40:40Z", | |||
"published" : "2007-02-22", | |||
"abbreviation" : "TORCH", | |||
"briefResultsDescription" : "Trend towards mortality benefit", | "briefResultsDescription" : "Trend towards mortality benefit", | ||
" | "diseases" : "Chronic Obstructive Pulmonary Disease", | ||
"pageName" : "TORCH", | "pageName" : "TORCH", | ||
" | "trainingLevel" : "Student", | ||
" | "expansion" : "Towards a Revolution in COPD Health", | ||
" | "citation" : "Calverley PM, <i>et al</i>. \"Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2007. 356(8):775-789.", | ||
" | "pageid" : 124 | ||
}, | }, | ||
{ | { | ||
" | "subspecialties" : "Neurology", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2402980", | |||
"briefDesignDescription" : "tPA 4.5-24h post-stroke if ideal MRI/CT", | "briefDesignDescription" : "tPA 4.5-24h post-stroke if ideal MRI/CT", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2402980", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2402980", | ||
"statusUsableDate" : "2024-07-28", | "statusUsableDate" : "2024-07-28", | ||
"pmid" : "38884324", | |||
"title" : "Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy", | |||
"timestamp" : "2024-08-08T20:44:43Z", | |||
"published" : "2024-07-18", | |||
"abbreviation" : "TRACE-III", | |||
"briefResultsDescription" : "tPA improves recovery after stroke", | "briefResultsDescription" : "tPA improves recovery after stroke", | ||
" | "diseases" : "Stroke", | ||
"pageName" : "TRACE-III", | "pageName" : "TRACE-III", | ||
" | "trainingLevel" : "resident", | ||
" | "expansion" : "Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III", | ||
" | "citation" : "Xiong Y, <i>et al</i>. \"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy\". <i>The New England Journal of Medicine</i>. 2024. 391(3):203-212.", | ||
" | "pageid" : 5557 | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Intern", | ||
"pageName" : "Transfusion Strategies for Acute Upper Gastrointestinal Bleeding", | |||
"diseases" : "Gastrointestinal Hemorrhage;Hemorrhage", | |||
"briefResultsDescription" : "Restrictive transfusions lower mortality in UGIB", | |||
"pageid" : 1191, | |||
"citation" : "Villanueva C <i>et al</i>. \"Transfusion strategies for acute upper gastrointestinal bleeding\". <i>The New England Journal of Medicine</i>. 2013. 368(1):11-21.", | |||
"expansion" : "", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1211801", | |||
"briefDesignDescription" : "Transfusion thresholds in UGIB", | "briefDesignDescription" : "Transfusion thresholds in UGIB", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1211801", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1211801", | ||
"subspecialties" : "Gastroenterology", | "subspecialties" : "Gastroenterology", | ||
" | "abbreviation" : "", | ||
"published" : "2013-01-03", | "published" : "2013-01-03", | ||
" | "timestamp" : "2017-12-03T22:39:47Z", | ||
"title" : "Transfusion strategies for acute upper gastrointestinal bleeding", | "title" : "Transfusion strategies for acute upper gastrointestinal bleeding", | ||
"statusUsableDate" : "2013-02-01", | |||
"pmid" : "23281973" | "pmid" : "23281973" | ||
}, | }, | ||
{ | { | ||
" | "citation" : "Pengo V, <i>et al</i>. \"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome\". <i>Blood</i>. 2018. 132(13):1365-1371.", | ||
"pageid" : 3700, | "pageid" : 3700, | ||
" | "expansion" : "Trial on Rivaroxaban in AntiPhospholipid Syndrome", | ||
"trainingLevel" : "Fellow", | "trainingLevel" : "Fellow", | ||
"briefResultsDescription" : "Rivaroxaban inferior to warfarin in high-risk APLS", | "briefResultsDescription" : "Rivaroxaban inferior to warfarin in high-risk APLS", | ||
"diseases" : "Antiphospholipid Syndrome", | |||
"pageName" : "TRAPS", | |||
"timestamp" : "2021-05-26T13:37:31Z", | |||
"published" : "2018-09-27", | "published" : "2018-09-27", | ||
"abbreviation" : "TRAPS", | "abbreviation" : "TRAPS", | ||
"pmid" : "30002145", | |||
"statusUsableDate" : "2018-10-19", | |||
"title" : "Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome", | "title" : "Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome", | ||
" | "pdfurl" : null, | ||
"subspecialties" : "Hematology;Rheumatology", | |||
"fulltexturl" : "https://doi.org/10.1182/blood-2018-04-848333", | |||
"briefDesignDescription" : "Rivaroxaban in high-risk APLS" | |||
}, | }, | ||
{ | { | ||
"pmid" : "19880844", | |||
"statusUsableDate" : "2012-03-01", | |||
"title" : "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease", | |||
"timestamp" : "2015-03-09T17:49:43Z", | "timestamp" : "2015-03-09T17:49:43Z", | ||
"published" : "2009-11-19", | |||
"abbreviation" : "TREAT", | |||
"subspecialties" : "Nephrology;Hematology;Endocrinology", | |||
"fulltexturl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0907845", | |||
"briefDesignDescription" : "Darbepoetin in CKD and T2DM", | "briefDesignDescription" : "Darbepoetin in CKD and T2DM", | ||
"pdfurl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0907845", | "pdfurl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0907845", | ||
" | "expansion" : "Trial to Reduce Cardiovascular Events With Aranesp Therapy", | ||
"citation" : "Pfeffer MA, <i>et al</i>. \"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease\". <i>The New England Journal of Medicine</i>. 2009. 361(21):2019-32.", | "citation" : "Pfeffer MA, <i>et al</i>. \"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease\". <i>The New England Journal of Medicine</i>. 2009. 361(21):2019-32.", | ||
" | "pageid" : 5, | ||
"briefResultsDescription" : "No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM", | "briefResultsDescription" : "No mortality benefit when targeting higher hemoglobin with ESAs in patients with CKD and T2DM", | ||
" | "diseases" : "Chronic Kidney Disease;Anemia;Diabetes Mellitus", | ||
"pageName" : "TREAT", | "pageName" : "TREAT", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2019-06-20", | |||
"pmid" : "30429050", | |||
"title" : "Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial", | |||
"published" : "2018-11-09", | |||
"timestamp" : "2019-06-27T20:30:21Z", | "timestamp" : "2019-06-27T20:30:21Z", | ||
"abbreviation" : "TRED-HF", | |||
"fulltexturl" : "https://doi.org/10.1016/S0140-6736(18)32484-X", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Withdrawal of medications in dilated cardiomyopathy", | "briefDesignDescription" : "Withdrawal of medications in dilated cardiomyopathy", | ||
" | "pdfurl" : "https://pdf.sciencedirectassets.com/271074/1-s2.0-S0140673618X00567/1-s2.0-S014067361832484X/main.pdf", | ||
"expansion" : "Treatment for heart failure in patients with recovered dilated cardiomyopathy", | |||
"pageid" : 3747, | "pageid" : 3747, | ||
"citation" : "Halliday BP, <i>et al</i>. \"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial\". <i>The Lancet</i>. 2019. 393(10166):61-73.", | "citation" : "Halliday BP, <i>et al</i>. \"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial\". <i>The Lancet</i>. 2019. 393(10166):61-73.", | ||
" | "diseases" : "Heart Failure;Dilated Cardiomyopathy", | ||
"briefResultsDescription" : "Withdrawal of medications increases relapse of heart failure", | "briefResultsDescription" : "Withdrawal of medications increases relapse of heart failure", | ||
"pageName" : "TRED-HF", | "pageName" : "TRED-HF", | ||
" | "trainingLevel" : "Resident" | ||
}, | }, | ||
{ | { | ||
" | "expansion" : "Transfusion Requirements in Critical Care", | ||
"pageid" : 104, | "pageid" : 104, | ||
" | "citation" : "Hebert PC, <i>et al</i>. \"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care\". <i>The New England Journal of Medicine</i>. 1999. 340(6):409-417.", | ||
"diseases" : "Anemia", | |||
"briefResultsDescription" : "Restrictive hemoglobin goals improved mortality", | |||
"pageName" : "TRICC", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pmid" : "9971864", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care", | ||
"published" : "1999-02-11", | "published" : "1999-02-11", | ||
" | "timestamp" : "2021-08-05T17:53:04Z", | ||
"abbreviation" : "TRICC", | "abbreviation" : "TRICC", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199902113400601", | ||
" | "subspecialties" : "Critical Care;Hematology;Transfusion Medicine", | ||
"briefDesignDescription" : "Transfusion thresholds in ICU", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199902113400601" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "TRICS III", | ||
" | "diseases" : "Anemia", | ||
" | "briefResultsDescription" : "Restrictive noninferior to liberal RBC transfusions", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Transfusion Requirements in Cardiac Surgery", | |||
"pageid" : 3536, | "pageid" : 3536, | ||
"citation" : "Mazer CD, <i>et al</i>. \"Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery\". <i>The New England Journal of Medicine</i>. 2017. 377(22):2133-44.", | "citation" : "Mazer CD, <i>et al</i>. \"Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery\". <i>The New England Journal of Medicine</i>. 2017. 377(22):2133-44.", | ||
"briefDesignDescription" : "Transfusion thresholds for cardiac surgery", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1711818", | |||
"subspecialties" : "Surgery;Hematology", | "subspecialties" : "Surgery;Hematology", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1711818", | ||
"title" : "Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery", | |||
"statusUsableDate" : "2018-04-26", | "statusUsableDate" : "2018-04-26", | ||
" | "pmid" : "29130845", | ||
"abbreviation" : "TRICS III", | |||
"published" : "2017-11-30", | "published" : "2017-11-30", | ||
" | "timestamp" : "2018-04-26T17:40:38Z" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "TRISS", | ||
"briefResultsDescription" : "Similar mortality; Fewer transfusions with restrictive", | |||
"diseases" : "Sepsis;Shock;Anemia", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Transfusion Requirements in Septic Shock", | |||
"citation" : "Holst L, <i>et al</i>. \"Transfusion thresholds in Septic Shock\". <i>The New England Journal of Medicine</i>. 2014. 371(15):1381-1391.", | |||
"pageid" : 2268, | |||
"briefDesignDescription" : "Transfusion thresholds in sepsis", | "briefDesignDescription" : "Transfusion thresholds in sepsis", | ||
"subspecialties" : "Critical Care;Hematology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1406617", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1406617", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406617", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1406617", | ||
" | "title" : "Transfusion thresholds in Septic Shock", | ||
"statusUsableDate" : "2014-12-01", | "statusUsableDate" : "2014-12-01", | ||
" | "pmid" : "25270275", | ||
"abbreviation" : "TRISS", | "abbreviation" : "TRISS", | ||
" | "timestamp" : "2022-12-01T19:01:46Z", | ||
" | "published" : "2014-10-09" | ||
}, | }, | ||
{ | { | ||
"title" : "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes", | |||
"statusUsableDate" : "2013-04-01", | |||
"pmid" : "17982182", | |||
"abbreviation" : "TRITON-TIMI 38", | |||
"published" : "2007-11-15", | |||
"timestamp" : "2017-12-03T22:39:43Z", | "timestamp" : "2017-12-03T22:39:43Z", | ||
"briefDesignDescription" : "Prasugrel vs. clopidogrel in ACS", | "briefDesignDescription" : "Prasugrel vs. clopidogrel in ACS", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0706482", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0706482", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0706482", | |||
"expansion" : "Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38", | |||
"pageid" : 1398, | "pageid" : 1398, | ||
"citation" : "Wiviott ST, <i>et al</i>. \"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2007. 357(20):2001-2015.", | "citation" : "Wiviott ST, <i>et al</i>. \"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes\". <i>The New England Journal of Medicine</i>. 2007. 357(20):2001-2015.", | ||
"pageName" : "TRITON-TIMI 38", | "pageName" : "TRITON-TIMI 38", | ||
"diseases" : "Acute Coronary Syndrome", | "diseases" : "Acute Coronary Syndrome", | ||
" | "briefResultsDescription" : "Prasugrel decreases CV mortality/morbidity, increases bleeding", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "diseases" : "Paroxysmal Nocturnal Hemoglobinuria", | ||
" | "briefResultsDescription" : "Eculizumab decreases transfusion requirements in PNH", | ||
" | "pageName" : "TRIUMPH", | ||
"trainingLevel" : "Intern", | |||
"expansion" : "Transfusion Reduction Efficacy and Safety Clinical Investigation, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria", | |||
"pageid" : 2810, | "pageid" : 2810, | ||
"citation" : "Hillmen P, <i>et al</i>. \"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria\". <i>The New England Journal of Medicine</i>. 2006. 355(12):1233-1243.", | "citation" : "Hillmen P, <i>et al</i>. \"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria\". <i>The New England Journal of Medicine</i>. 2006. 355(12):1233-1243.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa061648", | |||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
" | "briefDesignDescription" : "Eculizumab in PNH", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa061648", | |||
"statusUsableDate" : "2017-08-01", | "statusUsableDate" : "2017-08-01", | ||
" | "pmid" : "16990386", | ||
"title" : "The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria", | |||
"published" : "2006-09-21", | "published" : "2006-09-21", | ||
" | "timestamp" : "2017-12-03T22:39:45Z", | ||
"abbreviation" : "TRIUMPH" | |||
"abbreviation" : "TRIUMPH | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest", | ||
"pageid" : 1783, | "pageid" : 1783, | ||
"citation" : "Nielsen N, <i>et al</i>. \"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2013. 369(23):2197-2206.", | "citation" : "Nielsen N, <i>et al</i>. \"Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2013. 369(23):2197-2206.", | ||
"pageName" : "TTM", | "pageName" : "TTM", | ||
"diseases" : "Cardiac Arrest", | "diseases" : "Cardiac Arrest", | ||
"briefResultsDescription" : "33°C cooling provides no survival benefit over 36°C", | |||
"trainingLevel" : "Resident", | |||
"title" : "Target Temperature Management 33°C vs. 36°C after Out-of Hospital Cardiac Arrest", | |||
"pmid" : "24237006", | |||
"statusUsableDate" : "2014-03-01", | |||
"abbreviation" : "TTM", | "abbreviation" : "TTM", | ||
" | "published" : "2014-03-19", | ||
" | "timestamp" : "2017-12-03T22:39:46Z", | ||
"briefDesignDescription" : "33 vs. 36°C body temperature after cardiac arrest", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1310519", | |||
"subspecialties" : "Cardiology;Neurology;Critical Care", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1310519" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100591", | ||
"briefDesignDescription" : "33°C vs. normothermia after cardiac arrest", | "briefDesignDescription" : "33°C vs. normothermia after cardiac arrest", | ||
"subspecialties" : "Emergency Medicine;Critical Care;Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2100591", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa2100591", | ||
" | "abbreviation" : "TTM2", | ||
" | "timestamp" : "2023-04-13T17:09:26Z", | ||
"published" : "2021-06-17", | |||
"title" : "Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest", | |||
"pmid" : "34133859", | |||
"statusUsableDate" : "2021-07-30", | |||
"trainingLevel" : "resident", | "trainingLevel" : "resident", | ||
" | "pageName" : "TTM2", | ||
"briefResultsDescription" : "No difference in survival or functional outcomes", | "briefResultsDescription" : "No difference in survival or functional outcomes", | ||
"diseases" : "Cardiac Arrest", | "diseases" : "Cardiac Arrest", | ||
" | "citation" : "Dankiewicz J, <i>et al</i>. \"Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest\". <i>The New England Journal of Medicine</i>. 2021. 384(24):2283-2294.", | ||
"pageid" : 4433, | |||
" | "expansion" : "Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest 2" | ||
}, | }, | ||
{ | { | ||
" | "briefResultsDescription" : "Twice-daily RT with better response, PFS, survival than once-daily RT for limited SCLC", | ||
"diseases" : "Lung Cancer", | |||
" | "pageName" : "Twice-daily RT for SCLC", | ||
" | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"expansion" : "", | |||
"citation" : "Turrisi AT, <i>et al</i>. \"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide\". <i>The New England Journal of Medicine</i>. 1999. 340(4):265-271.", | "citation" : "Turrisi AT, <i>et al</i>. \"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide\". <i>The New England Journal of Medicine</i>. 1999. 340(4):265-271.", | ||
"pageid" : 1773, | |||
"subspecialties" : "Oncology;Pulmonology;Radiation Oncology", | "subspecialties" : "Oncology;Pulmonology;Radiation Oncology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199901283400403", | ||
"briefDesignDescription" : "Twice-daily RT in limited SCLC", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199901283400403", | |||
"statusUsableDate" : "2013-12-01", | "statusUsableDate" : "2013-12-01", | ||
" | "pmid" : "9920950", | ||
"title" : "Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide", | |||
"timestamp" : "2017-12-03T22:39:48Z", | |||
"published" : "1999-01-28", | "published" : "1999-01-28", | ||
"abbreviation" : "" | |||
"abbreviation" : " | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "", | ||
" | "citation" : "Zahed R. \"Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial\". <i>Academic Emergency Medicine</i>. 2018. 25(3):261-266.", | ||
"pageid" : 3564, | "pageid" : 3564, | ||
" | "pageName" : "TXA for Epistaxis Associated with Antiplatelet Agents", | ||
"briefResultsDescription" : "TXA improved bleeding cessation time, rebleeding risk, and patient satisfaction", | |||
"diseases" : "Epistaxis", | |||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "title" : "Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial", | ||
"pmid" : "29125679", | |||
" | |||
"statusUsableDate" : "2023-09-21", | "statusUsableDate" : "2023-09-21", | ||
" | "abbreviation" : "", | ||
"timestamp" : "2023-09-22T22:59:11Z", | |||
"published" : "2018-03-01", | "published" : "2018-03-01", | ||
" | "briefDesignDescription" : "TXA vs. packing for antiplatelet agent-related epistaxis", | ||
" | "subspecialties" : "Emergency Medicine", | ||
" | "fulltexturl" : "https://onlinelibrary.wiley.com/doi/abs/10.1111/acem.13345", | ||
" | "pdfurl" : "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/acem.13345" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "Reduction in microvascular complications", | ||
" | "pageName" : "UKPDS 33", | ||
"trainingLevel" : "Intern", | |||
"expansion" : "United Kingdom Prospective Diabetes Study", | |||
"pageid" : 253, | "pageid" : 253, | ||
"citation" : "Turner R, <i>et al</i>. \"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\". <i>The Lancet</i>. 1998. 352(9131):837-53.", | "citation" : "Turner R, <i>et al</i>. \"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes\". <i>The Lancet</i>. 1998. 352(9131):837-53.", | ||
"fulltexturl" : "http://linkinghub.elsevier.com/retrieve/pii/S0140673698070196", | |||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
" | "briefDesignDescription" : "Intensive glycemic therapy in T2DM", | ||
"pdfurl" : "", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "9742976", | ||
"title" : "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes", | |||
"published" : "1998-09-12", | "published" : "1998-09-12", | ||
" | "timestamp" : "2022-08-27T02:08:15Z", | ||
"abbreviation" : "UKPDS" | |||
"abbreviation" : "UKPDS | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673698070378.pdf", | ||
"briefDesignDescription" : "Metformin in T2DM", | "briefDesignDescription" : "Metformin in T2DM", | ||
"subspecialties" : "Endocrinology", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext", | ||
" | "abbreviation" : "UKPDS 34", | ||
" | "timestamp" : "2017-12-03T22:39:50Z", | ||
"published" : "1998-11-07", | |||
"title" : "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.", | |||
"statusUsableDate" : "2014-01-01", | |||
"pmid" : "9742977", | |||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "UKPDS 34", | ||
"briefResultsDescription" : "Metformin better than diet alone in T2DM", | "briefResultsDescription" : "Metformin better than diet alone in T2DM", | ||
"diseases" : "Diabetes Mellitus", | "diseases" : "Diabetes Mellitus", | ||
" | "citation" : "UKPDS Study Group. \"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.\". <i>The Lancet</i>. 1998. 352(9131):854-865.", | ||
"pageid" : 1747, | |||
" | "expansion" : "UK Prospective Diabetes Study 34" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "UPLIFT", | ||
"briefResultsDescription" : "Decreased exacerbations and mortality", | |||
"diseases" : "Chronic Obstructive Pulmonary Disease", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "Understanding Potential Long-Term Impacts on Function with Tiotropium", | |||
"citation" : "Tashkin DP, <i>et al</i>. \"A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease\". <i>The New England Journal of Medicine</i>. 2008. 395(15):1543-1554.", | |||
"pageid" : 123, | |||
"briefDesignDescription" : "Tiotropium in COPD", | "briefDesignDescription" : "Tiotropium in COPD", | ||
"subspecialties" : "Pulmonology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0805800", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0805800", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805800", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0805800", | ||
" | "title" : "A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "18836213", | ||
"abbreviation" : "UPLIFT", | "abbreviation" : "UPLIFT", | ||
" | "timestamp" : "2012-10-29T23:28:48Z", | ||
" | "published" : "2008-10-09" | ||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "student", | ||
"pageName" : "V-HeFT", | |||
"diseases" : "Heart Failure", | |||
"briefResultsDescription" : "Trend towards mortality benefit in ISDN/hydralazine", | |||
"pageid" : 155, | |||
"citation" : "Cohn JN, <i>et al</i>. \"Effect of vasodilator therapy on mortality in chronic congestive heart failure\". <i>The New England Journal of Medicine</i>. 1986. 314(24):1547-52.", | |||
"expansion" : "Vasodilator Heart Failure Trial", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198606123142404", | |||
"briefDesignDescription" : "ISDN/hydralazine in HFrEF", | "briefDesignDescription" : "ISDN/hydralazine in HFrEF", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198606123142404", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198606123142404", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "V-HeFT", | ||
"published" : "1986-06-12", | "published" : "1986-06-12", | ||
" | "timestamp" : "2017-12-03T22:39:51Z", | ||
"title" : "Effect of vasodilator therapy on mortality in chronic congestive heart failure", | "title" : "Effect of vasodilator therapy on mortality in chronic congestive heart failure", | ||
"pmid" : "3520315" | "pmid" : "3520315", | ||
"statusUsableDate" : "2012-12-01" | |||
}, | }, | ||
{ | { | ||
" | "citation" : "Cohn JN, <i>et al</i>. \"A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure\". <i>The New England Journal of Medicine</i>. 1991. 325(5):303-310.", | ||
"pageid" : 2943, | "pageid" : 2943, | ||
" | "expansion" : "Vasodilator Heart Failure Trial II", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "pageName" : "V-HeFT II", | ||
"briefResultsDescription" : "Enalapril improves survival in HFrEF", | "briefResultsDescription" : "Enalapril improves survival in HFrEF", | ||
"diseases" : "Heart Failure", | "diseases" : "Heart Failure", | ||
"abbreviation" : "V-HeFT II", | "abbreviation" : "V-HeFT II", | ||
"timestamp" : "2018-04-13T13:08:04Z", | |||
"published" : "1991-08-01", | |||
"title" : "A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure", | "title" : "A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure", | ||
"pmid" : "2057035" | "statusUsableDate" : "2017-11-01", | ||
"pmid" : "2057035", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199108013250502", | |||
"briefDesignDescription" : "Enalapril vs. ISDN/hydralazine in HFrEF", | |||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199108013250502" | |||
}, | }, | ||
{ | { | ||
"pageid" : 261, | "pageid" : 261, | ||
"citation" : "Lewis HD, <i>et al</i>. \"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study\". <i>The New England Journal of Medicine</i>. 1983. 309(7):396-403.", | "citation" : "Lewis HD, <i>et al</i>. \"Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study\". <i>The New England Journal of Medicine</i>. 1983. 309(7):396-403.", | ||
"expansion" : null, | "expansion" : null, | ||
" | "trainingLevel" : "Resident", | ||
"diseases" : "Acute Coronary Syndrome", | |||
"briefResultsDescription" : "Aspirin decreases mortality", | "briefResultsDescription" : "Aspirin decreases mortality", | ||
"pageName" : "VA Cooperative Study", | |||
"published" : "1983-08-18", | "published" : "1983-08-18", | ||
" | "timestamp" : "2014-09-24T22:23:54Z", | ||
"abbreviation" : null, | "abbreviation" : null, | ||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "6135989", | |||
"title" : "Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study", | "title" : "Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina -- Results of a Veterans Administration Cooperative Study", | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM198308183090703", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM198308183090703", | |||
"subspecialties" : "Cardiology", | |||
"briefDesignDescription" : "Aspirin in unstable angina" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "VA-NEPHRON D", | |||
"diseases" : "Diabetes Mellitus;Diabetic Nephropathy", | |||
"briefResultsDescription" : "ACE+ARB no more effective than monotherapy, increases complications", | |||
"pageid" : 1798, | |||
"citation" : "Fried LF, <i>et al</i>. \"Combined angiotensin inhibition for the treatment of diabetic nephropathy\". <i>The New England Journal of Medicine</i>. 2013. 369(20):1892-1903.", | |||
"expansion" : "Veterans Affairs Nephropathy in Diabetes", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1303154", | |||
"briefDesignDescription" : "ACE+ARB in DM nephropathy", | "briefDesignDescription" : "ACE+ARB in DM nephropathy", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1303154", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1303154", | ||
"subspecialties" : "Nephrology;Endocrinology", | "subspecialties" : "Nephrology;Endocrinology", | ||
" | "abbreviation" : "VA NEPHRON-D", | ||
"published" : "2013-11-14", | "published" : "2013-11-14", | ||
" | "timestamp" : "2018-01-11T18:14:18Z", | ||
"title" : "Combined angiotensin inhibition for the treatment of diabetic nephropathy", | "title" : "Combined angiotensin inhibition for the treatment of diabetic nephropathy", | ||
"statusUsableDate" : "2014-05-01", | |||
"pmid" : "24206457" | "pmid" : "24206457" | ||
}, | }, | ||
{ | { | ||
" | "diseases" : "Diabetes Mellitus", | ||
" | "briefResultsDescription" : "No effect on macrovascular or severe microvascular outcomes", | ||
" | "pageName" : "VADT", | ||
"trainingLevel" : "Resident", | |||
"expansion" : "Veterans Affairs Diabetes Trial", | |||
"pageid" : 254, | "pageid" : 254, | ||
"citation" : "Duckworth W, <i>et al</i>. \"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2009. 360(2):129-39.", | "citation" : "Duckworth W, <i>et al</i>. \"Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes\". <i>The New England Journal of Medicine</i>. 2009. 360(2):129-39.", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa0808431", | |||
"subspecialties" : "Endocrinology", | "subspecialties" : "Endocrinology", | ||
" | "briefDesignDescription" : "Intensive glycemic therapy in T2DM", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa0808431", | |||
"pmid" : "19092145", | |||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "title" : "Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes", | ||
"published" : "2009-01-08", | "published" : "2009-01-08", | ||
" | "timestamp" : "2018-08-12T16:18:00Z", | ||
"abbreviation" : "VADT" | |||
"abbreviation" : "VADT | |||
}, | }, | ||
{ | { | ||
" | "expansion" : "Valsartan Heart Failure Trial", | ||
" | "citation" : "Cohn JN, <i>et al</i>. \"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure\". <i>New England Journal of Medicine</i>. 2001. 345(23):1667-75.", | ||
"pageid" : 20, | "pageid" : 20, | ||
" | "briefResultsDescription" : "No mortality benefit of valsartan in NYHA II-IV HF", | ||
"diseases" : "Heart Failure", | |||
"pageName" : "Val-HeFT", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
" | "pmid" : "11759645", | ||
"title" : "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", | |||
"timestamp" : "2014-08-24T17:55:57Z", | |||
"published" : "2001-12-06", | "published" : "2001-12-06", | ||
"abbreviation" : "Val-HeFT", | "abbreviation" : "Val-HeFT", | ||
" | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa010713", | ||
"briefDesignDescription" : "Valsartan in HFrEF", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa010713" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "VALENCE", | |||
"timestamp" : "2017-12-03T22:39:54Z", | "timestamp" : "2017-12-03T22:39:54Z", | ||
"published" : "2014-05-22", | |||
"title" : "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", | |||
"statusUsableDate" : "2014-12-01", | |||
"pmid" : "24795201", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316145", | |||
"briefDesignDescription" : "Sofosbuvir+ribavirin for HCV genotypes 2 or 3", | "briefDesignDescription" : "Sofosbuvir+ribavirin for HCV genotypes 2 or 3", | ||
"subspecialties" : "Infectious Disease;Gastroenterology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1316145", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1316145", | ||
"citation" : "Zeuzem S, <i>et al</i>. \"Sofosbuvir and ribavirin in HCV genotypes 2 and 3\". <i>The New England Journal of Medicine</i>. 2014. 370(21):1993-2001.", | |||
"pageid" : 2261, | "pageid" : 2261, | ||
" | "expansion" : "", | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
" | "pageName" : "VALENCE", | ||
"briefResultsDescription" : "Sofosbuvir+ribavirin effective without IFN", | "briefResultsDescription" : "Sofosbuvir+ribavirin effective without IFN", | ||
"diseases" : "Hepatitis C" | |||
"diseases" : "Hepatitis C | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "pageName" : "VALIANT", | ||
" | "briefResultsDescription" : "Valsartan as effective as captopril", | ||
"diseases" : "Heart Failure;Acute Coronary Syndrome;Myocardial Infarction", | |||
"citation" : "Pfeffer MA, <i>et al</i>. \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both\". <i>The New England Journal of Medicine</i>. 2003. 349(20):1893-1903.", | |||
"pageid" : 462, | "pageid" : 462, | ||
"expansion" : "Valsartan in Acute Myocardial Infarction Trial", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa032292", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa032292", | ||
" | "briefDesignDescription" : "Valsartan vs. captopril in MI with LV dysfunction", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa032292", | ||
" | "abbreviation" : "VALIANT", | ||
" | "timestamp" : "2019-04-11T17:06:09Z", | ||
"published" : "2003-11-13", | "published" : "2003-11-13", | ||
"title" : "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both", | "title" : "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both", | ||
"pmid" : "12921816" | "pmid" : "12921816", | ||
"statusUsableDate" : "2012-03-01" | |||
}, | }, | ||
{ | { | ||
"timestamp" : " | "abbreviation" : null, | ||
"timestamp" : "2025-07-26T15:24:13Z", | |||
"published" : "2007-08-01", | |||
"title" : "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "17599306", | |||
"pdfurl" : "http://cid.oxfordjournals.org/content/45/3/302.full.pdf", | |||
"briefDesignDescription" : "Vancomycin vs. metronidazole in C. difficile", | "briefDesignDescription" : "Vancomycin vs. metronidazole in C. difficile", | ||
"subspecialties" : "Infectious Disease;Gastroenterology", | |||
"fulltexturl" : "http://cid.oxfordjournals.org/content/45/3/302.long", | "fulltexturl" : "http://cid.oxfordjournals.org/content/45/3/302.long", | ||
"citation" : "Zar FA, <i>et al</i>. \"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity\". <i>Clinical Infectious Diseases</i>. 2007. 45(3):302-7.", | |||
"pageid" : 6, | "pageid" : 6, | ||
" | "expansion" : null, | ||
"trainingLevel" : "Intern", | "trainingLevel" : "Intern", | ||
" | "pageName" : "Vancomycin vs. Metronidazole in C. difficile Diarrhea", | ||
"briefResultsDescription" : "Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea", | "briefResultsDescription" : "Vancomycin is superior to metronidazole in severe C. difficile-associated diarrhea", | ||
"diseases" : "Clostridium difficile" | |||
"diseases" : "Clostridium difficile | |||
}, | }, | ||
{ | { | ||
"title" : "Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs", | |||
"statusUsableDate" : "2016-06-01", | |||
"pmid" : "27149033", | |||
"abbreviation" : "VANISH", | |||
"published" : "2016-05-05", | |||
"timestamp" : "2017-12-03T22:39:56Z", | "timestamp" : "2017-12-03T22:39:56Z", | ||
"briefDesignDescription" : "Ablation vs. antiarrhythmic drugs in VT", | "briefDesignDescription" : "Ablation vs. antiarrhythmic drugs in VT", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1513614", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1513614", | ||
"subspecialties" : "Cardiology", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1513614", | |||
"expansion" : "Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs", | |||
"pageid" : 2783, | "pageid" : 2783, | ||
"citation" : "Sapp JL, <i>et al</i>. \"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs\". <i>The New England Journal of Medicine</i>. 2016. 375(2):111-121.", | "citation" : "Sapp JL, <i>et al</i>. \"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs\". <i>The New England Journal of Medicine</i>. 2016. 375(2):111-121.", | ||
"pageName" : "VANISH", | "pageName" : "VANISH", | ||
"diseases" : "Ventricular Tachycardia", | "diseases" : "Ventricular Tachycardia", | ||
" | "briefResultsDescription" : "VT ablation superior to escalation of antiarrhythmic drugs", | ||
"trainingLevel" : "Resident" | |||
" | |||
}, | }, | ||
{ | { | ||
" | "trainingLevel" : "Resident", | ||
" | "diseases" : "Sepsis;Shock", | ||
" | "briefResultsDescription" : "Vasopressin doesn't reduce mortality in shock", | ||
"pageName" : "VASST", | |||
"pageid" : 1910, | "pageid" : 1910, | ||
"citation" : "Russel JA, <i>et al</i>. \"Vasopressin versus norepinephrine infusion in patients with septic shock\". <i>The New England Journal of Medicine</i>. 2008. 358(9):877-887.", | |||
"expansion" : "Vasopressin and Septic Shock Trial", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa067373", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa067373", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa067373", | ||
"subspecialties" : "Critical Care", | "subspecialties" : "Critical Care", | ||
" | "briefDesignDescription" : "Vasopressin in septic shock", | ||
"published" : "2008-02-28", | "published" : "2008-02-28", | ||
" | "timestamp" : "2020-11-22T18:00:12Z", | ||
"abbreviation" : "VASST", | "abbreviation" : "VASST", | ||
"title" : "Vasopressin versus norepinephrine infusion in patients with septic shock | "pmid" : "18305265", | ||
"statusUsableDate" : "2014-08-01", | |||
"title" : "Vasopressin versus norepinephrine infusion in patients with septic shock" | |||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1800781", | ||
"briefDesignDescription" : "Wearable cardioverter-defibrillator post-MI", | "briefDesignDescription" : "Wearable cardioverter-defibrillator post-MI", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800781", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800781", | ||
"subspecialties" : "Cardiology", | "subspecialties" : "Cardiology", | ||
" | "abbreviation" : "VEST", | ||
"published" : "2018-09-27", | |||
"timestamp" : "2019-10-17T17:47:55Z", | |||
"title" : "Wearable cardioverter-defibrillator after myocardial infarction", | |||
"pmid" : "30280654", | |||
"statusUsableDate" : "2018-10-11", | "statusUsableDate" : "2018-10-11", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "VEST", | "pageName" : "VEST", | ||
"diseases" : "Sudden Cardiac Death", | "diseases" : "Sudden Cardiac Death", | ||
" | "briefResultsDescription" : "Wearable cardioverter-defibrillator doesn't reduce arrhythmic death", | ||
" | "pageid" : 3716, | ||
" | "citation" : "Olgin JE, <i>et al</i>. \"Wearable cardioverter-defibrillator after myocardial infarction\". <i>The New England Journal of Medicine</i>. 2018. 379(13):1205-1215.", | ||
"expansion" : "Vest Prevention of Early Sudden Death" | |||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "Antiepileptics in status epilepticus", | "briefDesignDescription" : "Antiepileptics in status epilepticus", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199809173391202", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199809173391202", | ||
" | "subspecialties" : "Neurology", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJM199809173391202", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJM199809173391202", | ||
" | "title" : "A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus", | ||
"pmid" : "9738086", | |||
" | |||
"statusUsableDate" : "2022-12-20", | "statusUsableDate" : "2022-12-20", | ||
" | "abbreviation" : "Veterans Affairs Status Epilepticus Study", | ||
"published" : "1998-09-17", | "published" : "1998-09-17", | ||
"timestamp" : "2022-12-21T16:29:52Z", | |||
"pageName" : "Veterans Affairs Status Epilepticus Cooperative Study Group", | "pageName" : "Veterans Affairs Status Epilepticus Cooperative Study Group", | ||
"diseases" : "Epilepsy", | "diseases" : "Epilepsy", | ||
" | "briefResultsDescription" : "No difference between four antiepileptics", | ||
" | "trainingLevel" : "Intern", | ||
"expansion" : "", | |||
"pageid" : 2461, | |||
"citation" : "Veterans Affairs Status Epilepticus Cooperative Study Group. \"A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus\". <i>New England Journal of Medicine</i>. 1998. 339(12):792-798." | |||
}, | }, | ||
{ | { | ||
"pageid" : 4192, | "pageid" : 4192, | ||
"citation" : "Fujii T, <i>et al</i>. \"Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial\". <i>JAMA</i>. 2020. 323(5):423-431.", | "citation" : "Fujii T, <i>et al</i>. \"Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial\". <i>JAMA</i>. 2020. 323(5):423-431.", | ||
"expansion" : "The VitamIn C, HydrocorTisone and ThiAMINe in Patients With Septic Shock Trial", | "expansion" : "The VitamIn C, HydrocorTisone and ThiAMINe in Patients With Septic Shock Trial", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "VITAMINS", | "pageName" : "VITAMINS", | ||
"diseases" : "Sepsis;Shock", | "diseases" : "Sepsis;Shock", | ||
"briefResultsDescription" : "No difference with triple-therapy in septic shock", | |||
"abbreviation" : "VITAMINS", | "abbreviation" : "VITAMINS", | ||
"published" : "2020-02-04", | |||
"timestamp" : "2025-06-19T18:34:21Z", | |||
"title" : "Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial", | "title" : "Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: The VITAMINS randomized clinical trial", | ||
"pmid" : "31950979" | "statusUsableDate" : "2020-09-03", | ||
"pmid" : "31950979", | |||
"pdfurl" : "", | |||
"briefDesignDescription" : "Vitamin C, hydrocortisone, & thiamine in septic shock", | |||
"fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2019.22176", | |||
"subspecialties" : "Critical Care" | |||
}, | }, | ||
{ | { | ||
" | "pageName" : "VOYAGER-PAD", | ||
"briefResultsDescription" : "Low-dose rivaroxaban lowers PAD events", | |||
"diseases" : "Peripheral Artery Disease", | |||
"trainingLevel" : "resident", | |||
"expansion" : null, | |||
"citation" : "Bonaca M, <i>et al</i>. \"Rivaroxaban in Peripheral Artery Disease after Revascularization\". <i>The New England Journal of Medicine</i>. 2020. 382(21):1994-2004.", | |||
"pageid" : 5305, | |||
"briefDesignDescription" : "Rivaroxaban 2.5mg BID in PAD", | "briefDesignDescription" : "Rivaroxaban 2.5mg BID in PAD", | ||
"subspecialties" : "Cardiology", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2000052", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa2000052", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2000052", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2000052", | ||
" | "title" : "Rivaroxaban in Peripheral Artery Disease after Revascularization", | ||
"pmid" : "32222135", | |||
" | |||
"statusUsableDate" : "2023-04-20", | "statusUsableDate" : "2023-04-20", | ||
"abbreviation" : "VOYAGER", | "abbreviation" : "VOYAGER", | ||
" | "timestamp" : "2024-08-28T14:43:50Z", | ||
" | "published" : "2020-05-21" | ||
}, | }, | ||
{ | { | ||
"briefDesignDescription" : "tPA if stroke >4.5h and ideal MRI", | "briefDesignDescription" : "tPA if stroke >4.5h and ideal MRI", | ||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1804355", | "fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1804355", | ||
" | "subspecialties" : "Neurology", | ||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1804355", | "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1804355", | ||
" | "title" : "MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset", | ||
"statusUsableDate" : "2024-07-15", | "statusUsableDate" : "2024-07-15", | ||
" | "pmid" : "29766770", | ||
"abbreviation" : "WAKE-UP", | |||
"published" : "2018-08-16", | "published" : "2018-08-16", | ||
"timestamp" : "2024-08-09T09:57:23Z", | |||
"pageName" : "WAKE-UP", | "pageName" : "WAKE-UP", | ||
"diseases" : "Stroke", | "diseases" : "Stroke", | ||
" | "briefResultsDescription" : "tPA >4.5 with improved outcomes post-stroke if ideal MRI", | ||
" | "trainingLevel" : "Student", | ||
"expansion" : "", | |||
"pageid" : 3723, | |||
"citation" : "Thomalla G, <i>et al</i>. \"MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset\". <i>New England Journal of Medicine</i>. 2018. 379(7):611-622." | |||
}, | }, | ||
{ | { | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1114238", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1114238", | ||
"subspecialties" : "Hematology", | "subspecialties" : "Hematology", | ||
" | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1114238", | ||
" | "briefDesignDescription" : "Aspirin after VTE treatment", | ||
" | "timestamp" : "2017-12-03T22:39:59Z", | ||
"published" : "2012-05-24", | "published" : "2012-05-24", | ||
"abbreviation" : "WARFASA", | "abbreviation" : "WARFASA", | ||
"pmid" : "22621626", | |||
"statusUsableDate" : "2013-03-01", | |||
"title" : "Aspirin for preventing the recurrence of venous thromboembolism", | "title" : "Aspirin for preventing the recurrence of venous thromboembolism", | ||
" | "trainingLevel" : "resident", | ||
"briefResultsDescription" : "Aspirin reduces recurrent VTE", | |||
"diseases" : "Deep Vein Thrombosis;Pulmonary Embolism;Venous Thromboembolism", | |||
"pageName" : "WARFASA", | |||
"citation" : "Becattini C, <i>et al</i>. \"Aspirin for preventing the recurrence of venous thromboembolism\". <i>The New England Journal of Medicine</i>. 2012. 366(21):1959-1967.", | |||
"pageid" : 1244, | |||
"expansion" : "Warfarin and Aspirin" | |||
}, | }, | ||
{ | { | ||
"statusUsableDate" : "2022-03-10", | |||
"pmid" : "11794192", | |||
"title" : "A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke", | |||
"timestamp" : "2022-03-10T20:02:17Z", | "timestamp" : "2022-03-10T20:02:17Z", | ||
"published" : "2001-11-15", | |||
"abbreviation" : "WARSS", | |||
"subspecialties" : "Neurology", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa011258", | |||
"briefDesignDescription" : "Aspirin vs. warfarin in ischemic stroke", | "briefDesignDescription" : "Aspirin vs. warfarin in ischemic stroke", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011258", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa011258", | ||
" | "expansion" : "Warfarin–Aspirin Recurrent Stroke Study", | ||
"citation" : "Mohr J, <i>et al</i>. \"A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2001. 345(20):1444-1451.", | "citation" : "Mohr J, <i>et al</i>. \"A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke\". <i>The New England Journal of Medicine</i>. 2001. 345(20):1444-1451.", | ||
" | "pageid" : 2784, | ||
"briefResultsDescription" : "Warfarin did not reduce rates of death/stroke, caused more bleeding", | "briefResultsDescription" : "Warfarin did not reduce rates of death/stroke, caused more bleeding", | ||
" | "diseases" : "Stroke", | ||
"pageName" : "WARSS", | "pageName" : "WARSS", | ||
" | "trainingLevel" : "Intern" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "WASID", | ||
"diseases" : "Stroke", | |||
"briefResultsDescription" : "Warfarin had higher adverse events", | |||
"trainingLevel" : "Intern", | |||
"expansion" : "Warfarin-Aspirin Symptomatic Intracranial Disease", | |||
"pageid" : 2427, | |||
"citation" : "Chimowitz MI, <i>et al</i>. \"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis\". <i>The New England Journal of Medicine</i>. 2005. 352(13):1305-1306.", | |||
"briefDesignDescription" : "Warfarin vs. aspirin for intracranial atherosclerosis", | "briefDesignDescription" : "Warfarin vs. aspirin for intracranial atherosclerosis", | ||
"fulltexturl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033", | "fulltexturl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033", | ||
" | "subspecialties" : "Neurology;Cardiology", | ||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033", | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa043033", | ||
" | "title" : "Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis", | ||
"pmid" : "15800226", | |||
" | |||
"statusUsableDate" : "2019-06-27", | "statusUsableDate" : "2019-06-27", | ||
" | "abbreviation" : "WASID", | ||
"published" : "2005-03-31", | "published" : "2005-03-31", | ||
" | "timestamp" : "2019-06-27T17:24:44Z" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://jama.jamanetwork.com/data/Journals/JAMA/4840/JOC21036.pdf", | ||
"briefDesignDescription" : "Postmenopausal estrogen/progesterone", | "briefDesignDescription" : "Postmenopausal estrogen/progesterone", | ||
"fulltexturl" : null, | "fulltexturl" : null, | ||
"subspecialties" : "Gynecology;Endocrinology", | "subspecialties" : "Gynecology;Endocrinology", | ||
" | "abbreviation" : "WHI E+P", | ||
"published" : "2002-07-17", | |||
"timestamp" : "2017-12-03T22:40:01Z", | |||
"title" : "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial", | |||
"statusUsableDate" : "2013-07-01", | "statusUsableDate" : "2013-07-01", | ||
" | "pmid" : "12117397", | ||
" | "trainingLevel" : "Student", | ||
"pageName" : "WHI", | "pageName" : "WHI", | ||
"diseases" : "Coronary Artery Disease;Menopause", | "diseases" : "Coronary Artery Disease;Menopause", | ||
" | "briefResultsDescription" : "Postmenopausal estrogen/progesterone HRT increases rates of MI and breast cancer", | ||
" | "pageid" : 1507, | ||
" | "citation" : "Rossouw JE, <i>et al</i>. \"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial\". <i>The Journal of the American Medical Association</i>. 2002. 288(3):321-333.", | ||
"expansion" : "Women's Health Initiative Estrogen and Progestin Trial" | |||
}, | }, | ||
{ | { | ||
"abbreviation" : "WISDOM", | |||
"published" : "2014-10-02", | |||
"timestamp" : "2017-12-03T22:40:03Z", | "timestamp" : "2017-12-03T22:40:03Z", | ||
"title" : "Withdrawal of inhaled glucocorticoids and exacerbations of COPD", | |||
"pmid" : "25196117", | |||
"statusUsableDate" : "2015-05-01", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1407154", | |||
"briefDesignDescription" : "ICS withdrawal in COPD", | "briefDesignDescription" : "ICS withdrawal in COPD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1407154", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJMoa1407154", | ||
"subspecialties" : "Pulmonology", | |||
"pageid" : 2318, | "pageid" : 2318, | ||
"citation" : "Magnussen H, <i>et al</i>. \"Withdrawal of inhaled glucocorticoids and exacerbations of COPD\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1285-1295.", | "citation" : "Magnussen H, <i>et al</i>. \"Withdrawal of inhaled glucocorticoids and exacerbations of COPD\". <i>The New England Journal of Medicine</i>. 2014. 371(14):1285-1295.", | ||
"expansion" : "Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management", | "expansion" : "Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "WISDOM", | "pageName" : "WISDOM", | ||
"diseases" : "Chronic Obstructive Pulmonary Disease", | "diseases" : "Chronic Obstructive Pulmonary Disease", | ||
" | "briefResultsDescription" : "ICS withdrawal may reduce FEV1, no change in COPD flares" | ||
}, | }, | ||
{ | { | ||
" | "pageName" : "WOEST", | ||
"diseases" : "Coronary Artery Disease", | |||
"briefResultsDescription" : "ASA increases bleeding when added to clopidogrel if chronic OAC", | |||
"trainingLevel" : "Resident", | |||
"expansion" : "What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing", | |||
"pageid" : 1792, | |||
"citation" : "Dewilde WJM, <i>et al</i>. \"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial\". <i>The Lancet</i>. 2013. 381(9872):1107-1115.", | |||
"briefDesignDescription" : "Clopidogrel ± ASA after PCI if on OAC", | "briefDesignDescription" : "Clopidogrel ± ASA after PCI if on OAC", | ||
"fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0140673612621771", | "fulltexturl" : "http://www.sciencedirect.com/science/article/pii/S0140673612621771", | ||
" | "subspecialties" : "Cardiology;Hematology", | ||
"pdfurl" : "", | "pdfurl" : "", | ||
" | "title" : "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial", | ||
"statusUsableDate" : "2015-06-01", | "statusUsableDate" : "2015-06-01", | ||
" | "pmid" : "23415013", | ||
"abbreviation" : "WOEST", | |||
"published" : "2013-03-30", | "published" : "2013-03-30", | ||
" | "timestamp" : "2017-12-03T22:40:05Z" | ||
}, | }, | ||
{ | { | ||
"abbreviation" : "WOSCOPS", | |||
"published" : "1995-11-16", | |||
"timestamp" : "2014-12-12T19:39:51Z", | "timestamp" : "2014-12-12T19:39:51Z", | ||
"title" : "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia", | |||
"statusUsableDate" : "2012-03-01", | |||
"pmid" : "7566020", | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199511163332001", | |||
"briefDesignDescription" : "Pravastatin in CAD", | "briefDesignDescription" : "Pravastatin in CAD", | ||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199511163332001", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199511163332001", | ||
"subspecialties" : "Cardiology", | |||
"pageid" : 172, | "pageid" : 172, | ||
"citation" : "Shepherd J, <i>et al</i>. \"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia\". <i>The New England Journal of Medicine</i>. 1995. 333(20):1301-1308.", | "citation" : "Shepherd J, <i>et al</i>. \"Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia\". <i>The New England Journal of Medicine</i>. 1995. 333(20):1301-1308.", | ||
"expansion" : "West of Scotland Coronary Prevention Study", | "expansion" : "West of Scotland Coronary Prevention Study", | ||
" | "trainingLevel" : "Resident", | ||
"pageName" : "WOSCOPS", | "pageName" : "WOSCOPS", | ||
"diseases" : "Hyperlipidemia;Coronary Artery Disease", | "diseases" : "Hyperlipidemia;Coronary Artery Disease", | ||
" | "briefResultsDescription" : "Pravastatin reduces MIs and CV mortality" | ||
}, | }, | ||
{ | { | ||
" | "pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM199105233242101", | ||
"briefDesignDescription" : "RSBI for predicting weaning", | "briefDesignDescription" : "RSBI for predicting weaning", | ||
"subspecialties" : "Pulmonology;Critical Care", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199105233242101", | "fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM199105233242101", | ||
" | "abbreviation" : "", | ||
" | "timestamp" : "2017-12-03T22:40:06Z", | ||
"published" : "1991-05-23", | |||
"title" : "A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation", | |||
"statusUsableDate" : "2013-01-01", | |||
"pmid" : "2023603", | |||
"trainingLevel" : "Resident", | "trainingLevel" : "Resident", | ||
" | "pageName" : "Yang-Tobin Study", | ||
"briefResultsDescription" : "RSBI predicts success and failure of weaning from mechanical ventilation", | "briefResultsDescription" : "RSBI predicts success and failure of weaning from mechanical ventilation", | ||
"diseases" : "Critical Illness", | "diseases" : "Critical Illness", | ||
" | "citation" : "Yang KL, Tobin MJ. \"A Prospective Study of Indexes Predicting the Outcome of Trials of Weaning from Mechanical Ventilation\". <i>The New England Journal of Medicine</i>. 1991. 324(21):1445-1450.", | ||
"pageid" : 75, | |||
" | "expansion" : "" | ||
} | } | ||
] | ], | ||
"topic" : "all" | |||
} | } | ||
} | } | ||